rearrangement	amino_acid	frame_type	rearrangement_type	templates	reads	frequency	productive_frequency	cdr3_length	v_family	v_gene	v_allele	d_family	d_gene	d_allele	j_family	j_gene	j_allele	v_deletions	d5_deletions	d3_deletions	j_deletions	n2_insertions	n1_insertions	v_index	n1_index	n2_index	d_index	j_index	v_family_ties	v_gene_ties	v_allele_ties	d_family_ties	d_gene_ties	d_allele_ties	j_family_ties	j_gene_ties	j_allele_ties	sequence_tags	v_shm_count	v_shm_indexes	antibody	bio_identity	v_resolved	d_resolved	j_resolved	sample_name	species	locus	product_subtype	kit_pool	sku	test_name	sample_catalog_tags	sample_rich_tags	sample_rich_tags_json	kit_control	total_templates	productive_templates	outofframe_templates	stop_templates	dj_templates	total_rearrangements	productive_rearrangements	outofframe_rearrangements	stop_rearrangements	dj_rearrangements	total_reads	total_productive_reads	total_outofframe_reads	total_stop_reads	total_dj_reads	productive_clonality	productive_entropy	sample_clonality	sample_entropy	sample_amount_ng	sample_cells_mass_estimate	fraction_productive_of_cells_mass_estimate	sample_cells	fraction_productive_of_cells	max_productive_frequency	max_frequency	counting_method	primer_set	sequence_result_status	release_date	upload_date	sample_tags	fraction_productive	order_name	kit_id	total_t_cells	total_templates_agg
GACTCGGCCATGTATCGCTGTGCCAGCAGCCGGGTCCCGGTGGTAGAGACCCAGTACTTCGGGCCA	CASSRVPVVETQYF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	42	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	5	8	4	4	0	10	18	-1	34	30	44						01,02								CASSRVPVVETQYF+TCRBV07-06+TCRBJ02-05	TCRBV07-06*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCCATGTGGCAGGGGGCTCCTACGAGCAGTACTTCGGGCCG	CASSHVAGGSYEQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	45	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	1	0	7	0	18	30	-1	37	44														CASSHVAGGSYEQYF+TCRBV07-06+TCRBJ02-07	TCRBV07-06*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTCGGGAGACCGGGACTGGGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	61	8.744780011439892E-5		49	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	0	10	2	9	3	18	32	47	41	50						01,02								X+TCRBV07-06+TCRBJ02-07	TCRBV07-06*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCATGTATCGCTGTGCCAGCGCCAGGGAGGGACCGTACACCGGGGAGCTGTTTTTTGGAGAA	CASAREGPYTGELFF	In	VDJ	1	64	9.174851159543494E-5	1.1006529967857494E-4	45	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	8	9	0	3	4	5	18	27	38	31	43														CASAREGPYTGELFF+TCRBV07-06+TCRBJ02-02	TCRBV07-06*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTAGGGGGACCGAAGCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	67	9.604922307647095E-5		52	TCRBV07	TCRBV07-06	01				TCRBJ01	TCRBJ01-06	01	1	0	7	0	1	5	18	34	40	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV07-06+TCRBJ01-06	TCRBV07-06*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGTCAGAAGCTTAAGTGGGGGGGATCAGCCCCAGCATTTTGGTGAT	CVRSLSGGDQPQHF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	42	TCRBV07	TCRBV07-05	02	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	2	9	0	5	3	0	18	33	-1	36	43														CVRSLSGGDQPQHF+TCRBV07-05+TCRBJ01-05	TCRBV07-05*02	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCTTACGGACGAGGACACGAGCAGTACTTCGGGCCG		Out	VDJ	1	78	1.1181849850693633E-4		40	TCRBV07	TCRBV07-05	01				TCRBJ02	TCRBJ02-07	01	1	1	7	5	1	6	19	34	39	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV07-05+TCRBJ02-07	TCRBV07-05*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGATCAGGGGACAGGGAACTATGGCTACACCTTCGGTTCG	CASSVDQGTGNYGYTF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	0	3	2	5	0	23	39	-1	44	53			01,02										Vb 1	CASSVDQGTGNYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCGGACGGGCTAGCGGAAACAGATACGCAGTATTTTGGCCCA	CASSADGLAETDTQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	4	5	3	8	2	23	36	51	44	53			01,02			01,02							Vb 1	CASSADGLAETDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCGCGGACAGGGAAGACCCAGTACTTCGGGCCA	CASSPRTGKTQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	39	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	3	6	4	1	23	35	47	39	48			01,02										Vb 1	CASSPRTGKTQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGATGGACAGCTCTAGGCAGCTACGAGCAGTACTTCGGGCCG	CARWTALGSYEQYF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	1	5	3	2	10	23	31	39	33	49			01,02										Vb 1	CARWTALGSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTATGGGGAGGGACTACGAGCAGTACTTCGGGCCG	CASSMGRDYEQYF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	9	0	3	4	1	23	34	45	38	46			01,02										Vb 1	CASSMGRDYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCTAGGACCGGGGAACCAGGGGGCTACACCTTCGGTTCG	CASSPRTGEPGGYTF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	45	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-02	01	4	4	3	8	16	0	23	35	-1	51	56			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSPRTGEPGGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCACCGGGGGGGAAAGGACTGTTTTTTGGCAGT	CASSPPGGKGLFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	4	8	0	13	4	5	23	35	47	39	52			01,02										Vb 1	CASSPPGGKGLFF+TCRBV09-01+TCRBJ01-04	TCRBV09-01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCTTCACTAGCGGGGGTACCGGGGAGCTGTTTTTTGGAGAA	CASSFTSGGTGELFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	45	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	4	3	2	5	3	1	23	35	49	38	50			01,02										Vb 1	CASSFTSGGTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCACCCCCCCGGGGACAACTACGAGTCGACTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	52	7.454566567129089E-5		53	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	9	0	6	0	8	12	23	30	44	38	56			01,02										Vb 1	X+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGAAGGGGACAGGGCGACTGAAGCTTTCTTTGGACAA	CASSEGDRATEAFF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	3	5	5	2	23	34	48	39	50			01,02										Vb 1	CASSEGDRATEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCATCGTGTGAGGAACTAGCGGGGGGGCTAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	54	7.741280665864823E-5		52	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	2	3	0	4	7	2	23	37	57	44	59			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCTCCCAAGCAAGTTACAATCAGCCCCAGCATTTTGGTGAT	CASSQASYNQPQHF	In	VDJ	1	54	7.741280665864823E-5	9.286759660379759E-5	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	7	6	7	3	5	6	23	32	40	37	46			01,02			01,02							Vb 1	CASSQASYNQPQHF+TCRBV09-01+TCRBJ01-05	TCRBV09-01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAACGACCACCGGGGAGCTGTTTTTTGGAGAA	CASSVTTTGELFF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	39	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-02	01	1	2	7	4	2	0	23	38	-1	40	43			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVTTTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGATATCGGCCAGGGGGCGGGAGGAAACACCATATATTTTGGAGAG	CASSDIGQGAGGNTIYF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	51	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	4	0	4	10	4	23	34	52	44	56			01,02										Vb 1	CASSDIGQGAGGNTIYF+TCRBV09-01+TCRBJ01-03	TCRBV09-01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGGGGTGGAGGACAGGGCTCTGGAAACACCATATATTTTGGAGAG	CASSGGGGQGSGNTIYF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	51	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	1	3	0	8	0	23	36	-1	44	52			01,02										Vb 1	CASSGGGGQGSGNTIYF+TCRBV09-01+TCRBJ01-03	TCRBV09-01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTTCTTTCAGGGGTTTTGAGCAGTACTTCGGGCCG		Out	VDJ	1	62	8.88813706080776E-5		41	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	2	7	5	4	23	37	48	42	52			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGATCCCACCGGGGTAGATACGCAGTATTTTGGCCCA	CASSDPTGVDTQYF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	8	3	5	9	1	23	34	48	43	49			01,02										Vb 1	CASSDPTGVDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGCCGGCTAACCGATGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	62	8.88813706080776E-5		49	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-02	01	5	2	7	4	19	0	23	34	-1	53	56			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	X+TCRBV09-01+TCRBJ01-02	TCRBV09-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCTGAGCGTCGGGACAGGATCACACGAGCAGTACTTCGGGCCG	CASSLSVGTGSHEQYF	In	VDJ	1	77	1.1038492801325766E-4	1.3242231367578547E-4	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	4	5	9	5	23	35	52	44	57			01,02										Vb 1	CASSLSVGTGSHEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGACATACAGGGCTCTACAATGAGCAGTTCTTCGGGCCA	CASSGHTGLYNEQFF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	3	3	3	5	2	23	36	47	41	49			01,02										Vb 1	CASSGHTGLYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGACGGACAGCTCCTCTATGGCTACACCTTCGGTTCG	CASSVDGQLLYGYTF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	1	5	4	2	5	23	39	47	41	52			01,02										Vb 1	CASSVDGQLLYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCACCCGGATGGCCCGGGGAGCTGTTTTTTGGAGAA	CASSPPGWPGELFF	In	VDJ	1	90	1.290213444310804E-4	1.5477932767299599E-4	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-02	01	4	1	8	6	6	4	23	35	44	41	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSPPGWPGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGTGGGACAGGGGGTAGAAAAACTGTTTTTTGGCAGT	CASSVVGQGVEKLFF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	0	1	8	1	2	23	39	51	40	53			01,02										Vb 1	CASSVVGQGVEKLFF+TCRBV09-01+TCRBJ01-04	TCRBV09-01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGGTTATCCTCTGGTACTGAAGCTTTCTTTGGACAA	CASRLSSGTEAFF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	39	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-01	01	5	0	10	5	10	1	23	34	46	44	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASRLSSGTEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGATTCAAGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSDSSSGANVLTF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-06	01	5	2	8	0	1	6	23	34	37	35	43			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSDSSSGANVLTF+TCRBV09-01+TCRBJ02-06	TCRBV09-01		TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTGGGACAGGGACCCTACGAGCAGTACTTCGGGCCG	CASSVGQGPYEQYF	In	VDJ	1	103	1.476577608489031E-4	1.7713634167020652E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	0	3	2	0	2	23	-1	46	37	48			01,02										Vb 1	CASSVGQGPYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCTAATATCAACTAGCGGTGACTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	104	1.4909133134258178E-4		55	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	3	5	0	9	3	23	39	56	48	59			01,02			01,02							Vb 1	X+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCAACAGAAGGTGGAAACACCATATATTTTGGAGAG	CASSATEGGNTIYF	In	VDJ	1	108	1.5482561331729645E-4	1.8573519320759518E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	3	5	3	2	4	23	36	42	38	46			01,02										Vb 1	CASSATEGGNTIYF+TCRBV09-01+TCRBJ01-03	TCRBV09-01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGTAGGGGCCGGGGAGCTGTTTTTTGGAGAA	CASSVVGAGELFF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	39	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	5	2	6	1	0	23	39	-1	40	45			01,02										Vb 1	CASSVVGAGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGGGATACACCGGGGAGCTGTTTTTTGGAGAA	CASSVEGYTGELFF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-02	01	0	0	8	3	1	1	23	39	44	40	45			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVEGYTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCACCTCGTCGGGGGAGGGGGATACGCAGTATTTTGGCCCA	CASTSSGEGDTQYF	In	VDJ	1	111	1.5912632479833248E-4	1.908945041300284E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	9	0	6	9	1	23	33	49	42	50			01,02										Vb 1	CASTSSGEGDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGTGGTGACTATGGCTACACCTTCGGTTCG	CASSVGGDYGYTF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	39	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-02	01	0	0	10	3	2	2	23	39	43	41	45			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGGDYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGCAGACAGGCAACTATGGCTACACCTTCGGTTCG	CASSVEQTGNYGYTF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	4	2	4	1	23	39	49	43	50			01,02										Vb 1	CASSVEQTGNYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAACGGCTAGCGGGGGGCCCACAGATACGCAGTATTTTGGCCCA	CASSVTASGGPTDTQYF	In	VDJ	1	117	1.677277477604045E-4	2.012131259748948E-4	51	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	4	1	2	4	2	23	38	53	42	55			01,02										Vb 1	CASSVTASGGPTDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGTACGTCTGTCCGCTCCTACGAGCAGTACTTCGGGCCG	CASSVGTSVRSYEQYF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	48	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-07	01	0	3	7	0	2	9	23	39	43	41	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGTSVRSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGGGGGCCAGAGGACAATGAGCAGTTCTTCGGGCCA	CASSGGPEDNEQFF	In	VDJ	1	132	1.8923130516558455E-4	2.270096805870608E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	6	0	5	0	6	23	-1	42	36	48			01,02										Vb 1	CASSGGPEDNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCAAAATTACGGACGGGACACTGAAGCTTTCTTTGGACAA	CASSQNYGRDTEAFF	In	VDJ	1	133	1.9066487565926323E-4	2.2872945089453853E-4	45	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-01	01	4	1	7	3	9	3	23	35	48	44	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSQNYGRDTEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCGGTGGCTCGCCTACACTTGGGCAACACAGATACGCAGTATTTTGGCCCA	CASSVAVARLHLGNTDTQYF	In	VDJ	1	148	2.121684330644433E-4	2.545260055067045E-4	60	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	8	0	2	19	2	21	37	60	56	62			01,02										Vb 1	CASSVAVARLHLGNTDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGATCCGGCAGGGGGCTCAGATACGCAGTATTTTGGCCCA	CASSDPAGGSDTQYF	In	VDJ	1	155	2.22203426520194E-4	2.6656439765904865E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	4	0	4	8	1	23	34	50	42	51			01,02										Vb 1	CASSDPAGGSDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGCCAGGGACATCGGCGAGCAGTACTTCGGGCCG	CASSVARDIGEQYF	In	VDJ	1	180	2.580426888621608E-4	3.0955865534599197E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	6	6	3	4	23	39	48	42	52			01,02										Vb 1	CASSVARDIGEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGTAAACCCCCCGGGGACTGGGAATATGCAGACCCAGTACTTCGGGCCA		Out	VDJ	1	181	2.5947625935583945E-4		55	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	0	10	6	12	10	23	36	54	48	64			01,02			01,02							Vb 1	X+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGCCTTAGGGGGAGTGGGGAGGAGACCCAGTACTTCGGGCCA	CASSVGLRGSGEETQYF	In	VDJ	1	191	2.7381196429262616E-4	3.2847612872824705E-4	51	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	5	1	5	5	9	23	39	50	44	59			01,02										Vb 1	CASSVGLRGSGEETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCGCCGTTCGCGGCAACACCGGGGAGCTGTTTTTTGGAGAA	CASAVRGNTGELFF	In	VDJ	1	197	2.8241338725469817E-4	3.3879475057311344E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	7	5	2	7	1	23	32	43	39	44			01,02			01,02							Vb 1	CASAVRGNTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCTCGGGAGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSPRESSYEQYF	In	VDJ	1	200	2.867140987357342E-4	3.4395406149554666E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	8	2	0	3	2	23	35	44	38	46			01,02										Vb 1	CASSPRESSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGACGGACAGCTCCAGGCAGCTACGAGCAGTACTTCGGGCCG	CARRTAPGSYEQYF	In	VDJ	1	216	3.096512266345929E-4	3.7147038641519037E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	1	5	3	2	10	23	31	39	33	49			01,02										Vb 1	CARRTAPGSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAAGGACTAGCGGGATCTACAATGAGCAGTTCTTCGGGCCA	CASSVRTSGIYNEQFF	In	VDJ	2	234	3.35455495520809E-4	4.024262519497896E-4	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	1	3	3	1	1	23	38	51	39	52			01,02										Vb 1	CASSVRTSGIYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTATAGCTAGCGGGAGTATGTGATACGCAGTATTTTGGCCCA	CASSV*LAGVCDTQYF	Stop	VDJ	2	301	4.3150471859727997E-4		48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	4	2	6	3	5	23	38	51	41	56			01,02										Vb 1	CASSV*LAGVCDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGGGTCAGCGGGAGGGTCTCCATGAGCAGTTCTTCGGGCCA	CASSVGGQREGLHEQFF	In	VDJ	2	325	4.6591041044556804E-4	5.589253499302633E-4	51	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	6	0	8	6	5	23	39	55	45	60			01,02										Vb 1	CASSVGGQREGLHEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTTACAGGGGAAATCGATGGCTACACCTTCGGTTCG	CASSVTGEIDGYTF	In	VDJ	2	327	4.687775514329254E-4	5.623648905452188E-4	42	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	3	2	6	1	6	23	37	45	38	51			01,02										Vb 1	CASSVTGEIDGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGGGATCGGCTAATGAGCAGTTCTTCGGGCCA	CASSVEGSANEQFF	In	VDJ	2	352	5.046168137748921E-4	6.053591482321621E-4	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-01	01	0	0	8	7	1	6	23	39	44	40	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVEGSANEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGGACAGGGAAATTTTAGGGACATTCAGTACTTCGGCGCC	CASSGQGNFRDIQYF	In	VDJ	3	459	6.5800885659851E-4	7.893745711322796E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	1	3	8	1	11	23	34	43	35	54			01,02										Vb 1	CASSGQGNFRDIQYF+TCRBV09-01+TCRBJ02-04	TCRBV09-01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGTTGAGGACTATGGCTACACCTTCGGTTCG	CASSVVEDYGYTF	In	VDJ	3	516	7.397223747381942E-4	8.874014786585104E-4	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	11	1	3	2	0	23	39	-1	41	45			01,02										Vb 1	CASSVVEDYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTATCTACAGGGACTAATGAAAAACTGTTTTTTGGCAGT	CASSVSTGTNEKLFF	In	VDJ	3	526	7.540580796749809E-4	9.045991817332877E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	3	3	2	3	0	23	38	-1	41	47			01,02										Vb 1	CASSVSTGTNEKLFF+TCRBV09-01+TCRBJ01-04	TCRBV09-01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCACGAGGATCCAGCGGGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSPRGSSGSSYEQYF	In	VDJ	6	874	0.0012529406114751584	0.001503079248735539	51	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	6	2	0	12	0	23	35	-1	47	55			01,02										Vb 1	CASSPRGSSGSSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCTTTGGGTCTTACAATGAGCAGTTCTTCGGGCCA	CASSFGSYNEQFF	In	VDJ	7	1092	0.0015654589790971086	0.0018779891757656848	39	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-01	01	4	0	9	4	3	3	23	35	41	38	44			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSFGSYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAAGGGAAAGCCTACGAGCAGTACTTCGGGCCG	CASSVEGKAYEQYF	In	VDJ	10	1456	0.002087278638796145	0.0025039855676875795	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-07	01	0	0	8	2	2	3	23	39	45	41	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVEGKAYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGACAGGCGGCCAAGAGACCCAGTACTTCGGGCCA	CASSVETGGQETQYF	In	VDJ	14	2102	0.003013365177712566	0.0036149571863181955	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	2	4	1	1	3	23	39	46	40	49			01,02										Vb 1	CASSVETGGQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGTTTGACCCTATCACTAGCGGGAGGGTCCTCCTACGAGTAGTACTTCGGGCCG	CASSLTLSLAGGSSYE*YF	Stop	VDJ	1	57	8.171351813968424E-5		57	TCRBV11	TCRBV11-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	3	0	11	12	13	19	30	55	42	68														CASSLTLSLAGGSSYE*YF+TCRBV11-01+TCRBJ02-07	TCRBV11-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCACACAGGGGTGGAGGGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	42	6.020996073450418E-5		44	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	3	2	5	3	6	29	42	52	45	58													Vb 16	X+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGCTAGCGGGGACTGCTGGGACCGGGGAGCTGTTTTTTGGAGAA	CASSQLAGTAGTGELFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	51	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	3	4	3	5	1	9	29	43	53	44	62													Vb 16	CASSQLAGTAGTGELFF+TCRBV14-01+TCRBJ02-02	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGCCACTCTCCCTAGAGGGAAAAACTGTTTTTTGGCAGT	CASSRHSP*REKLFF	Stop	VDJ	1	53	7.597923616496956E-5		45	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	4	4	8	8	10	3	29	42	56	52	59						01,02							Vb 16	CASSRHSP*REKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCGACTTTCGGTGAGCAGTTCTTCGGGCCA	CASSQATFGEQFF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	2	10	9	1	5	29	45	50	46	55						01,02							Vb 16	CASSQATFGEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATGGCGGCAGGGGGCCAGGCTACACCTTCGGTTCG	CASSQDGGRGPGYTF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	0	8	6	2	29	46	60	52	62													Vb 16	CASSQDGGRGPGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACTCGGGCGGGGGGCGCACGTTACGCAGTATTTTGGCCCA	CASSQLGRGAHVTQYF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	7	1	8	5	7	29	44	57	49	64													Vb 16	CASSQLGRGAHVTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGAGGGAGGTATCAGCCCCAGCATTTTGGTGAT	CASSQGGRYQPQHF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	1	9	1	5	2	1	29	45	53	47	54													Vb 16	CASSQGGRYQPQHF+TCRBV14-01+TCRBJ01-05	TCRBV14-01*01	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATCTTCTAGCGGGGGGGCTCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	73	1.0465064603854297E-4		52	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	4	0	4	4	2	29	46	62	50	64													Vb 16	X+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAATACCGGCAGAGTGGCTACACCTTCGGTTCG	CASSQYRQSGYTF	In	VDJ	1	88	1.2615420344372303E-4	1.5133978705804052E-4	39	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-02	01	2	4	5	7	6	2	29	44	53	50	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQYRQSGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTCTCGAGCAGGGAGCTCTAGCTACACCTTCGGTTCG		Out	VDJ	1	106	1.5195847232993913E-4		43	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-02	01	4	4	3	9	7	7	29	42	54	49	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAATTCGGGGGGAGAACTAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	111	1.5912632479833248E-4		50	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	2	8	1	1	2	7	29	44	53	46	60													Vb 16	X+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGTGTCAGGGGTGGTGGCTACACCTTCGGTTCG	CASSVRGGGYTF	In	VDJ	1	117	1.677277477604045E-4	2.012131259748948E-4	36	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	2	7	3	3	29	40	49	43	52													Vb 16	CASSVRGGGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGAGGCCCCAGTCGTGAGCAGTTCTTCGGGCCA	CASSRGPSREQFF	In	VDJ	1	124	1.777627412161552E-4	2.1325151812723892E-4	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	11	1	9	0	9	29	-1	46	42	55													Vb 16	CASSRGPSREQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAAGGGGGGCTACACCTTCGGTTCG		Out	VDJ	1	126	1.8062988220351252E-4		32	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	5	2	8	0	0	29	-1	-1	44	49													Vb 16	X+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGGGGGACGGCGTCCTATAATTCACCCCTCCACTTTGGGAAC	CASRGTASYNSPLHF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	45	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-06	01	6	0	7	1	1	4	29	40	46	41	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASRGTASYNSPLHF+TCRBV14-01+TCRBJ01-06	TCRBV14-01*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGGGACGACTCACAGATACGCAGTATTTTGGCCCA	CASSQGRLTDTQYF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	42	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-03	01	3	0	7	2	0	4	29	-1	48	43	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQGRLTDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCGACAGGGGGTACTACTCTTCATACGCAGTATTTTGGCCCA	CASSPTGGTTLHTQYF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	2	1	7	1	11	29	42	52	43	63													Vb 16	CASSPTGGTTLHTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCCCTCGGACGGGGGATTCACCCCTCTACTTTGGGAAC		Out	VDJ	1	144	2.0643415108972861E-4		47	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	1	8	2	20	8	12	29	45	59	53	71													Vb 16	X+TCRBV14-01+TCRBJ01-06	TCRBV14-01*01	TCRBD02-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGGGCCCCGGGCCTCCCAAAAGTAGCTGGCACAGATACGCAGTATTTTGGCCCA	CARAPGLPKVAGTDTQYF	In	VDJ	1	151	2.164691445454793E-4	2.596853164291377E-4	54	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-03	01	9	8	0	1	6	16	27	35	45	41	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CARAPGLPKVAGTDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCGACACAGGGGAGGTCGGCTGAAGCTTTCTTTGGACAA	CASSPTQGRSAEAFF	In	VDJ	1	152	2.1790271503915797E-4	2.614050867366155E-4	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	2	6	4	7	29	42	53	46	60													Vb 16	CASSPTQGRSAEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGTGGCAGAACTGGAGGATTCTGGAGTTATTTCTGTGCCAGCAGCCAAGGTTTAGGCCAGGGTCACGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	152	2.1790271503915797E-4		47	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	23	4	3	5	29	5	34	28	62	57	67													Vb 16	X+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACTACCGCCGGGACAGAACCTCTATGGCTACACCTTCGGTTCG	CASSQLPPGQNLYGYTF	In	VDJ	1	163	2.3367199046962336E-4	2.803225601188705E-4	51	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	0	5	4	8	5	29	44	59	52	64													Vb 16	CASSQLPPGQNLYGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAAGTCCGTGGCAGGCGAACACTGAAGCTTTCTTTGGACAA	CASSQSPWQANTEAFF	In	VDJ	1	173	2.4800769540641004E-4	2.975202631936479E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	4	1	9	1	29	44	57	53	58													Vb 16	CASSQSPWQANTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACGGTACGGGACACTTAATGAAAAACTGTTTTTTGGCAGT	CASSQRYGTLNEKLFF	In	VDJ	1	193	2.7667910527998346E-4	3.319156693432025E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	0	6	4	6	2	29	44	56	50	58													Vb 16	CASSQRYGTLNEKLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGAGAACGGGACGACTGTTTTTTGGCAGT	CASSQRTGRLFF	In	VDJ	1	201	2.8814766922941287E-4	3.4567383180302436E-4	36	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-04	01	3	0	7	13	6	1	29	43	54	49	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQRTGRLFF+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAGTTTGGGGGGATAATGAACACTGAAGCTTTCTTTGGACAA	CASSQEFGGIMNTEAFF	In	VDJ	1	213	3.053505151535569E-4	3.663110754927572E-4	51	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	9	1	0	4	4	29	46	56	50	60													Vb 16	CASSQEFGGIMNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGTGATCGCGAACACTGAAGCTTTCTTTGGACAA	CASSQVIANTEAFF	In	VDJ	1	219	3.1395193811562894E-4	3.766296973376236E-4	42	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	1	2	8	1	1	4	29	45	48	46	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQVIANTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATCAAGGCAAAAATGAGCAGTTCTTCGGGCCA	CASSQDQGKNEQFF	In	VDJ	1	222	3.1825264959666497E-4	3.817890082600568E-4	42	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-01	01	0	5	4	7	3	4	29	46	52	49	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQDQGKNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTTGGACTAGCGGCCTTCTACAATGAGCAGTTCTTCGGGCCA	CASSLGLAAFYNEQFF	In	VDJ	2	247	3.540919119386317E-4	4.2478326594700013E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	1	5	3	2	4	29	42	54	44	58						01,02							Vb 16	CASSLGLAAFYNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGACCTAGCGGGAGCCAATGAGCAGTTCTTCGGGCCA	CASSQDLAGANEQFF	In	VDJ	2	253	3.626933349007037E-4	4.351018877918665E-4	45	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	4	2	6	1	1	29	46	57	47	58													Vb 16	CASSQDLAGANEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGTACAGCTTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSQYSFSGANVLTF	In	VDJ	2	294	4.2146972514152923E-4	5.056124703984536E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	3	5	0	2	3	29	43	49	45	52													Vb 16	CASSQYSFSGANVLTF+TCRBV14-01+TCRBJ02-06	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGACTGGACAAGCCGAACACTGAAGCTTTCTTTGGACAA	CASSRLDKPNTEAFF	In	VDJ	2	306	4.386725710656733E-4	5.262497140881864E-4	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	1	6	1	4	4	29	42	51	46	55													Vb 16	CASSRLDKPNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAATACAGGCAAGAGACCCAGTACTTCGGGCCA	CASSQYRQETQYF	In	VDJ	2	358	5.132182367369642E-4	6.156777700770285E-4	39	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	3	4	2	1	0	29	44	-1	45	50													Vb 16	CASSQYRQETQYF+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCGCATATCTGGACAGGGTCCATGGCTACACCTTCGGTTCG	CASSAYLDRVHGYTF	In	VDJ	2	359	5.146518072306429E-4	6.173975403845062E-4	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	3	6	8	3	29	41	57	49	60													Vb 16	CASSAYLDRVHGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCACCTACGGGGGCGGGGTGAACACTGAAGCTTTCTTTGGACAA	CASTYGGGVNTEAFF	In	VDJ	2	363	5.203860892053576E-4	6.242766216144172E-4	45	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	7	6	0	0	5	4	29	39	50	44	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASTYGGGVNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGCTCTCGGGGCCCCGCCCCGCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	3	389	5.57658922041003E-4		53	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-02	01	1	7	0	6	6	9	28	44	55	50	64				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ02-02	TCRBV14-01*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCTACGGACAGTCTAGCACAGATACGCAGTATTTTGGCCCA	CASSYGQSSTDTQYF	In	VDJ	3	447	6.408060106743659E-4	7.687373274425467E-4	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	5	0	3	3	29	41	50	44	53													Vb 16	CASSYGQSSTDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCGAGCGCCGGCTACGAGCAGTACTTCGGGCCG	CASSQASAGYEQYF	In	VDJ	3	471	6.75211702522654E-4	8.100118148220124E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	6	6	3	2	4	29	45	51	47	55						01,02							Vb 16	CASSQASAGYEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACGCCCTGGGGGGTGGAATCAGCCCCAGCATTTTGGTGAT	CASSQRPGGWNQPQHF	In	VDJ	3	480	6.881138369657621E-4	8.25489747589312E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	2	9	1	4	6	3	29	44	56	50	59													Vb 16	CASSQRPGGWNQPQHF+TCRBV14-01+TCRBJ01-05	TCRBV14-01*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGCGGGTCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	3	480	6.881138369657621E-4		40	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	3	7	4	2	0	1	29	-1	48	43	49						01,02							Vb 16	X+TCRBV14-01+TCRBJ02-04	TCRBV14-01*01	TCRBD02-01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGAGTTTATTTCTGTGCCAGCAGCCCCTCTTTCGGGCTAGCGGGGCTCAACTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPSFGLAGLNSYNEQFF	In	VDJ	4	550	7.88463771523269E-4	9.458736691127533E-4	60	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	4	3	0	11	5	12	25	45	36	50													Vb 16	CASSPSFGLAGLNSYNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCAGCTTTGGGGGGAATGAGCAGTTCTTCGGGCCA	CASSSFGGNEQFF	In	VDJ	5	690	9.89163640638283E-4	0.0011866415121596359	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	9	1	7	6	0	29	41	-1	47	53													Vb 16	CASSSFGGNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTAAGACAACATGAGCAGTTCTTCGGGCCA	CASSLRQHEQFF	In	VDJ	5	699	0.001002065775081391	0.0012021194449269355	36	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	2	6	8	3	2	29	42	49	45	51													Vb 16	CASSLRQHEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCACCCTCGGCCCGGAACGTATTCACCCCTCCACTTTGGGAAC	CASSHPRPGTYSPLHF	In	VDJ	6	875	0.001254374181968837	0.0015047990190430165	48	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-06	01	3	1	8	8	10	4	29	43	56	53	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSHPRPGTYSPLHF+TCRBV14-01+TCRBJ01-06	TCRBV14-01*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGGCATTCGCGATCGGGGAGCTGTTTTTTGGAGAA	CASSQAFAIGELFF	In	VDJ	6	979	0.0014034655133114188	0.0016836551310207008	42	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-02	01	3	9	0	7	0	9	29	-1	46	43	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQAFAIGELFF+TCRBV14-01+TCRBJ02-02	TCRBV14-01*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCGTGGGGACAGGGGGCATTACAGATACGCAGTATTTTGGCCCA	CASSVGTGGITDTQYF	In	VDJ	7	1097	0.001572626831565502	0.0018865880273030735	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	0	3	3	3	29	41	56	44	59													Vb 16	CASSVGTGGITDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCTTGGGGCCGGGTTATGGAAACACCATATATTTTGGAGAG	CASSLGPGYGNTIYF	In	VDJ	8	1228	0.0017604245662374079	0.0021118779375826563	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	7	0	3	2	7	29	41	48	43	55													Vb 16	CASSLGPGYGNTIYF+TCRBV14-01+TCRBJ01-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGTACTAGCGGGGGCGCCAGCGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	10	1557	0.0022320692586576905		53	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	3	2	1	2	7	28	41	54	43	61													Vb 16	X+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAAGCAGGACAGGGGGCTTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	11	1682	0.0024112655703675246		47	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	1	0	1	4	1	29	39	54	43	55													Vb 16	X+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAAGGCAGGTGGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	14	2104	0.0030162323186999234		44	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	4	4	3	3	3	29	46	53	49	56													Vb 16	X+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACAGGGGGCCCTGAGCACTGAAGCTTTCTTTGGACAA	CASSQQGALSTEAFF	In	VDJ	29	4390	0.006293374467249365	0.0075497916498272494	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	0	4	0	6	29	-1	52	44	58													Vb 16	CASSQQGALSTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGTTTAGGCCAGGGTCACGACGAGCAGTACTTCGGGCCG	CASSQGLGQGHDEQYF	In	VDJ	67	10096	0.014473327704179861	0.017362801024295195	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	3	5	8	5	29	45	58	53	63													Vb 16	CASSQGLGQGHDEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTCCCCGGGACACCTAACCACTTTAGAGGGGGCTTTCTTTGGACAA	CASSSPGHLTTLEGAFF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	51	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	6	11	5	19	24	36	47	41	66														CASSSPGHLTTLEGAFF+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGCTGACGGCAGGGGGGGGGAAAAACTGTTTTTTGGCAGT	CASSVADGRGGEKLFF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	48	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-04	01	5	4	1	8	11	3	24	36	54	47	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVADGRGGEKLFF+TCRBV21-or09_02+TCRBJ01-04	TCRBV21-or09_02*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCATGTGATTCATGAATGACTGAGTGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	55	7.88463771523269E-5		55	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	10	2	10	4	17	11	24	31	52	48	63						01,02								X+TCRBV21-or09_02+TCRBJ01-02	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCAGAGTAGGGGACAGCGACCTCACCGGGGAGCTGTTTTTTGGAGAA	CASSRVGDSDLTGELFF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	51	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	0	5	4	6	6	24	37	50	43	56														CASSRVGDSDLTGELFF+TCRBV21-or09_02+TCRBJ02-02	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTCTTTAACGGGGCGAGGATCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	100	1.433570493678671E-4		47	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-07	01	5	7	0	3	8	6	24	36	49	44	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGCAGGGACAGGGGGCCACTACGAGCAGTACTTCGGGCCG	CASSAGTGGHYEQYF	In	VDJ	1	128	1.8349702319086987E-4	2.2013059935714987E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	0	3	3	2	24	36	51	39	53														CASSAGTGGHYEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGTAGCAAAGTCGGGACACTAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	134	1.920984461529419E-4		50	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	0	6	0	2	4	24	40	48	42	52														X+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTCCCTAACAGGGGAGGCGTCTAAAGAGACCCAGTACTTCGGGCCA	CASSSLTGEASKETQYF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	51	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	3	2	3	6	9	24	36	49	42	58														CASSSLTGEASKETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGTAGGTGGGAGCGCAGATACGCAGTATTTTGGCCCA	CASSVVGGSADTQYF	In	VDJ	1	160	2.2937127898858736E-4	2.7516324919643734E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	9	2	4	9	2	24	36	50	45	52														CASSVVGGSADTQYF+TCRBV21-or09_02+TCRBJ02-03	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTCAGACTAGTTTCCCCGACAATGAGCAGTTCTTCGGGCCA	CASSQTSFPDNEQFF	In	VDJ	1	189	2.709448233052688E-4	3.250365881132916E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	2	8	5	3	8	24	35	44	38	52						01,02								CASSQTSFPDNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAACCCGGACAGGGGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	298	4.2720400711624394E-4		41	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	10	1	2	2	7	0	24	31	-1	38	47														X+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTAGGTGGTCAGGGGGCACGCGAGCAGTACTTCGGGCCG	CASSLGGQGAREQYF	In	VDJ	4	575	8.243030338652358E-4	9.888679267996967E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	0	6	9	3	24	36	53	45	56														CASSLGGQGAREQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGACAGGGGGGCATATTCACCCCTCCACTTTGGGAAC	CASSEDRGAYSPLHF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	45	TCRBV06	TCRBV06-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	1	3	1	8	0	4	23	-1	47	39	51														CASSEDRGAYSPLHF+TCRBV06-01+TCRBJ01-06	TCRBV06-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCAGGGGGGGAGACCCAGTACTTCGGGCCA	CASSEAGGETQYF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	39	TCRBV06	TCRBV06-01	01				TCRBJ02	TCRBJ02-05	01	0	5	1	5	0	1	23	-1	46	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEAGGETQYF+TCRBV06-01+TCRBJ02-05	TCRBV06-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCTGTAGGGTACGAGCAGTACTTCGGGCCG	CASSEAVGYEQYF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	39	TCRBV06	TCRBV06-01	01				TCRBJ02	TCRBJ02-07	01	0	5	3	4	3	0	23	40	-1	43	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEAVGYEQYF+TCRBV06-01+TCRBJ02-07	TCRBV06-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCGAGGACAGGATTCACAGATACGCAGTATTTTGGCCCA	CASSEARTGFTDTQYF	In	VDJ	1	148	2.121684330644433E-4	2.545260055067045E-4	48	TCRBV06	TCRBV06-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	1	4	2	2	3	23	40	49	42	52														CASSEARTGFTDTQYF+TCRBV06-01+TCRBJ02-03	TCRBV06-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCCTCAGAGAACACTGAAGCTTTCTTTGGACAA	CASSEASENTEAFF	In	VDJ	2	295	4.229032956352079E-4	5.073322407059313E-4	42	TCRBV06	TCRBV06-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	5	1	2	1	23	40	45	42	46														CASSEASENTEAFF+TCRBV06-01+TCRBJ01-01	TCRBV06-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCTGAGAAAGGGATTCACAATGAGCAGTTCTTCGGGCCA	CASSEAEKGIHNEQFF	In	VDJ	4	540	7.741280665864823E-4	9.28675966037976E-4	48	TCRBV06	TCRBV06-01	01				TCRBJ02	TCRBJ02-01	01	0	0	8	5	7	3	23	40	51	47	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEAEKGIHNEQFF+TCRBV06-01+TCRBJ02-01	TCRBV06-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCACCCCGGGACAGGGCCCCAATGAGCAGTTCTTCGGGCCA	CATPGQGPNEQFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	39	TCRBV07	TCRBV07-04	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	10	0	3	6	4	3	22	29	42	33	45														CATPGQGPNEQFF+TCRBV07-04+TCRBJ02-01	TCRBV07-04*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCTCCCGACCCAGGGCGGGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSSRPRAGSNQPQHF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	51	TCRBV07	TCRBV07-04	01				TCRBJ01	TCRBJ01-05	01	4	4	3	0	7	4	22	35	47	42	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSRPRAGSNQPQHF+TCRBV07-04+TCRBJ01-05	TCRBV07-04*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACTTTACCGGGAGGGCCAAGTGAGCAGTTCTTCGGGCCA		Out	VDJ	1	57	8.171351813968424E-5		47	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	8	0	9	7	5	26	40	55	47	60													Vb 20	X+TCRBV30-01+TCRBJ02-01	TCRBV30-01*02	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTTGGGGGACAGGGGGCGCAGGCAGCCCCAGCATTTTGGTGAT	CALGDRGRRQPQHF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	0	0	7	3	5	26	33	48	36	53													Vb 20	CALGDRGRRQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTTCAGCACACCGGGGAGCTGTTTTTTGGAGAA	CAWSVQHTGELFF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	39	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-02	01	0	4	5	3	1	1	26	40	44	41	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVQHTGELFF+TCRBV30-01+TCRBJ02-02	TCRBV30-01*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTCACAGGGTTACACGAGCAGTACTTCGGGCCG	CAWSVTGLHEQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	39	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	3	5	1	4	26	40	47	41	51													Vb 20	CAWSVTGLHEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*02	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTTAGATCAGGAGGATGAGCAGTTCTTCGGGCCA	CALDQEDEQFF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	33	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	10	1	8	7	0	26	33	-1	40	45													Vb 20	CALDQEDEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGGGACCAGGGATCGGGGACCTATGGCTACACCTTCGGTTCG	CAWRDQGSGTYGYTF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	45	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-02	01	3	0	7	4	13	0	26	37	-1	50	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWRDQGSGTYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*02		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGAGGACAGCCGGGATGAAAAACTGTTTTTTGGCAGT	CAWEDSRDEKLFF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	39	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	5	6	2	5	26	35	43	37	48			unresolved										Vb 20	CAWEDSRDEKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTTTGGAGGGAGCAGGACATAATTCACCCCTCCACTTTGGGAAC	CAWSLEGAGHNSPLHF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	48	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	2	10	0	5	2	8	26	38	46	40	54													Vb 20	CAWSLEGAGHNSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*02	TCRBD02-01*02	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGACACAGGGGGCGGTCAGCCCCAGCATTTTGGTGAT	CAWDTGGGQPQHF	In	VDJ	1	77	1.1038492801325766E-4	1.3242231367578547E-4	39	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	3	0	6	3	2	26	35	47	38	49			unresolved										Vb 20	CAWDTGGGQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAGTTCGTAGGGACAGGGGTCAGACCAACCCCAGCATTTTGGTGAT		Out	VDJ	1	81	1.1611920998797234E-4		53	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	0	2	10	8	9	26	40	58	48	67													Vb 20	X+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGGGGGTAGCAATCAGCCCCAGCATTTTGGTGAT	CAWSGGSNQPQHF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	39	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-05	01	1	6	2	0	0	0	26	-1	-1	39	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSGGSNQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGCCGGACAGGGCGGGGGCTACACCTTCGGTTCG	CAWAGQGGGYTF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	36	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	3	8	3	4	26	35	46	38	50													Vb 20	CAWAGQGGGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAACTCATTCAGGATATGGCTACACCTTCGGTTCG	CAWSVTHSGYGYTF	In	VDJ	1	113	1.619934657856898E-4	1.9433404474498387E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	4	5	8	1	26	40	52	48	53													Vb 20	CAWSVTHSGYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGGAGAGGTACAGGGCGTACTGGACGTGCAGTACTTCGGGCCG	CAWGEVQGVLDVQYF	In	VDJ	1	121	1.734620297351192E-4	2.0809220720480572E-4	45	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	3	9	8	12	26	35	49	43	61													Vb 20	CAWGEVQGVLDVQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGGGCAGGGGGCCGTAATTCACCCCTCCACTTTGGGAAC	CAWRAGGRNSPLHF	In	VDJ	1	125	1.7919631170983387E-4	2.1497128843471665E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	3	4	0	6	2	2	26	37	47	39	49			unresolved										Vb 20	CAWRAGGRNSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTACCCAATATTGGGTGGGAAACACCATATATTTTGGAGAG	CAWSTQYWVGNTIYF	In	VDJ	1	128	1.8349702319086987E-4	2.2013059935714987E-4	45	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-03	01	2	0	9	4	10	2	26	38	51	48	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSTQYWVGNTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*02		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTAAGGGGTTCCTCGGAAACACCATATATTTTGGAGAG	CAWSKGFLGNTIYF	In	VDJ	1	130	1.8636416417822723E-4	2.2357013997210533E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	5	2	4	1	6	26	38	44	39	50			unresolved										Vb 20	CAWSKGFLGNTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCGCAGGGTTATGGCTACACCTTCGGTTCG	CAWSAQGYGYTF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	36	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	4	3	5	2	1	26	39	46	41	47			unresolved										Vb 20	CAWSAQGYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCCTTGGAAGTTTGGGGGTTGCTGAAGCTTTCTTTGGACAA	CAWSLGSLGVAEAFF	In	VDJ	1	162	2.3223841997594468E-4	2.786027898113928E-4	45	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-01	01	3	6	1	6	12	3	26	37	54	49	57			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSLGSLGVAEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*02		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCGGTAACAGGGGCTACGAGCAGTACTTCGGGCCG	CAGNRGYEQYF	In	VDJ	1	163	2.3367199046962336E-4	2.803225601188705E-4	33	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	2	3	4	0	26	32	-1	36	43													Vb 20	CAGNRGYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGTTTGCCGGGACAGGGGAGGGCTAATGAAAAACTGTTTTTTGGCAGT	CACLPGQGRANEKLFF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	48	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	0	2	3	6	4	26	34	50	40	54			unresolved										Vb 20	CACLPGQGRANEKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCCCCACCAGTGGCTACACCTTCGGTTCG	CAWSPTSGYTF	In	VDJ	1	172	2.465741249127314E-4	2.958004928861701E-4	33	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	5	7	6	0	26	37	-1	43	46													Vb 20	CAWSPTSGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTAGCAGTGACTCTGGAAACACCATATATTTTGGAGAG	CAWSSSDSGNTIYF	In	VDJ	1	176	2.5230840688744607E-4	3.0267957411608104E-4	42	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-03	01	2	4	5	0	2	3	26	38	43	40	46			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSSSDSGNTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTTCTCTAGCGGGCAGGCCTACAATGAGCAGTTCTTCGGGCCA	CAFSSGQAYNEQFF	In	VDJ	1	180	2.580426888621608E-4	3.0955865534599197E-4	42	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	4	4	2	3	4	26	33	44	36	48			unresolved			01,02							Vb 20	CAFSSGQAYNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*02	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAGGACGGGCGGGGCAGTTCTTCGGGCCA	CAWSVGRAGQFF	In	VDJ	1	188	2.6951125281159013E-4	3.233168178058139E-4	36	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	7	4	12	7	0	26	40	-1	47	52			unresolved			01,02							Vb 20	CAWSVGRAGQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*02	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGACCCCGGCAAGGGACGGCTACGAGCAGTACTTCGGGCCG	CAWTPARDGYEQYF	In	VDJ	1	195	2.795462462673408E-4	3.35355209958158E-4	42	TCRBV30	TCRBV30-01	02				TCRBJ02	TCRBJ02-07	01	4	0	7	3	9	2	26	36	50	45	52			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWTPARDGYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*02		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACACGGCGAGCCAACATATTATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	216	3.096512266345929E-4		55	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-01	01	0	3	6	0	0	18	26	-1	43	40	61			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	X+TCRBV30-01+TCRBJ01-01	TCRBV30-01*02		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCCGGGACAATCTACGAGCAGTACTTCGGGCCG	CAWSAGTIYEQYF	In	VDJ	1	220	3.153855086093076E-4	3.7834946764510135E-4	39	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	0	6	3	2	2	26	39	47	41	49			unresolved										Vb 20	CAWSAGTIYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCACATAGCGGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CAWSHIAGGYNEQFF	In	VDJ	1	226	3.239869315713796E-4	3.8866808948996774E-4	45	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	5	0	4	4	0	26	38	-1	42	53			unresolved										Vb 20	CAWSHIAGGYNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGATTCTTGGAGGGGGCGGCTGGCTATGGCTACACCTTCGGTTCG		Out	VDJ	2	248	3.555254824323104E-4		46	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	5	0	4	7	6	26	36	50	43	56			unresolved										Vb 20	X+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTCCCCGGGGGGTCTGGAAACACCATATATTTTGGAGAG	CAWSVPGGSGNTIYF	In	VDJ	2	267	3.8276332181220513E-4	4.5917867209655476E-4	45	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-03	01	0	8	1	1	3	0	26	40	-1	43	50													Vb 20	CAWSVPGGSGNTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01	TCRBD02-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCCCCTCTGGAAACACCATATATTTTGGAGAG	CAWSPSGNTIYF	In	VJ	2	282	4.0426687921738517E-4	4.8497522670872076E-4	36	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-03	01	3	0	0	0	0	3	26	-1	37	-1	40			unresolved										Vb 20	CAWSPSGNTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGAGACAGGGGAACTGAAGCTTTCTTTGGACAA	CAWRDRGTEAFF	In	VDJ	2	304	4.3580543007831594E-4	5.22810173473231E-4	36	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	2	2	5	1	1	26	37	46	38	47			unresolved										Vb 20	CAWRDRGTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGATCAAATTGCCTCGAGGGAAAAACTGTTTTTTGGCAGT	CAWSDQIASREKLFF	In	VDJ	2	308	4.4153971205303065E-4	5.296892547031419E-4	45	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	1	11	1	8	13	0	26	39	-1	52	56			unresolved										Vb 20	CAWSDQIASREKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*01	TCRBD02-01*02	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGCAGTGACAGTGACGAACACTGAAGCTTTCTTTGGACAA	CAWAVTVTNTEAFF	In	VDJ	3	390	5.590924925346816E-4	6.70710419916316E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	5	1	5	4	26	35	45	40	49			unresolved										Vb 20	CAWAVTVTNTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCCTCGACGTTCACCCCTCCACTTTGGGAAC	CAWSPRRSPLHF	In	VDJ	3	401	5.748617679651471E-4	6.89627893298571E-4	36	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-06	01	2	2	7	9	4	1	26	38	45	42	46			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSPRRSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCTGGCTTCTATCTCTGTGCCTACTGATTATCGTGTAAGAGAGCACTAGCGGGAGGGGAGAATGAGCAGTTCTTCGGGCCA	CAY*LSCKRALAGGENEQFF	Stop	VDJ	3	419	6.006660368513631E-4		60	TCRBV30	TCRBV30-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	3	0	7	22	3	15	22	57	44	60			01,02										Vb 20	CAY*LSCKRALAGGENEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGGAATTGGGCCCCGGGACAGGGTCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	421	6.035331778387205E-4		52	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	3	0	12	1	26	37	58	49	59													Vb 20	X+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGGGCTCCAGGGGGCCCGGGGGGACGAGCAGTACTTCGGGCCG	CAWGLQGARGDEQYF	In	VDJ	3	453	6.494074336364379E-4	7.790559492874132E-4	45	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	0	5	6	8	26	35	49	41	57													Vb 20	CAWGLQGARGDEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTACCAAGCAACTTGGGGCCCAGTACTTCGGGCCA	CAWSTKQLGAQYF	In	VDJ	3	461	6.608759975858673E-4	7.92814111747235E-4	39	TCRBV30	TCRBV30-01	02				TCRBJ02	TCRBJ02-05	01	2	6	2	9	12	0	26	38	-1	50	54			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSTKQLGAQYF+TCRBV30-01+TCRBJ02-05	TCRBV30-01*02		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCCCCAGGGAAAACAACTATGGCTACACCTTCGGTTCG	CAWSPRENNYGYTF	In	VDJ	3	461	6.608759975858673E-4	7.92814111747235E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	3	2	3	5	26	37	45	40	50													Vb 20	CAWSPRENNYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCGACTCGCCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CAWSRLASGANVLTF	In	VDJ	3	485	6.952816894341553E-4	8.340885991267006E-4	45	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	2	2	10	0	1	3	26	38	43	39	46			unresolved			01,02							Vb 20	CAWSRLASGANVLTF+TCRBV30-01+TCRBJ02-06	TCRBV30-01*01	TCRBD02-01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTTTAGCAGGGAATCAGCCCCAGCATTTTGGTGAT	CAWSLAGNQPQHF	In	VDJ	3	492	7.053166828899061E-4	8.461269912790447E-4	39	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	4	3	4	4	0	26	38	-1	42	47			unresolved										Vb 20	CAWSLAGNQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTATGGATCCCCGGGGTGGAGGGGGAGCAGTACTTCGGGCCG	CAWSVWIPGVEGEQYF	In	VDJ	3	502	7.196523878266928E-4	8.633246943538221E-4	48	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	10	0	7	15	1	26	40	61	55	62													Vb 20	CAWSVWIPGVEGEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACGAGGGAGCCGCGCCTACAATGAGCAGTTCTTCGGGCCA	CAWSVRGSRAYNEQFF	In	VDJ	4	560	8.027994764600557E-4	9.630713721875306E-4	48	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	9	2	2	4	5	26	40	49	44	54													Vb 20	CAWSVRGSRAYNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCCGACACAAGCGCTGAAGCTTTCTTTGGACAA	CAWSADTSAEAFF	In	VDJ	5	684	9.80562217676211E-4	0.0011763228903147697	39	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-01	01	1	2	6	6	2	6	26	39	45	41	51			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSADTSAEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGACGAGGGAGTAGCCCAAGAGACCCAGTACTTCGGGCCA	CAWDEGVAQETQYF	In	VDJ	6	836	0.001198464932715369	0.001437727977051385	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	9	2	1	5	4	26	35	45	40	49			unresolved										Vb 20	CAWDEGVAQETQYF+TCRBV30-01+TCRBJ02-05	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCTAGGACCTTACAATGAGCAGTTCTTCGGGCCA	CAWSLGPYNEQFF	In	VDJ	7	986	0.0014135005067671695	0.001695693523173045	39	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-01	01	2	1	7	4	3	2	26	38	45	41	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSLGPYNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGCCACGACTGGTTCAATGAGCAGTTCTTCGGGCCA	CACHDWFNEQFF	In	VDJ	16	2352	0.003371757801132234	0.004044899763187629	36	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	2	10	6	4	4	26	34	42	38	46			unresolved			01,02							Vb 20	CACHDWFNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGGGCGGCGGTTGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	33	5048	0.007236663852089931		41	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	7	5	1	1	6	26	37	42	38	48			unresolved			01,02							Vb 20	X+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGCCGGGGGGAGGACTGAAGCTTTCTTTGGACAA	CASSQAGGRTEAFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	42	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	1	8	1	5	1	3	23	39	47	40	50														CASSQAGGRTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAGGCCCCTAGCGGGGGGTTGGCCCCCGCAGTTCTTCGGGCCA		Out	VDJ	1	48	6.881138369657621E-5		49	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	1	12	5	9	23	37	53	42	62														X+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAAACAGGGGGCGCCTTCTTGCGGGAAGCTTTCTTTGGACAA	CASSQETGGAFLREAFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	51	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	0	8	1	12	23	40	50	41	62														CASSQETGGAFLREAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAGGGGGTTTGAGGACCTCACCCTCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	55	7.88463771523269E-5		55	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-03	01	3	6	1	2	0	17	23	-1	42	37	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAACATACCGGGACTAGCGGATACGAGCAGTACTTCGGGCCG	CASSQHTGTSGYEQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	0	5	4	6	1	23	38	55	44	56						01,02								CASSQHTGTSGYEQYF+TCRBV01-01+TCRBJ02-07	TCRBV01-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGGGGGCTCGCGAATTTGGGATACGCAGTATTTTGGCCCA	CASSQGGSRIWDTQYF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	48	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	7	0	6	0	12	23	-1	44	39	56														CASSQGGSRIWDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATCAGACTAGCGGGAGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSQDQTSGRSYNEQFF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	54	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	2	1	1	3	0	23	40	-1	43	56														CASSQDQTSGRSYNEQFF+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATCGGGCAGGGACCAGCAATCAGCCCCAGCATTTTGGTGAT	CASSQDRAGTSNQPQHF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	51	TCRBV01	TCRBV01-01	01				TCRBJ01	TCRBJ01-05	01	0	0	7	1	7	1	23	40	52	47	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDRAGTSNQPQHF+TCRBV01-01+TCRBJ01-05	TCRBV01-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCCAGGGAGGGCCAGGATGGGAAACACCATATATTTTGGAGAG	CASSPGRARMGNTIYF	In	VDJ	1	159	2.2793770849490868E-4	2.734434788889596E-4	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	4	9	0	4	2	8	23	36	45	38	53														CASSPGRARMGNTIYF+TCRBV01-01+TCRBJ01-03	TCRBV01-01*01	TCRBD02-01*02	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCAAGTATAGGCCTAGCGGGAGTGATCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	164	2.3510556096330203E-4		56	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	4	2	2	7	4	23	39	56	46	60														X+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCCGGACAGGGTTGGCGAAAAACTGTTTTTTGGCAGT	CASSPDRVGEKLFF	In	VDJ	1	188	2.6951125281159013E-4	3.233168178058139E-4	42	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	1	3	8	1	5	23	36	45	37	50														CASSPDRVGEKLFF+TCRBV01-01+TCRBJ01-04	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCTGCACCAGCAGCCAAGTTCGGGCCGACTAGCGGGAGGTCGGATCGCGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	196	2.809798167610195E-4		68	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	1	2	1	0	8	8	2	18	39	26	47														X+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCCCGAGGGGTCCTACGAGCAGTACTTCGGGCCG	CASSPEGSYEQYF	In	VDJ	1	204	2.9244838071044885E-4	3.508331427254576E-4	39	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-07	01	4	5	2	1	3	0	23	36	-1	39	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPEGSYEQYF+TCRBV01-01+TCRBJ02-07	TCRBV01-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCTGCCCCGGGGGAACACTGAAGCTTTCTTTGGACAA	CASSLPRGNTEAFF	In	VDJ	1	218	3.1251836762195026E-4	3.7490992703014583E-4	42	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	4	8	3	1	5	0	23	36	-1	41	46														CASSLPRGNTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCCGTTATCCGAGTCGGGCCCGAGCTCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	307	4.4010614155935197E-4		53	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-02	01	4	8	0	7	13	7	23	36	53	49	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCACCGGCGGGACTACCTACACCGGGGAGCTGTTTTTTGGAGAA	CATGGTTYTGELFF	In	VDJ	2	319	4.5730898748349603E-4	5.486067280853969E-4	42	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	10	0	9	3	5	3	23	30	42	35	45						01,02								CATGGTTYTGELFF+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGGTCCGGGGGGGCCGTCAGATACGCAGTATTTTGGCCCA	CASSQGPGGPSDTQYF	In	VDJ	2	357	5.117846662432855E-4	6.139579997695508E-4	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	8	0	4	3	4	23	39	50	42	54														CASSQGPGGPSDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAGTATACTCTGGGCCAAGAGACCCAGTACTTCGGGCCA	CASSQEYTLGQETQYF	In	VDJ	3	466	6.680438500542606E-4	8.014129632846237E-4	48	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-05	01	0	0	9	1	9	0	23	40	-1	49	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEYTLGQETQYF+TCRBV01-01+TCRBJ02-05	TCRBV01-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAGACAGACATTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSQTDISNQPQHF	In	VDJ	4	634	9.088836929922774E-4	0.001090334374940883	45	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	2	5	0	0	4	23	-1	42	37	46														CASSQTDISNQPQHF+TCRBV01-01+TCRBJ01-05	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGTATCCGTTAACTACAGGCCCGGAGAACGAACACTGAAGCTTTCTTTGGACAA	CTSIR*LQARRTNTEAFF	Stop	VDJ	6	879	0.0012601084639435518		54	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	9	3	4	1	12	10	23	31	48	43	58														CTSIR*LQARRTNTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTTATCGAAGCGGCTCTCAAGAGGGCATACGCAGTATTTTGGCCCA	CASSLSKRLSRGHTQYF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	51	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	6	5	7	2	13	23	40	47	42	60						01,02							Vb 14	CASSLSKRLSRGHTQYF+TCRBV27-01+TCRBJ02-03	TCRBV27-01*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCACCCGGACAGGGATCGGGGAGCTGTTTTTTGGAGAA	CATRTGIGELFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	36	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	10	1	3	7	3	2	23	30	41	33	43													Vb 14	CATRTGIGELFF+TCRBV27-01+TCRBJ02-02	TCRBV27-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGGGCCGAGGGGAAGGCCACTAATGAAAAACTGTTTTTTGGCAGT	CASRAEGKATNEKLFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	48	TCRBV27	TCRBV27-01	01				TCRBJ01	TCRBJ01-04	01	6	5	2	2	5	6	23	34	44	39	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 14	CASRAEGKATNEKLFF+TCRBV27-01+TCRBJ01-04	TCRBV27-01*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTTTATCATGGGACAGTGTAGGACAGCCCCAGCATTTTGGTGAT	CASSLSWDSVGQPQHF	In	VDJ	2	261	3.7416189885013313E-4	4.4886005025168837E-4	48	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	0	5	7	2	7	33	50	59	52	66													Vb 14	CASSLSWDSVGQPQHF+TCRBV27-01+TCRBJ01-05	TCRBV27-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGAAGGGGCTGCCACTGAAGCTTTCTTTGGACAA	CSVEEGAATEAFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	5	2	4	0	4	25	-1	44	39	48													Vb 4	CSVEEGAATEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCCAGGCGGTTAACTATGGCTACACCTTCGGTTCG	CSAQAVNYGYTF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	36	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-02	01	7	4	4	1	2	4	25	32	38	34	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSAQAVNYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCCCGGACCTACAATGAGCAGTTCTTCGGGCCA	CSVARTYNEQFF	In	VDJ	1	54	7.741280665864823E-5	9.286759660379759E-5	36	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-01	01	4	1	8	2	3	0	25	35	-1	38	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVARTYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAAGCCAGGGGCGGGGGGCCAACGTCCTGACTTTCGGGGCC	CSVESQGRGANVLTF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	2	4	2	4	3	3	25	37	46	40	49													Vb 4	CSVESQGRGANVLTF+TCRBV29-01+TCRBJ02-06	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAATCCAGCGGGAGTCTGAATGAGCAGTTCTTCGGGCCA	CSVESSGSLNEQFF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	6	2	7	3	4	25	37	48	40	52													Vb 4	CSVESSGSLNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCGGGACTAGCGGGAGGATCCTACAATGAGCAGTTCTTCGGGCCA	CSAGLAGGSYNEQFF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	45	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	0	1	1	1	1	25	32	48	33	49													Vb 4	CSAGLAGGSYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTTCTCTGGGGCCAGGGGCCGAAGGCCAACGTCCTGACTTTCGGGGCC	CSVVLWGQGPKANVLTF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	51	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	4	2	6	11	5	25	35	52	46	57													Vb 4	CSVVLWGQGPKANVLTF+TCRBV29-01+TCRBJ02-06	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGGGGGACTGGCTCCTACGAGCAGTACTTCGGGCCG	CSVGGTGSYEQYF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	39	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	0	10	0	2	2	25	35	43	37	45						01,02							Vb 4	CSVGGTGSYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCTCTGAGCAACTGGGGTACGAGCAGTACTTCGGGCCG	CSVSEQLGYEQYF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	39	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-07	01	6	6	2	4	12	0	25	33	-1	45	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVSEQLGYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAATAGCACGACTAGCGGGAAAGACACCGAGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	87	1.2472063295004436E-4		52	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	2	2	3	10	6	10	25	37	54	43	64													Vb 4	X+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGGGTCCGATCACTCTGGAAACACCATATATTTTGGAGAG	CSVEGSDHSGNTIYF	In	VDJ	1	94	1.3475562640579507E-4	1.6165840890290694E-4	45	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-03	01	1	0	10	0	0	8	25	-1	40	38	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVEGSDHSGNTIYF+TCRBV29-01+TCRBJ01-03	TCRBV29-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTTCGGAGACCAGGGGCCGGGGCCAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSVVRRPGAGASSYNEQFF	In	VDJ	1	101	1.4479061986154577E-4	1.7369680105525106E-4	57	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	2	0	9	10	24	34	49	43	59													Vb 4	CSVVRRPGAGASSYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCACTAGGTCTAGGCGGGAGGACTGCAGATACGCAGTATTTTGGCCCA	CSALGLGGRTADTQYF	In	VDJ	1	113	1.619934657856898E-4	1.9433404474498387E-4	48	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	7	7	1	4	12	4	25	32	52	44	56													Vb 4	CSALGLGGRTADTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCAGGGGTCTTCCAGATACGCAGTATTTTGGCCCA	CSARGLPDTQYF	In	VDJ	1	134	1.920984461529419E-4	2.3044922120201626E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	7	4	2	4	1	5	25	32	39	33	44													Vb 4	CSARGLPDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTTACACAGGGGGGCATTATGGCTACACCTTCGGTTCG	CSVYTGGHYGYTF	In	VDJ	1	134	1.920984461529419E-4	2.3044922120201626E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	1	5	3	4	25	34	45	37	49													Vb 4	CSVYTGGHYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTTTATCAGGGTCGAACACTGAAGCTTTCTTTGGACAA	CSVLSGSNTEAFF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	3	1	4	2	25	34	43	38	45													Vb 4	CSVLSGSNTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTAGGGGACAGGGGGCGAAGTTGTGGCTACACCTTCGGTTCG		Out	VDJ	1	143	2.0500058059604994E-4		43	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	0	7	2	7	25	34	48	36	55													Vb 4	X+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCTTAGGGGACAGCTCCTACGAGCAGTACTTCGGGCCG	CSALGDSSYEQYF	In	VDJ	1	148	2.121684330644433E-4	2.545260055067045E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	5	0	6	0	25	32	-1	38	45													Vb 4	CSALGDSSYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTTCGGACAGGGACTATGGCTACACCTTCGGTTCG	CSVSDRDYGYTF	In	VDJ	1	159	2.2793770849490868E-4	2.734434788889596E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	3	3	2	0	25	34	-1	36	44													Vb 4	CSVSDRDYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTGAGTCTTGGGACAGGACTAAACACTGAAGCTTTCTTTGGACAA	CSVSLGTGLNTEAFF	In	VDJ	1	165	2.365391314569807E-4	2.8376210073382597E-4	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	4	2	7	4	25	33	48	40	52													Vb 4	CSVSLGTGLNTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGATGGGCCGGGGTACGACGAGCAGTACTTCGGGCCG	CSVDGPGYDEQYF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	39	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	8	3	5	5	4	25	36	46	41	50													Vb 4	CSVDGPGYDEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGGGGTCCAGCAGGATTCACAGATACGCAGTATTTTGGCCCA	CSVGGPAGFTDTQYF	In	VDJ	1	170	2.4370698392537407E-4	2.9236095227121465E-4	45	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-03	01	4	4	4	2	9	3	25	35	48	44	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVGGPAGFTDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCACAACTAGCGGGAGCTACGAGCAGTACTTCGGGCCG	CSTTSGSYEQYF	In	VDJ	1	177	2.5374197738112475E-4	3.043993444235588E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	8	3	2	3	3	0	25	31	-1	34	45													Vb 4	CSTTSGSYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCCGGGACGGTAAAGAGACCCAGTACTTCGGGCCA	CSVRDGKETQYF	In	VDJ	1	178	2.551755478748034E-4	3.061191147310365E-4	36	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-05	01	6	0	7	3	2	4	25	33	40	35	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVRDGKETQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGGGCGGGGAACTAATGAAAAACTGTTTTTTGGCAGT	CSGRGTNEKLFF	In	VDJ	1	185	2.652105413305541E-4	3.1815750688338066E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	7	7	3	1	1	0	25	32	-1	33	39													Vb 4	CSGRGTNEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGAACCGGGAGCCCTAACTATGGCTACACCTTCGGTTCG	CSVGTGSPNYGYTF	In	VDJ	1	190	2.723783937989475E-4	3.2675635842076934E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	4	8	2	0	4	2	25	35	45	39	47													Vb 4	CSVGTGSPNYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGGACACACCTATGGCTACACCTTCGGTTCG	CSVEGHTYGYTF	In	VDJ	1	199	2.852805282420555E-4	3.422342911880689E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	2	6	4	0	3	25	-1	42	38	45													Vb 4	CSVEGHTYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTGGGGGGGGGAACCCCTAGCACAGATACGCAGTATTTTGGCCCA	CSVGGGTPSTDTQYF	In	VDJ	1	205	2.938819512041275E-4	3.5255291303293534E-4	45	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	9	0	0	0	9	25	-1	40	33	49													Vb 4	CSVGGGTPSTDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTTAGCGGCACCTTGAACACTGAAGCTTTCTTTGGACAA	CSVVSGTLNTEAFF	In	VDJ	1	213	3.053505151535569E-4	3.663110754927572E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	4	5	5	0	1	5	25	35	42	36	47						01,02							Vb 4	CSVVSGTLNTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCGCCTTAGCGGTAGCCAAAAACATTCAGTACTTCGGCGCC	CSVALAVAKNIQYF	In	VDJ	1	217	3.110847971282716E-4	3.731901567226681E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	6	5	5	0	5	1	25	33	44	38	45						01,02							Vb 4	CSVALAVAKNIQYF+TCRBV29-01+TCRBJ02-04	TCRBV29-01*01	TCRBD02-01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGATGGAAGGGGAGGGGGTTCTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	2	255	3.6556047588806107E-4		52	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	3	9	0	0	6	6	25	36	49	42	55													Vb 4	X+TCRBV29-01+TCRBJ02-04	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGATCAGGCAGGCCTCTCTGGAAACAYCATATATTTTGGAGAG	CSVEDQAGLSGNXIYF	In	VDJ	2	257	3.684276168754184E-4	4.4198096902177744E-4	48	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	4	4	0	1	7	25	39	44	40	51													Vb 4	CSVEDQAGLSGNXIYF+TCRBV29-01+TCRBJ01-03	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGACAAGGTCAGCTCTGGAAACACCATATATTTTGGAGAG	CSVDKVSSGNTIYF	In	VDJ	2	292	4.186025841541719E-4	5.021729297834981E-4	42	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-03	01	3	4	5	0	6	0	25	36	-1	42	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVDKVSSGNTIYF+TCRBV29-01+TCRBJ01-03	TCRBV29-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTACAGGGGGTCTACAATGAGCAGTTCTTCGGGCCA	CSVQGVYNEQFF	In	VDJ	2	293	4.2003615464785056E-4	5.038927000909759E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	3	1	3	0	1	25	-1	41	33	42													Vb 4	CSVQGVYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGACGACAGGGAGGACAATGAGCAGTTCTTCGGGCCA	CSVDDREDNEQFF	In	VDJ	2	313	4.48707564521424E-4	5.382881062405305E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	2	3	5	1	3	25	36	44	37	47													Vb 4	CSVDDREDNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAGGTGGGTATAACCCCGGGGGTGTACAAAGAGACCCAGTACTTCGGGCCA	CSVEVGITPGVYKETQYF	In	VDJ	2	322	4.61609698964532E-4	5.537660390078301E-4	54	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	8	2	3	14	6	25	36	56	50	62													Vb 4	CSVEVGITPGVYKETQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCCGGGACTTTATATCCAATGAGCAGTTCTTCGGGCCA	CSARDFISNEQFF	In	VDJ	2	331	4.745118334076401E-4	5.692439717751298E-4	39	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	0	10	6	3	7	25	32	41	35	48						01,02							Vb 4	CSARDFISNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCTACGGACAGGGGGCGCCGGGCACCGGGGAGCTGTTTTTTGGAGAA	CSYGQGAPGTGELFF	In	VDJ	2	346	4.960153908128201E-4	5.950405263872958E-4	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	8	1	0	4	3	6	25	31	45	34	51													Vb 4	CSYGQGAPGTGELFF+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCTCCGGCCGACTAGCGCTCAATGAGCAGTTCTTCGGGCCA	CSSGRLALNEQFF	In	VDJ	2	377	5.404560761168589E-4	6.483534059191055E-4	39	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	2	6	6	7	2	25	31	46	38	48						01,02							Vb 4	CSSGRLALNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGACAGGACGGACAGATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	3	392	5.61959633522039E-4		44	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	1	5	0	6	1	25	36	48	42	49													Vb 4	X+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTTAAGACAGGCGTCACCGGGGAGCTGTTTTTTGGAGAA	CSVVKTGVTGELFF	In	VDJ	3	404	5.791624794461831E-4	6.947872042210042E-4	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	2	4	4	4	3	25	35	45	39	48													Vb 4	CSVVKTGVTGELFF+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGAACCCCTATATGGCTACAYCTTCGGTTCG	CSVEEPLYGYXF	In	VDJ	3	412	5.906310433956124E-4	7.085453666808261E-4	36	TCRBV29	TCRBV29-01	01	unresolved			TCRBJ01	TCRBJ01-02	01	0	4	9	5	4	0	25	39	-1	43	46				TCRBD01,TCRBD02									Vb 4	CSVEEPLYGYXF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	unresolved	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTGCAGGGTATGAACCTTGAAAAACTGTTTTTTGGCAGT	CSVQGMNLEKLFF	In	VDJ	3	466	6.680438500542606E-4	8.014129632846237E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	4	3	7	1	9	25	33	39	34	48													Vb 4	CSVQGMNLEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCCCTCAGGAGGGACAGGGTCACAATGAGCAGTTCTTCGGGCCA	CSVPQEGQGHNEQFF	In	VDJ	3	510	7.311209517761221E-4	8.77082856813644E-4	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	3	5	9	2	25	33	51	42	53													Vb 4	CSVPQEGQGHNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCCCCGGGACAGGGGGCTAGAGAGCAGTACTTCGGGCCG	CSVAPGQGAREQYF	In	VDJ	5	711	0.001019268621005535	0.0012227566886166684	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	0	7	4	4	25	35	51	39	55													Vb 4	CSVAPGQGAREQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTAATCTGATGGGCAAGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	10	1542	0.0022105657012525103		40	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	8	0	6	8	3	25	34	46	42	49													Vb 4	X+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGGCAGGCGCTATACAATGAGCAGTTCTTCGGGCCA	CSVGQALYNEQFF	In	VDJ	11	1734	0.0024858112360388153	0.0029820817131663894	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	4	4	2	5	25	35	41	37	46													Vb 4	CSVGQALYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGGACAGGCGGAACTAATGAAAAACTGTTTTTTGGCAGT	CSVGTGGTNEKLFF	In	VDJ	12	1753	0.00251304907541871	0.0030147573490084665	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	1	4	1	0	3	25	-1	42	35	45													Vb 4	CSVGTGGTNEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTTACGCAAACGGGCCGGGTTTAAATGAAAAACTGTTTTTTGGCAGT	CASSYANGPGLNEKLFF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	51	TCRBV06	unresolved					TCRBJ01	TCRBJ01-04	01	2	8	0	5	6	8	23	38	48	44	56		TCRBV06-05,TCRBV06-06,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYANGPGLNEKLFF+TCRBV06-X+TCRBJ01-04	unresolved		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTCRGCYGTGTATCTCTGTGCCAGCAGCTCCAGGGGGTTAGGAAAACTGTTTTTTGGCAGT	CASSSRGLGKLFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	39	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	4	1	10	1	5	18	31	39	32	44		TCRBV07-02,TCRBV07-04												CASSSRGLGKLFF+TCRBV07-X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTCRGCYGTGTATCTCTGTGCCAGCAGCCAAGGGGGTTTCTACGAGCAGTACTTCGGGCCG	CASSQGGFYEQYF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	39	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	5	1	3	2	3	22	34	42	36	45		TCRBV07-02,TCRBV07-04												CASSQGGFYEQYF+TCRBV07-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTWTACTTCTGTGCCAGCAGCGGGGGGAACCCCTACGAGCAGTACTTCGGGCCG	CASSGGNPYEQYF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	39	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	8	1	2	0	4	26	-1	44	37	48		TCRBV06-07,TCRBV06-09												CASSGGNPYEQYF+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTGACCACGAGGACTAGCGGGGGACGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	48	6.881138369657621E-5		50	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	1	2	8	5	3	28	43	61	48	64		TCRBV06-04,TCRBV06-08												X+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGGGGGACTTACACCTCCTACGAGCAGTACTTCGGGCCG	CASRGTYTSYEQYF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	42	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	10	0	1	5	23	34	41	35	46		TCRBV06-07,TCRBV06-08				01,02								CASRGTYTSYEQYF+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATCTCTGTGCCAGCAGCTTGCACAGCGGGGGGGCCGATGAGCAGTTCTTCGGGCCA	CASSLHSGGADEQFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	45	TCRBV07	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	6	0	8	4	3	19	33	47	37	50		TCRBV07-02,TCRBV07-05												CASSLHSGGADEQFF+TCRBV07-X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTCRGCYGTGTATCTCTGTGCCAGCAGCGATGGACCTTCCAATGAGCAGTTCTTCGGGCCA	CASSDGPSNEQFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	39	TCRBV07	unresolved					TCRBJ02	TCRBJ02-01	01	5	1	7	6	3	4	18	30	37	33	41		TCRBV07-02,TCRBV07-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDGPSNEQFF+TCRBV07-X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTYGGCYGTGTATCTCTGTGCCAGCAGCATCAAGCCCTCGAATGAGCAGTTCTTCGGGCCA	CASSIKPSNEQFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	39	TCRBV07	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	6	7	7	4	5	22	34	41	38	46		TCRBV07-01,TCRBV07-02				01,02								CASSIKPSNEQFF+TCRBV07-X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYRTGTATCKCTGTGCCAGCAGCTCCACATTAGGAACTAGCACAGATACGCAGTATTTTGGCCCA	CASSSTLGTSTDTQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	48	TCRBV07	unresolved					TCRBJ02	TCRBJ02-03	01	3	1	8	0	8	3	19	32	43	40	46		TCRBV07-05,TCRBV07-06		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSTLGTSTDTQYF+TCRBV07-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGGACTCSGCCGTGTATCTCTGTGCCAGCAGCTTAGCTGGCGCAGATACGCAGTATTTTGGCCCA	CASSLAGADTQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	39	TCRBV07	unresolved					TCRBJ02	TCRBJ02-03	01	0	9	0	4	1	1	18	35	39	36	40		TCRBV07-02,TCRBV07-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAGADTQYF+TCRBV07-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACTCTACCTTCGACAGGGCGGCGAATCAGCCCCAGCATTTTGGTGAT	CASSYSTFDRAANQPQHF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	54	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	2	3	4	7	5	23	40	54	47	59		TCRBV06-07,TCRBV06-08												CASSYSTFDRAANQPQHF+TCRBV06-X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACTCGGGGGGGTCTGAAGCTTTCTTTGGACAA	CASSYSGGSEAFF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	39	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	9	0	6	0	1	26	-1	50	43	51		TCRBV06-07,TCRBV06-08												CASSYSGGSEAFF+TCRBV06-X+TCRBJ01-01	unresolved	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGAAGGACAGGGCATCTTAGAAGCTTTCTTTGGACAA	CASSEGQGILEAFF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	3	8	3	7	26	38	49	41	56		TCRBV06-01,TCRBV06-07												CASSEGQGILEAFF+TCRBV06-X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACCCCGGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSYPGGTGELFF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	2	8	2	4	2	0	26	41	-1	43	49		TCRBV06-07,TCRBV06-08												CASSYPGGTGELFF+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGAAAAGGTCACCACTGAAGCTTTCTTTGGACAA	CASSEKVTTEAFF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	39	TCRBV06	unresolved					TCRBJ01	TCRBJ01-01	01	2	5	4	4	1	4	23	38	42	39	46		TCRBV06-01,TCRBV06-07,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEKVTTEAFF+TCRBV06-X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTTACCCGAGGACAGGTGCCCGGAGGCAGTACTTCGGGCCG	CASSYPRTGARRQYF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	45	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	4	9	7	9	28	40	54	47	63		TCRBV06-04,TCRBV06-08												CASSYPRTGARRQYF+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTWTACTTCTGTGCCAGCAGCCCCGCGGCCAGTAATTCACCCCTCCACTTTGGGAAC	CASSPAASNSPLHF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	42	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	6	7	5	6	4	4	26	37	45	41	49		TCRBV06-07,TCRBV06-09				01,02								CASSPAASNSPLHF+TCRBV06-X+TCRBJ01-06	unresolved	TCRBD02-01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGGGGACACACCTATGGCTACACCTTCGGTTCG	CASRGHTYGYTF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	36	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	6	4	0	3	23	-1	40	34	43		TCRBV06-07,TCRBV06-08												CASRGHTYGYTF+TCRBV06-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACCCAAGCGGGAGTGTCACCGGGGAGCTGTTTTTTGGAGAA	CASSYPSGSVTGELFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	48	TCRBV06	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	2	6	2	4	3	3	23	38	49	41	52		TCRBV06-07,TCRBV06-08												CASSYPSGSVTGELFF+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGAAGCGGCAGGACAGGGTGGGTGGGATACGCAGTATTTTGGCCCA	CASSEAAGQGGWDTQYF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	51	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	1	3	6	4	7	23	40	52	44	59		TCRBV06-01,TCRBV06-07												CASSEAAGQGGWDTQYF+TCRBV06-X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGATGGAGGGAAGGGGGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	87	1.2472063295004436E-4		44	TCRBV10	unresolved					TCRBJ01	TCRBJ01-01	01	3	5	1	4	8	0	23	37	-1	45	51		TCRBV10-01,TCRBV10-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV10-X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCCCCCGAGGCAGGGTCGGGGGGCTACACCTTCGGTTCG		Out	VDJ	1	93	1.333220559121164E-4		40	TCRBV10	unresolved					TCRBJ01	TCRBJ01-02	01	8	4	3	8	8	6	26	35	48	43	54		TCRBV10-01,TCRBV10-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV10-X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCACTCCTCGTACAGGGAGGGAGGAGCAGTTCTTCGGGCCA	CASTPRTGREEQFF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	42	TCRBV12	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	12	9	0	10	16	2	26	31	54	47	56		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASTPRTGREEQFF+TCRBV12-X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTYRGCTGTGTATCTCTGTGCCAGCAGCCCAATGACAGGGAACGAGCAGTTCTTCGGGCCA	CASSPMTGNEQFF	In	VDJ	1	107	1.5339204282361778E-4	1.8401542290011745E-4	39	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	2	3	10	5	3	22	34	46	39	49		TCRBV07-01,TCRBV07-04												CASSPMTGNEQFF+TCRBV07-X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGCCGACAGGGGACGGACCAGGGGCTACACCTTCGGTTCG	CASSADRGRTRGYTF	In	VDJ	1	108	1.5482561331729645E-4	1.8573519320759518E-4	45	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	2	8	3	10	23	35	46	38	56		TCRBV06-07,TCRBV06-08												CASSADRGRTRGYTF+TCRBV06-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAAACCGGGACGCCTAACCTACGAGCAGTACTTCGGGCCG	CASKPGRLTYEQYF	In	VDJ	1	112	1.6055989529201113E-4	1.9261427443750614E-4	42	TCRBV12	unresolved					TCRBJ02	TCRBJ02-07	01	12	0	7	2	9	6	26	31	45	40	51		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASKPGRLTYEQYF+TCRBV12-X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCCGCAGGGGGGCAGCGGAGACCCAGTACTTCGGGCCA	CASRRGAAETQYF	In	VDJ	1	122	1.7489560022879784E-4	2.0981197751228345E-4	39	TCRBV12	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	8	4	1	5	2	6	22	31	40	33	46		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRRGAAETQYF+TCRBV12-X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCACCCCCGGGGGCCTCAAAAACATTCAGTACTTCGGCGCC	CASTPGGLKNIQYF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	42	TCRBV12	unresolved					TCRBJ02	TCRBJ02-04	01	12	6	0	3	10	2	26	31	47	41	49		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTPGGLKNIQYF+TCRBV12-X+TCRBJ02-04	unresolved		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTTCTGCGCCAGCAGTGAGATCATAAGGACAGGGTAAATTGTAACCTTACTTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	143	2.0500058059604994E-4		65	TCRBV10	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	1	3	4	7	17	4	19	34	26	51		TCRBV10-01,TCRBV10-02												X+TCRBV10-X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGCCCGACTAGCGGGGGAATCACAGATACGCAGTATTTTGGCCCA	CASSPTSGGITDTQYF	In	VDJ	1	152	2.1790271503915797E-4	2.614050867366155E-4	48	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	2	2	2	3	3	26	37	52	40	55		TCRBV06-07,TCRBV06-08												CASSPTSGGITDTQYF+TCRBV06-X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTGCGGCTAGCGGGGGGGCTTACAATGAGCAGTTCTTCGGGCCA	CASSAASGGAYNEQFF	In	VDJ	1	155	2.22203426520194E-4	2.6656439765904865E-4	48	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	4	0	4	4	2	23	35	51	39	53		TCRBV06-04,TCRBV06-08												CASSAASGGAYNEQFF+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGTAGTGGGAAGGGGATCCTGTTCTACGAGCAGTACTTCGGGCCG	CASSGKGILFYEQYF	In	VDJ	1	183	2.6234340034319675E-4	3.147179662684252E-4	45	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	5	2	3	4	8	23	35	44	39	52		TCRBV06-07,TCRBV06-08												CASSGKGILFYEQYF+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCATACTGGAACAGGGGGACAACCTCATTCTTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	197	2.8241338725469817E-4		50	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	3	1	4	7	13	23	30	45	37	58		TCRBV06-07,TCRBV06-08												X+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGTGGGACAGGGCACCTATGAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	204	2.9244838071044885E-4		46	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	0	3	7	2	8	26	38	49	40	57		TCRBV06-07,TCRBV06-08												X+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTATGACCCGATGGATACGCAGTATTTTGGCCCA	CASSYDPMDTQYF	In	VDJ	2	237	3.39756207001845E-4	4.075855628722228E-4	39	TCRBV06	unresolved					TCRBJ02	TCRBJ02-03	01	3	2	7	6	1	6	23	37	41	38	47		TCRBV06-07,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYDPMDTQYF+TCRBV06-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCGGGAACTAGCGGGGACTGTACCAAGAGACCCAGTACTTCGGGCCA	CAGN*RGLYQETQYF	Stop	VDJ	2	342	4.902811088381055E-4		45	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	11	3	3	0	4	5	26	32	46	36	51		TCRBV06-07,TCRBV06-08												CAGN*RGLYQETQYF+TCRBV06-X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCACCAAGACAGAAAGGGGAGACCCAGTACTTCGGGCCA		Out	VDJ	5	729	0.0010450728898917512		40	TCRBV10	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	2	5	5	4	6	26	36	45	40	51		TCRBV10-01,TCRBV10-02												X+TCRBV10-X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGGGAGACATCCTCTGGCGAGCAGTACTTCGGGCCG	CASRETSSGEQYF	In	VDJ	9	1305	0.0018708094942506655	0.002244300251258442	39	TCRBV10	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	3	6	6	0	8	26	-1	44	41	52		TCRBV10-01,TCRBV10-02												CASRETSSGEQYF+TCRBV10-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTTCTGCGCCAGCGGATCCTCCTTATTTAGCCGAGACACCGGCGCCATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	15	2301	0.003298645705954622		65	TCRBV10	unresolved					TCRBJ01	TCRBJ01-05	01	8	2	6	0	21	9	4	13	38	34	47		TCRBV10-01,TCRBV10-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV10-X+TCRBJ01-05	unresolved		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTAATCCCGTCTTCTAGCACAGATACGCAGTATTTTGGCCCA	CASSLIPSSSTDTQYF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	48	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	4	10	0	8	3	19	33	43	41	46						01,02							Vb 5.1	CASSLIPSSSTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCCATCAGGGCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	43	6.164353122818285E-5		41	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	4	3	4	4	0	19	32	-1	36	41													Vb 5.1	X+TCRBV05-01+TCRBJ02-02	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCTGTAGGCCAAACCGAGACCCAGTACTTCGGGCCA	CASSSVGQTETQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	42	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-05	01	3	5	4	5	4	7	19	32	39	36	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSSVGQTETQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTACAGGGGTTCGAAACTGAAGCTTTCTTTGGACAA	CASSLQGFETEAFF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	3	2	5	0	6	19	-1	40	33	46													Vb 5.1	CASSLQGFETEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGCCCAGCGGGAGTTCGGACGAGCAGTACTTCGGGCCG	CASSLPSGSSDEQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	6	2	5	3	5	19	34	45	37	50													Vb 5.1	CASSLPSGSSDEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGCTGGGGAGGTGTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	44	6.307710172186152E-5		47	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	1	9	1	1	3	2	19	34	43	37	45													Vb 5.1	X+TCRBV05-01+TCRBJ01-03	TCRBV05-01*01	TCRBD02-01*02	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCAGGGACAGTGAACACTGAAGCTTTCTTTGGACAA	CASSLAGTVNTEAFF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	5	0	2	0	19	35	-1	37	44													Vb 5.1	CASSLAGTVNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGTCGCACGGACTAGCGGCAGCTTTCTTTGGACAA	CASSLSHGLAAAFF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	1	5	10	6	1	19	34	50	40	51						01,02							Vb 5.1	CASSLSHGLAAAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGAGAATAGGACTGAACACTGAAGCTTTCTTTGGACAA	CASSLRIGLNTEAFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	45	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-01	01	1	1	7	0	6	0	19	34	-1	40	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLRIGLNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCAGGGGATAATTCACCCCTCCACTTTGGGAAC	CASSLAGDNSPLHF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	4	2	5	0	0	19	-1	-1	35	41													Vb 5.1	CASSLAGDNSPLHF+TCRBV05-01+TCRBJ01-06	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCCGGACAGACAAGCACAGATACGCAGTATTTTGGCCCA	CASSSGQTSTDTQYF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	1	5	0	2	3	19	32	40	34	43													Vb 5.1	CASSSGQTSTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCTTCGGCGGGGGATAGGGACCCAGTACTTCGGGCCA	CASSLRRGIGTQYF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	4	7	2	7	5	5	19	31	43	36	48													Vb 5.1	CASSLRRGIGTQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGGGGAGCGGACACAAACACTGAAGCTTTCTTTGGACAA	CASRGADTNTEAFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	42	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-01	01	5	1	6	2	6	2	19	30	41	36	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASRGADTNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTAACAGGGGGCAGAGTCGAGACCCAGTACTTCGGGCCA	CASSLTGGRVETQYF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	3	0	5	1	6	19	33	43	34	49													Vb 5.1	CASSLTGGRVETQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGGAAGTCAGGACAGGGCAAGTGAAGCTTTCTTTGGACAA		Out	VDJ	1	51	7.311209517761221E-5		40	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	1	3	7	7	4	19	27	42	34	46													Vb 5.1	X+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCTTTTCGGGGGCGGGTTGAAAAACTGTTTTTTGGCAGT	CASSLAFRGRVEKLFF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	48	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-04	01	0	6	0	7	6	4	19	35	47	41	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLAFRGRVEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTCGGGGGGGCCTCCTACGAGCAGTACTTCGGGCCG	CASSFGGASYEQYF	In	VDJ	1	54	7.741280665864823E-5	9.286759660379759E-5	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	8	0	0	0	1	19	-1	41	33	42													Vb 5.1	CASSFGGASYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGGGCGCGGTGGCCTGGAAACACCATATATTTTGGAGAG	CASSLGARWPGNTIYF	In	VDJ	1	54	7.741280665864823E-5	9.286759660379759E-5	48	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-03	01	0	8	0	2	0	8	19	-1	39	35	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLGARWPGNTIYF+TCRBV05-01+TCRBJ01-03	TCRBV05-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGGGTTCGGCCCCCCTAGGGACACAGATACGCAGTATTTTGGCCCA	CASSGFGPPRDTDTQYF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	51	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-03	01	4	0	8	2	16	0	19	31	-1	47	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSGFGPPRDTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCTATTCGGCCTAGTAAAGCGGGGAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	58	8.314708863336292E-5		49	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	7	6	3	3	15	1	19	28	50	43	51													Vb 5.1	X+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGCCCTTACAGCTATTGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSLPLQLLGYNEQFF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	3	5	3	5	8	19	34	43	39	51													Vb 5.1	CASSLPLQLLGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGTGGGGCCCCGAGAATGAGGAAGCTTTCTTTGGACAA	CASSLWGPENEEAFF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	7	0	8	1	12	19	34	40	35	52													Vb 5.1	CASSLWGPENEEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGACTAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	62	8.88813706080776E-5		44	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	2	8	0	0	0	19	-1	-1	35	41						01,02							Vb 5.1	X+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTCGGGGAGAGCACAGATACGCAGTATTTTGGCCCA	CASSFGESTDTQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	8	3	0	0	2	19	-1	38	33	40						01,02							Vb 5.1	CASSFGESTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCCTCCCAGGGACAGGGATATCTGAAGCTTTCTTTGGACAA	CASSLALPGTGISEAFF	In	VDJ	1	64	9.174851159543494E-5	1.1006529967857494E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	3	6	8	4	19	35	52	43	56													Vb 5.1	CASSLALPGTGISEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGTTCTGACCTAAGCGCAAACATTCAGTACTTCGGCGCC	CASSSDLSANIQYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	5	6	6	6	10	1	19	30	44	40	45						01,02							Vb 5.1	CASSSDLSANIQYF+TCRBV05-01+TCRBJ02-04	TCRBV05-01*01	TCRBD02-01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCCGCTCGGATGTGGGGAACACTGAAGCTTTCTTTGGACAA	CASRSDVGNTEAFF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	42	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-01	01	3	0	9	1	7	0	19	32	-1	39	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASRSDVGNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGCGGAAATCTCAACAGGGAGGCTGGCCAAAAACATTCAGTACTTCGGCGCC	CASSAEISTGRLAKNIQYF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	57	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-04	01	4	3	3	1	12	6	19	31	49	43	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSAEISTGRLAKNIQYF+TCRBV05-01+TCRBJ02-04	TCRBV05-01*01		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCGACAGGTTCTACGAGCAGTACTTCGGGCCG	CASSLADRFYEQYF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	2	4	3	2	2	19	35	43	37	45													Vb 5.1	CASSLADRFYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCAGAGGCCTGGGTTACACCGGGGAGCTGTTTTTTGGAGAA	CASSRGLGYTGELFF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	11	1	3	1	8	19	31	36	32	44													Vb 5.1	CASSRGLGYTGELFF+TCRBV05-01+TCRBJ02-02	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCGGCCCTTTATCTTTGCGCCAGCAGCTTGACACCGCGACAGTCAACCGACTCGACGACACCCGATGGGAAGCTTTCTTTGGACAA		Out	VDJ	1	72	1.0321707554486431E-4		65	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	5	8	7	26	16	31	43	38	69													Vb 5.1	X+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCCCGCCTTCCAATGAGCAGTTCTTCGGGCCA	CASSLAPPSNEQFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	42	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-01	01	0	10	0	6	4	4	19	35	41	39	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLAPPSNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGTGAAGGGTACAATGAGCAGTTCTTCGGGCCA	CASSLGEGYNEQFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	42	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-01	01	0	5	3	4	4	0	19	35	-1	39	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLGEGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCGGCACAGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSLAGTGGYNEQFF	In	VDJ	1	77	1.1038492801325766E-4	1.3242231367578547E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	3	1	3	5	0	19	35	-1	40	48													Vb 5.1	CASSLAGTGGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGACCCGGGATATAGGGGAGCAGTACTTCGGGCCG	CASSLTRDIGEQYF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	8	3	7	3	7	19	34	42	37	49													Vb 5.1	CASSLTRDIGEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCCCCGCCCGGGGCCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPPPGASYNEQFF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	48	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-01	01	4	7	0	0	9	0	19	31	-1	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSPPPGASYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCACAAACAGGGAGAAGCGAGACCCAGTACTTCGGGCCA	CASSSQTGRSETQYF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	3	3	5	5	6	19	32	43	37	49													Vb 5.1	CASSSQTGRSETQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGGTACAGTAATGAAAAACTGTTTTTTGGCAGT	CASSLGYSNEKLFF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	3	5	4	3	0	19	35	-1	38	42													Vb 5.1	CASSLGYSNEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGAGGCATTCATCTCCTACGAGCAGTACTTCGGGCCG	CASSLEAFISYEQYF	In	VDJ	1	83	1.1898635097532968E-4	1.4274093552065186E-4	45	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-07	01	0	5	4	0	0	7	19	-1	38	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLEAFISYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGGGGGACAGGGAAAATCTCTGAAGCTTTCTTTGGACAA	CASRGTGKISEAFF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	3	6	1	7	19	30	40	31	47													Vb 5.1	CASRGTGKISEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGGGAAAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLGESSYNEQFF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	45	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-01	01	0	0	8	0	0	3	19	-1	39	35	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLGESSYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTAGACAGGGGAGACACAGATACGCAGTATTTTGGCCCA	CASSLDRGDTDTQYF	In	VDJ	1	89	1.275877739374017E-4	1.5305955736551825E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	2	2	2	1	3	19	33	42	34	45													Vb 5.1	CASSLDRGDTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGATTGGGGTTAGGGACAGGTGGGGAGACCCAGTACTTCGGGCCA	CASRLGLGTGGETQYF	In	VDJ	1	90	1.290213444310804E-4	1.5477932767299599E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	0	4	5	5	4	19	35	48	40	52													Vb 5.1	CASRLGLGTGGETQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGGGGGACAGGGGGCAGCTAATGAAAAACTGTTTTTTGGCAGT	CASSGGQGAANEKLFF	In	VDJ	1	92	1.318884854184377E-4	1.5821886828795145E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	0	0	3	2	2	19	31	45	33	47													Vb 5.1	CASSGGQGAANEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCCCGAGAGTCAGGGCCGACAGATACGCAGTATTTTGGCCCA	CASSPRESGPTDTQYF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	4	3	3	10	3	19	31	46	41	49													Vb 5.1	CASSPRESGPTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGAGTGGGAGGGGGGCCTGGAGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	100	1.433570493678671E-4		52	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	9	0	6	3	10	19	35	45	38	55													Vb 5.1	X+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGACAACAGGCTGACTGAAGCTTTCTTTGGACAA	CASSLDNRLTEAFF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	4	5	3	3	19	35	43	38	46													Vb 5.1	CASSLDNRLTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCATACAGGGACTAGCGGGAGAGACCCAGTACTTCGGGCCA	CASSIQGLAGETQYF	In	VDJ	1	131	1.8779773467190588E-4	2.2528991027958307E-4	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	0	4	4	5	0	19	31	-1	36	48						01,02							Vb 5.1	CASSIQGLAGETQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGCGGCGGGACAGGGGTATGGCTACACCTTCGGTTCG	CASSAAGQGYGYTF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	0	2	5	5	0	19	31	-1	36	46													Vb 5.1	CASSAAGQGYGYTF+TCRBV05-01+TCRBJ01-02	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGATGGGTACGGGGGGACTGAAGCTTTCTTTGGACAA	CASSLDGYGGTEAFF	In	VDJ	1	152	2.1790271503915797E-4	2.614050867366155E-4	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	8	1	5	7	0	19	35	-1	42	49													Vb 5.1	CASSLDGYGGTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTGGGGCGGGGGAGGTAATGAGCAGTTCTTCGGGCCA	CASSWGGGGNEQFF	In	VDJ	1	173	2.4800769540641004E-4	2.975202631936479E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	7	2	7	3	4	19	32	42	35	46													Vb 5.1	CASSWGGGGNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGAACACCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	214	3.0678408564723556E-4		43	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	3	6	0	1	1	19	35	39	36	40													Vb 5.1	X+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCCGGACAGGTGATCTACAATGAGCAGTTCTTCGGGCCA	CASSSGQVIYNEQFF	In	VDJ	2	229	3.2828764305241565E-4	3.938274004124009E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	1	4	3	2	4	19	32	41	34	45													Vb 5.1	CASSSGQVIYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGTCGATGCGGGCACAGATACGCAGTATTTTGGCCCA	CASSLVDAGTDTQYF	In	VDJ	2	280	4.0139973823002787E-4	4.815356860937653E-4	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	7	5	1	5	0	19	35	-1	40	44						01,02							Vb 5.1	CASSLVDAGTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTTTACAGGCCCTATACTGAGCGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSFYRPYTERVNTEAFF	In	VDJ	3	404	5.791624794461831E-4	6.947872042210042E-4	57	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	2	6	4	0	17	0	19	33	-1	50	56						01,02							Vb 5.1	CASSFYRPYTERVNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGATGGGACAGGCCTATTCGAGCAGTACTTCGGGCCG	CASSLDGTGLFEQYF	In	VDJ	3	437	6.264703057375792E-4	7.515396243677695E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	4	6	2	6	19	35	45	37	51													Vb 5.1	CASSLDGTGLFEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGAACGTGATCTAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLERDLNTGELFF	In	VDJ	4	658	9.432893848405655E-4	0.0011316088623203485	48	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	4	9	2	8	0	19	35	-1	43	46						01,02							Vb 5.1	CASSLERDLNTGELFF+TCRBV05-01+TCRBJ02-02	TCRBV05-01*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCGAGGAGGGTTGGGGCGGCGATGGCTACACCTTCGGTTCG	CASEEGWGGDGYTF	In	VDJ	5	696	9.977650636003549E-4	0.0011969601340045023	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	7	10	0	6	2	11	19	28	36	30	47													Vb 5.1	CASEEGWGGDGYTF+TCRBV05-01+TCRBJ01-02	TCRBV05-01*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCGGCAGAGCAGGGTAGCTACGAGCAGTACTTCGGGCCG	CASSSAEQGSYEQYF	In	VDJ	11	1733	0.0024843776655451367	0.0029803619428589116	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	3	3	8	3	19	32	45	40	48													Vb 5.1	CASSSAEQGSYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGTAGCGGGGCCGACACAGATACGCAGTATTTTGGCCCA	CASSRSGADTDTQYF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	5	3	2	3	4	25	36	47	39	51													Vb 3	CASSRSGADTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCCTGGGACAGGGGCACTCCTACGAGCAGTACTTCGGGCCG	CASSSLGQGHSYEQYF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	2	0	4	2	25	38	52	42	54													Vb 3	CASSSLGQGHSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATGACAGCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	42	6.020996073450418E-5		41	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	3	5	0	0	0	25	-1	-1	42	46													Vb 3	X+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGTCCCCTAGCGTAAACTTATACAAAAAAGTTTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	45	6.45106722155402E-5		59	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	4	6	4	5	20	22	35	46	40	66						01,02							Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCGACATCGTCAATGAGCAGTTCTTCGGGCCA	CASSSDIVNEQFF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	2	6	6	2	4	25	38	44	40	48													Vb 3	CASSSDIVNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCCGATGGTCCGGACAGGGGGAGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	47	6.737781320289753E-5		53	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	1	2	12	2	25	37	59	49	61													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCGGGGACAGCCTGAACACTGAAGCTTTCTTTGGACAA	CASSPGDSLNTEAFF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	0	4	2	25	37	48	41	50													Vb 3	CASSPGDSLNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTACCTAGGCGGAACGTCTACGCAGTATTTTGGCCCA	CASSYLGGTSTQYF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	4	8	8	2	10	25	38	44	40	54						01,02							Vb 3	CASSYLGGTSTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCCCCCGGACAGGGTCGAGACCCAGTACTTCGGGCCA	CASTPPDRVETQYF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	1	3	5	7	2	25	35	50	42	52													Vb 3	CASTPPDRVETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGGCTGCCCGGGACAGCGAGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	50	7.167852468393355E-5		50	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	5	2	9	4	25	38	54	47	58													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCCTCCCCGGTCGGGAGCAGTACTTCGGGCCG	CASSPLPGREQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	8	5	7	8	4	25	37	48	45	52						01,02							Vb 3	CASSPLPGREQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACATATCGCTCTAGGTGAAGCTTTCTTTGGACAA	CASSLHIALGEAFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	2	4	8	7	9	1	25	40	53	49	54						01,02							Vb 3	CASSLHIALGEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAAGGACAGGTGCTTACGAGCAGTACTTCGGGCCG	CASSLRTGAYEQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	4	4	1	4	25	40	48	41	52													Vb 3	CASSLRTGAYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCCGGCCAGGAGACCCAGTACTTCGGGCCA	CASSPGQETQYF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	36	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-05	01	6	4	5	5	7	0	25	36	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSPGQETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCTTCCCCTCGGACAGGGAGAGACCCAGTACTTCGGGCCA	CASSLPLGQGETQYF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	1	3	4	9	0	25	37	-1	46	54													Vb 3	CASSLPLGQGETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTGTCGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSFVATNEKLFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	3	8	6	0	3	0	25	39	-1	42	44						01,02							Vb 3	CASSFVATNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCTCCGCGACAGGGGAGAGACCCAGTACTTCGGGCCA	CASSLRDRGETQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	2	2	4	6	0	25	37	-1	43	51													Vb 3	CASSLRDRGETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCTCGGGGGGAGCGCACTCGGTCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	63	9.031494110175626E-5		52	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	8	1	4	3	12	25	38	48	41	60													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCACTAGAGGTCCCGAAATTCCACCCCTCCACTTTGGGAAC	CASSTRGPEIPPLHF	In	VDJ	1	64	9.174851159543494E-5	1.1006529967857494E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	6	3	8	11	1	14	25	36	42	37	56						01,02							Vb 3	CASSTRGPEIPPLHF+TCRBV28-01+TCRBJ01-06	TCRBV28-01*01	TCRBD02-01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCTCGGGGGGGGTCTCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	64	9.174851159543494E-5		46	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	5	8	0	3	3	4	25	37	48	40	52													Vb 3	X+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGCTCACGGAACACTGAAGCTTTCTTTGGACAA	CASSRSRNTEAFF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	5	3	7	1	5	1	25	37	44	42	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSRSRNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAACCCAGGGGATGAGGGGTTCATACTTCGGGCCG	CASSLTQGMRGSYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	2	13	3	12	25	40	49	43	61													Vb 3	CASSLTQGMRGSYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGGAACTTCCACAGATACGCAGTATTTTGGCCCA	CASGTSTDTQYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	36	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-03	01	8	1	8	2	0	5	25	-1	37	34	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASGTSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCCAGGTTGGGACTCGGAACTGAAGCTTTCTTTGGACAA	CASSPRLGLGTEAFF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	0	10	5	9	4	25	36	51	45	55						01,02							Vb 3	CASSPRLGLGTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTTGCGGGAACCGGGGAGCTGTTTTTTGGAGAA	CASSLFAGTGELFF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	1	7	3	5	2	0	25	41	-1	43	49													Vb 3	CASSLFAGTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCAATGGACAGGTCTACGAGCAGTACTTCGGGCCG	CASSNGQVYEQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	4	3	4	1	25	36	47	40	48													Vb 3	CASSNGQVYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCAGGCCAAGAGACCCAGTACTTCGGGCCA	CASSPGQETQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	4	4	1	2	0	25	36	-1	38	42													Vb 3	CASSPGQETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCCTCACAGGGATTCCACAAGATACGCAGTATTTTGGCCCA	CASSFLTGIPQDTQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	3	3	5	4	8	25	39	49	43	57													Vb 3	CASSFLTGIPQDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTGAGATCCCCTACGAGCAGTACTTCGGGCCG	CASSFEIPYEQYF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	11	2	2	1	4	25	39	43	40	47													Vb 3	CASSFEIPYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCCCCCCTTTAGCGGGAGTCTCGGGGGGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	76	1.0895135751957899E-4		56	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	5	2	6	10	10	25	36	55	46	65													Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACAGGGGTGGGGCTACACCTTCGGTTCG	CASSLQGWGYTF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	2	8	0	3	25	-1	46	40	49													Vb 3	CASSLQGWGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTCGGGCGGGAGTAGGTCCCAATGAGCAGTTCTTCGGGCCA	CASSFRAGVGPNEQFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	7	2	6	4	7	25	39	50	43	57													Vb 3	CASSFRAGVGPNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGAGACAGGGAGGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSETGRNTGELFF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	2	3	1	2	2	25	37	46	39	48													Vb 3	CASSETGRNTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAAGGGGACAGGGGTATGGCTACACCTTCGGTTCG	CASSLRGQGYGYTF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	0	2	5	2	0	25	40	-1	42	52													Vb 3	CASSLRGQGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCCCGCGGAGAAGCTTTCTTTGGACAA	CASSLSRGEAFF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	7	5	8	3	1	25	41	48	44	49						01,02							Vb 3	CASSLSRGEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCGCGGGTGGGAGTACGAGCAGTACTTCGGGCCG	CASRGWEYEQYF	In	VDJ	1	80	1.1468563949429368E-4	1.3758162459821867E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	8	7	4	4	1	6	25	34	40	35	46						01,02							Vb 3	CASRGWEYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGTATCGGACAGGGGGCGACAGCCCCAGCATTTTGGTGAT	CASRVSDRGRQPQHF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	1	0	7	6	2	25	36	53	42	55													Vb 3	CASRVSDRGRQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGACCCACAGGGTTTAATGGCTACACCTTCGGTTCG	CASRPTGFNGYTF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	3	6	4	4	25	36	46	40	50													Vb 3	CASRPTGFNGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGCAGGGGGATGGCGCGAGCAGTACTTCGGGCCG	CASSAGGWREQYF	In	VDJ	1	83	1.1898635097532968E-4	1.4274093552065186E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	1	6	1	6	25	37	45	38	51													Vb 3	CASSAGGWREQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCGCCACCCTGGGGGCCGATCAGCCCCAGCATTTTGGTGAT	CASSATLGADQPQHF	In	VDJ	1	89	1.275877739374017E-4	1.5305955736551825E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	6	0	5	9	2	25	36	51	45	53													Vb 3	CASSATLGADQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCAGGCAGGGGGGGGAAAGGAAAAGACCCAGTACTTCGGGCCA	CASSQAGGGKEKTQYF	In	VDJ	1	91	1.3045491492475906E-4	1.5649909798047372E-4	48	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-05	01	5	4	1	6	4	11	25	37	48	41	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSQAGGGKEKTQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCCGCCCATAGCACAGATACGCAGTATTTTGGCCCA	CASSLSAHSTDTQYF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-03	01	1	4	6	0	5	1	25	41	48	46	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLSAHSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGTGCCAGCAGTTCAGGTTAGAACGGGCAGGAAACAGGGGCTTCCATCTGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	95	1.3618919689947374E-4		67	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	3	2	5	20	10	0	13	40	33	50													Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCGACAGGAAAGGACTGAAGCTTTCTTTGGACAA	CASTRQERTEAFF	In	VDJ	1	97	1.3905633788683107E-4	1.6681771982534013E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	2	4	5	3	5	25	35	44	38	49													Vb 3	CASTRQERTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGCCGGGACTAGCCGCTACGAGCAGTACTTCGGGCCG	CASSLAGTSRYEQYF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	0	7	3	3	2	25	40	52	43	54						01,02							Vb 3	CASSLAGTSRYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAATGTGACAAGTCCTCAGCCCCAGCATTTTGGTGAT	CANVTSPQPQHF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	10	2	6	6	4	5	25	32	40	36	45													Vb 3	CANVTSPQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTAGAGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLLESNQPQHF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	1	5	8	1	0	2	25	-1	44	41	46						01,02							Vb 3	CASSLLESNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAACACTCTAGCGGGAGAGTACTCCTACGAGCAGTACTTCGGGCCG	CASNTLAGEYSYEQYF	In	VDJ	1	101	1.4479061986154577E-4	1.7369680105525106E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	4	2	0	5	4	25	35	50	40	54													Vb 3	CASNTLAGEYSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCTTACCCTGGAGGGGCACAGTACGTTCCGGGGTTCG	CASSLTLEGHSTFR	In	VDJ	1	101	1.4479061986154577E-4	1.7369680105525106E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	5	10	0	20	8	16	25	37	51	45	67													Vb 3	CASSLTLEGHSTFR+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGCGGGACAGGGTGGGGCAGATACGCAGTATTTTGGCCCA	CASSLAGQGGADTQYF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	3	4	2	5	25	40	51	42	56													Vb 3	CASSLAGQGGADTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGAAATACAGGGGGCGCGAGCACTGAAGCTTTCTTTGGACAA	CASRNTGGASTEAFF	In	VDJ	1	103	1.476577608489031E-4	1.7713634167020652E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	3	0	4	4	5	25	36	49	40	54													Vb 3	CASRNTGGASTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGTCAGCAGCTTACAAAGAGTTGGGACTGAAGCTTTCTTTGGACAA	CVSSLQRVGTEAFF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	2	0	9	5	9	0	25	40	-1	49	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CVSSLQRVGTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGCCAGGGGAGTAGCACAGATACGCAGTATTTTGGCCCA	CASSRQGSSTDTQYF	In	VDJ	1	106	1.5195847232993913E-4	1.8229565259263972E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	4	2	0	3	3	25	37	46	40	49													Vb 3	CASSRQGSSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCTCTCAACCTCGACTAGCGGGGGGGCCGGAGACCCAGTACTTCGGGCCA	CASSSSQPRLAGGPETQYF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	57	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	4	2	0	5	12	3	24	37	63	49	66													Vb 3	CASSSSQPRLAGGPETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCACTTACCGGGCCGTGGGCCCTATAATTCACCCCTCCACTTTGGGAAC	CASSHLPGRGPYNSPLHF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	54	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-06	01	6	8	0	2	9	7	25	36	49	45	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSHLPGRGPYNSPLHF+TCRBV28-01+TCRBJ01-06	TCRBV28-01*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGGGGGGCAAGGCTACACCTTCGGTTCG		Out	VDJ	1	111	1.5912632479833248E-4		35	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-02	01	3	6	0	8	1	2	25	39	46	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGCCCGGGCTACGGCAGCCCCAGCATTTTGGTGAT	CASSWPGLRQPQHF	In	VDJ	1	112	1.6055989529201113E-4	1.9261427443750614E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-05	01	4	8	0	7	5	5	25	38	47	43	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSWPGLRQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCAAACTAGCGGGAGGAGGGAACAGTACTTCGGGCCG	CASSQTSGRREQYF	In	VDJ	1	113	1.619934657856898E-4	1.9433404474498387E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	3	1	10	4	6	25	36	52	40	58													Vb 3	CASSQTSGRREQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGAGGGGCAACGAGCAGTACTTCGGGCCG	CASSLRGNEQYF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	36	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	3	5	2	5	1	2	25	39	45	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLRGNEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGGGTGAGGTGGGGTCGGGAGGAGAGACCCAGTACTTCGGGCCA	CASSLGEVGSGGETQYF	In	VDJ	1	117	1.677277477604045E-4	2.012131259748948E-4	51	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	8	1	4	14	0	25	39	-1	53	60													Vb 3	CASSLGEVGSGGETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCATAGGACAGGGAGCTACGAGCAGTACTTCGGGCCG	CASSHRTGSYEQYF	In	VDJ	1	119	1.7059488874776184E-4	2.0465266658985026E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	3	3	5	2	25	36	49	41	51													Vb 3	CASSHRTGSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGGGGCGGACTAGCGGGAAGAGCCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	124	1.777627412161552E-4		50	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	1	3	6	6	5	25	36	54	42	59													Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGACCGGGACGGATAATTCACCCCTCCACTTTGGGAAC	CASRTGTDNSPLHF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-06	01	6	0	7	5	4	2	25	36	45	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASRTGTDNSPLHF+TCRBV28-01+TCRBJ01-06	TCRBV28-01*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCTTGGTCTGGAAACACCATATATTTTGGAGAG	CASSLSWSGNTIYF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-03	01	1	0	10	1	3	0	25	41	-1	44	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLSWSGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCTCCCCGGGAGCTAGCACAGATACGCAGTATTTTGGCCCA	CASSFSPGASTDTQYF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	8	2	0	5	2	25	39	50	44	52													Vb 3	CASSFSPGASTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCTGTTGAGGGTGGGGGGAACACTGAAGCTTTCTTTGGACAA	CASSSVEGGGNTEAFF	In	VDJ	1	131	1.8779773467190588E-4	2.2528991027958307E-4	48	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	4	6	1	1	11	0	25	38	-1	49	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSSVEGGGNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGCAGGGGGGATGAACACTGAAGCTTTCTTTGGACAA	CASSAGGMNTEAFF	In	VDJ	1	133	1.9066487565926323E-4	2.2872945089453853E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	1	0	1	2	25	37	45	38	47													Vb 3	CASSAGGMNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGCGACAGGGGGGAGTTTTGGCGAGCAGTACTTCGGGCCG	CASATGGSFGEQYF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	2	1	6	2	9	25	34	45	36	54													Vb 3	CASATGGSFGEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCAAGGACAGGGGAGGGACTGAAGCTTTCTTTGGACAA	CASSKDRGGTEAFF	In	VDJ	1	139	1.9926629862133526E-4	2.3904807273940492E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	2	5	3	4	25	36	48	39	52													Vb 3	CASSKDRGGTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCTCATCGGGACGGTTCTACGAGCAGTACTTCGGGCCG	CASSGRFYEQYF	In	VDJ	1	139	1.9926629862133526E-4	2.3904807273940492E-4	36	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	11	0	7	3	5	4	25	31	41	36	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSGRFYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCTCAGAGGTTCACCCCTCCACTTTGGGAAC	CASSLRGSPLHF	In	VDJ	1	143	2.0500058059604994E-4	2.4592715396931587E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	5	11	1	9	4	0	25	37	-1	41	45													Vb 3	CASSLRGSPLHF+TCRBV28-01+TCRBJ01-06	TCRBV28-01*01	TCRBD02-01*02	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTACTGGGGCGCCCTACGAGCAGTACTTCGGGCCG	CASSFTGAPYEQYF	In	VDJ	1	143	2.0500058059604994E-4	2.4592715396931587E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	7	0	2	4	2	25	39	48	43	50													Vb 3	CASSFTGAPYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACAGGGGGTYTAGGCTACACCTTCGGTTCG	CASSTGGLGYTF	In	VDJ	1	144	2.0643415108972861E-4	2.476469242767936E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	1	8	0	4	25	-1	45	37	49													Vb 3	CASSTGGLGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGGCAGACTAGCGGGGAGATTAAATGAGCAGTTCTTCGGGCCA	CASSLGRLAGRLNEQFF	In	VDJ	1	144	2.0643415108972861E-4	2.476469242767936E-4	51	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	2	3	7	4	6	25	40	55	44	61													Vb 3	CASSLGRLAGRLNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCGGACAGCAGTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSSGQQYSNQPQHF	In	VDJ	1	156	2.2363699701387265E-4	2.682841679665264E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	1	5	0	2	5	25	38	46	40	51													Vb 3	CASSSGQQYSNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCAGGGTAGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	158	2.2650413800123E-4		40	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	3	3	0	4	25	-1	44	39	48													Vb 3	X+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCTGGACAGGGGAGGTTTGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSSGQGRFATNEKLFF	In	VDJ	1	161	2.30804849482266E-4	2.7688301950391504E-4	54	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	1	2	0	2	7	25	38	49	40	56													Vb 3	CASSSGQGRFATNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTCGCCGCAAGACTAGCGGTGAGGAGAGACCCAGTACTTCGGGCCA	CASSSPQD*R*GETQYF	Stop	VDJ	1	163	2.3367199046962336E-4		51	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	2	5	4	10	5	25	36	55	46	60						01,02							Vb 3	CASSSPQD*R*GETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACCCGACAGGGGCGGCAATACGCAGTATTTTGGCCCA	CASSLPDRGGNTQYF	In	VDJ	1	163	2.3367199046962336E-4	2.803225601188705E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	2	2	7	3	5	25	40	51	43	56													Vb 3	CASSLPDRGGNTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGGACAGGAATGGCTATGGCTACACCTTCGGTTCG	CASSLDRNGYGYTF	In	VDJ	1	163	2.3367199046962336E-4	2.803225601188705E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	4	4	0	5	25	-1	46	39	51													Vb 3	CASSLDRNGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCCTCGGGAGTCTTTACAATGAGCAGTTCTTCGGGCCA	CASSSLGSLYNEQFF	In	VDJ	1	164	2.3510556096330203E-4	2.8204233042634826E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	8	2	4	4	4	25	38	48	42	52													Vb 3	CASSSLGSLYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGAAGCGGGCCCGCCTACAATGAGCAGTTCTTCGGGCCA	CASSRSGPAYNEQFF	In	VDJ	1	168	2.408398429380167E-4	2.889214116562592E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	6	4	2	4	4	25	36	46	40	50						01,02							Vb 3	CASSRSGPAYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGTGGACAAGGGCTATGGCTACACCTTCGGTTCG	CASVDKGYGYTF	In	VDJ	1	168	2.408398429380167E-4	2.889214116562592E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	8	1	6	4	2	4	25	34	41	36	45													Vb 3	CASVDKGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGGGGCTCTTGCGGGCGCGGGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	174	2.494412659000887E-4		52	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-01	01	2	7	0	5	0	15	25	-1	45	40	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCCGACAGTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	175	2.508748363937674E-4		38	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	2	5	3	3	1	25	38	46	41	47													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCGTACAGACAGGGAACCGAAAACTGTTTTTTGGCAGT	CAVQTGNRKLFF	In	VDJ	1	175	2.508748363937674E-4	3.0095980380860334E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	11	2	3	10	5	5	25	31	43	36	48													Vb 3	CAVQTGNRKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCCCCCTACGGACACCTCAGCCCCAGCATTTTGGTGAT	CASSFPLRTPQPQHF	In	VDJ	1	177	2.5374197738112475E-4	3.043993444235588E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	1	6	6	8	2	25	39	52	47	54													Vb 3	CASSFPLRTPQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTGGGATTTTGGAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	179	2.566091183684821E-4		41	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-05	01	1	0	8	8	1	6	25	41	46	42	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCACCCCGGACTAGCTTATTAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	181	2.5947625935583945E-4		49	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	1	7	3	6	5	25	38	52	44	57						01,02							Vb 3	X+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTAACAGCAGGGGTCCGGGTTATGGCTACACCTTCGGTTCG	CASSNSRGPGYGYTF	In	VDJ	1	185	2.652105413305541E-4	3.1815750688338066E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	2	5	5	7	25	37	48	42	55													Vb 3	CASSNSRGPGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCTCGGGAGGGACCTATGGCTACACCTTCGGTTCG	CASSGGTYGYTF	In	VDJ	1	197	2.8241338725469817E-4	3.3879475057311344E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	8	8	0	4	1	2	25	34	43	35	45													Vb 3	CASSGGTYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGGGGGTGATTTGGGCTTTCTTTGGACAA	CASSWGVIWAFF	In	VDJ	1	204	2.9244838071044885E-4	3.508331427254576E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	4	9	1	11	0	8	25	-1	44	38	52													Vb 3	CASSWGVIWAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCCGGGGTAATGAAAAACTGTTTTTTGGCAGT	CASSFRGNEKLFF	In	VDJ	1	206	2.953155216978062E-4	3.5427268334041305E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	3	8	3	4	1	0	25	39	-1	40	45													Vb 3	CASSFRGNEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGAGAACAGAGTTCTGAAGCTTTCTTTGGACAA	CASREQSSEAFF	In	VDJ	1	209	2.9961623317884223E-4	3.5943199426284627E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	3	5	6	3	4	25	36	43	39	47													Vb 3	CASREQSSEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCACGGGACAGGGATCCTACAATGAGCAGTTCTTCGGGCCA	CASTTGQGSYNEQFF	In	VDJ	1	210	3.010498036725209E-4	3.61151764570324E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	0	3	1	4	1	25	35	48	39	49													Vb 3	CASTTGQGSYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCAGGACGAGGACCTACAATGAGCAGTTCTTCGGGCCA	CASSRTRTYNEQFF	In	VDJ	1	211	3.024833741661996E-4	3.6287153487780173E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-01	01	6	1	7	2	2	5	25	36	42	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSRTRTYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCACTATAAAAAGCGGGGGGGACAATGAGCAGTTCTTCGGGCCA	CATIKSGGDNEQFF	In	VDJ	1	218	3.1251836762195026E-4	3.7490992703014583E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	10	6	0	5	8	0	25	32	-1	40	50													Vb 3	CATIKSGGDNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGCCTCCTCGAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	219	3.1395193811562894E-4		44	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	11	2	0	8	0	25	39	-1	47	50													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCTACCGGAGGAGAAAACACCATATATTTTGGAGAG	CASSSTGGENTIYF	In	VDJ	1	221	3.168190791029863E-4	3.8006923795257905E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	4	10	1	6	5	3	25	38	48	43	51													Vb 3	CASSSTGGENTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCGTACTAGCGGGACGGGGCGAGCAGTACTTCGGGCCG	CASSVLAGRGEQYF	In	VDJ	1	223	3.196862200903436E-4	3.835087785675345E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	3	3	6	3	5	25	36	49	39	54													Vb 3	CASSVLAGRGEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATCTCCGGGACAGACGTACAATGAGCAGTTCTTCGGGCCA	CASSLSPGQTYNEQFF	In	VDJ	1	224	3.2111979058402227E-4	3.8522854887501227E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	0	5	4	4	3	25	41	52	45	55													Vb 3	CASSLSPGQTYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCTGAGGGACAGTAAAACACAAAACATTCAGTACTTCGGCGCC	CASSLRDSKTQNIQYF	In	VDJ	1	225	3.2255336107770094E-4	3.8694831918249E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	0	5	5	4	8	25	37	48	41	56													Vb 3	CASSLRDSKTQNIQYF+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCTATTTTTCGGTGGGAGGCCAAAAACATTCAGTACTTCGGCGCC	CASSPIFRWEAKNIQYF	In	VDJ	2	240	3.4405691848288103E-4	4.12744873794656E-4	51	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	5	9	2	1	13	0	25	37	-1	50	55													Vb 3	CASSPIFRWEAKNIQYF+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCAAGGACAGGGGTAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	246	3.5265834144495304E-4		46	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	1	2	1	3	2	25	38	50	41	52													Vb 3	X+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCAATCCCATCCCGGACAGACAACCTACGAGCAGTACTTCGGGCCG	CASQSHPGQTTYEQYF	In	VDJ	2	250	3.5839262341966774E-4	4.299425768694333E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	1	5	2	12	4	25	34	52	46	56													Vb 3	CASQSHPGQTTYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTAGGCTAGCGGGAGGGCTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	261	3.7416189885013313E-4		53	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	4	0	0	4	2	25	39	55	43	57													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGTGGCAGCCGAACACTGAAGCTTTCTTTGGACAA	CASRWQPNTEAFF	In	VDJ	2	265	3.798961808248478E-4	4.557391314815993E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	6	4	5	1	4	2	25	36	43	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASRWQPNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTCGGACCCGGCGGAAGAAAAACTGTTTTTTGGCAGT	CASSSDPAEEKLFF	In	VDJ	2	268	3.841968923058838E-4	4.608984424040325E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-04	01	6	1	7	8	3	9	25	36	43	39	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSSDPAEEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCACCCTACAGGGACCTCTACGAGCAGTACTTCGGGCCG	CASSSPYRDLYEQYF	In	VDJ	2	277	3.9709902674899184E-4	4.7637637517133213E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	3	3	3	6	4	25	38	50	44	54													Vb 3	CASSSPYRDLYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCTAGCAGTTTTACAGGGGCGCCCTACGAGCAGTACTTCGGGCCG	CASSFTGAPYEQYF	In	VDJ	2	280	4.0139973823002787E-4	4.815356860937653E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	3	2	2	1	3	25	39	47	40	50													Vb 3	CASSFTGAPYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTGGGGACTAGCGTCTACAATGAGCAGTTCTTCGGGCCA	CASSLLGTSVYNEQFF	In	VDJ	2	294	4.2146972514152923E-4	5.056124703984536E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	0	6	3	2	1	25	41	53	43	54						01,02							Vb 3	CASSLLGTSVYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCGGGGATTCCGGATACAATGAGCAGTTCTTCGGGCCA	CASSGDSGYNEQFF	In	VDJ	2	300	4.300711481036013E-4	5.159310922433199E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	8	3	4	0	8	25	-1	41	36	49													Vb 3	CASSGDSGYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTTTATGGGGCCGCGGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSLWGRGGTGELFF	In	VDJ	2	309	4.429732825467093E-4	5.314090250106196E-4	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	0	7	2	4	5	0	33	50	-1	55	62													Vb 3	CASSLWGRGGTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACGTCAGGGAGTCTCTGGAAACACCATATATTTTGGAGAG	CASSLRQGVSGNTIYF	In	VDJ	2	311	4.458404235340667E-4	5.34848565625575E-4	48	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-03	01	2	4	3	0	3	3	25	40	48	43	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLRQGVSGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGACAGGATTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSDRISNQPQHF	In	VDJ	2	312	4.472739940277453E-4	5.365683359330528E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	2	4	0	0	2	25	-1	43	37	45													Vb 3	CASSDRISNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGCCCAGGGGGGGTAAGGACACTGAAGCTTTCTTTGGACAA	CASRPRGGKDTEAFF	In	VDJ	2	319	4.5730898748349603E-4	5.486067280853969E-4	45	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	6	4	1	3	3	7	25	36	46	39	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASRPRGGKDTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAACTTGGCAGGGCGAGATGAAAAACTGTTTTTTGGCAGT	CASNLAGRDEKLFF	In	VDJ	2	322	4.61609698964532E-4	5.537660390078301E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	4	3	6	6	4	25	35	46	41	50													Vb 3	CASNLAGRDEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGTGTCCGGGACAGGGGCCGGGCCGGGGAGCTGTTTTTTGGAGAA	CASVRDRGRAGELFF	In	VDJ	2	345	4.945818203191415E-4	5.933207560798179E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	9	0	2	6	5	5	25	33	48	38	53													Vb 3	CASVRDRGRAGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACCAGACAGGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSTRQANTGELFF	In	VDJ	2	346	4.960153908128201E-4	5.950405263872958E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	2	4	0	4	0	25	37	-1	41	47													Vb 3	CASSTRQANTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCGGGACCGATGGACCACTCTGGAAACACCATATATTTTGGAGAG	CASSSGPMDHSGNTIYF	In	VDJ	2	357	5.117846662432855E-4	6.139579997695508E-4	51	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-03	01	4	0	7	0	1	10	25	38	44	39	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSSGPMDHSGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATGATTAGACTAGCGGGAGGTTCCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	366	5.246868006863935E-4		56	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	2	1	1	4	3	25	42	59	46	62													Vb 3	X+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCTCATTACAGGGCGGATGAACACTGAAGCTTTCTTTGGACAA	CASSLITGRMNTEAFF	In	VDJ	3	378	5.418896466105376E-4	6.500731762265832E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	3	3	0	7	4	25	36	49	43	53													Vb 3	CASSLITGRMNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGTAACCGGGACTAGCCATGAGCAGTTCTTCGGGCCA	CASSVTGTSHEQFF	In	VDJ	3	432	6.193024532691858E-4	7.429407728303807E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	7	8	6	1	25	37	52	43	53						01,02							Vb 3	CASSVTGTSHEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCCCGAGGGAGGTCCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	435	6.236031647502218E-4		44	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	9	1	0	7	2	25	35	48	42	50													Vb 3	X+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACAGGGGCTTGAGTTTCAAGATACGCAGTATTTTGGCCCA		Out	VDJ	3	460	6.594424270921886E-4		46	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	2	5	0	11	25	-1	44	37	55													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCTCGAGCATACGCGGGAGAAGCTCCTACGAGCAGTACTTCGGGCCG	CASSIRGRSSYEQYF	In	VDJ	3	471	6.75211702522654E-4	8.100118148220124E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	11	7	2	0	10	3	25	31	48	41	51													Vb 3	CASSIRGRSSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCAAGCAGAAATCAGCCCCAGCATTTTGGTGAT	CASSSSRNQPQHF	In	VDJ	4	531	7.612259321433742E-4	9.131980332706764E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-05	01	4	4	5	4	4	1	25	38	45	42	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSSSRNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTAGGGGACAGGGCCACAATGAGCAGTTCTTCGGGCCA	CASSFRGQGHNEQFF	In	VDJ	4	539	7.726944960928036E-4	9.269561957304983E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	0	3	5	3	2	25	39	51	42	53													Vb 3	CASSFRGQGHNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTTAACTAGCGGGAGGGGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	4	600	8.601422962072026E-4		52	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	3	0	0	3	1	25	39	55	42	56													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGGACAGGGGGCAGGGGAGGAAACACCATATATTTTGGAGAG	CASSRTGGRGGNTIYF	In	VDJ	4	620	8.88813706080776E-4	0.0010662575906361946	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	1	0	4	2	6	25	36	49	38	55													Vb 3	CASSRTGGRGGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACCCCCCCTTATTCCCCAAACAATGAGCAGTTCTTCGGGCCA	CASTPPYSPNNEQFF	In	VDJ	4	633	9.074501224985987E-4	0.001088614604633405	45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-01	01	7	4	6	5	15	1	25	35	52	50	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASTPPYSPNNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCACTCGACAGGGCTATGGCTACACCTTCGGTTCG	CASSPTRQGYGYTF	In	VDJ	4	661	9.475900963216015E-4	0.0011367681732427817	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	3	4	7	0	25	37	-1	44	51													Vb 3	CASSPTRQGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAAAACCTCGGGGGGCGAGAATCAGCCCCAGCATTTTGGTGAT	CASKTSGGENQPQHF	In	VDJ	4	664	9.518908078026374E-4	0.001141927484165215	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	7	8	1	4	6	4	25	35	48	41	52													Vb 3	CASKTSGGENQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGCACAGGGGGACGAGGAGGAAACACCATATATTTTGGAGAG	CASSRTGGRGGNTIYF	In	VDJ	5	707	0.0010135343390308203	0.0012158776073867574	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	3	1	4	3	7	25	37	48	40	55													Vb 3	CASSRTGGRGGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTACGGCGGACCGGGAACACTGAAGCTTTCTTTGGACAA	CASSLRRTGNTEAFF	In	VDJ	5	711	0.001019268621005535	0.0012227566886166684	45	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	2	1	7	1	4	3	25	40	48	44	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLRRTGNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAAGCAGCGGGGGAGCACAGATACGCAGTATTTTGGCCCA	CASKQRGSTDTQYF	In	VDJ	6	833	0.0011941642212343329	0.0014325686661289519	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	6	2	0	3	0	25	35	-1	38	46													Vb 3	CASKQRGSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGCTGAGGACTAGCGGGAACAATGAGCAGTTCTTCGGGCCA	CASRLRTSGNNEQFF	In	VDJ	6	840	0.0012041992146900836	0.001444607058281296	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	1	3	5	5	0	25	36	-1	41	53													Vb 3	CASRLRTSGNNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCAACAGGGGGGCACAATGAGCAGTTCTTCGGGCCA	CASSPTGGHNEQFF	In	VDJ	6	896	0.001284479162336089	0.001540914195500049	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	1	5	3	2	25	37	48	40	50													Vb 3	CASSPTGGHNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCAGCGGACTAGCGGGAGGGCCTACGAGCAGTACTTCGGGCCG	CASSQRTSGRAYEQYF	In	VDJ	8	1156	0.0016572074906925436	0.00198805447544426	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	1	0	2	4	0	25	37	-1	41	56													Vb 3	CASSQRTSGRAYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGGGTCCCGGACAACCCAGCATTTTGGTGAT	CASSLGSRTTQHF	In	VDJ	8	1173	0.001681578189085081	0.002017290570671381	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	1	6	11	7	1	25	40	52	47	53													Vb 3	CASSLGSRTTQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGTGAGCGGGAGGGTTTCCTACGAGCAGTACTTCGGGCCG	CASSVSGRVSYEQYF	In	VDJ	9	1362	0.0019525230123903499	0.002342327158784673	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	6	0	1	3	2	25	37	50	40	52													Vb 3	CASSVSGRVSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGAAAGGGACCACAGGGTCCGGGTCAATGAGCAGTTCTTCGGGCCA	CASRERDHRVRVNEQFF	In	VDJ	10	1548	0.0022191671242145824	0.002662204435975531	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	3	3	6	11	7	25	36	53	47	60													Vb 3	CASRERDHRVRVNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGACGAAGGACAGGGAACACTGAAGCTTTCTTTGGACAA	CASSRRRTGNTEAFF	In	VDJ	10	1576	0.0022593070980375853	0.0027103580045849075	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	4	1	8	0	25	36	-1	44	51													Vb 3	CASSRRRTGNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCACGATAAACACCATATATTTTGGAGAG	CASSPTINTIYF	In	VDJ	13	1909	0.002736686072432583	0.0032830415169749928	36	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-03	01	5	2	8	6	5	1	25	37	44	42	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSPTINTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATACCACGTTTCAGGGTCCTAACCTACGAGCAGTACTTCGGGCCG	CASIPRFRVLTYEQYF	In	VDJ	13	2006	0.002875742410319414	0.003449859236800333	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	4	3	2	10	6	25	35	50	45	56													Vb 3	CASIPRFRVLTYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTGGGGGACAGGGGGCGGAACTGAAGCTTTCTTTGGACAA	CASSWGTGGGTEAFF	In	VDJ	15	2290	0.0032828764305241564	0.00393827400412401	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	0	5	2	3	25	38	52	40	55													Vb 3	CASSWGTGGGTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGACTAGCGGGAGACACCGGGGAGCTGTTTTTTGGAGAA	CASSRLAGDTGELFF	In	VDJ	25	3822	0.00547910642683988	0.006572962115179897	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	2	2	3	1	0	25	37	-1	38	50													Vb 3	CASSRLAGDTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGTGCCTGAAGACGTAAGGCGGGAGGTAAGGCGGGAGATCCCAGGGGAACACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	45	6.45106722155402E-5		68	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	12	7	1	2	13	23	0	5	26	18	49														X+TCRBV12-02+TCRBJ02-03	TCRBV12-02*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCACCCCGGGGGTCTACAAGTTAAAGAGCAGTTCTTCGGGCCA		Out	VDJ	1	66	9.461565258279228E-5		41	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	12	8	2	10	5	13	18	23	34	28	47														X+TCRBV12-02+TCRBJ02-01	TCRBV12-02*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCTTAGCGGGAGGGGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	82	1.1755278048165102E-4		43	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	9	0	3	0	2	18	-1	42	35	44														X+TCRBV12-02+TCRBJ01-01	TCRBV12-02*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCTTAGACCATCCTAGCACAGATACGCAGTATTTTGGCCCA	CASRLDHPSTDTQYF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	45	TCRBV12	TCRBV12-02	01				TCRBJ02	TCRBJ02-03	01	1	3	7	0	0	6	18	-1	36	34	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRLDHPSTDTQYF+TCRBV12-02+TCRBJ02-03	TCRBV12-02*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCGGGTTAGGCCAGGCGGCCGTCATAGCTCTGGAAATACCATATATTTTGGAGAG		Out	VDJ	1	134	1.920984461529419E-4		53	TCRBV12	TCRBV12-02	01				TCRBJ01	TCRBJ01-03	01	12	4	4	10	10	22	18	23	37	33	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-02+TCRBJ01-03	TCRBV12-02*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTTAGTTACAACGGAGCCCTCTCTCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	56	8.027994764600557E-5		58	TCRBV07	TCRBV07-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	4	10	2	0	10	8	22	35	49	45	57														X+TCRBV07-01+TCRBJ01-04	TCRBV07-01*01	TCRBD02-01*02	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTTAGGCGGGGACAATGAGCAGTTCTTCGGGCCA	CASSLGGDNEQFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	39	TCRBV07	TCRBV07-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	7	3	5	3	0	22	35	-1	38	44														CASSLGGDNEQFF+TCRBV07-01+TCRBJ02-01	TCRBV07-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCCGTAACGTCGAGGGGGAGCTGTTTTTTGGAGAA	CASSRNVEGELFF	In	VDJ	1	88	1.2615420344372303E-4	1.5133978705804052E-4	39	TCRBV07	TCRBV07-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	11	2	8	9	0	22	34	-1	43	46														CASSRNVEGELFF+TCRBV07-01+TCRBJ02-02	TCRBV07-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTTATCCGGTGGTGTGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	157	2.2507056750755133E-4		47	TCRBV07	TCRBV07-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	4	8	5	2	4	7	22	35	42	39	49						01,02								X+TCRBV07-01+TCRBJ01-05	TCRBV07-01*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTATTCTGTGCACTTCTAACAAAGCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	66	9.461565258279228E-5		55	TCRBV10	TCRBV10-02	01				TCRBJ02	TCRBJ02-06	01	5	3	6	5	16	4	23	35	54	51	58				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-02+TCRBJ02-06	TCRBV10-02*01		TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGCGAGACAGGGACTGGAAACACCATATATTTTGGAGAG	CASSETGTGNTIYF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	42	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	3	3	2	0	1	23	-1	44	38	45													Vb 12	CASSETGTGNTIYF+TCRBV10-02+TCRBJ01-03	TCRBV10-02*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGGGGAGGACAGGGTGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRGGQGANTGELFF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	48	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	1	3	0	4	2	23	34	46	38	48													Vb 12	CASRGGQGANTGELFF+TCRBV10-02+TCRBJ02-02	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTAAGTCGGGCGGCCCCGGAGCCGATAGGTACTTCGGGCCA	CASSKSGGPGADRYF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	45	TCRBV10	TCRBV10-02	01				TCRBJ02	TCRBJ02-05	01	0	8	0	13	0	17	23	-1	44	40	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASSKSGGPGADRYF+TCRBV10-02+TCRBJ02-05	TCRBV10-02*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCATGCTAGCGGGAGATAAAAACATTCAGTACTTCGGCGCC	CASMLAGDKNIQYF	In	VDJ	1	93	1.333220559121164E-4	1.599386385954292E-4	42	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	7	4	2	4	2	2	23	33	45	35	47													Vb 12	CASMLAGDKNIQYF+TCRBV10-02+TCRBJ02-04	TCRBV10-02*01	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGCGAACGGGACAGGGGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSERDRGVNTEAFF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	48	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	1	0	5	1	23	34	50	39	51													Vb 12	CASSERDRGVNTEAFF+TCRBV10-02+TCRBJ01-01	TCRBV10-02*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGAGAACGGGGATCAGCACAGATACGCAGTATTTTGGCCCA	CAISERTGISTDTQYF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	48	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	8	3	0	4	3	23	38	47	42	50													Vb 12	CAISERTGISTDTQYF+TCRBV10-03+TCRBJ02-03	TCRBV10-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCGCCCAAGGACCTGGCGACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	50	7.167852468393355E-5		40	TCRBV10	TCRBV10-03	01				TCRBJ02	TCRBJ02-07	01	11	1	7	2	6	7	24	30	40	36	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-03+TCRBJ02-07	TCRBV10-03*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGAGAACGGAGATCAACACAGATACGCAGTATTTTGGCCCA	CAISERTEINTDTQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	48	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	10	2	2	5	5	23	38	47	43	52													Vb 12	CAISERTEINTDTQYF+TCRBV10-03+TCRBJ02-03	TCRBV10-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCACCTCCGGACCGCGGGCCCCTTACGAGCAGTACTTCGGGCCG	CATSGPRAPYEQYF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	42	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	10	7	4	4	10	5	24	31	46	41	51						01,02							Vb 12	CATSGPRAPYEQYF+TCRBV10-03+TCRBJ02-07	TCRBV10-03*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCCGGGACAGGGCTCGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CAISESGTGLANTGELFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	54	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	0	3	0	1	4	23	40	50	41	54													Vb 12	CAISESGTGLANTGELFF+TCRBV10-03+TCRBJ02-02	TCRBV10-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCGACAGGGGTATACACTGAAGCTTTCTTTGGACAA	CAISESTGVYTEAFF	In	VDJ	1	145	2.078677215834073E-4	2.4936669458427134E-4	45	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	2	2	3	0	3	23	-1	48	40	51													Vb 12	CAISESTGVYTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCGCACAATGAGCAGTTCTTCGGGCCA	CAISESHNEQFF	In	VDJ	1	147	2.1073486257076462E-4	2.528062351992268E-4	36	TCRBV10	TCRBV10-03	01				TCRBJ02	TCRBJ02-01	01	0	10	0	5	0	0	23	-1	-1	40	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAISESHNEQFF+TCRBV10-03+TCRBJ02-01	TCRBV10-03*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGCCCCCCGAAACTAGCGGCCGCACAGATACGCAGTATTTTGGCCCA	CAISEPPETSGRTDTQYF	In	VDJ	1	183	2.6234340034319675E-4	3.147179662684252E-4	54	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	3	5	1	9	2	23	38	55	47	57						01,02							Vb 12	CAISEPPETSGRTDTQYF+TCRBV10-03+TCRBJ02-03	TCRBV10-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTCAAGGGGGAAGAACACTGAAGCTTTCTTTGGACAA	CAISESRGKNTEAFF	In	VDJ	5	715	0.0010250029029802497	0.0012296357698465793	45	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	5	1	1	1	2	23	40	47	41	49													Vb 12	CAISESRGKNTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGATATTGGGGCAGAACACTGAAGCTTTCTTTGGACAA	CAISEILGQNTEAFF	In	VDJ	15	2260	0.003239869315713796	0.0038866808948996774	45	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	7	0	1	5	1	23	38	48	43	49													Vb 12	CAISEILGQNTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGCTTTCCCTCAATGAGCAGTTCTTCGGGCCA	CASSIGLSLNEQFF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	3	8	0	6	1	7	27	41	46	42	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIGLSLNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGAGGGCTCGGGGAGACCCAGTACTTCGGGCCA	CASSGGLGETQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	10	0	5	0	6	27	-1	45	39	51			01,02										Vb 17	CASSGGLGETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGACTGTCGGTGCAGAGAGAGACCCAGTACTTCGGGCCA	CASGLSVQRETQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	8	1	10	4	0	12	27	-1	41	36	53			01,02			01,02							Vb 17	CASGLSVQRETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGCAGGGACCAGCCCCAGCATTTTGGTGAT	CASSIGRDQPQHF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	1	0	7	7	3	0	27	43	-1	46	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIGRDQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGCGGGACTAGCGGGAGTATCTCCGGGGAGCTGTTTTTTGGAGAA	CASSSGTSGSISGELFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	51	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	0	2	6	2	5	27	40	56	42	61			01,02										Vb 17	CASSSGTSGSISGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCTAGTAGTACCTGGACGGGGACCACCGGGGAGCTGTTTTTTGGAGAA	CASSTWTGTTGELFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-02	01	4	0	7	4	8	0	27	40	-1	48	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSTWTGTTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCCGGGACAGGGTAATTGGGAATCAGCCCCAGCATTTTGGTGAT	CASRDRVIGNQPQHF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	9	0	3	4	2	8	27	35	46	37	54			01,02										Vb 17	CASRDRVIGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCTCCGTTTTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASTSVLNTGELFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	4	10	1	1	7	27	37	40	38	47			01,02			01,02							Vb 17	CASTSVLNTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTTCAGAGAAAACACTGAAGCTTTCTTTGGACAA	CASFRENTEAFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	36	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	8	4	5	2	2	4	27	36	41	38	45			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASFRENTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGGGTTTCGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSIGVSGTGELFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	1	8	4	4	6	0	27	43	-1	49	53			01,02			01,02							Vb 17	CASSIGVSGTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCCAGGGGGGCGAGCAGTACTTCGGGCCG	CASSTQGGEQYF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	1	6	2	1	27	40	49	42	50			01,02										Vb 17	CASSTQGGEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTGGTGCCAAAAGAACCCGACAGTTTCTATCTCTGTGCCAGTAGTATGGCAGGGTCTCGAGCCAAAAACATTCAGTACTTCGGCGCC	CASSMAGSRAKNIQYF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	3	4	3	0	2	5	33	47	54	49	59			01,02										Vb 17	CASSMAGSRAKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGCTTTCTATCTCTGTGCCAGTAGTATAGCCGGGCAGACTACCGGCCAACTAGCCAAAAACATTCAGTACTTCGGCGCC	CASSIAGQTTGQLAKNIQYF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	60	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	1	2	9	0	7	10	14	30	42	37	52			01,02			01,02							Vb 17	CASSIAGQTTGQLAKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD02-01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGACGGACAGGACGATCAACTATGGCTACACCTTCGGTTCG	CASSMTDRTINYGYTF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	4	2	3	6	27	41	51	44	57			01,02										Vb 17	CASSMTDRTINYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAACCTAGCGGACTCCTACAATGAGCAGTTCTTCGGGCCA	CASSNLADSYNEQFF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	4	5	0	2	1	27	40	49	42	50			01,02			01,02							Vb 17	CASSNLADSYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTGGACAGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSIGQGTGELFF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	1	3	4	1	0	27	41	-1	42	50			01,02										Vb 17	CASSIGQGTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCCGGGCTCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	59	8.458065912704158E-5		37	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-03	01	5	8	0	4	3	1	27	39	46	42	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-03	TCRBV19-01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTTGGAGTTGGAACACTGAAGCTTTCTTTGGACAA	CASSIWSWNTEAFF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	10	2	1	2	3	27	41	47	43	50			01,02										Vb 17	CASSIWSWNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGCTTCAGGGAAAGCAATCAGCCCCAGCATTTTGGTGAT	CASGFRESNQPQHF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	4	3	1	5	2	27	36	46	41	48			01,02										Vb 17	CASGFRESNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGCCGTCCTGGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASRAVLGGNQPQHF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	45	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	6	6	1	2	9	0	27	38	-1	47	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRAVLGGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTATCAGGCACTGGCACAGATACGCAGTATTTTGGCCCA	CASSIVSGTGTDTQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	4	4	1	3	5	27	43	50	46	55			01,02										Vb 17	CASSIVSGTGTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCCACTAGCGGGGTACCTCGAAGGTTCTTCGGGCCA	CASSPTSGVPRRFF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	3	3	15	3	10	27	39	52	42	62			01,02										Vb 17	CASSPTSGVPRRFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCTAGTAGTATCCGGGACTGGTCTGTTTCGGATGAGCAGTTCTTCGGGCCA	CASSIRDWSVSDEQFF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	0	10	8	2	12	27	41	49	43	61			01,02			01,02							Vb 17	CASSIRDWSVSDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCATCAAGACAGGGGGCAAAGAGGCTACACCTTCGGTTCG	CASSHQDRGQRGYTF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	0	8	7	5	27	38	55	45	60			01,02										Vb 17	CASSHQDRGQRGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACTCTCGGACGGACCCAAGAGACCCAGTACTTCGGGCCA	CASSTLGRTQETQYF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	4	1	7	1	5	4	27	40	49	45	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSTLGRTQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCTATGGGGACTCCTACGAGCAGTACTTCGGGCCG	CASSIYGDSYEQYF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	3	0	8	0	5	0	27	41	-1	46	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIYGDSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAACAGTGGGACGGCCGCTAGCACAGATACGCAGTATTTTGGCCCA	CASNSGTAASTDTQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	48	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-03	01	7	0	7	0	5	7	27	37	47	42	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASNSGTAASTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGGGACAGGGACAATCAGCCCCAGCATTTTGGTGAT	CASSRDRDNQPQHF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	3	3	1	1	27	39	49	40	50			01,02										Vb 17	CASSRDRDNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTTTCTATCTCTGTGCCAGTAGTATACGGTTTTCTTTGCGGGAGGGCCCTACAACGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	75	1.0751778702590032E-4		61	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	7	0	6	11	10	12	27	47	38	57			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGTTGGGGGGCACCCAAGAGACCCAGTACTTCGGGCCA	CASSMLGGTQETQYF	In	VDJ	1	80	1.1468563949429368E-4	1.3758162459821867E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	3	6	0	1	4	2	27	41	51	45	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSMLGGTQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCGGTCCGGGGGGCTCCTACAATGAGCAGTTCTTCGGGCCA	CAGPGGSYNEQFF	In	VDJ	1	80	1.1468563949429368E-4	1.3758162459821867E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	11	8	1	0	4	0	27	33	-1	37	44			01,02										Vb 17	CAGPGGSYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCTCGGCCCCCGCAGGGGGCGATCAGCCCCAGCATTTTGGTGAT	CASTSAPAGGDQPQHF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	4	0	5	12	1	27	37	57	49	58			01,02										Vb 17	CASTSAPAGGDQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGACGTTGGATGGCTACACCTTCGGTTCG	CASRTLDGYTF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	33	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	6	2	7	6	0	5	27	-1	41	38	46			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRTLDGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGACCAGGGGGGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSIDQGGSNQPQHF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	48	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	0	4	1	1	1	2	27	44	52	45	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIDQGGSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGAAGGACAGGACAGAACTATGGCTACACCTTCGGTTCG	CASRRTGQNYGYTF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	1	4	2	2	4	27	38	47	40	51			01,02										Vb 17	CASRRTGQNYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGAGCGGCGGGGGCGGGGAGCCCCAGCATTTTGGTGAT	CASSMSGGGGEPQHF	In	VDJ	1	88	1.2615420344372303E-4	1.5133978705804052E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	3	7	2	8	5	5	27	41	53	46	58			01,02										Vb 17	CASSMSGGGGEPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTATAGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSIIGGNQPQHF	In	VDJ	1	91	1.3045491492475906E-4	1.5649909798047372E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	5	2	2	3	0	27	41	-1	44	49			01,02										Vb 17	CASSIIGGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCCGCGGAACTGAAGCTTTCTTTGGACAA	CASSIRGTEAFF	In	VDJ	1	93	1.333220559121164E-4	1.599386385954292E-4	36	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	7	5	5	2	1	27	41	47	43	48			01,02			01,02							Vb 17	CASSIRGTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAAAGGGACTAGCGGGATTACCGGGGAGCTGTTTTTTGGAGAA	CASKGTSGITGELFF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	7	0	3	5	2	2	27	37	52	39	54			01,02										Vb 17	CASKGTSGITGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCTCAGGGAGGCGGATCGCCCAAAACACCATATATTTTGGAGAG	CASTSGRRIAQNTIYF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	7	9	1	6	5	11	27	37	48	42	59			01,02										Vb 17	CASTSGRRIAQNTIYF+TCRBV19-01+TCRBJ01-03	TCRBV19-01	TCRBD02-01*02	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAACCAGCGGGGGCCAAAATGAGCAGTTCTTCGGGCCA	CASSITSGGQNEQFF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	6	2	7	3	4	27	42	53	45	57			01,02										Vb 17	CASSITSGGQNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGAAGGGGTGCTCAATCAGCCCCAGCATTTTGGTGAT	CASSMEGVLNQPQHF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	5	2	3	3	4	27	41	49	44	53			01,02										Vb 17	CASSMEGVLNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGTTTAAAGGGGGCTCGGGGCAATGAGCAGTTCTTCGGGCCA	CASSGLKGARGNEQFF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	5	0	6	7	6	27	39	53	46	59			01,02										Vb 17	CASSGLKGARGNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGACTTCCGGGACAGGAAAAGCTTTCTTTGGACAA		Out	VDJ	1	100	1.433570493678671E-4		40	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	4	9	7	2	27	39	54	46	56			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCAACAGGGGCGGTCTGAAGCTTTCTTTGGACAA	CASQQGRSEAFF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	3	2	6	2	4	27	36	45	38	49			01,02										Vb 17	CASQQGRSEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCGGGAAAGACTAGCGGGAGGAAGGCGAGCAGTACTTCGGGCCG		Out	VDJ	1	113	1.619934657856898E-4		50	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	2	1	6	8	4	27	39	60	47	64			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCTTGGGACAGGGTTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSILGQGYSNQPQHF	In	VDJ	1	120	1.7202845924144052E-4	2.06372436897328E-4	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	0	3	0	3	3	27	41	53	44	56			01,02										Vb 17	CASSILGQGYSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATACCGGGGTAGGACAGCGATACCTACGAGCAGTACTTCGGGCCG	CASSIPG*DSDTYEQYF	Stop	VDJ	1	122	1.7489560022879784E-4		51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	5	2	8	5	27	42	56	50	61			01,02										Vb 17	CASSIPG*DSDTYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGCGGGGAAAGAACACTGAAGCTTTCTTTGGACAA	CASSIGRGKNTEAFF	In	VDJ	1	125	1.7919631170983387E-4	2.1497128843471665E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	3	7	3	1	3	3	27	41	50	44	53			01,02										Vb 17	CASSIGRGKNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAGCGGACTTATGGCTACACCTTCGGTTCG	CASSIERTYGYTF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	1	10	5	2	0	27	44	-1	46	51			01,02			01,02							Vb 17	CASSIERTYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCGCGCTATTCTAATGAAAAACTGTTTTTTGGCAGT	CASSPRYSNEKLFF	In	VDJ	1	133	1.9066487565926323E-4	2.2872945089453853E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	5	4	9	3	5	2	27	39	47	44	49			01,02			01,02							Vb 17	CASSPRYSNEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCCTGACAGGGCTGAACACTGAAGCTTTCTTTGGACAA	CASLTGLNTEAFF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	9	2	3	0	3	1	27	35	45	38	46			01,02										Vb 17	CASLTGLNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCAACAGGGTAGCAGGGCTCAATCAGCCCCAGCATTTTGGTGAT	CASSNRVAGLNQPQHF	In	VDJ	1	144	2.0643415108972861E-4	2.476469242767936E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	3	3	2	10	27	38	46	40	56			01,02										Vb 17	CASSNRVAGLNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACTGGACAGGGCCAAGAGACCCAGTACTTCGGGCCA	CASTGQGQETQYF	In	VDJ	1	145	2.078677215834073E-4	2.4936669458427134E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	1	3	1	2	0	27	37	-1	39	47			01,02										Vb 17	CASTGQGQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATGGGACAGTACAAGAGACCCAGTACTTCGGGCCA	CASSIDGTVQETQYF	In	VDJ	1	145	2.078677215834073E-4	2.4936669458427134E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	0	5	2	1	2	27	44	52	45	54			01,02										Vb 17	CASSIDGTVQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGACTAGTGCAGGGCCCATGGATGGCTACACCTTCGGTTCG		Out	VDJ	1	146	2.0930129207708594E-4		41	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	9	4	3	6	7	7	27	35	47	42	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCGGAGTACTTGGGGACAGGGGGGCGGCAATCAGCCCCAGCATTTTGGTGAT	CASRSTWGQGGGNQPQHF	In	VDJ	1	147	2.1073486257076462E-4	2.528062351992268E-4	54	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	0	1	2	11	3	27	36	58	47	61			01,02										Vb 17	CASRSTWGQGGGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCTAGGGAGGTGAAGACCCAGTACTTCGGGCCA	CASSPREVKTQYF	In	VDJ	1	154	2.2076985602651532E-4	2.6484462735157095E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	9	1	6	4	3	27	39	49	43	52			01,02										Vb 17	CASSPREVKTQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAATATGACAGGGTCTCGAGCCAAAAACATTCAGTACTTCGGCGCC	CASNMTGSRAKNIQYF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	3	2	3	0	0	5	27	-1	48	41	53			01,02										Vb 17	CASNMTGSRAKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTTGGCGGACTAGCGGACGAGAGACCCAGTACTTCGGGCCA	CASSIWRTSGRETQYF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	1	5	4	5	3	27	41	56	46	59			01,02			01,02							Vb 17	CASSIWRTSGRETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACACTCAACCGGCCCCATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	165	2.365391314569807E-4		41	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	10	9	0	4	9	4	27	34	46	43	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTACAGACTTATAATTCACCCCTCCACTTTGGGAAC	CASSIVQTYNSPLHF	In	VDJ	1	165	2.365391314569807E-4	2.8376210073382597E-4	45	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-06	01	1	3	5	4	1	3	27	43	48	44	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIVQTYNSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCACGGGACAGGGACAAGAGACCCAGTACTTCGGGCCA	CATTGQGQETQYF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	10	0	3	2	4	1	27	34	47	38	48			01,02										Vb 17	CATTGQGQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCCCGGGACAGGGTATCGCTGAGCAGTTCTTCGGGCCA	CASSIPGQGIAEQFF	In	VDJ	1	170	2.4370698392537407E-4	2.9236095227121465E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	0	3	9	3	6	27	41	53	44	59			01,02										Vb 17	CASSIPGQGIAEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCAGCCCTTCGGGGGGGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	170	2.4370698392537407E-4		47	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	8	0	1	8	0	27	39	-1	47	55			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACTCGGGAGGGAGCCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CATREGASGANVLTF	In	VDJ	1	175	2.508748363937674E-4	3.0095980380860334E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	10	8	0	0	2	3	27	34	44	36	47			01,02										Vb 17	CATREGASGANVLTF+TCRBV19-01+TCRBJ02-06	TCRBV19-01	TCRBD02-01*02	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTCTCGTTCTCAGCCCCAGCATTTTGGTGAT	CASSRSQPQHF	In	VDJ	1	176	2.5230840688744607E-4	3.0267957411608104E-4	33	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	8	4	10	6	1	5	27	36	39	37	44			01,02			01,02							Vb 17	CASSRSQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTGGGGTGATGGCTACACCTTCGGTTCG	CASSWGDGYTF	In	VDJ	1	177	2.5374197738112475E-4	3.043993444235588E-4	33	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	5	6	2	6	1	2	27	39	44	40	46			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSWGDGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGGACAGACAGGGGGCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	185	2.652105413305541E-4		46	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	9	2	1	0	4	0	27	35	-1	39	48			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-06	TCRBV19-01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCCGGGGAAGAACCCCCTGGGGTTTGACTGAAGCTTTCTTTGGACAA	CASRGRTPWGLTEAFF	In	VDJ	1	192	2.7524553478630484E-4	3.301958990357248E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	9	8	3	5	1	19	27	35	41	36	60			01,02										Vb 17	CASRGRTPWGLTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGAGCGGGGTAACCTTAGGAATTCACCCCTCCACTTTGGGAAC	CASERGNLRNSPLHF	In	VDJ	1	195	2.795462462673408E-4	3.35355209958158E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	8	6	3	7	1	10	27	36	44	37	54			01,02										Vb 17	CASERGNLRNSPLHF+TCRBV19-01+TCRBJ01-06	TCRBV19-01	TCRBD02-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGACTGAGTTATGRCTACACCTTCGGTTCG	CASSIGLSYXYTF	In	VDJ	1	199	2.852805282420555E-4	3.422342911880689E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	1	2	10	5	0	4	27	-1	47	43	51			01,02			01,02							Vb 17	CASSIGLSYXYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTGGTTGGGGGGAGAAATACGAGCAGTACTTCGGGCCG	CASSIGWGEKYEQYF	In	VDJ	1	201	2.8814766922941287E-4	3.4567383180302436E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	9	1	4	5	5	27	41	52	46	57			01,02										Vb 17	CASSIGWGEKYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAAGGTGGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSIEGGSGANVLTF	In	VDJ	1	208	2.9818266268516355E-4	3.577122239553685E-4	48	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-06	01	0	5	4	0	0	3	27	-1	47	44	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIEGGSGANVLTF+TCRBV19-01+TCRBJ02-06	TCRBV19-01		TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGATCAGTGATTTTTGGCTACACCTTCGGTTCG	CASGSVIFGYTF	In	VDJ	1	208	2.9818266268516355E-4	3.577122239553685E-4	36	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	8	1	8	7	0	11	27	-1	39	36	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASGSVIFGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGACAGAGACCACCCAATCAGCCCCAGCATTTTGGTGAT	CASRQRPPNQPQHF	In	VDJ	1	212	3.0391694465987826E-4	3.6459130518527944E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	5	3	0	8	27	-1	42	38	50			01,02										Vb 17	CASRQRPPNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATCAGTCATAGGCGGTGGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	215	3.0821765614091423E-4		41	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	7	7	5	5	10	2	27	37	51	47	53			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCATTTCGAAACGGACGGAGACCCAGTACTTCGGGCCA	CAISKRTETQYF	In	VDJ	1	223	3.196862200903436E-4	3.835087785675345E-4	36	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	10	1	7	5	9	1	27	34	47	43	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CAISKRTETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGTCGACAGACGCACAATGAAAAACTGTTTTTTGGCAGT	CASSSRQTHNEKLFF	In	VDJ	2	240	3.4405691848288103E-4	4.12744873794656E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	2	5	5	3	6	27	40	48	43	54			01,02										Vb 17	CASSSRQTHNEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCTCGGACGGCCGCAATCAGCCCCAGCATTTTGGTGAT	CASTSDGRNQPQHF	In	VDJ	2	241	3.454904889765597E-4	4.1446464410213374E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	7	1	7	2	4	4	27	37	45	41	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASTSDGRNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGCCCGAACAGGGGGCGAAGACGAGCAGTACTTCGGGCCG	CASSARTGGEDEQYF	In	VDJ	2	242	3.469240594702384E-4	4.1618441440961144E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	0	5	6	4	27	39	54	45	58			01,02										Vb 17	CASSARTGGEDEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGCCAAGAGACCCAGTACTTCGGGCCA	CASSSQETQYF	In	VJ	2	243	3.48357629963917E-4	4.179041847170892E-4	33	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	4	0	0	1	0	1	27	-1	40	-1	41			01,02										Vb 17	CASSSQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGCCCCTGAGAACACTGAAGCTTTCTTTGGACAA	CASAPENTEAFF	In	VDJ	2	244	3.497912004575957E-4	4.196239550245669E-4	36	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	8	2	8	1	6	0	27	36	-1	42	44			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASAPENTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGAGGGGGCAGGGAGACCCAGTACTTCGGGCCA	CASSRGGRETQYF	In	VDJ	2	247	3.540919119386317E-4	4.2478326594700013E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	5	0	5	2	3	27	39	48	41	51			01,02										Vb 17	CASSRGGRETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGTGGGAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	251	3.598261939133464E-4		37	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	9	2	0	2	0	27	38	-1	40	45			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTCGACTAGCGGGAATGAGCAGTTCTTCGGGCCA	CASSTSGNEQFF	In	VDJ	2	252	3.6125976440702504E-4	4.3338211748438876E-4	36	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	2	4	7	2	0	27	36	-1	38	48			01,02			01,02							Vb 17	CASSTSGNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGACGTGGGCAGGGGTTCTGGCTACACCTTCGGTTCG	CASSIDVGRGSGYTF	In	VDJ	2	257	3.684276168754184E-4	4.4198096902177744E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	2	7	6	3	27	44	56	50	59			01,02										Vb 17	CASSIDVGRGSGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCTGTATAGAAGGGTTTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	259	3.712947578627758E-4		46	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	6	5	3	4	10	2	27	38	52	48	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTTGGGGACACGCGCAAGAGACCCAGTACTTCGGGCCA	CASSIWGHAQETQYF	In	VDJ	2	263	3.7702903983749043E-4	4.5229959086664383E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	6	2	3	4	27	41	50	44	54			01,02										Vb 17	CASSIWGHAQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTTCTGAGAGGGGCGCGTAAGGAGACCCAGTACTTCGGGCCA	CASSFLRGARKETQYF	In	VDJ	2	264	3.784626103311691E-4	4.540193611741216E-4	48	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	5	5	2	5	8	8	27	39	52	47	60			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSFLRGARKETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTGAACAGCTCTATGGCTACACCTTCGGTTCG	CASSIEQLYGYTF	In	VDJ	2	267	3.8276332181220513E-4	4.5917867209655476E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	5	4	3	2	27	41	48	44	50			01,02										Vb 17	CASSIEQLYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCGGGACACCAACCCAGGAGGAAAAACTGTTTTTTGGCAGT	CASTGTPTQEEKLFF	In	VDJ	2	268	3.841968923058838E-4	4.608984424040325E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	0	6	8	2	12	27	37	45	39	57			01,02										Vb 17	CASTGTPTQEEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGACACGGGGGGGCAGGAGCGGGAGACCCAGTACTTCGGGCCA	CASSDTGGQERETQYF	In	VDJ	2	277	3.9709902674899184E-4	4.7637637517133213E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	8	0	5	4	9	27	39	51	43	60			01,02										Vb 17	CASSDTGGQERETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGCATCGGCCAACGAGCAGTACTTCGGGCCG	CASSIASANEQYF	In	VDJ	2	284	4.071340202047425E-4	4.884147673236762E-4	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	1	9	0	5	4	2	27	43	50	47	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIASANEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATACAGGGAGGTACAGATACGCAGTATTTTGGCCCA	CASSIQGGTDTQYF	In	VDJ	2	288	4.1286830217945723E-4	4.952938485535872E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	9	1	3	2	1	27	42	50	44	51			01,02										Vb 17	CASSIQGGTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGGACAAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSMGQNTGELFF	In	VDJ	2	288	4.1286830217945723E-4	4.952938485535872E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	0	6	2	0	1	27	-1	47	41	48			01,02										Vb 17	CASSMGQNTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGTGCGGGTCCCACAGATACGCAGTATTTTGGCCCA	CASSIGAGPTDTQYF	In	VDJ	2	293	4.2003615464785056E-4	5.038927000909759E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	7	4	2	4	3	27	41	50	45	53			01,02			01,02							Vb 17	CASSIGAGPTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGACAGGGATTGGGCCTGAAGCTTTCTTTGGACAA	CASSMTGIGPEAFF	In	VDJ	2	306	4.386725710656733E-4	5.262497140881864E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	2	3	6	0	7	27	-1	48	41	55			01,02										Vb 17	CASSMTGIGPEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGGCTCACGACGGCTACACCTTCGGTTCG	CASSIGAHDGYTF	In	VDJ	2	312	4.472739940277453E-4	5.365683359330528E-4	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	3	7	0	8	1	7	27	41	47	42	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIGAHDGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGTCCCGGGGACAGGGGGCGTTCAGCCCCAGCATTTTGGTGAT	CASSVPGTGGVQPQHF	In	VDJ	2	323	4.630432694582107E-4	5.554858093153079E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	0	6	6	2	27	39	57	45	59			01,02										Vb 17	CASSVPGTGGVQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGAATGGGGGTTGAAAAACCCGACCCAGCATTTTGGTGAT	CASSMEWGLKNPTQHF	In	VDJ	2	332	4.759454039013187E-4	5.709637420826075E-4	48	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	3	6	1	11	5	13	27	41	51	46	64			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSMEWGLKNPTQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACTCAAGCTAGCGGGGGTTCCGCCCGGGGGCTGTTTTTTGGAGAA	CASSTQASGGSARGLFF	In	VDJ	2	338	4.845468268633908E-4	5.812823639274739E-4	51	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	4	4	2	13	6	12	27	40	56	46	68			01,02										Vb 17	CASSTQASGGSARGLFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGGGGGGACACCAGATATCAGCCCCAGCATTTTGGTGAT	CASSIGGDTRYQPQHF	In	VDJ	2	342	4.902811088381055E-4	5.881614451573848E-4	48	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	1	0	6	5	3	6	27	43	52	46	58			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIGGDTRYQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGGAACGACCTAGGCAATCAGCCCCAGCATTTTGGTGAT	CASSRNDLGNQPQHF	In	VDJ	2	349	5.003161022938561E-4	6.001998373097289E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	5	4	8	2	9	0	27	39	-1	48	52			01,02			01,02							Vb 17	CASSRNDLGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCTTACAGATAACCTACGAGAGCAGTACTTCGGGCCG	CASSLTDNLREQYF	In	VDJ	2	354	5.074839547622495E-4	6.087986888471176E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	5	7	3	11	27	39	46	42	57			01,02										Vb 17	CASSLTDNLREQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGGCCGGGACAGGGGAGGGCAGATACGCAGTATTTTGGCCCA	CASGPGQGRADTQYF	In	VDJ	2	364	5.218196596990363E-4	6.259963919218949E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	8	0	2	4	5	4	27	36	51	41	55			01,02										Vb 17	CASGPGQGRADTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGGGAGCTCTGGGATGAGCAGTTCTTCGGGCCA	CASSRELWDEQFF	In	VDJ	3	393	5.633932040157177E-4	6.758697308387492E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	9	2	8	0	7	27	-1	45	40	52			01,02										Vb 17	CASSRELWDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCCTGAGGGACCAGCCCCAGCATTTTGGTGAT	CASSTLRDQPQHF	In	VDJ	3	400	5.734281974714684E-4	6.879081229910933E-4	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	4	0	7	7	6	0	27	40	-1	46	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSTLRDQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTATCCGGGAGAGCGGGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	3	413	5.920646138892911E-4		49	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	6	4	4	10	0	27	43	-1	53	59			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATGGCGTCCGGACGGATTGAGCAGTTCTTCGGGCCA	CASMASGRIEQFF	In	VDJ	3	422	6.049667483323992E-4	7.257430697556035E-4	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	7	1	7	9	8	4	27	37	49	45	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASMASGRIEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCAGGGTGCAGATACGCAGTATTTTGGCCCA	CASSQGADTQYF	In	VDJ	3	440	6.307710172186152E-4	7.566989352902027E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	4	3	4	1	2	27	38	44	39	46			01,02										Vb 17	CASSQGADTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGGGGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSIGGSNQPQHF	In	VDJ	3	467	6.694774205479393E-4	8.031327335921015E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	3	8	2	0	0	0	27	-1	-1	41	47			01,02										Vb 17	CASSIGGSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGCAGTCGGACAGGGCAAGGCCTACGAGCAGTACTTCGGGCCG	CASSIAVGQGKAYEQYF	In	VDJ	3	476	6.823795549910474E-4	8.18610666359401E-4	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	1	3	2	5	5	27	43	56	48	61			01,02										Vb 17	CASSIAVGQGKAYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAAGGGGTTTAAGGGCAATGAGCAGTTCTTCGGGCCA	CASKGFKGNEQFF	In	VDJ	3	489	7.0101597140887E-4	8.409676803566115E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	5	2	6	0	8	27	-1	42	37	50			01,02										Vb 17	CASKGFKGNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGTACGGCCAGGGGAACACTGAAGCTTTCTTTGGACAA	CASSMYGQGNTEAFF	In	VDJ	3	515	7.382888042445155E-4	8.856817083510326E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	3	1	7	0	27	41	-1	48	53			01,02										Vb 17	CASSMYGQGNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGTCGAGCGGATACTTTTCCAGCAGTACTTCGGGCCG		Out	VDJ	3	518	7.425895157255516E-4		46	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	6	5	8	4	10	27	43	52	47	62			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTCCCCCTTAGCGGGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CPP*RGGYNEQFF	Stop	VDJ	3	523	7.497573681939449E-4		39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	14	5	0	3	6	0	27	30	-1	36	47			01,02										Vb 17	CPP*RGGYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCTTATGGGCACAGGGAGAAAGGTAGACACTGAAGCTTTCTTTGGACAA	CASLMGTGRKVDTEAFF	In	VDJ	4	542	7.769952075738397E-4	9.321155066529315E-4	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	3	3	3	9	10	27	36	51	45	61			01,02										Vb 17	CASLMGTGRKVDTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAAGGAAACACCATATATTTTGGAGAG	CASSIEGNTIYF	In	VJ	4	556	7.97065194485341E-4	9.561922909576197E-4	36	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-03	01	0	0	0	4	0	1	27	-1	44	-1	45			01,02										Vb 17	CASSIEGNTIYF+TCRBV19-01+TCRBJ01-03	TCRBV19-01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCCCAGCGGGGGGCGCAGATACGCAGTATTTTGGCCCA	CASSIPAGGADTQYF	In	VDJ	4	560	8.027994764600557E-4	9.630713721875306E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	6	1	4	3	2	27	41	53	44	55			01,02										Vb 17	CASSIPAGGADTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCACGGGACAGGGCACAGATACGCAGTATTTTGGCCCA	CATTGQGTDTQYF	In	VDJ	4	563	8.071001879410918E-4	9.682306831099638E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	10	0	4	1	4	0	27	34	-1	38	46			01,02										Vb 17	CATTGQGTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTTCATCTTAACAGTGAAGCTTTCTTTGGACAA	CASSIVHLNSEAFF	In	VDJ	4	566	8.114008994221277E-4	9.73389994032397E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	3	5	7	9	0	27	43	-1	52	56			01,02										Vb 17	CASSIVHLNSEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACGGGACAGGGGAGAGATGAGCAGTTCTTCGGGCCA	CASTGQGRDEQFF	In	VDJ	4	577	8.271701748525931E-4	9.923074674146521E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	0	2	8	1	4	27	37	48	38	52			01,02										Vb 17	CASTGQGRDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGAATCAGGGCCCCGTGGGCGTTCACCCCTCCACTTTGGGAAC		Out	VDJ	4	586	8.400723092957011E-4		47	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	4	3	9	4	11	27	38	47	42	58			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-06	TCRBV19-01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTGGGACGGCAAAAACATTCAGTACTTCGGCGCC	CASSWDGKNIQYF	In	VDJ	4	589	8.443730207767371E-4	0.0010129447111043848	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-04	01	5	0	7	3	1	2	27	39	45	40	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSWDGKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGATCCTCACGTGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASRSSRATNEKLFF	In	VDJ	4	615	8.816458536123826E-4	0.001057658739098806	45	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	6	3	7	0	6	3	27	38	46	44	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRSSRATNEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCACCTTTTGGGACGCAGTATTTTGGCCCA	CASSSPFGTQYF	In	VDJ	4	616	8.830794241060613E-4	0.0010593785094062838	36	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-03	01	5	0	9	9	9	0	27	39	-1	48	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSSPFGTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATCACTGGGACTTCCTCCCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	5	713	0.0010221357619928924		53	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	0	10	4	5	6	27	44	55	49	61			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCCCACTGACTAGCGGTCATTACAATGAGCAGTTCTTCGGGCCA	CASSIPLTSGHYNEQFF	In	VDJ	5	816	0.0011697935228417954	0.0014033325709018303	51	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	2	5	4	6	4	27	41	56	47	60			01,02			01,02							Vb 17	CASSIPLTSGHYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCAGGGATCCACGAGCAGTACTTCGGGCCG	CASSSGIHEQYF	In	VDJ	6	942	0.001350423405045308	0.0016200236296440248	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	3	5	1	4	27	39	45	40	49			01,02										Vb 17	CASSSGIHEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTACAGACTTCGGAATGAAAAACTGTTTTTTGGCAGT	CASSYRLRNEKLFF	In	VDJ	7	985	0.0014120669362734908	0.0016939737528655673	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	5	3	5	5	1	7	27	39	44	40	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSYRLRNEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCGGGGGACAGCATATACGAGCAGTACTTCGGGCCG	CASSSGDSIYEQYF	In	VDJ	8	1137	0.0016299696513126488	0.0019553788396021827	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	5	4	4	4	27	39	50	43	54			01,02										Vb 17	CASSSGDSIYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTGCGTCGGGAGACTCGTTGATGAGCAGTTCTTCGGGCCA	CASCVGRLVDEQFF	In	VDJ	8	1141	0.0016357039332873635	0.0019622579208320935	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	8	2	8	5	8	27	36	47	41	55			01,02										Vb 17	CASCVGRLVDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGTATGACAGGGGGGTTGGACGAGCAGTACTTCGGGCCG	CASSRMTGGLDEQYF	In	VDJ	9	1372	0.0019668587173271366	0.00235952486185945	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	2	1	5	5	5	27	39	53	44	58			01,02										Vb 17	CASSRMTGGLDEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCGTTAACAGGGCTATGAACACTGAAGCTTTCTTTGGACAA	CATVNRAMNTEAFF	In	VDJ	10	1485	0.002128852183112826	0.002553858906604434	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	3	3	0	6	3	27	34	46	40	49			01,02										Vb 17	CATVNRAMNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGACGGAACACTGAAGCTTTCTTTGGACAA	CASSIGRNTEAFF	In	VDJ	10	1505	0.0021575235929863997	0.0025882543127539884	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	1	2	7	1	0	1	27	-1	46	43	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIGRNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAAGGGGGATTCATGGGAAAAACTGTTTTTTGGCAGT	CASSKGDSWEKLFF	In	VDJ	22	3280	0.00470211121926604	0.0056408466085269655	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	5	1	8	0	8	27	-1	46	40	54			01,02										Vb 17	CASSKGDSWEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATTTCGGGACAGATTCCTACGAGCAGTACTTCGGGCCG	CASSIDFGTDSYEQYF	In	VDJ	25	3777	0.00541459575462434	0.006495572451343398	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	5	1	4	2	27	44	55	48	57			01,02										Vb 17	CASSIDFGTDSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAACTCCAGGGATGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSIELQGWSNQPQHF	In	VDJ	40	6080	0.00871610860156632	0.010456203469464619	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	3	1	4	4	27	44	53	48	57			01,02										Vb 17	CASSIELQGWSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGCAGGGTCTCGAGCCAAAAACATTCAGTACTTCGGCGCC	CASSMAGSRAKNIQYF	In	VDJ	60	9041	0.012960910833348863	0.015548443349906186	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	3	4	3	0	2	5	27	41	48	43	53			01,02										Vb 17	CASSMAGSRAKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAACTCCGACAGGACAACTATGGCTACACCTTCGGTTCG	CASSELRQDNYGYTF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	45	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	2	4	2	4	2	23	38	48	42	50													Vb 11	CASSELRQDNYGYTF+TCRBV25-01+TCRBJ01-02	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATACCCCTTCTACAATGAGCAGTTCTTCGGGCCA	CASSEYPFYNEQFF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	42	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	4	10	3	3	1	23	40	45	43	46						01,02							Vb 11	CASSEYPFYNEQFF+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGGGTAGGACAGAACCACCGGGGAGCTGTTTTTTGGAGAA	CASSG*DRTTGELFF	Stop	VDJ	1	52	7.454566567129089E-5		45	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	1	5	4	4	3	23	36	46	40	49													Vb 11	CASSG*DRTTGELFF+TCRBV25-01+TCRBJ02-02	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAGTCAGGGGGATCGGTATCGATGAAGCTTTCTTTGGACAA		Out	VDJ	1	54	7.741280665864823E-5		47	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	1	7	2	11	23	37	46	39	57													Vb 11	X+TCRBV25-01+TCRBJ01-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTATAGCAGGGGTTCAAGAGACCCAGTACTTCGGGCCA	CASSIAGVQETQYF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	42	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	4	2	2	4	2	23	35	45	39	47													Vb 11	CASSIAGVQETQYF+TCRBV25-01+TCRBJ02-05	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTAAGGACAGTTGGGATGAGCAGTTCTTCGGGCCA	CASSKDSWDEQFF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	39	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	1	5	8	2	5	23	35	43	37	48													Vb 11	CASSKDSWDEQFF+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATTGACAGGGGGCCTTGRCACCGGGGAGCTGTTTTTTGGAGAA	CASSELTGGLXTGELFF	In	VDJ	1	104	1.4909133134258178E-4	1.7885611197768426E-4	51	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	2	0	4	1	5	23	39	50	40	55													Vb 11	CASSELTGGLXTGELFF+TCRBV25-01+TCRBJ02-02	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTAAGTGGCGAAAACTGGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	134	1.920984461529419E-4		56	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	1	6	5	14	5	23	35	54	49	59													Vb 11	X+TCRBV25-01+TCRBJ02-06	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGCCCATCTCCCGGGGTACGATAATTCACCCCTCCACTTTGGGAAC	CASSAHLPGYDNSPLHF	In	VDJ	1	161	2.30804849482266E-4	2.7688301950391504E-4	51	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	4	8	3	5	9	4	23	36	50	45	54													Vb 11	CASSAHLPGYDNSPLHF+TCRBV25-01+TCRBJ01-06	TCRBV25-01*01	TCRBD02-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGCTTTCCAGGGGGCGGATAATTCACCCCTCCACTTTGGGAAC	CASSAFQGADNSPLHF	In	VDJ	1	179	2.566091183684821E-4	3.0783888503851427E-4	48	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	4	0	5	5	2	23	36	49	41	51													Vb 11	CASSAFQGADNSPLHF+TCRBV25-01+TCRBJ01-06	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTAAGTACAGGGCCACTGAAGCTTTCTTTGGACAA	CASSKYRATEAFF	In	VDJ	1	218	3.1251836762195026E-4	3.7490992703014583E-4	39	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	3	4	4	1	23	35	45	39	46													Vb 11	CASSKYRATEAFF+TCRBV25-01+TCRBJ01-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATCGGGTGGGCGGGGTGGCTACACCTTCGGTTCG	CASSESGGRGGYTF	In	VDJ	2	236	3.3832263650816633E-4	4.0586579256474505E-4	42	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	1	7	3	7	7	0	23	39	-1	46	52													Vb 11	CASSESGGRGGYTF+TCRBV25-01+TCRBJ01-02	TCRBV25-01*01	TCRBD02-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGGTGGACACATGACACTGAAGCTTTCTTTGGACAA	CASRWTHDTEAFF	In	VDJ	2	280	4.0139973823002787E-4	4.815356860937653E-4	39	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	6	3	2	4	23	34	41	36	45													Vb 11	CASRWTHDTEAFF+TCRBV25-01+TCRBJ01-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAGGCGACTAGCGGCGGCAATGAGCAGTTCTTCGGGCCA	CASSEATSGGNEQFF	In	VDJ	3	380	5.44756787597895E-4	6.535127168415387E-4	45	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	2	5	6	3	3	23	37	49	40	52						01,02							Vb 11	CASSEATSGGNEQFF+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAAGGGTACACTGAAGCTTTCTTTGGACAA	CASSEGYTEAFF	In	VDJ	3	397	5.691274859904324E-4	6.827488120686601E-4	36	TCRBV25	TCRBV25-01	01				TCRBJ01	TCRBJ01-01	01	2	0	9	3	0	1	23	-1	41	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	CASSEGYTEAFF+TCRBV25-01+TCRBJ01-01	TCRBV25-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAAGACTTTAAGGGATCGCCCCAGCATTTTGGTGAT	CASSEDFKGSPQHF	In	VDJ	3	412	5.906310433956124E-4	7.085453666808261E-4	42	TCRBV25	TCRBV25-01	01				TCRBJ01	TCRBJ01-05	01	2	0	8	9	8	2	23	38	50	46	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	CASSEDFKGSPQHF+TCRBV25-01+TCRBJ01-05	TCRBV25-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAAAAGTTAGGGGGGATTGGCTACACCTTCGGTTCG	CASSEKLGGIGYTF	In	VDJ	4	532	7.626595026370529E-4	9.149178035781541E-4	42	TCRBV25	TCRBV25-01	01				TCRBJ01	TCRBJ01-02	01	2	5	1	7	5	3	23	38	49	43	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	CASSEKLGGIGYTF+TCRBV25-01+TCRBJ01-02	TCRBV25-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAACGTCGGACGGCGCACTGAAGCTTTCTTTGGACAA	CASNVGRRTEAFF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	39	TCRBV02	TCRBV02-01	01				TCRBJ01	TCRBJ01-01	01	7	1	7	4	5	4	23	33	42	38	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASNVGRRTEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCACCTCGGACGGTTTGTCTGGAAACACCATATATTTTGGAGAG	CATSDGLSGNTIYF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	42	TCRBV02	TCRBV02-01	01				TCRBJ01	TCRBJ01-03	01	10	1	7	1	4	6	23	30	38	34	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CATSDGLSGNTIYF+TCRBV02-01+TCRBJ01-03	TCRBV02-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCACCCCCCCCCGGGGACAACTACGAGTCGACTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	54	7.741280665864823E-5		55	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	10	0	6	0	10	12	23	30	46	40	58													Vb 22	X+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGCGGGACTTTCGGGGAGCTGTTTTTTGGAGAA	CASSGTFGELFF	In	VDJ	1	54	7.741280665864823E-5	9.286759660379759E-5	36	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	0	10	7	1	2	23	34	41	35	43						01,02							Vb 22	CASSGTFGELFF+TCRBV02-01+TCRBJ02-02	TCRBV02-01*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGGGGACACCAATCAGCCCCAGCATTTTGGTGAT	CASSGDTNQPQHF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	39	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	0	6	3	0	1	23	-1	42	36	43													Vb 22	CASSGDTNQPQHF+TCRBV02-01+TCRBJ01-05	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTAGGGACAGGGGAACTAATGAAAAACTGTTTTTTGGCAGT	CASSRDRGTNEKLFF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	0	2	1	1	0	23	35	-1	36	46													Vb 22	CASSRDRGTNEKLFF+TCRBV02-01+TCRBJ01-04	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGCCCCGGGACAGGGACAAATGGCTACACCTTCGGTTCG	CASSPGTGTNGYTF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	42	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	3	6	4	4	23	34	47	38	51													Vb 22	CASSPGTGTNGYTF+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGAAGTAGGGACAGGGATTGGCTACACCTTCGGTTCG	CASSEVGTGIGYTF	In	VDJ	1	77	1.1038492801325766E-4	1.3242231367578547E-4	42	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	3	7	2	2	23	39	50	41	52													Vb 22	CASSEVGTGIGYTF+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGAACAGGGGATGGTGAACACTGAAGCTTTCTTTGGACAA	CASSEQGMVNTEAFF	In	VDJ	1	92	1.318884854184377E-4	1.5821886828795145E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	2	0	0	4	23	-1	44	38	48													Vb 22	CASSEQGMVNTEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTTCAACACTAGCGGGACCTGAATCCAATGAGCAGTTCTTCGGGCCA	CASSSTLAGPESNEQFF	In	VDJ	1	112	1.6055989529201113E-4	1.9261427443750614E-4	51	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	3	3	6	5	8	23	35	50	40	58													Vb 22	CASSSTLAGPESNEQFF+TCRBV02-01+TCRBJ02-01	TCRBV02-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGGCCCAGGACGGCAATCAGCCCCAGCATTTTGGTGAT	CASRAQDGNQPQHF	In	VDJ	1	113	1.619934657856898E-4	1.9433404474498387E-4	42	TCRBV02	TCRBV02-01	01				TCRBJ01	TCRBJ01-05	01	6	1	7	2	6	1	23	34	44	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASRAQDGNQPQHF+TCRBV02-01+TCRBJ01-05	TCRBV02-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTTACCGGGACATCACTAACTATGGCTACACCTTCGGTTCG	CASSYRDITNYGYTF	In	VDJ	1	124	1.777627412161552E-4	2.1325151812723892E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	6	0	4	3	23	35	45	39	48													Vb 22	CASSYRDITNYGYTF+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCACCCTGAAACCCTGGACAGGCCAGCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	129	1.8493059368454855E-4		58	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	7	1	4	0	12	4	23	33	52	45	56													Vb 22	X+TCRBV02-01+TCRBJ01-06	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCTGTAACTTTGATAGCAATCAGCCCCAGCATTTTGGTGAT	CASCNFDSNQPQHF	In	VDJ	1	137	1.963991576339779E-4	2.3560853212444946E-4	42	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	8	3	10	0	4	4	23	32	39	36	43						01,02							Vb 22	CASCNFDSNQPQHF+TCRBV02-01+TCRBJ01-05	TCRBV02-01*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGGCTACCTTAGGGACTAGCGGGAGAAGGGAGACCCAGTACTTCGGGCCA	CASRATLGTSGRRETQYF	In	VDJ	1	172	2.465741249127314E-4	2.958004928861701E-4	54	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	0	2	5	10	4	23	34	58	44	62													Vb 22	CASRATLGTSGRRETQYF+TCRBV02-01+TCRBJ02-05	TCRBV02-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCGTTCGGGACAGTACTCACAATGAGCAGTTCTTCGGGCCA	CASVRDSTHNEQFF	In	VDJ	1	208	2.9818266268516355E-4	3.577122239553685E-4	42	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	8	0	5	5	4	5	23	32	43	36	48													Vb 22	CASVRDSTHNEQFF+TCRBV02-01+TCRBJ02-01	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGACCCTAGCGGGGGGGCGGATACGCAGTATTTTGGCCCA	CASSDPSGGADTQYF	In	VDJ	1	222	3.1825264959666497E-4	3.817890082600568E-4	45	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	4	0	6	2	2	23	37	51	39	53													Vb 22	CASSDPSGGADTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGAAAGGGCGTCTCCAGCCCTAGTTTACGAGCAGTACTTCGGGCCG	CASSERASPALVYEQYF	In	VDJ	2	231	3.31154784039773E-4	3.9726694102735637E-4	51	TCRBV02	TCRBV02-01	01				TCRBJ02	TCRBJ02-07	01	2	5	3	4	0	17	23	-1	42	38	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASSERASPALVYEQYF+TCRBV02-01+TCRBJ02-07	TCRBV02-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCATTGGGGACTCACCCGCCCGGTATGACGAAGCTTTCTTTGGACAA	CASIGDSPARYDEAFF	In	VDJ	3	412	5.906310433956124E-4	7.085453666808261E-4	48	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	7	0	10	8	3	17	23	33	42	36	59						01,02							Vb 22	CASIGDSPARYDEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGTACCCTCTCAGACATCTGTGTACTTCTGTGCCAGCATAAAGGGAGGGGTTGCTTTCTTTGGACAA	CASIKGGVAFF	In	VDJ	1	181	2.5947625935583945E-4	3.1127842565346973E-4	33	TCRBV06	TCRBV06-04		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	7	9	0	11	4	3	28	38	49	42	52			01,02											CASIKGGVAFF+TCRBV06-04+TCRBJ01-01	TCRBV06-04	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTGGCAGATCCTCTGGAAACACCATATATTTTGGAGAG	CASSGRSSGNTIYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	42	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	4	5	0	2	3	26	38	43	40	46														CASSGRSSGNTIYF+TCRBV06-07+TCRBJ01-03	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTCCTGGACAGGGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	71	1.0178350505118563E-4		40	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	3	4	3	0	26	39	-1	42	50														X+TCRBV06-07+TCRBJ02-05	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTACCGGATCGCAGGGAGGGGGGGCAGGATGGCTACACCTTCGGTTCG		Out	VDJ	1	74	1.0608421653222165E-4		53	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	2	9	0	6	13	4	26	41	61	54	65						01,02								X+TCRBV06-07+TCRBJ01-02	TCRBV06-07*01	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCCAAGGGGCCATGGGCACATGGGGCGGGGTGACCCAGTACTTCGGGCCA	CASSQGAMGTWGGVTQYF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	54	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	7	3	7	23	1	26	37	66	60	67														CASSQGAMGTWGGVTQYF+TCRBV06-07+TCRBJ02-05	TCRBV06-07*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTCATCCACCTAGCGGGGGCCAGACACCAGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	87	1.2472063295004436E-4		53	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	4	2	9	7	10	26	38	55	45	65														X+TCRBV06-07+TCRBJ02-02	TCRBV06-07*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCACCTTCCGGCCTTAGCCATCTCCGGACACAGATACGCAGTATTTTGGCCCA	CATFRP*PSPDTDTQYF	Stop	VDJ	1	112	1.6055989529201113E-4		51	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	10	5	7	2	11	10	26	33	48	44	58						01,02								CATFRP*PSPDTDTQYF+TCRBV06-07+TCRBJ02-03	TCRBV06-07*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTGAAGGGCACAGGGAATCACCCCTCCACTTTGGGAAC	CASSEGHRESPLHF	In	VDJ	1	125	1.7919631170983387E-4	2.1497128843471665E-4	42	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	3	3	10	7	2	26	38	51	45	53														CASSEGHRESPLHF+TCRBV06-07+TCRBJ01-06	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGATCTCCTAGGGGCACGTTCTACGAGCAGTACTTCGGGCCG	CASRSPRGTFYEQYF	In	VDJ	1	156	2.2363699701387265E-4	2.682841679665264E-4	45	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	5	2	3	7	6	26	37	49	44	55														CASRSPRGTFYEQYF+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCCCCCAGGGACAGGGATACGAGCAGTACTTCGGGCCA	CASSPQGQGYEQYF	In	VDJ	1	159	2.2793770849490868E-4	2.734434788889596E-4	42	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	0	3	11	6	7	26	37	52	43	59														CASSPQGQGYEQYF+TCRBV06-07+TCRBJ02-05	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCCCTTACAATGAGCAGTTCTTCGGGCCA	CASSPYNEQFF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	33	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	4	10	4	2	0	26	37	-1	39	41						01,02								CASSPYNEQFF+TCRBV06-07+TCRBJ02-01	TCRBV06-07*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTGAAGCGAAGCTCGGGGGCCCGATTTACAATGAGCAGTTCTTCGGGCCA	CASSEAKLGGPIYNEQFF	In	VDJ	1	187	2.6807768231791146E-4	3.215970474983361E-4	54	TCRBV06	TCRBV06-07	01				TCRBJ02	TCRBJ02-01	01	5	6	0	4	12	6	26	38	56	50	62				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEAKLGGPIYNEQFF+TCRBV06-07+TCRBJ02-01	TCRBV06-07*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCTTAGGCTTTCGGCTAGCGGGGGGGATAGATACGCAGTATTTTGGCCCA	CASSLGFRLAGGIDTQYF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	54	TCRBV07	TCRBV07-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	4	0	5	8	2	19	35	55	43	57														CASSLGFRLAGGIDTQYF+TCRBV07-07+TCRBJ02-03	TCRBV07-07*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCTTACACAGGGGGAACTATGGCTACACCTTCGGTTCG	CASSLHRGNYGYTF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	42	TCRBV07	TCRBV07-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	3	1	2	1	0	19	34	-1	35	43														CASSLHRGNYGYTF+TCRBV07-07+TCRBJ01-02	TCRBV07-07*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCCAGACAGATGGAAACACCATATATTTTGGAGAG	CASSQTDGNTIYF	In	VDJ	2	287	4.1143473168577855E-4	4.935740782461094E-4	39	TCRBV16	TCRBV16-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	2	5	3	0	1	29	-1	48	43	49			01,02											CASSQTDGNTIYF+TCRBV16-01+TCRBJ01-03	TCRBV16-01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCCAACCAGACAGGGGGAATCAGCCCCAGCATTTTGGTGAT	CASSQPDRGNQPQHF	In	VDJ	4	600	8.601422962072026E-4	0.0010318621844866399	45	TCRBV16	TCRBV16-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	2	1	4	3	0	29	44	-1	47	56			01,02											CASSQPDRGNQPQHF+TCRBV16-01+TCRBJ01-05	TCRBV16-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCCAATCCAGCTACGAGCAGTACTTCGGGCCG	CASSQSSYEQYF	In	VDJ	5	714	0.001023569332486571	0.0012279159995391017	36	TCRBV16	TCRBV16-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	5	3	0	0	29	-1	-1	46	49			01,02											CASSQSSYEQYF+TCRBV16-01+TCRBJ02-07	TCRBV16-01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCCAACCGGACAGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSQPDRGNQPQHF	In	VDJ	14	2047	0.0029345188005602393	0.00352036981940692	45	TCRBV16	TCRBV16-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	1	3	2	2	0	29	44	-1	46	54			01,02											CASSQPDRGNQPQHF+TCRBV16-01+TCRBJ01-05	TCRBV16-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGCCACGTTTGGTGGGACTCGGCCGTGTTGTCTGTGCCAGCAGCAACACGAACCTACAGGATTACAATGAGCAGTTCTTCGGGCCA	CASSNTNLQDYNEQFF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	48	TCRBV21	TCRBV21-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	3	4	4	9	2	33	47	61	56	63														CASSNTNLQDYNEQFF+TCRBV21-01+TCRBJ02-01	TCRBV21-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCATACCACGTTTCAGGGTCCTAACCTACGAGCAGTACTTCGGGCCG	CASIPRFRVLTYEQYF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	48				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	4	3	2	10	6	33	43	58	53	64	TCRBV25,TCRBV27,TCRBV28	TCRBV25-01,TCRBV25-or09_02,TCRBV27-01,TCRBV28-01												CASIPRFRVLTYEQYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTTAGCCGGGGAGATACGCAGTATTTTGGCCCA	CATSDFSRGDTQYF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	42	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	8	3	5	4	0	24	41	-1	45	50		TCRBV24-01,TCRBV24-or09_02												CATSDFSRGDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGGGCCGAACACTGAAGCTTTCTTTGGACAA	CASSLGPNTEAFF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	9	0	1	0	1	26	-1	45	42	46		TCRBV12-03,TCRBV12-04												CASSLGPNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCACGGGACATACCAAGAGACCCAGTACTTCGGGCCA	CSASHGTYQETQYF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	6	0	4	1	26	37	47	41	48		TCRBV20-01,TCRBV20-or09_02												CSASHGTYQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGCGTAGGGGGGTACGGGGAGCTGTTTTTTGGAGAA	CASSVGGYGELFF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	39	unresolved						TCRBJ02	TCRBJ02-02	01	6	5	1	7	3	3	22	33	42	36	45	TCRBV12,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVGGYGELFF+X+TCRBJ02-02	unresolved		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCTGGGGGACGACTGACCTGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	42	6.020996073450418E-5		58	unresolved						TCRBJ01	TCRBJ01-06	01	5	0	7	0	4	12	18	30	39	34	51	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-06	unresolved		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGGGGGGAGGTGGATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	42	6.020996073450418E-5		43	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	0	9	1	6	1	3	19	35	42	36	45	TCRBV05,TCRBV11					unresolved								X+X+TCRBJ01-04	unresolved	TCRBD02-01*02	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGGACAGGGGGCGGGCGGCACTGAAGCTTTCTTTGGACAA	CASSLGQGAGGTEAFF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	0	4	0	6	26	-1	52	42	58		TCRBV12-03,TCRBV12-04												CASSLGQGAGGTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGTAGCGGGAGTTACAGATACGCAGTATTTTGGCCCA	CSAVAGVTDTQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	5	2	3	1	2	26	35	45	36	47		TCRBV20-01,TCRBV20-or09_02												CSAVAGVTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAATGAGGTAGCGGGCAGGGGAAAGACCCAGTACTTCGGGCCA	CASNEVAGRGKTQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	7	5	4	6	6	8	22	32	45	38	53	TCRBV02,TCRBV12					01,02								CASNEVAGRGKTQYF+X+TCRBJ02-05	unresolved	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGGGGGCAGGGAAGAGGGGACAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	43	6.164353122818285E-5		52	unresolved			unresolved			TCRBJ02	TCRBJ02-05	01	1	4	3	2	4	9	18	34	43	38	52	TCRBV05,TCRBV11			TCRBD01,TCRBD02										X+X+TCRBJ02-05	unresolved	unresolved	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCACCAGTGGACTAGCGGGAGGTCTAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	44	6.307710172186152E-5		50				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	1	1	0	0	5	31	-1	57	43	62	TCRBV23,TCRBV24,TCRBV25	TCRBV23-or09_02,TCRBV24-01,TCRBV24-or09_02,TCRBV25-01,TCRBV25-or09_02												X+X+TCRBJ02-07		TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGATCAGTGGGGGGCAAGCAATCAGCCCCAGCATTTTGGTGAT	CSADQWGASNQPQHF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	45	TCRBV20						TCRBJ01	TCRBJ01-05	01	5	6	0	1	8	1	26	35	49	43	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSADQWGASNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGGGAAAGGGACCACAGGGTCCGGGTCAATGAGCAGTTCTTCGGGCCA	CASRERDHRVRVNEQFF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	51	TCRBV25			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	3	3	6	7	7	30	45	58	52	65		TCRBV25-01,TCRBV25-or09_02												CASRERDHRVRVNEQFF+TCRBV25-X+TCRBJ02-01	TCRBV25	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGTTGCTACCGGGACTAGCGGCCCCGAACTGTTTTTTGGAGAA		Out	VDJ	1	44	6.307710172186152E-5		46	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	0	5	14	8	7	18	29	48	37	55	TCRBV07,TCRBV11					01,02								X+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGGACTCSGCCGTGTATSTCTGTGCCAGCAGCCTCCGGGACAGGGGGGAGCTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLRDRGELNTGELFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	0	1	1	4	5	20	32	47	36	52	TCRBV07,TCRBV11													CASSLRDRGELNTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGGACTCGGCCSTGTATCTCTGTGCCAGCAGTTCCGGGACCGAGGACGAGCAGTACTTCGGGCCG	CASSSGTEDEQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	39	unresolved						TCRBJ02	TCRBJ02-07	01	5	0	7	5	4	5	20	31	40	35	45	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGTEDEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCAGGTCGGGAATGGCTACACCTTCGGTTCG	CSARDQVGNGYTF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	8	3	6	6	0	26	40	-1	46	51		TCRBV20-01,TCRBV20-or09_02												CSARDQVGNGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGTGCGAGAAACCGCAGACTAGCGGGAAAGGACGAGCAGTACTTCGGGCCG	CSAGARNRRLAGKDEQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	54	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	2	3	5	16	4	26	35	62	51	66		TCRBV20-01,TCRBV20-or09_02												CSAGARNRRLAGKDEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGRAGACWCRGCMCTGTATCTCTGCGCCAGCAGCCAAGAGAGTGGTGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSQESGAGANVLTF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	0	11	2	2	0	5	23	-1	43	40	48	TCRBV04,TCRBV23													CASSQESGAGANVLTF+X+TCRBJ02-06	unresolved	TCRBD02-01*02	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGAGGGCTAGCGGGAGGGTTTGGCCGGGAGAGACCCAGTACTTCGGGCCA	CASSLARASGRVWPGETQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	60				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	4	0	4	5	10	18	35	52	40	62	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLARASGRVWPGETQYF+X+TCRBJ02-05		TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGGGCGAACACTGAAGCTTTCTTTGGACAA	CASSLAGANTEAFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	6	0	1	0	0	18	-1	-1	35	41	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGANTEAFF+X+TCRBJ01-01		TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCTCGGCCTTAGTAGCGGGAGGCTACGAGCAGTACTTCGGGCCG	CASSALVAGGYEQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	5	1	3	10	0	19	28	-1	38	48	TCRBV05,TCRBV11													CASSALVAGGYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGGGTCGATGAGCAGTTCTTCGGGCCA	CSARDRVDEQFF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	36	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	8	4	8	1	3	26	40	45	41	48		TCRBV20-01,TCRBV20-or09_02				01,02								CSARDRVDEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGCTTGGACCTAGCGACTTTAAATGAGCAGTTCTTCGGGCCA	CASSLDLATLNEQFF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	4	6	7	7	6	22	33	46	40	52	TCRBV09,TCRBV12					01,02								CASSLDLATLNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCCTCCCTTGGGCCCTGAACAATGAGCAGTTCTTCGGGCCA	CASSLPWALNNEQFF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	45	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	8	0	5	7	5	19	31	42	38	47		TCRBV05-06,TCRBV05-07												CASSLPWALNNEQFF+TCRBV05-X+TCRBJ02-01	TCRBV05	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTGCCGGAGGCAGGTTCACTGAAGCTTTCTTTGGACAA	CASSAGGRFTEAFF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	42	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	10	1	4	3	6	26	38	46	41	52		TCRBV12-03,TCRBV12-04												CASSAGGRFTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTGACCAGCGGGAGCTGGGGTGAGCAGTTCTTCGGGCCA	CASSLTSGSWGEQFF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	45	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	6	2	9	4	6	26	40	52	44	58		TCRBV12-03,TCRBV12-04												CASSLTSGSWGEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATACGGCGGGAGTAGGGGTGTTCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	47	6.737781320289753E-5		52	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	7	2	4	4	10	26	40	51	44	61		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCCGGGGTGGACATAGCCAAAAACATTCAGTACTTCGGCGCC	CSARAGVDIAKNIQYF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	48	TCRBV20						TCRBJ02	TCRBJ02-04	01	1	1	6	0	7	1	26	39	51	46	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARAGVDIAKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTGAAGCAACCGGACTAGCGGGAGAAGGGACCGGGGAGCTGTTTTTTGGAGAA	CASSEATGLAGEGTGELFF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	57	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	1	2	5	9	5	22	34	56	43	61	TCRBV09,TCRBV12													CASSEATGLAGEGTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTTGCGGTCGCCGGGGAGCTGTTTTTTGGAGAA	CASSFAVAGELFF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	39	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	7	5	6	1	3	22	36	41	37	44		TCRBV12-03,TCRBV12-04				01,02								CASSFAVAGELFF+TCRBV12-X+TCRBJ02-02	TCRBV12	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCWMCCAGACAKCTSTKTACTTSTGTGCCAGCAGTTACAACGTCCATCCGGGACAGGGGGCTGACGGCTACACCTTCGGTTCG	CASSYNVHPGQGADGYTF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	0	0	8	11	4	23	38	61	49	65	TCRBV06,TCRBV24													CASSYNVHPGQGADGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCATCAAATCCTGGACCGGCCGGGGCGAGCAGTACTTCGGGCCG	CAIKSWTGRGEQYF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	10	8	3	6	17	0	23	30	-1	47	52	TCRBV06,TCRBV10													CAIKSWTGRGEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCCGATCGGGACAGGGGGCTGGAAACACCATATATTTTGGAGAG	CASSRSGQGAGNTIYF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	0	1	2	5	0	23	35	-1	40	51	TCRBV09,TCRBV21													CASSRSGQGAGNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGCGTCTTGGGTATTGGGAACACTGAAGCTTTCTTTGGACAA	CSGVLGIGNTEAFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	42	TCRBV20						TCRBJ01	TCRBJ01-01	01	7	0	9	1	7	6	26	33	43	40	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSGVLGIGNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGATCTAAGTGTGGCTGAAGCTTTCTTTGGACAA	CASSQDLSVAEAFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	42				TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	0	4	9	6	1	7	18	35	39	36	46	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03				01,02								CASSQDLSVAEAFF+X+TCRBJ01-01		TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTGGCAAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCACCAGTGATTTAAGAGTTAGTGAGCAGTTCTTCGGGCCA	CATSDLRVSEQFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	5	8	9	6	0	42	59	-1	65	68		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDLRVSEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGTCGCCGCATCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSVAASNTGELFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	45	unresolved						TCRBJ02	TCRBJ02-02	01	4	4	6	0	6	1	23	36	44	42	45	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVAASNTGELFF+X+TCRBJ02-02	unresolved		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCAGGGAGCCGAATCAGCCCCAGCATTTTGGTGAT	CASSREPNQPQHF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	39	TCRBV12						TCRBJ01	TCRBJ01-05	01	6	4	3	4	0	5	26	-1	42	37	47		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSREPNQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCCCTAGCGGGAGTAGAGTGAGCAGTTCTTCGGGCCA		Out	VDJ	1	49	7.024495419025487E-5		44	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	4	2	9	2	5	26	40	52	42	57		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGCCACGGTAGGGCTCAGGAGCAGTACTTCGGGCCG	CASSHGRAQEQYF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	39	unresolved						TCRBJ02	TCRBJ02-07	01	6	5	3	7	7	5	24	35	46	42	51	TCRBV06,TCRBV10			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHGRAQEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTGAGCGGGCGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CSARVSGRGTGELFF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	1	6	4	4	2	5	26	39	47	41	52		TCRBV20-01,TCRBV20-or09_02				01,02								CSARVSGRGTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATGGCGGGACCGAGAGACCCAGTACTTCGGGCCA	CSARWRDRETQYF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	7	3	4	2	3	26	38	46	40	49		TCRBV20-01,TCRBV20-or09_02												CSARWRDRETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTACGGATGAGGAACACTGAAGCTTTCTTTGGACAA	CASSLRMRNTEAFF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	42	TCRBV24						TCRBJ01	TCRBJ01-01	01	6	1	8	1	4	4	24	36	43	40	47		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRMRNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTTGGACTAGCGGGAGCCAATGAGCAGTTCTTCGGGCCA	CASSFGLAGANEQFF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	1	2	6	1	1	19	33	47	34	48	TCRBV07,TCRBV11													CASSFGLAGANEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCCTGACCGTCTTGGCTACACTTTCGGTTCG	CASSPDRLGYTF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	36	TCRBV12						TCRBJ01	TCRBJ01-02	01	6	2	7	17	4	15	26	37	44	41	59		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPDRLGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGGTGGTTTAGGCGAGCAGTTCTTCGGGCCA	CASSGGLGEQFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	36	TCRBV12						TCRBJ02	TCRBJ02-01	01	5	5	4	10	8	1	26	38	49	46	50		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGGLGEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTGTCGGGTGGAGGAAACACCATATATTTTGGAGAG	CASSLSGGGNTIYF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	42	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	3	8	4	4	2	4	26	40	46	42	50		TCRBV12-03,TCRBV12-04				01,02								CASSLSGGGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12	TCRBD02-01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACGTTTGGTGCATCCTGAAGACAGCAGCTTCTCATCTGCAGTGCTAGATCCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	50	7.167852468393355E-5		44	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	19	4	3	0	19	0	37	32	-1	51	60		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTAGAGCGGGCCCCTAACTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	50	7.167852468393355E-5		46	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	6	4	0	3	7	26	37	46	40	53		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCCTGGCGCCGGGACAGGGTTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	50	7.167852468393355E-5		53	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	8	0	3	0	8	2	23	32	49	40	51	TCRBV02,TCRBV09													X+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTGGTGACTCTGCTGTGTATTTCTGTCCTTTAAGAAGGGGACTAGCGGGAGTTGGGGGGGACCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	50	7.167852468393355E-5		58	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	14	0	2	2	11	11	23	26	51	37	62		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGACGGACAGGGTTTTACGAGCAGTACTTCGGGCCG	CASSRRTGFYEQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	1	3	4	3	3	26	39	50	42	53		TCRBV03-01,TCRBV03-02												CASSRRTGFYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGGTTGGGGCTCAACCTACGAGCAGTACTTCGGGCCG	CSARGWGSTYEQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	7	0	2	5	4	26	37	47	42	51		TCRBV20-01,TCRBV20-or09_02												CSARGWGSTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTATGAAAGCGGGAGGTACAGATACGCAGTATTTTGGCCCA	CSAMKAGGTDTQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	4	6	1	3	4	1	26	36	49	40	50		TCRBV20-01,TCRBV20-or09_02												CSAMKAGGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAAGAGGGCAGGGGGGCTTTCTTTGGACAA	CASSQEEGRGAFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	1	11	6	0	23	40	-1	46	53	TCRBV01,TCRBV04													CASSQEEGRGAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGGCTACAGGACGGGCTCTATGGCTACACCTTCGGTTCG	CASRLQDGLYGYTF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	3	4	4	3	7	24	35	43	38	50		TCRBV24-01,TCRBV24-or09_02												CASRLQDGLYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGTCTCTAGCAACTACGAGCAGTACTTCGGGCCG	CASSVSSNYEQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	4	7	3	3	2	24	37	45	40	47		TCRBV24-01,TCRBV24-or09_02				01,02								CASSVSSNYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCAGGGTGACAGGGGGCAAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	51	7.311209517761221E-5		50				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	2	0	1	5	1	18	30	45	35	46	TCRBV05,TCRBV11	TCRBV05-03,TCRBV11-03												X+X+TCRBJ01-04		TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTCCCTCTCACGGGACCTAACTCCTACGAGCAGTACTTCGGGCCG	CASSFPLTGPNSYEQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	51	unresolved						TCRBJ02	TCRBJ02-07	01	3	0	7	0	9	4	19	33	47	42	51	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFPLTGPNSYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYRGRRGACWCAGCMMKGTAYTTCTGTGCCAGCTGTCTCGGACGGGTGAACACTGAAGCTTTCTTTGGACAA	CASCLGRVNTEAFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	42	unresolved						TCRBJ01	TCRBJ01-01	01	10	1	7	0	8	3	24	31	43	39	46	TCRBV02,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASCLGRVNTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCATCAGTGGAGCGGGGGGGATGGATACGCAGTATTTTGGCCCA	CAISGAGGMDTQYF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	6	0	6	1	3	24	37	48	38	51	TCRBV06,TCRBV10													CAISGAGGMDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGCCAGGGCCACTGAAGCTTTCTTTGGACAA	CASSQDARATEAFF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	3	4	3	1	26	43	51	46	52		TCRBV03-01,TCRBV03-02												CASSQDARATEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCACCGGGAAACAATATAGCAATCAGCCCCAGCATTTTGGTGAT	CSATGKQYSNQPQHF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	6	8	3	0	3	7	26	34	42	37	49		TCRBV20-01,TCRBV20-or09_02												CSATGKQYSNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGGAGGGACTAGGGTCCTACGAGCAGTACTTCGGGCCG	CSARGEGLGSYEQYF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	0	8	1	4	2	26	39	51	43	53		TCRBV20-01,TCRBV20-or09_02				01,02								CSARGEGLGSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCGGCGGGAGCCCCAGCATTCTGGTGAT		Out	VDJ	1	52	7.454566567129089E-5		35	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	6	7	2	21	4	11	24	36	47	40	58		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCTACCCGACAGGGGGTGCCACTGAAGCTTTCTTTGGACAA	CASYPTGGATEAFF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	11	2	1	4	7	3	24	31	47	38	50		TCRBV24-01,TCRBV24-or09_02												CASYPTGGATEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCCAGGGACTAGCCGACTACGAGCAGTACTTCGGGCCG	CASSQGLADYEQYF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	7	3	2	3	18	30	41	32	44	TCRBV07,TCRBV11					01,02								CASSQGLADYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGACAGAACTATGGCTACACCTTCGGTTCG	CASRQNYGYTF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	33	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	5	2	0	0	26	-1	-1	37	41		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRQNYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAAGGGACAGGGATATGGCTACACCTTCGGTTCG		Out	VDJ	1	53	7.597923616496956E-5		41	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	0	3	5	1	1	26	41	51	42	52		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAGGGACAGGGGATAGCCTACGAGCAGTACTTCGGGCCG	CASSQGQGIAYEQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	2	2	0	4	23	-1	47	37	51	TCRBV01,TCRBV04													CASSQGQGIAYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGGGGGGGGGAGCCAGCCCCAGCATTTTGGTGAT	CSARDGGGSQPQHF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	0	9	0	7	1	5	26	40	48	41	53		TCRBV20-01,TCRBV20-or09_02												CSARDGGGSQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCTAACTAGCGGGAGGGCGGATGAGCAGTTCTTCGGGCCA	CSALTSGRADEQFF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	3	0	8	3	3	26	35	51	38	54		TCRBV20-01,TCRBV20-or09_02												CSALTSGRADEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCACGTTTGGTGCCCCAACCAGACAGTCTTTACTTCTGTGCCACCAGTGGCGGGACTAGCGAGACCTACGAGCAGTACTTCGGGCCG	CATSGGTSETYEQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	6	2	2	3	36	49	61	51	64		TCRBV24-01,TCRBV24-or09_02				01,02								CATSGGTSETYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGATGGACGAGGACGGGGTTCAGATACGCAGTATTTTGGCCCA	CASSDGRGRGSDTQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	48	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	8	3	4	9	2	24	39	53	48	55		TCRBV24-01,TCRBV24-or09_02												CASSDGRGRGSDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGYTTAGCGAGAGCAGGGGCGGATGAGCAGTACTTCGGGCCG	CASSLARAGADEQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	45				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	2	7	5	5	18	35	46	40	51	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLARAGADEQYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCCCGGGACAGGGAGGTGAAAAACTGTTTTTTGGCAGT	CASSPGQGGEKLFF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	0	3	7	2	3	19	31	42	33	45	TCRBV05,TCRBV11													CASSPGQGGEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGTAACAGGGGCAATGGAAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	54	7.741280665864823E-5		47	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	3	2	5	2	7	19	34	43	36	50	TCRBV05,TCRBV11													X+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTACCCGACAGGTTAACACTGAAGCTTTCTTTGGACAA	CASSTRQVNTEAFF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	4	2	4	2	26	38	48	42	50		TCRBV12-03,TCRBV12-04												CASSTRQVNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACGTTTGGTGCATCCTGAAGACAGCAGCTTCTAATCTGCAGTGCTAGATCCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	55	7.88463771523269E-5		44	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	18	4	3	0	18	0	37	33	-1	51	60		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGACCCCGCGGACTAATCGGGCTGAAGCTTTCTTTGGACAA	CSARTPRTNRAEAFF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	1	9	6	8	6	26	37	51	45	57		TCRBV20-01,TCRBV20-or09_02				01,02								CSARTPRTNRAEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGCACGGACGGAAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSAGTDGSSYNEQFF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	45	TCRBV20						TCRBJ02	TCRBJ02-01	01	5	1	7	0	5	5	26	35	44	40	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAGTDGSSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGACACCCAGGCTACTACAATGAGCAGTTCTTCGGGCCA	CASRHPGYYNEQFF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	4	4	3	5	3	24	35	44	40	47		TCRBV24-01,TCRBV24-or09_02												CASRHPGYYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GRGACWCGGCMCTSTATCTCTGYGCCAGCAGCCTGGATTATGGGCAGGGGTCAGAGACCCAGTACTTCGGGCCA	CASSLDYGQGSETQYF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	4	2	4	8	2	19	35	49	43	51	TCRBV05,TCRBV23													CASSLDYGQGSETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTAGCGGGGGGGTAGATACGCAGTATTTTGGCCCA	CASSFSGGVDTQYF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	5	0	5	0	1	26	-1	51	40	52		TCRBV12-03,TCRBV12-04												CASSFSGGVDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTAGTGGGAGGCGGCAATGAGCAGTTCTTCGGGCCA	CASSQVVGGGNEQFF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	45	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	9	1	6	4	3	26	42	52	46	55		TCRBV03-01,TCRBV03-02												CASSQVVGGGNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGACAGGGTACAATGAGCAGTTCTTCGGGCCA	CSARGTGYNEQFF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	1	3	4	0	0	26	-1	-1	39	47		TCRBV20-01,TCRBV20-or09_02												CSARGTGYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTCCACACCATGGACAGGGACAGTACAATGAGCAGTTCTTCGGGCCA	CASSPHHGQGQYNEQFF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	51	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	1	3	4	9	4	22	34	51	43	55		TCRBV12-03,TCRBV12-04												CASSPHHGQGQYNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCGCTACCAGGGACTCCTACGAGCAGTACTTCGGGCCG	CATATRDSYEQYF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	9	4	3	0	5	1	24	33	43	38	44		TCRBV24-01,TCRBV24-or09_02												CATATRDSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTGGGGACATTCCATCGAGACCCAGTACTTCGGGCCA	CASSWGHSIETQYF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	6	5	1	7	19	32	39	33	46	TCRBV07,TCRBV11													CASSWGHSIETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGACAGAGCCCACGAGCAGTACTTCGGGCCG	CASSDRAHEQYF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	2	5	5	0	5	26	-1	43	38	48		TCRBV03-01,TCRBV03-02												CASSDRAHEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAACAACCGTTCCAATCAGCCCCAGCATTTTGGTGAT	CSANNRSNQPQHF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	6	3	2	7	26	34	39	36	46		TCRBV20-01,TCRBV20-or09_02												CSANNRSNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGGGTCGGCCCAATCGGAGACCATGAACACTGAAGCTTTCTTTGGACAA	CSAGSAQSETMNTEAFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	51	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	8	4	0	0	19	26	-1	38	34	57		TCRBV20-01,TCRBV20-or09_02				01,02								CSAGSAQSETMNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCAGACTAGCGGGAGGGTTTCCCGATGAGCAGTTCTTCGGGCCA	CSATRLAGGFPDEQFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	2	0	8	3	7	26	36	53	39	60		TCRBV20-01,TCRBV20-or09_02												CSATRLAGGFPDEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTCGGGTAGCGGTTACACTCTCTCCTACGAGCAGTACTTCGGGCCG	CSARDSGSGYTLSYEQYF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	54	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	5	5	0	6	9	26	40	52	46	61		TCRBV20-01,TCRBV20-or09_02				01,02								CSARDSGSGYTLSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTGAACAAGGGCTTAATGAGCAGTTCTTCGGGCCA	CASSEQGLNEQFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	39	TCRBV12						TCRBJ02	TCRBJ02-01	01	5	5	3	7	5	3	22	34	43	39	46		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEQGLNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTCGGCCCTGGACAGGGGAGGGGATGAAAAACTGTTTTTTGGCAGT	CASSSALDRGGDEKLFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	51	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	1	2	6	7	5	22	35	51	42	56		TCRBV12-03,TCRBV12-04												CASSSALDRGGDEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGGCAGTTGCCAGTATTTTGGCCCA		Out	VDJ	1	57	8.171351813968424E-5		35	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	4	5	12	1	4	24	42	46	43	50		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTACCCGTTTGAGAGGGGGCATAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	57	8.171351813968424E-5		50	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	5	0	1	11	1	24	36	54	47	55		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTCTCCGACAGGGAGAGAGACCCAGTACTTCGGGCCA	CSASPTGRETQYF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	2	3	4	6	2	26	34	47	40	49		TCRBV20-01,TCRBV20-or09_02												CSASPTGRETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAACGAGCCGGGACCTGGGGTATGGCTACACCTTCGGTTCG	CSARTSRDLGYGYTF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	45	TCRBV20						TCRBJ01	TCRBJ01-02	01	2	0	7	5	7	6	26	38	50	45	56		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARTSRDLGYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCTTGGGGGGACCCAAGAGACCCAGTACTTCGGGCCA	CSARDLGGTQETQYF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	9	1	1	4	2	26	40	50	44	52		TCRBV20-01,TCRBV20-or09_02												CSARDLGGTQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTTATCACCCTCTGGAAACACCATATATTTTGGAGAG	CASSLSPSGNTIYF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	42	TCRBV12						TCRBJ01	TCRBJ01-03	01	2	3	7	0	2	1	22	37	41	39	42		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLSPSGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTAATGTGGAGGTGTGGGACACAGATACGCAGTATTTTGGCCCA	CASSNVEVWDTDTQYF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	10	1	2	5	7	23	35	45	40	52	TCRBV06,TCRBV10													CASSNVEVWDTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCAGGGTTGAGGGCCGAGAAGGTATGGCTACACCTTCGGTTCG		Out	VDJ	1	58	8.314708863336292E-5		47				TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	4	11	0	5	6	9	18	30	41	36	50	TCRBV05,TCRBV11	TCRBV05-03,TCRBV11-03												X+X+TCRBJ01-02		TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTCGGGCCGCGGGAGGTCCTACGAGCAGTACTTCGGGCCG	CSARDSGRGRSYEQYF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	7	1	1	8	0	26	40	-1	48	56		TCRBV20-01,TCRBV20-or09_02												CSARDSGRGRSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGTCGCGGGGAGGGCCCCTTTGAGCAGTTCTTCGGGCCA		Out	VDJ	1	59	8.458065912704158E-5		44	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	9	0	9	4	6	23	37	48	41	54	TCRBV09,TCRBV12													X+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAACATAACACCGGGGAGCTGTTTTTTGGAGAA	CASSQHNTGELFF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	4	6	2	0	1	23	-1	40	38	41	TCRBV01,TCRBV04													CASSQHNTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAAAGTGGGGGCTTTGACGAACACTGAAGCTTTCTTTGGACAA	CASKVGALTNTEAFF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	6	0	1	4	6	18	28	38	32	44	TCRBV07,TCRBV11													CASKVGALTNTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCTCCAGCCGAACCCGGGGAGAGACCCAGTACTTCGGGCCA	CSAPSSRTRGETQYF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	8	3	4	15	0	26	35	-1	50	55		TCRBV20-01,TCRBV20-or09_02												CSAPSSRTRGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATACCAGGGTCTAAGTGGCTACACCTTCGGTTCG	CASSLYQGLSGYTF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	3	7	6	6	24	36	47	42	53		TCRBV24-01,TCRBV24-or09_02												CASSLYQGLSGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTGCAAGAATACGAGCAGTACTTCGGGCCG	CASSLQEYEQYF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	36	TCRBV12						TCRBJ02	TCRBJ02-07	01	3	2	8	4	4	1	26	40	46	44	47		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLQEYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGAGGCAGGGCGGAGGAGCCCCAGCATTTTGGTGAT	CSARDRGRAEEPQHF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	45	TCRBV20						TCRBJ01	TCRBJ01-05	01	0	4	3	8	6	6	26	40	51	46	57		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDRGRAEEPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTCGGGACAGGGTAGGAGTAATTCACCCCTCCACTTTGGGAAC	CASSSGQGRSNSPLHF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	0	3	6	1	6	22	35	45	36	51		TCRBV12-03,TCRBV12-04												CASSSGQGRSNSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCCTCTAGCGACGAGACCCAGTACTTCGGGCCA	CATSDSSSDETQYF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	4	6	5	3	2	24	40	49	43	51		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDSSSDETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCCGTGGGACAGCGAACACTGAAGCTTTCTTTGGACAA	CASSRGTANTEAFF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	1	3	1	19	31	41	34	42	TCRBV07,TCRBV11													CASSRGTANTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTCTCAGGAGCTAACTATGGCTACACCTTCGGTTCG	CASSQVSGANYGYTF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	45	TCRBV03						TCRBJ01	TCRBJ01-02	01	1	4	4	0	3	2	26	42	49	45	51		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQVSGANYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGTACGACGCCTACCAAGAGACCCAGTACTTCGGGCCA	CSAYDAYQETQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	39	TCRBV20						TCRBJ02	TCRBJ02-05	01	6	2	7	0	4	4	26	34	41	38	45		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAYDAYQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCCACGACAGGGGGCCCGAACACTGAAGCTTTCTTTGGACAA	CSARPTTGGPNTEAFF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	2	0	1	5	2	26	38	53	43	55		TCRBV20-01,TCRBV20-or09_02												CSARPTTGGPNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTCGGCGGACTGGCCTACGAGCAGTACTTCGGGCCG	CSVGGLAYEQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	36	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	1	10	2	5	2	26	33	43	38	45		TCRBV20-01,TCRBV20-or09_02				01,02								CSVGGLAYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCACCAGCGCACAAATACAGGGTGTGAATGCTTTCTTTGGACAA	CATSAQIQGVNAFF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	3	3	11	9	7	22	33	48	42	55	TCRBV02,TCRBV12													CATSAQIQGVNAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGAGAGTAGGGACCCAACACTAAGTAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	63	9.031494110175626E-5		49	TCRBV12						TCRBJ01	TCRBJ01-05	01	9	0	7	4	6	12	22	30	41	36	53		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-X+TCRBJ01-05	TCRBV12		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTGAAGTAGGGCTAATCCCAGATACGCAGTATTTTGGCCCA	CASSEVGLIPDTQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	45	unresolved						TCRBJ02	TCRBJ02-03	01	5	5	3	4	5	7	22	34	43	39	50	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEVGLIPDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGACAGGTTGAGAGCTGGAAACACCATATATTTTGGAGAG	CASSLADRLRAGNTIYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	51				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	1	4	2	0	7	18	-1	42	35	49	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLADRLRAGNTIYF+X+TCRBJ01-03		TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTGGCGGGTTCTAATGAAAAACTGTTTTTTGGCAGT	CASSLAGSNEKLFF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	3	7	4	3	1	2	18	32	38	33	40	TCRBV07,TCRBV11					01,02								CASSLAGSNEKLFF+X+TCRBJ01-04	unresolved	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCRGCCRTGTATSKCTGTGCTAGCAGCTTAGAGAGCGGGAGAGGGGAGACCCAGTATTTCGGGCCA	CASSLESGRGETQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02			1	6	2	19	2	16	19	35	45	37	61	TCRBV07,TCRBV11							TCRBJ02-01,TCRBJ02-05						CASSLESGRGETQYF+X+TCRBJ02-X	unresolved	TCRBD02-01*02	TCRBJ02	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCAGACAGCTCTTTACTTCTGTGCCAGCAATCGCTTAAGCTAGCGGGACCTCCGAGGAGGGACCGGGGAGCTGTTTTTTGGAGAA	CASNRLS*RDLRGGTGELFF	Stop	VDJ	1	64	9.174851159543494E-5		60	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	11	4	3	5	13	13	21	28	50	41	63		TCRBV24-01,TCRBV24-or09_02												CASNRLS*RDLRGGTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTAAAGCCCCAGCAGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CASS*SPSRQSRANVLTF	Stop	VDJ	1	64	9.174851159543494E-5		54	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	2	6	5	12	5	26	39	55	51	60		TCRBV12-03,TCRBV12-04												CASS*SPSRQSRANVLTF+TCRBV12-X+TCRBJ02-06	TCRBV12	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCATCCCCTCCTCCTAGCGACTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	64	9.174851159543494E-5		52	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	6	0	14	3	26	34	54	48	57		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATGCCAGGAGCTAGGGGCTACACCTTCGGTTCG		Out	VDJ	1	64	9.174851159543494E-5		40	TCRBV24						TCRBJ01	TCRBJ01-02	01	3	4	4	8	2	7	24	39	45	41	52		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGACTGACAGGGGCGGACACTGAAGCTTTCTTTGGACAA	CASRLTGADTEAFF	In	VDJ	1	64	9.174851159543494E-5	1.1006529967857494E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	2	3	3	3	18	29	40	32	43	TCRBV07,TCRBV11													CASRLTGADTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGACTCGGCGGGGTCAACTAATGAAAAACTGTTTTTTGGCAGT	CSADSAGSTNEKLFF	In	VDJ	1	65	9.318208208911361E-5	1.1178506998605267E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	6	7	3	0	7	1	26	34	47	41	48		TCRBV20-01,TCRBV20-or09_02												CSADSAGSTNEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGCGCCTCAACAATGAGCAGTTCTTCGGGCCA	CSARLNNEQFF	In	VDJ	1	65	9.318208208911361E-5	1.1178506998605267E-4	33	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	7	6	5	0	5	26	-1	37	34	42		TCRBV20-01,TCRBV20-or09_02				01,02								CSARLNNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTCACAGGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSSQGGYNEQFF	In	VDJ	1	65	9.318208208911361E-5	1.1178506998605267E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	3	1	3	2	1	24	36	46	38	47	TCRBV24,TCRBV27													CASSSQGGYNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTAGGGGGTTCGGGGAGGAAGGAAAAACTGTTTTTTGGCAGT	CASSLGGSGRKEKLFF	In	VDJ	1	65	9.318208208911361E-5	1.1178506998605267E-4	48	TCRBV05						TCRBJ01	TCRBJ01-04	01	2	5	1	8	0	13	19	-1	39	33	52		TCRBV05-06,TCRBV05-07		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGSGRKEKLFF+TCRBV05-X+TCRBJ01-04	TCRBV05		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCTCCTTCGGGCGGGCAGGGCTTAATGAAAAACTGTTTTTTGGCAGT	CASSFGRAGLNEKLFF	In	VDJ	1	65	9.318208208911361E-5	1.1178506998605267E-4	48	unresolved						TCRBJ01	TCRBJ01-04	01	8	4	3	4	13	2	23	32	50	45	52	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFGRAGLNEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCACAGACAGGGACAATCAGCCCCAGCATTTTGGTGAT	CSATTDRDNQPQHF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	2	3	3	5	1	26	36	48	41	49		TCRBV20-01,TCRBV20-or09_02												CSATTDRDNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCACAGGGAGGCTATGGCTACACCTTCGGTTCG	CSARAQGGYGYTF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	39	TCRBV20						TCRBJ01	TCRBJ01-02	01	1	3	3	4	1	3	26	39	46	40	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARAQGGYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTATACCGTGGGGGTTCACTGAAGCTTTCTTTGGACAA	CSASIPWGFTEAFF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	42	TCRBV20						TCRBJ01	TCRBJ01-01	01	3	6	1	4	8	2	26	37	50	45	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASIPWGFTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGGGGCAAGGGGGGTCTCCTACGAGCAGTACTTCGGGCCG	CSASGARGVSYEQYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	45	TCRBV20						TCRBJ02	TCRBJ02-07	01	3	5	1	0	7	2	26	37	50	44	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASGARGVSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGTCAGACAGGGGGTCGGGGGACCCAGTACTTCGGGCCA	CSGQTGGRGTQYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	2	1	7	4	6	26	33	46	37	52		TCRBV20-01,TCRBV20-or09_02												CSGQTGGRGTQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTCCCTACTACAACGCACAGATACGCAGTATTTTGGCCCA	CASSSLLQRTDTQYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	3	9	1	4	4	18	31	39	35	43	TCRBV07,TCRBV11					01,02								CASSSLLQRTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
SGACTCGGCYRTGTATCTCTGTGCCAGCAGCTTAAGGAAGAGACAGCCTGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	66	9.461565258279228E-5		56	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	2	2	5	0	7	4	19	34	46	41	50	TCRBV07,TCRBV11													X+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTCCGCGGTTCTATTCCGGGACAGGGGCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	66	9.461565258279228E-5		61	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	0	2	0	15	0	19	32	-1	47	57		TCRBV05-06,TCRBV05-07												X+TCRBV05-X+TCRBJ01-04	TCRBV05	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCCCGACACCTTTGACAATGAGCAGTTCTTCGGGCCA	CATSDPDTFDNEQFF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	2	6	5	3	6	24	39	46	42	52		TCRBV24-01,TCRBV24-or09_02												CATSDPDTFDNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTACCCTCCGGGACAGGGGCGACCCAGTACTTCGGGCCA	CASSLPSGTGATQYF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	0	2	7	6	1	18	33	49	39	50	TCRBV07,TCRBV11													CASSLPSGTGATQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGCCTAGTACCGACTCCTACTACGAGTAGTACTTCGGGCCG		Out	VDJ	1	68	9.748279357014962E-5		47	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	2	10	11	10	12	26	39	53	49	65		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAAGCTTCGGACTAGCGGTGGCCCTCGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	68	9.748279357014962E-5		62				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	2	1	5	0	7	7	18	33	50	40	57	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03				01,02								X+X+TCRBJ02-02		TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCATTCTGTGGAGGACAGGGGGCCAGACGAACACCGGGGAGCTGTTTTTTGGAGAA	CASILWRTGGQTNTGELFF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	57	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	1	0	0	9	4	18	28	48	37	52	TCRBV07,TCRBV11													CASILWRTGGQTNTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCCCCTTTATTCGGGGGGAGAGCCGGGGAGCTGTTTTTTGGAGAA	CASSSPLFGGRAGELFF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	51	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	4	8	1	6	10	4	26	39	56	49	60		TCRBV12-03,TCRBV12-04												CASSSPLFGGRAGELFF+TCRBV12-X+TCRBJ02-02	TCRBV12	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTGGCCCGAGCGGGAGAAGGTCAATGAGCAGTTCTTCGGGCCA	CSAWPEREKVNEQFF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	6	2	6	8	5	26	34	50	42	55		TCRBV20-01,TCRBV20-or09_02												CSAWPEREKVNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCTCAAACCTGGCGAAGGCCCCGGATGGCTACACCTTCGGTTCG	CATSSNLAKAPDGYTF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	48	TCRBV24						TCRBJ01	TCRBJ01-02	01	7	5	4	6	14	6	24	35	52	49	58		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSSNLAKAPDGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTCGACTAGCGGGAGACACCGGGGAGCTGTTTTTTGGAGAA	CASSRLAGDTGELFF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	45				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	2	2	3	1	0	36	48	-1	49	61	TCRBV25,TCRBV27,TCRBV28	TCRBV25-01,TCRBV25-or09_02,TCRBV27-01,TCRBV28-01												CASSRLAGDTGELFF+X+TCRBJ02-02		TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCAGACAGATTGAGCAGTTCTTCGGGCCA	CASSPRQIEQFF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	2	5	9	3	2	26	39	47	42	49		TCRBV03-01,TCRBV03-02												CASSPRQIEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCTCTAGCGGGAGTTCGGTACGAGCAGTACTTCGGGCCG	CSARPLAGVRYEQYF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	2	4	2	4	3	5	26	38	51	41	56		TCRBV20-01,TCRBV20-or09_02												CSARPLAGVRYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTACTCGGGACAAAGCAATCAGCCCCAGCATTTTGGTGAT	CASSYSGQSNQPQHF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	0	6	1	4	1	22	35	45	39	46		TCRBV12-03,TCRBV12-04												CASSYSGQSNQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGAAGGGATCGTGGAAACTGTTTTTTGGCAGT		Out	VDJ	1	70	1.0034993455750697E-4		38	TCRBV24						TCRBJ01	TCRBJ01-04	01	5	0	8	11	3	6	24	37	44	40	50		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-04	TCRBV24		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCAACCACGAGACGTCGTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	70	1.0034993455750697E-4		47	unresolved						TCRBJ01	TCRBJ01-04	01	5	2	7	4	9	4	18	30	42	39	46	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGAGTTCAGGGTTAATTCACCCCTCCACTTTGGGAAC	CASSLAEFRVNSPLHF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	48				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	4	3	6	6	1	18	35	46	41	47	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAEFRVNSPLHF+X+TCRBJ01-06		TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCCCGGACAGGGGATTCACCCCTCCACTTTGGGAAC	CASSSRTGDSPLHF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	1	2	8	3	0	26	39	-1	42	51		TCRBV12-03,TCRBV12-04												CASSSRTGDSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTGACTCGACAGGGGGCACAGATACGCAGTATTTTGGCCCA	CASSDSTGGTDTQYF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	2	2	1	3	0	24	38	-1	41	49	TCRBV06,TCRBV10													CASSDSTGGTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAATGCTAGAGTGGCAGGGGGGCACCAAGAGACCCAGTACTTCGGGCCA	CNARVAGGHQETQYF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	4	1	0	3	2	26	39	49	42	51		TCRBV20-01,TCRBV20-or09_02												CNARVAGGHQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGACCCCAGGCGGGGGGATACGCAGTATTTTGGCCCA	CSARDPRRGDTQYF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	7	2	6	6	0	26	40	-1	46	53		TCRBV20-01,TCRBV20-or09_02												CSARDPRRGDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAGCAGGGCGAACACTGAAGCTTTCTTTGGACAA	CSARDSRANTEAFF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	3	1	3	1	26	40	48	43	49		TCRBV20-01,TCRBV20-or09_02												CSARDSRANTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTGACAGGGCGCAATCAGCCCCAGCATTTTGGTGAT	CASSLTGRNQPQHF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	2	3	2	2	1	24	36	45	38	46	TCRBV24,TCRBV27													CASSLTGRNQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGAGGGCAGTACAAGCAGTACTTCGGGCCG	CASRGQYKQYF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	33	TCRBV12						TCRBJ02	TCRBJ02-07	01	6	5	3	8	0	7	26	-1	41	37	48		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGQYKQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAARCYYRRGGAYTCAGCWGTGTATTTTTGTGCCAGCAGTCACGGCAATCAGGGCCACACTGGGGAGTTGTTTTTTGGAGAA	CASSHGNQGHTGELFF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	48	unresolved						TCRBJ02	TCRBJ02-02	01	5	4	3	15	9	14	26	38	52	47	66	TCRBV12,TCRBV16			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHGNQGHTGELFF+X+TCRBJ02-02	unresolved		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACCCCATAGTAACAGATACGCAGTATTTTGGCCCA	CASSQDPIVTDTQYF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	5	8	3	5	2	26	43	51	48	53		TCRBV03-01,TCRBV03-02				01,02								CASSQDPIVTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAGGCCTTCGGACAGGGAAGCACAGATACGCAGTATTTTGGCCCA	CSAKAFGQGSTDTQYF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	3	0	8	1	26	36	52	44	53		TCRBV20-01,TCRBV20-or09_02												CSAKAFGQGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGGCTCCTAGCCAAAAACATTCAGTACTTCGGCGCC	CASRLLAKNIQYF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	39	TCRBV12						TCRBJ02	TCRBJ02-04	01	6	10	0	0	0	4	22	-1	35	33	39		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRLLAKNIQYF+TCRBV12-X+TCRBJ02-04	TCRBV12		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGCTTGGGGCGGTCAATATGGCTACACCTTCGGTTCG	CASSAWGGQYGYTF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	7	0	5	4	6	22	34	43	38	49	TCRBV02,TCRBV12													CASSAWGGQYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTAGACGGGAAGGGACAGTTGACTCCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	72	1.0321707554486431E-4		53	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	0	5	6	7	7	19	35	49	42	56	TCRBV07,TCRBV11													X+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGTCCGGGACAGGGACCGCTAGAGCAGTACTTCGGGCCG	CASSPGQGPLEQYF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	3	7	3	7	18	29	41	32	48	TCRBV07,TCRBV11													CASSPGQGPLEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGATATGGCCGGAGTCAGCCCCAGCATTTTGGTGAT	CASRYGRSQPQHF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	39	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	6	10	2	6	8	0	26	37	-1	45	49		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRYGRSQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTACAGGACAGGGCGGGTTCACAGATACGCAGTATTTTGGCCCA	CASSTGQGGFTDTQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	3	2	3	6	26	38	49	41	55		TCRBV12-03,TCRBV12-04												CASSTGQGGFTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACCGACAGGGGGCAGGAGAAAAACTGTTTTTTGGCAGT	CASSHRQGAGEKLFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	2	0	8	2	4	26	40	52	42	56		TCRBV03-01,TCRBV03-02												CASSHRQGAGEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAAGGACTAGCGGGAGATTACGAGCAGTACTTCGGGCCG	CSAKGLAGDYEQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	1	2	4	2	2	26	36	51	38	53		TCRBV20-01,TCRBV20-or09_02												CSAKGLAGDYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGGCCACAGGGGGAGTATGGCTACACCTTCGGTTCG	CASRPQGEYGYTF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	3	1	5	3	2	24	35	46	38	48	TCRBV24,TCRBV27													CASRPQGEYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCGTTACGAGGGAGCGGGAGATGAGCAGTTCTTCGGGCCA	CASSRYEGAGDEQFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	45	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	6	2	8	11	0	24	36	-1	47	55		TCRBV24-01,TCRBV24-or09_02												CASSRYEGAGDEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCCTATATCCGCCTTTTTGGACAGGGGCTCTACGAGCAGTACTTCGGGCCG	CASSSYIRLFGQGLYEQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	57	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	2	3	18	2	24	36	63	54	65		TCRBV24-01,TCRBV24-or09_02												CASSSYIRLFGQGLYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTAGCCGCATGCGGGAGGGCCTTTTCAATGAGTAGTTCTTCGGGCCA	CSSRMREGLFNE*FF	Stop	VDJ	1	74	1.0608421653222165E-4		45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	7	0	14	8	14	26	32	49	40	63		TCRBV20-01,TCRBV20-or09_02												CSSRMREGLFNE*FF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACGGGACAATGAGCAGTTCTTCGGGCCA	CSARRDNEQFF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	33	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	8	4	5	0	0	26	-1	-1	38	42		TCRBV20-01,TCRBV20-or09_02				01,02								CSARRDNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTCCCGGGGCCGGTTTCGGAGACCCAGTACTTCGGGCCA	CSARVPGPVSETQYF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	45	TCRBV20						TCRBJ02	TCRBJ02-05	01	1	7	0	5	4	8	26	39	48	43	56		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARVPGPVSETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGCACGGGGGAGTGAGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	74	1.0608421653222165E-4		44	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	8	2	5	4	6	26	37	47	41	53		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGATTGGGGGGCGCGGGAACTGAAGCTTTCTTTGGACAA	CASRLGGAGTEAFF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	42	TCRBV12						TCRBJ01	TCRBJ01-01	01	6	6	0	5	4	6	22	33	43	37	49		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRLGGAGTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTCGGGGCCCTGGGGCTGAAGCTTTCTTTGGACAA	CATSRGPGAEAFF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	39	TCRBV24						TCRBJ01	TCRBJ01-01	01	6	7	0	6	1	7	24	36	42	37	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSRGPGAEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCCCAATAGCGGGGGGCACAGATACGCAGTATTTTGGCCCA	CASSPIAGGTDTQYF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	5	2	1	4	0	18	30	-1	34	43	TCRBV07,TCRBV11													CASSPIAGGTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGCCCCGACAGGGGGCTTACGAGCAGTACTTCGGGCCG	CASSLPRQGAYEQYF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	2	0	4	5	1	18	32	47	37	48	TCRBV07,TCRBV11													CASSLPRQGAYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGGGGGCCCGGTACGAATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	74	1.0608421653222165E-4		50	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	6	0	0	0	10	18	-1	38	32	48	TCRBV07,TCRBV11													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGACCCTCAAGAGACCCAGTACTTCGGGCCA	CASSDPQETQYF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	36	unresolved			unresolved			TCRBJ02	TCRBJ02-05	01	3	4	10	2	2	0	23	37	-1	39	41	TCRBV02,TCRBV09			TCRBD01,TCRBD02										CASSDPQETQYF+X+TCRBJ02-05	unresolved	unresolved	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGTAGCGGTTCAGGGTGGAAACACCATATATTTTGGAGAG	CASSVAVQGGNTIYF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	6	5	5	3	2	7	26	37	45	39	52		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASSVAVQGGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12	TCRBD02-01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCCGGCCCTAACACTGAAGCTTTCTTTGGACAA	CASSSGPNTEAFF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	39	TCRBV12						TCRBJ01	TCRBJ01-01	01	4	9	0	2	2	3	26	39	44	41	47		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGPNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACAGTTACAATGAGCAGTTCTTCGGGCCA	CASSQDSYNEQFF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	4	5	4	0	1	26	-1	46	43	47		TCRBV03-01,TCRBV03-02												CASSQDSYNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCTAGGACAGCCCGGCCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	75	1.0751778702590032E-4		44	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	1	5	7	4	6	26	39	49	43	55		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCAGGAGTGGGGGGAGGTACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	75	1.0751778702590032E-4		49	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	9	1	0	9	4	26	36	51	45	55		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCAGGGGACCGATCGCTACACCTTCGGTTCG	CSATQGTDRYTF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	2	9	2	7	26	36	44	38	51		TCRBV20-01,TCRBV20-or09_02												CSATQGTDRYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGAGGCAGGGGGGGGTGAAAAACTGTTTTTTGGCAGT	CASSEAGGGEKLFF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	42	TCRBV24						TCRBJ01	TCRBJ01-04	01	4	4	1	7	2	3	24	38	47	40	50		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEAGGGEKLFF+TCRBV24-X+TCRBJ01-04	TCRBV24		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCATCAGTGAAGGGGTGAGCAATCAGCCCCAGCATTTTGGTGAT	CAISEGVSNQPQHF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	42	unresolved			unresolved			TCRBJ01	TCRBJ01-05	01	3	5	2	1	0	2	24	-1	43	38	45	TCRBV06,TCRBV10			TCRBD01,TCRBD02										CAISEGVSNQPQHF+X+TCRBJ01-05	unresolved	unresolved	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGCTAGATGGGGGGTGAATGAGCAGTTCTTCGGGCCA	CASSQARWGVNEQFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	9	1	7	8	2	26	40	54	48	56		TCRBV03-01,TCRBV03-02												CASSQARWGVNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTCGGAGCCTATCAGCCCCAGCATTTTGGTGAT	CSARVGAYQPQHF	In	VDJ	1	77	1.1038492801325766E-4	1.3242231367578547E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	1	10	2	5	2	3	26	39	45	41	48		TCRBV20-01,TCRBV20-or09_02												CSARVGAYQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAACCTGGACTAGCGGGAGTCCCGCCGGCGCGAGCAGTACTTCGGGCCG		Out	VDJ	1	77	1.1038492801325766E-4		55	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	1	2	6	4	11	24	38	55	42	66		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTAGTATCCAAGTAGGATCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	77	1.1038492801325766E-4		46	unresolved						TCRBJ01	TCRBJ01-02	01	0	1	8	4	10	1	19	35	48	45	49	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAACCGGTAGCGGGGGGGAGTTACAGATACGCAGTATTTTGGCCCA	CASNR*RGGVTDTQYF	Stop	VDJ	1	77	1.1038492801325766E-4		48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	5	0	3	5	4	23	33	49	38	53	TCRBV02,TCRBV12													CASNR*RGGVTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCGTGGGGCCTTAATGAAAAACTGTTTTTTGGCAGT	CASSLSWGLNEKLFF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	45				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	7	0	4	7	2	24	36	48	43	50	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01												CASSLSWGLNEKLFF+X+TCRBJ01-04		TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAAGGGCAATCGGGGAGCTGTTTTTTGGAGAA	CASSERAIGELFF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	39	TCRBV06						TCRBJ02	TCRBJ02-02	01	2	5	3	7	0	4	23	-1	42	38	46		TCRBV06-01,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSERAIGELFF+TCRBV06-X+TCRBJ02-02	TCRBV06		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
YRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGTAGCTACAGGGGCTAGCGGGAGGGTGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	78	1.1181849850693633E-4		58	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	4	0	1	9	1	23	39	60	48	61	TCRBV09,TCRBV21													X+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCTGACATCGATACTAAAGCTTTCTTTGGACAA	CSAPDIDTKAFF	In	VDJ	1	79	1.13252069000615E-4	1.3586185429074094E-4	36	TCRBV20						TCRBJ01	TCRBJ01-01	01	6	2	6	9	4	9	26	34	42	38	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPDIDTKAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAAGGGTGCAGGGCGGGACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	79	1.13252069000615E-4		41	TCRBV20						TCRBJ01	TCRBJ01-01	01	4	4	3	5	7	4	26	36	48	43	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSARESSYNEQFF	In	VDJ	1	79	1.13252069000615E-4	1.3586185429074094E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	11	2	0	0	0	26	-1	-1	40	43		TCRBV20-01,TCRBV20-or09_02												CSARESSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGCCAGCAGGCGCCCCGCCATTTCCCCGCCCTAGGGCCGTCTATGAATCATGAACACTGAAGCTTTCTTTGGACAA	CASRRPAISPP*GRL*IMNTEAFF	Stop	VDJ	1	79	1.13252069000615E-4		72							TCRBJ01	TCRBJ01-01	01	6	5	3	0	23	14	-1	9	36	32	50	TCRBV06,TCRBV12	TCRBV06-01,TCRBV06-02,TCRBV06-03,TCRBV06-04,TCRBV06-05,TCRBV06-06,TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRRPAISPP*GRL*IMNTEAFF+X+TCRBJ01-01			TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCCGGAATGAAGCCCCCGGGGTGAAAAACTGTTTTTTGGCAGT	CASSPE*SPRGEKLFF	Stop	VDJ	1	80	1.1468563949429368E-4		48	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	5	8	3	7	15	0	26	38	-1	53	58		TCRBV12-03,TCRBV12-04												CASSPE*SPRGEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGAGGGGGGGGGAATGAAAAACTGTTTTTTGGCAGT	CASSQGGGGNEKLFF	In	VDJ	1	80	1.1468563949429368E-4	1.3758162459821867E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	1	9	0	5	2	2	26	42	51	44	53		TCRBV03-01,TCRBV03-02												CASSQGGGGNEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTTGGGAGGGGTAGCTCCTACGAGCAGTACTTCGGGCCG	CSARVGRGSSYEQYF	In	VDJ	1	80	1.1468563949429368E-4	1.3758162459821867E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	9	0	0	2	4	26	39	48	41	52		TCRBV20-01,TCRBV20-or09_02												CSARVGRGSSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGGTTTTGGAGGGGGAGGCGGCTACACCTTCGGTTCG	CASSLGFGGGGGYTF	In	VDJ	1	80	1.1468563949429368E-4	1.3758162459821867E-4	45	unresolved						TCRBJ01	TCRBJ01-02	01	1	5	1	8	7	4	18	34	47	41	51	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGFGGGGGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTGGGTGAATGAGCAGTTCTTCGGGCCA	CSARDWVNEQFF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	36	TCRBV20						TCRBJ02	TCRBJ02-01	01	0	0	9	7	2	2	26	40	45	42	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDWVNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCCCTCGACAGAAGCTTTCTTTGGACAA	CATSDPSTEAFF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	36	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	2	6	8	5	0	24	39	-1	44	48		TCRBV24-01,TCRBV24-or09_02												CATSDPSTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAAGGTCGGTGTCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	82	1.1755278048165102E-4		43	TCRBV24						TCRBJ02	TCRBJ02-05	01	6	5	4	2	3	7	24	36	42	39	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-05	TCRBV24		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATACGGGGTAGTGAGTGAAAAACTGTTTTTTGGCAGT	CASSLYGVVSEKLFF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	45	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	6	8	3	7	5	7	24	36	46	41	53		TCRBV24-01,TCRBV24-or09_02												CASSLYGVVSEKLFF+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTGGCTCAGGGGATGGTAAACAATGAGCAGTTCTTCGGGCCA	CASSLAQGMVNNEQFF	In	VDJ	1	82	1.1755278048165102E-4	1.4102116521317413E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	4	2	5	4	7	18	32	42	36	49	TCRBV07,TCRBV11													CASSLAQGMVNNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGGGCGGGGGTTGGCACAGATACGCAGTATTTTGGCCCA	CASRAGVGTDTQYF	In	VDJ	1	83	1.1898635097532968E-4	1.4274093552065186E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	7	2	1	1	3	23	34	42	35	45	TCRBV01,TCRBV04													CASRAGVGTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGGCCAGGGGGGACGCGAGCAGTACTTCGGGCCG	CASSQDGQGGREQYF	In	VDJ	1	83	1.1898635097532968E-4	1.4274093552065186E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	1	6	4	4	26	43	54	47	58		TCRBV03-01,TCRBV03-02												CASSQDGQGGREQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACAGGGGGCAGCGAACACTGAAGCTTTCTTTGGACAA	CSARQGAANTEAFF	In	VDJ	1	83	1.1898635097532968E-4	1.4274093552065186E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	0	1	0	3	26	-1	46	38	49		TCRBV20-01,TCRBV20-or09_02												CSARQGAANTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGGGGCTGGGGCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	83	1.1898635097532968E-4		46	TCRBV24						TCRBJ02	TCRBJ02-02	01	0	6	2	4	5	0	24	42	-1	47	51		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGACCCTTTTGGAGACCCAGTACTTCGGGCCA	CASSQTLLETQYF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	39	TCRBV03						TCRBJ02	TCRBJ02-05	01	3	2	7	5	0	7	26	-1	43	40	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQTLLETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGGGGGACCTATGGCTACACCTTCGGTTCG	CASRGTYGYTF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	33	TCRBV03						TCRBJ01	TCRBJ01-02	01	6	0	7	4	1	0	26	37	-1	38	43		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGTYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGCAGCGGGAGCGCTACTAGCACAGATACGCAGTATTTTGGCCCA	CSSGSATSTDTQYF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	9	6	2	0	1	7	26	31	40	32	47		TCRBV20-01,TCRBV20-or09_02												CSSGSATSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGTACGAGGGGGCAACCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	84	1.2041992146900836E-4		49	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	1	5	0	2	4	2	23	39	50	43	52	TCRBV01,TCRBV04													X+X+TCRBJ02-04	unresolved	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTTTCCCAGGCTCAAGAGACCCAGTACTTCGGGCCA	CASSFSQAQETQYF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	4	4	2	4	2	18	32	40	36	42	TCRBV05,TCRBV11													CASSFSQAQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCATCACCCCCCACCCGAGCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	84	1.2041992146900836E-4		46	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	7	11	2	0	13	0	18	28	-1	41	44	TCRBV07,TCRBV11													X+X+TCRBJ01-02	unresolved	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACAGGGGACAGATCTCCTACGAGCAGTACTTCGGGCCG	CASSHRGQISYEQYF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	5	0	3	2	26	40	50	43	52		TCRBV03-01,TCRBV03-02												CASSHRGQISYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAGGGGTTTGGCTCGAGCAGTACTTCGGGCCG	CSAREGVWLEQYF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	5	2	6	0	7	26	-1	45	40	52		TCRBV20-01,TCRBV20-or09_02												CSAREGVWLEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCCTGGGACAGGGAAGAGACCCAGTACTTCGGGCCA	CSARPWDREETQYF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	3	3	5	0	26	37	-1	42	51		TCRBV20-01,TCRBV20-or09_02												CSARPWDREETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGATTTAGCTCTGGAAACACCATATATTTTGGAGAG	CASRFSSGNTIYF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	39	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	6	5	8	0	3	0	22	33	-1	36	39		TCRBV12-03,TCRBV12-04				01,02								CASRFSSGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12	TCRBD02-01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCCGGGCCGGGGGCTAAAGCCAAGAGACCCAGTACTTCGGGCCA	CARAGG*SQETQYF	Stop	VDJ	1	85	1.2185349196268703E-4		42	TCRBV24						TCRBJ02	TCRBJ02-05	01	12	6	0	1	6	5	24	30	42	36	47		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CARAGG*SQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACGTTTGGTGCATCCTGAGACAGCAGCTTCTACATCTGCAGTGCTAGATCCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA	CSARSLAGSTDTQYF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	4	3	0	3	0	36	48	-1	51	60		TCRBV20-01,TCRBV20-or09_02												CSARSLAGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ARCYYRGKGACTCWGCTGTGTATTTYTGTGCCAGCAGCATCTCGGGAGGGGCGACAGACTCCTACGAGCAGTACTTCGGGCCG	CASSISGGATDSYEQYF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	8	0	0	4	8	26	38	50	42	58	TCRBV03,TCRBV12													CASSISGGATDSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAGGCCCTAACACTGAAGCTTTCTTTGGACAA	CASSLGPNTEAFF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	39	TCRBV12						TCRBJ01	TCRBJ01-01	01	1	10	0	2	0	3	22	-1	40	38	43		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGPNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTMSCTCYCAGACWTCTGTKTACTTCTGTGCCAGCAGTGATGGGACTAGGGCTAATGAGCAGTTCTTCGGGCCA	CASSDGTRANEQFF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	8	7	3	4	26	38	49	41	53	TCRBV06,TCRBV10					01,02								CASSDGTRANEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGCCGGCACCGTTACTCGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	86	1.232870624563657E-4		52							TCRBJ02	TCRBJ02-05	01	0	9	0	2	3	11	18	35	41	38	52	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ02-05			TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGCCCCGCTCGCGTTGAGCAGTACTTCGGGCCG	CASSPARVEQYF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	36	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	7	6	7	8	2	23	34	45	42	47	TCRBV02,TCRBV09					01,02								CASSPARVEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAACAGGGAAGCGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	87	1.2472063295004436E-4		40	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	3	3	5	0	4	26	-1	47	41	51		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTGGGGACGCAGAACACTGAAGCTTTCTTTGGACAA	CASSLGTQNTEAFF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	42	TCRBV12						TCRBJ01	TCRBJ01-01	01	3	0	7	1	1	3	26	40	46	41	49		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGTQNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGACAGGGTCGTGGGGAGACCCAGTACTTCGGGCCA	CSARGQGRGETQYF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	2	3	5	0	7	26	-1	46	39	53		TCRBV20-01,TCRBV20-or09_02												CSARGQGRGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCACGTTTGGTGCCCCAACCAGACAGCTCTTACTTCTGTGCCACCAGTGGCGGGACTAGCGAGACCTACGAGCAGTACTTCGGGCCG	CATSGGTSETYEQYF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	6	2	2	3	36	49	61	51	64		TCRBV24-01,TCRBV24-or09_02				01,02								CATSGGTSETYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAAACTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSENYSNQPQHF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	42	TCRBV06			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	2	3	9	0	1	0	23	38	-1	39	43		TCRBV06-01,TCRBV06-08				01,02								CASSENYSNQPQHF+TCRBV06-X+TCRBJ01-05	TCRBV06	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGCGGACAGCTCCTACGAGCAGTACTTCGGGCCG	CASSADSSYEQYF	In	VDJ	1	87	1.2472063295004436E-4	1.496200167505628E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	1	5	0	1	0	23	36	-1	37	43	TCRBV02,TCRBV09													CASSADSSYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCTTTGGGGGGGTCGGCTACCCCCGTGAGCAGTTCTTCGGGCCA	CASSLFGGVGYPREQFF	In	VDJ	1	88	1.2615420344372303E-4	1.5133978705804052E-4	51	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	9	0	9	5	13	26	39	51	44	64		TCRBV03-01,TCRBV03-02												CASSLFGGVGYPREQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGACCCGGGACTAGCGGGAGCGGGGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	88	1.2615420344372303E-4		50	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	7	0	2	4	4	5	24	35	53	39	58	TCRBV24,TCRBV27													X+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGTGACAGGGGGCGGGAGGAGGTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	88	1.2615420344372303E-4		55				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	2	0	4	4	9	18	35	49	39	58	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												X+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCTTTCGCGGGTACAGCGGGGGGGCGAATACGCAGTATTTTGGCCCA	CASFRGYSGGANTQYF	In	VDJ	1	88	1.2615420344372303E-4	1.5133978705804052E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	8	6	0	7	12	3	18	27	49	39	52	TCRBV07,TCRBV11													CASFRGYSGGANTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAAAGACGGGGGCAGTTGAAAAACTGTTTTTTGGCAGT	CASSQKTGAVEKLFF	In	VDJ	1	89	1.275877739374017E-4	1.5305955736551825E-4	45	TCRBV03						TCRBJ01	TCRBJ01-04	01	2	6	0	7	5	3	26	41	52	46	55		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQKTGAVEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGGGTTAGCCTTCGGGGAGCTGTTTTTTGGAGAA	CSARDGLAFGELFF	In	VDJ	1	89	1.275877739374017E-4	1.5305955736551825E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	5	7	7	5	3	26	40	49	45	52		TCRBV20-01,TCRBV20-or09_02				01,02								CSARDGLAFGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTAATAGCGGGTGTCACCCAACAAGAGACCCAGTACTTCGGGCCA	CASSLIAGVTQQETQYF	In	VDJ	1	89	1.275877739374017E-4	1.5305955736551825E-4	51	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	5	4	2	4	10	24	36	47	40	57	TCRBV24,TCRBV27					01,02								CASSLIAGVTQQETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCGTATTGGGACTCCAATAAAAATGAGCAGTTCTTCGGGCCA	CAYWDSNKNEQFF	In	VDJ	1	89	1.275877739374017E-4	1.5305955736551825E-4	39	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	12	0	10	7	5	8	23	28	39	33	47	TCRBV06,TCRBV10					01,02								CAYWDSNKNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGAAGCGTGAGGAGGGGCGAACACTGAAGCTTTCTTTGGACAA	CASSEA*GGANTEAFF	Stop	VDJ	1	89	1.275877739374017E-4		48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	10	0	1	4	2	23	40	50	44	52	TCRBV02,TCRBV09													CASSEA*GGANTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCTCCCGGGGGACGGAGGTCACCCAGATACGCAGTATTTTGGCCCA	CATSDLLPGDGGHPDTQYF	In	VDJ	1	90	1.290213444310804E-4	1.5477932767299599E-4	57	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	8	2	4	4	12	24	42	52	46	64		TCRBV24-01,TCRBV24-or09_02												CATSDLLPGDGGHPDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCTCGATCCAGGCGTCCCAAGGCCACACTGAAGCTTTCTTTGGACAA	CASSSIQASQGHTEAFF	In	VDJ	1	91	1.3045491492475906E-4	1.5649909798047372E-4	51	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	4	3	7	12	26	37	48	44	60		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSSIQASQGHTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTAGGGTTTCCAATTCACCCCTCCACTTTGGGAAC	CASSFRVSNSPLHF	In	VDJ	1	91	1.3045491492475906E-4	1.5649909798047372E-4	42	TCRBV12						TCRBJ01	TCRBJ01-06	01	3	5	3	7	1	5	26	40	45	41	50		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFRVSNSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACTGGGACAGGGGGCCGACCGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	91	1.3045491492475906E-4		52	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	2	0	0	4	2	5	26	38	52	40	57		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCGGCAGGGCTCTCCTACGAGCAGTACTTCGGGCCG	CATSDSAGLSYEQYF	In	VDJ	1	91	1.3045491492475906E-4	1.5649909798047372E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	3	0	3	2	24	40	48	43	50		TCRBV24-01,TCRBV24-or09_02												CATSDSAGLSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCMTSTATCKCTGTGCCAGCAGCTTCTCCAGGGAGGTTTCGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	91	1.3045491492475906E-4		50	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	3	9	1	2	5	5	18	32	43	37	48	TCRBV05,TCRBV07													X+X+TCRBJ01-05	unresolved	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTAGATGAAGCCGGGGAGCTGTTTTTTGGAGAA	CASSLDEAGELFF	In	VDJ	1	91	1.3045491492475906E-4	1.5649909798047372E-4	39							TCRBJ02	TCRBJ02-02	01	1	2	8	6	2	2	18	34	38	36	40	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLDEAGELFF+X+TCRBJ02-02			TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGTGACTCTGCTGTGTATTTCTGTGCCAGCACCCACCCGTCCCCGGGACGCGAGTTACTAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	91	1.3045491492475906E-4		59	TCRBV03						TCRBJ01	TCRBJ01-05	01	3	0	7	0	9	9	22	36	50	45	59		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCAGGGACGGGAGCTAACTATGGCTACACCTTCGGTTCG	CASSPGTGANYGYTF	In	VDJ	1	92	1.318884854184377E-4	1.5821886828795145E-4	45	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	4	8	2	0	6	0	26	39	-1	45	51		TCRBV03-01,TCRBV03-02												CASSPGTGANYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAGAGTTCATGAACACTGAAGCTTTCTTTGGACAA	CSAEFMNTEAFF	In	VDJ	1	92	1.318884854184377E-4	1.5821886828795145E-4	36	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	11	2	0	1	4	26	34	38	35	42		TCRBV20-01,TCRBV20-or09_02												CSAEFMNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAGCCGGACAGGGGCGATAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	92	1.318884854184377E-4		49	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	1	2	4	1	3	22	39	49	40	52		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATAGCAGGTCTACAATGAAACAGTTCTTCGGGCCA	CASSQDSRSTMKQFF	In	VDJ	1	93	1.333220559121164E-4	1.599386385954292E-4	45	TCRBV03						TCRBJ02	TCRBJ02-01	01	0	4	4	13	3	12	26	43	50	46	62		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDSRSTMKQFF+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGAGGGAAGCTACACTGAAGCTTTCTTTGGACAA	CASSEGSYTEAFF	In	VDJ	1	93	1.333220559121164E-4	1.599386385954292E-4	39	unresolved			unresolved			TCRBJ01	TCRBJ01-01	01	3	0	8	3	0	4	23	-1	41	37	45	TCRBV02,TCRBV12			TCRBD01,TCRBD02										CASSEGSYTEAFF+X+TCRBJ01-01	unresolved	unresolved	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCATTGGCGGGAGGTCCAATGAGCAGTTCTTCGGGCCA	CASSFIGGRSNEQFF	In	VDJ	1	94	1.3475562640579507E-4	1.6165840890290694E-4	45	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	7	1	6	5	2	26	40	53	45	55		TCRBV12-03,TCRBV12-04												CASSFIGGRSNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACAACAGCCGTGTGGGAAGAGCAGTACTTCGGGCCG		Out	VDJ	1	94	1.3475562640579507E-4		43	TCRBV03						TCRBJ02	TCRBJ02-07	01	3	0	8	7	12	1	26	40	56	52	57		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCGATACAGGGGGCTGGCACAGATACGCAGTATTTTGGCCCA	CSAPIQGAGTDTQYF	In	VDJ	1	94	1.3475562640579507E-4	1.6165840890290694E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	0	1	5	2	26	35	49	40	51		TCRBV20-01,TCRBV20-or09_02												CSAPIQGAGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAYCMRGRGACWCAGCWSKGTATTTYTGTGCCAGCAGCGTCACAACTGGGGGGGGCGAGCAGTACTTCGGGCCG	CASSVTTGGGEQYF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	9	0	6	10	1	26	37	54	47	55	TCRBV12,TCRBV21													CASSVTTGGGEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCCAGGGCGGACACTATGGCTACACCTTCGGTTCG	CASSLQGGHYGYTF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	3	3	2	5	26	39	46	41	51		TCRBV03-01,TCRBV03-02												CASSLQGGHYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGACGCAGGGGCGAGGGCCATGGCTACACCTTCGGTTCG	CSGRRGEGHGYTF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	4	2	6	4	8	26	33	43	37	51		TCRBV20-01,TCRBV20-or09_02												CSGRRGEGHGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAGSSAMWCAGCTKTGTACTTCTGTGCCAGCAGTTTAGGACAGACCAATGAAAAACTGTTTTTTGGCAGT	CASSLGQTNEKLFF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	2	5	5	0	3	22	-1	43	38	46	TCRBV12,TCRBV22													CASSLGQTNEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTAGCCGGCAGGTGAACACTGAAGCTTTCTTTGGACAA	CASSFSRQVNTEAFF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	45	TCRBV12						TCRBJ01	TCRBJ01-01	01	3	4	4	0	7	0	26	40	-1	47	51		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFSRQVNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCCGGAAGACAGATAACACCGGGGAGCTGTTTTTTGGAGAA	CASRKTDNTGELFF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	2	5	2	5	2	23	32	42	37	44	TCRBV02,TCRBV09													CASRKTDNTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGATCTAGCTTCTACAATGAGCAGTTCTTCGGGCCA	CASSQGSSFYNEQFF	In	VDJ	1	97	1.3905633788683107E-4	1.6681771982534013E-4	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	4	7	3	3	2	26	42	50	45	52		TCRBV03-01,TCRBV03-02				01,02								CASSQGSSFYNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGCCTTTATATAGGGATTGGTACCGGGGAGCTGTTTTTTGGAGAA	CASSLYIGIGTGELFF	In	VDJ	1	97	1.3905633788683107E-4	1.6681771982534013E-4	48	TCRBV24						TCRBJ02	TCRBJ02-02	01	7	0	8	5	10	5	24	35	49	45	54		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLYIGIGTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAAGGGACGAGAGGGTGTACACTGAAGCTTTCTTTGGACAA	CASSLRDERVYTEAFF	In	VDJ	1	97	1.3905633788683107E-4	1.6681771982534013E-4	48	unresolved						TCRBJ01	TCRBJ01-01	01	2	0	7	3	1	10	18	33	39	34	49	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRDERVYTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCGAGAGGGGGCGGTGGTTGAAGCTTTCTTTGGACAA	CASSREGAVVEAFF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	6	0	7	0	6	23	-1	46	40	52	TCRBV01,TCRBV04													CASSREGAVVEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCGCACAGGGGGCTGGGGCCAACGTCCTGACTTTCGGGGCC	XASSAQGAGANVLTF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	3	1	2	2	0	23	35	-1	37	45	TCRBV01,TCRBV07,TCRBV17													XASSAQGAGANVLTF+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACGTTTGGTGCATCCTGAAGACAGCAGYTCTACATCTGCAGTGCTAGATCCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA	CSARSLAGSTDTQYF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	4	3	0	3	0	36	48	-1	51	60		TCRBV20-01,TCRBV20-or09_02												CSARSLAGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCTCAGGGGCGCGGGGAAGACCCAGTACTTCGGGCCA	CASSQDLRGAGKTQYF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	48	TCRBV03						TCRBJ02	TCRBJ02-05	01	0	4	2	6	3	8	26	43	52	46	60		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDLRGAGKTQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGGGGTCAGCCCCAGCATTTTGGTGAT	CASSQGGQPQHF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	36	TCRBV03						TCRBJ01	TCRBJ01-05	01	1	6	2	6	0	0	26	-1	-1	42	46		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGGQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCACGGACCGGGAGGCTTGGGGCTACACCTTCGGTTCG	CSATDREAWGYTF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	6	8	1	8	7	5	26	34	48	41	53		TCRBV20-01,TCRBV20-or09_02												CSATDREAWGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCAAGGCAGCATTAATGAAAAACTGTTTTTTGGCAGT	CSATQGSINEKLFF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	42	TCRBV20						TCRBJ01	TCRBJ01-04	01	4	4	5	4	7	3	26	36	46	43	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSATQGSINEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACKCRGCCRTGTAYSTSTGTGCCAGCAGCTTGGGAGGGGGCCCCATGAACACTGAAGCTTTCTTTGGACAA	CASSLGGGPMNTEAFF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	48	unresolved						TCRBJ01	TCRBJ01-01	01	3	5	0	0	3	4	18	32	42	35	46	TCRBV11,TCRBV15			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGGPMNTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGCTCCCCAACTAGCGGGAGTAATGAGCAGTTCTTCGGGCCA	CASSSPTSGSNEQFF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	3	2	7	7	1	23	34	52	41	53	TCRBV24,TCRBV27													CASSSPTSGSNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACAGTCGACAGGGGAGTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	99	1.4192347887418842E-4		46	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	2	2	3	5	3	24	38	51	43	54		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCAGGCTCCGCTTCTGGTAACAATGAGCAGTTCTTCGGGCCA	CASSPGSASGNNEQFF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	4	4	5	1	14	24	36	41	37	55		TCRBV24-01,TCRBV24-or09_02												CASSPGSASGNNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTGGCCCCCTCAGGGACTACACCCCTCCACTTTGGGAAC	CASSLAPSGTTPLHF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	6	0	9	11	12	0	24	36	-1	48	55		TCRBV24-01,TCRBV24-or09_02				01,02								CASSLAPSGTTPLHF+TCRBV24-X+TCRBJ01-06	TCRBV24	TCRBD02-01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGCCCCACAGGGGTATCTCCAGGAATACGCAGTATTTTGGCCCA		Out	VDJ	1	99	1.4192347887418842E-4		47	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	2	7	3	11	22	34	44	37	55	TCRBV07,TCRBV11													X+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCTGCGCCAGCAGCCAGAAACCACCGGCCTGTCTGGGCGCGCGGGGGTTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	99	1.4192347887418842E-4		68	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	7	2	0	24	2	2	16	47	40	49	TCRBV01,TCRBV04													X+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTCCCTCAGAGAATCAGCCCCAGCATTTTGGTGAT	CASSPSENQPQHF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	39	TCRBV12						TCRBJ01	TCRBJ01-05	01	5	4	5	4	4	2	26	38	45	42	47		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPSENQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGGGCTCGTTCCATTTCGTGTTAGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	100	1.433570493678671E-4		49	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	8	0	5	0	19	26	-1	42	38	61		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGGGTGGGGACGTAGTACCTACGAGCAGTACTTCGGGCCG	CSARDGWGRSTYEQYF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	48	TCRBV20						TCRBJ02	TCRBJ02-07	01	0	0	7	2	6	6	26	40	51	46	57		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDGWGRSTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCGGGGACTTTTCTAGCACAGATACGCAGTATTTTGGCCCA	CASGDFSSTDTQYF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	8	0	10	0	1	5	22	31	38	32	43	TCRBV02,TCRBV12					01,02								CASGDFSSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGATATCTCCCAAGGGGGGCACAATGAGCAGTTCTTCGGGCCA	CASSLDISQGGHNEQFF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	51	unresolved						TCRBJ02	TCRBJ02-01	01	0	5	1	5	9	2	18	35	50	44	52	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLDISQGGHNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACGTTTGGTGCATCCTGAAGACAGCAGCTTTACATCTGCAGTGCTAGATCCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	101	1.4479061986154577E-4		44	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	21	4	3	0	21	0	37	30	-1	51	60		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTTTAAAATGGACGGGACTTAATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	101	1.4479061986154577E-4		50				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	0	10	4	8	3	31	46	60	54	63	TCRBV27,TCRBV28	TCRBV27-01,TCRBV28-01				01,02								X+X+TCRBJ02-01		TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCACCCCGGAGGGGGTTGGCAATCAGCCCCAGCATTTTGGTGAT	CASTPEGVGNQPQHF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	45	TCRBV12						TCRBJ01	TCRBJ01-05	01	7	5	1	2	6	3	22	32	44	38	47		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTPEGVGNQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCGTGGGGGAGCGGATCCGGGGAGCTGTTTTTTGGAGAA	CASSSWGSGSGELFF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	45	TCRBV24						TCRBJ02	TCRBJ02-02	01	6	6	1	6	4	7	24	36	45	40	52		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSWGSGSGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTGGGACAGGGTTTTTACGAGCAGTACTTCGGGCCG	CASSLGQGFYEQYF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	3	4	2	4	24	36	47	38	51	TCRBV24,TCRBV27													CASSLGQGFYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGACAGGGACTAACTATGGCTACACCTTCGGTTCG	CASSQTGTNYGYTF	In	VDJ	1	103	1.476577608489031E-4	1.7713634167020652E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	3	0	0	1	26	-1	47	40	48		TCRBV03-01,TCRBV03-02												CASSQTGTNYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGCTTTAGCGGGGGGGCCGTGGATACGCAGTATTTTGGCCCA	CSARFSGGAVDTQYF	In	VDJ	1	103	1.476577608489031E-4	1.7713634167020652E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	5	0	6	5	5	26	35	51	40	56		TCRBV20-01,TCRBV20-or09_02												CSARFSGGAVDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGTTCGACAGGGGGTTATGACAATCAGCCCCAGCATTTTGGTGAT	CASSTGGYDNQPQHF	In	VDJ	1	104	1.4909133134258178E-4	1.7885611197768426E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	9	2	1	3	3	6	23	31	43	34	49	TCRBV24,TCRBV27													CASSTGGYDNQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTAGCTAGCGGAACCTCCTACAATGAGCAGTTCTTCGGGCCA	CSARVASGTSYNEQFF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	4	5	0	3	3	26	39	49	42	52		TCRBV20-01,TCRBV20-or09_02				01,02								CSARVASGTSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCCAGGCCGGATTGGACGAGCAGTACTTCGGGCCG	CSAPQAGLDEQYF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	4	5	3	9	26	35	42	38	51		TCRBV20-01,TCRBV20-or09_02												CSAPQAGLDEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTCTCGGACTAGCGGGACCCACTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSSRTSGTHSGANVLTF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	57	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	6	1	3	0	4	4	24	36	52	40	56	TCRBV24,TCRBV27													CASSSRTSGTHSGANVLTF+X+TCRBJ02-06	unresolved	TCRBD02-01*02	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTAGACCGGGAGCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	105	1.5052490183626045E-4		47	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	0	8	2	0	1	0	18	35	-1	36	42	TCRBV07,TCRBV11													X+X+TCRBJ01-04	unresolved	TCRBD02-01*02	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTCCCGCTTGACTAGCGCAGAGCAAGAGACCCAGTACTTCGGGCCA	CSASRLTSAEQETQYF	In	VDJ	1	106	1.5195847232993913E-4	1.8229565259263972E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	5	2	6	2	8	5	26	35	51	43	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSASRLTSAEQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGTCCGGACACCACTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	106	1.5195847232993913E-4		41	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	1	6	0	4	3	26	33	42	37	45		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-03	TCRBV20	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCCGGGTCCTCCTTATGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSPGPPYATNEKLFF	In	VDJ	1	107	1.5339204282361778E-4	1.8401542290011745E-4	51	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	5	8	4	0	1	11	26	38	43	39	54		TCRBV12-03,TCRBV12-04				01,02								CASSPGPPYATNEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTCGTTTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSRFSGANVLTF	In	VDJ	1	107	1.5339204282361778E-4	1.8401542290011745E-4	42	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	5	8	6	0	0	3	22	-1	36	34	39		TCRBV12-03,TCRBV12-04				01,02								CASSRFSGANVLTF+TCRBV12-X+TCRBJ02-06	TCRBV12	TCRBD02-01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCACCAATCTGAGTGGGACGTAAGGGGCTACACCTTCGGTTCG		Out	VDJ	1	107	1.5339204282361778E-4		44	unresolved						TCRBJ01	TCRBJ01-02	01	7	0	7	8	11	6	18	28	44	39	50	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAATCGGGAGTACGCAGTACTTCGGGCCG	CASSLIGSTQYF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	36	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	2	8	2	9	2	3	26	41	49	43	52		TCRBV12-03,TCRBV12-04												CASSLIGSTQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTATTTACCGAGTGGATCCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	110	1.576927543046538E-4		41	TCRBV20						TCRBJ01	TCRBJ01-05	01	8	1	8	3	11	2	26	32	46	43	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACTGGACGGCCATTCACCCCTCCACTTTGGGAAC	CSARELDGHSPLHF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	42	TCRBV20						TCRBJ01	TCRBJ01-06	01	0	1	7	8	3	4	26	40	47	43	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARELDGHSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTTTGCGAGCGGGAGAATCCACGAGCAGTACTTCGGGCCG	CSARDFASGRIHEQYF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	6	2	5	7	5	26	40	55	47	60		TCRBV20-01,TCRBV20-or09_02												CSARDFASGRIHEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCGGCAGAAGAACACTGAAGCTTTCTTTGGACAA	CSASRQKNTEAFF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	3	4	5	1	4	2	26	37	44	41	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASRQKNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCGCCCTCAGAACATGAACACTGAAGCTTTCTTTGGACAA	CATSDLRPQNMNTEAFF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	51	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	6	0	10	0	24	42	-1	52	55		TCRBV24-01,TCRBV24-or09_02												CATSDLRPQNMNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGGGACAGGCTTCAATCAGCCCCAGCATTTTGGTGAT	CASSLGTGFNQPQHF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	1	1	4	3	0	3	18	-1	41	34	44	TCRBV05,TCRBV11													CASSLGTGFNQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCTGACTAGCGGGAAGATCTCGAGGGAGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	111	1.5912632479833248E-4		62				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	4	2	3	1	3	15	18	31	45	34	60	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												X+X+TCRBJ02-03		TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAAGGCGGCCGACGAACACTGAAGCTTTCTTTGGACAA	CASSLRRPTNTEAFF	In	VDJ	1	112	1.6055989529201113E-4	1.9261427443750614E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	2	7	5	1	2	5	22	37	43	39	48		TCRBV12-03,TCRBV12-04				01,02								CASSLRRPTNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCCTAAATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSFLNSNQPQHF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	42	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	3	4	9	0	1	2	26	40	44	41	46		TCRBV12-03,TCRBV12-04				01,02								CASSFLNSNQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAAGGAGACAGGGGGCTTTCCGGGGCCAACGTCCTGACTTTCGGGGCC	CASSQEGDRGLSGANVLTF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	57	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	0	2	0	4	4	5	23	40	54	44	59	TCRBV01,TCRBV04													CASSQEGDRGLSGANVLTF+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACTGAGACAGGGGGCTTCTGAGCAGTTCTTCGGGCCA		Out	VDJ	1	114	1.6342703627936849E-4		47	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	2	0	9	4	3	26	43	57	47	60		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAGATGGACTAGCGGGAGCGAGCAGTACTTCGGGCCG	CSARRWTSGSEQYF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	2	1	2	6	4	0	26	38	-1	42	55		TCRBV20-01,TCRBV20-or09_02												CSARRWTSGSEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCAGGGCAACTATGGCTACACCTTCGGTTCG	CSASQGNYGYTF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	3	2	1	1	26	37	43	38	44		TCRBV20-01,TCRBV20-or09_02												CSASQGNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTCTAACAGGGAGGGAGTACGAGCAGTACTTCGGGCCG	CATSLTGREYEQYF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	42	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	9	0	4	6	2	24	36	49	42	51		TCRBV24-01,TCRBV24-or09_02												CATSLTGREYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGACTGGGCCCTGGGGATGGCTACACCTTCGGTTCG	CASRLGPGDGYTF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	39	unresolved						TCRBJ01	TCRBJ01-02	01	7	6	2	6	10	0	24	35	-1	45	49	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRLGPGDGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTCAGACACGGCTTCCTGGGGGAACACTGAAGCTTTCTTTGGACAA	CASSSDTASWGNTEAFF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	51	unresolved						TCRBJ01	TCRBJ01-01	01	0	6	2	1	11	0	18	35	-1	46	50	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSDTASWGNTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGCCTAGTCTACTCTACACAGATACGCAGTATTTTGGCCCA	CASSLAPSLLYTDTQYF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	51				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	4	8	2	2	9	18	35	41	37	50	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03				01,02								CASSLAPSLLYTDTQYF+X+TCRBJ02-03		TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGTTCGCGGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLFAANTGELFF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	7	5	0	4	0	18	32	-1	36	40	TCRBV07,TCRBV11					01,02								CASSLFAANTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACAGACAGGGAGGGCACAGATACGCAGTATTTTGGCCCA	CSATDREGTDTQYF	In	VDJ	1	115	1.6486060677304716E-4	1.9777358535993933E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	9	1	1	2	0	26	40	-1	42	48		TCRBV20-01,TCRBV20-or09_02												CSATDREGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTTCCCGGGGGCGTCGGCAATCAGCCCCAGCATTTTGGTGAT	CSVPGGVGNQPQHF	In	VDJ	1	115	1.6486060677304716E-4	1.9777358535993933E-4	42	TCRBV20						TCRBJ01	TCRBJ01-05	01	7	6	0	2	5	4	26	33	44	38	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSVPGGVGNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCGCCCTCGTAGCGGGGGGGCCGTATACGCAGTATTTTGGCCCA	CASSALVAGGPYTQYF	In	VDJ	1	115	1.6486060677304716E-4	1.9777358535993933E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	5	0	7	7	4	18	30	48	37	52	TCRBV05,TCRBV11													CASSALVAGGPYTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGGCATACGGGACCTTCTGGAAACACCATATATTTTGGAGAG	CASRHTGPSGNTIYF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	45	TCRBV12						TCRBJ01	TCRBJ01-03	01	6	0	7	1	6	2	26	37	48	43	50		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRHTGPSGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCGAGGGGGGGGCACAGATACGCAGTATTTTGGCCCA	CATSDLRGGGTDTQYF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	48	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	9	0	1	3	0	24	42	-1	45	52		TCRBV24-01,TCRBV24-or09_02												CATSDLRGGGTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCATGGACAGAGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPWTENTGELFF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	1	5	1	4	1	24	36	46	40	47		TCRBV24-01,TCRBV24-or09_02												CASSPWTENTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGTTTGGATCCGGGACAGGATCGTAGGGGCTACACCTTCGGTTCG	CASSLDPGQDRRGYTF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	4	8	9	8	18	29	46	38	54	TCRBV07,TCRBV11													CASSLDPGQDRRGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCTAGCAGCCCCGGACTAGCGCGAGACGAGCAGTTCTTCGGGCCA	CASSPGLARDEQFF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	1	6	10	3	6	18	30	42	33	48	TCRBV07,TCRBV11					01,02								CASSPGLARDEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCACCTCGGTAGCAAACGGGCGGACTGAAGCTTTCTTTGGACAA	CASSTSVANGRTEAFF	In	VDJ	1	117	1.677277477604045E-4	2.012131259748948E-4	48	TCRBV12						TCRBJ01	TCRBJ01-01	01	6	8	0	5	16	2	26	37	57	53	59		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSTSVANGRTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACTAGCAGATACGCAGTATTTTGGCCCA	CSARELADTQYF	In	VDJ	1	117	1.677277477604045E-4	2.012131259748948E-4	36	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	3	8	4	0	0	26	-1	-1	40	45		TCRBV20-01,TCRBV20-or09_02				01,02								CSARELADTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTAGCGGTCCAGGACAATGAGCAGTTCTTCGGGCCA	CASSLAVQDNEQFF	In	VDJ	1	117	1.677277477604045E-4	2.012131259748948E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	4	4	5	4	0	18	35	-1	39	43	TCRBV07,TCRBV11													CASSLAVQDNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGCGGGTTCGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLAGSSNQPQHF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	45	TCRBV12						TCRBJ01	TCRBJ01-05	01	0	0	9	1	0	4	26	-1	46	43	50		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAGSSNQPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCCCGTATATGGCTACACCTTCGGTTCG	CASSQDPVYGYTF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	5	9	5	5	0	26	43	-1	48	50		TCRBV03-01,TCRBV03-02				01,02								CASSQDPVYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCACTCCGGGACAGGGCAGGGGTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	118	1.6916131825408316E-4		43	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	0	3	0	4	6	26	30	43	34	49		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCCCCGGGGGGGGGCCGAGCACAGATACGCAGTATTTTGGCCCA	CATSPGGGPSTDTQYF	In	VDJ	1	119	1.7059488874776184E-4	2.0465266658985026E-4	48	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	8	0	0	3	5	24	35	46	38	51		TCRBV24-01,TCRBV24-or09_02												CATSPGGGPSTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTGGGGACAGGGGTTTGGCTACGAGCAGTACTTCGGGCCG	CSAWGQGFGYEQYF	In	VDJ	1	120	1.7202845924144052E-4	2.06372436897328E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	2	3	2	5	26	35	47	37	52		TCRBV20-01,TCRBV20-or09_02												CSAWGQGFGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGCTTCTACATCTGCAGTGCTAGTGGCCGAAACAGAACCCGAGACTAGCCCGCCCGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	121	1.734620297351192E-4		61	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	2	7	4	19	7	13	24	50	43	57		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGACGAATCTGGGGGGCTAGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASRRIWGASSNQPQHF	In	VDJ	1	122	1.7489560022879784E-4	2.0981197751228345E-4	51	unresolved						TCRBJ01	TCRBJ01-05	01	6	6	0	0	9	3	22	33	48	42	51	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRRIWGASSNQPQHF+X+TCRBJ01-05	unresolved		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGGCAAGCGGGAGGACTTCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	123	1.7632917072247652E-4		46	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	1	8	1	1	0	4	26	-1	49	42	53		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCACCCCAGGGACAGGGAAGAATTCACCCCTCCACTTTGGGAAC	CSATPGTGKNSPLHF	In	VDJ	1	123	1.7632917072247652E-4	2.1153174781976118E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	0	3	7	7	3	26	34	50	41	53		TCRBV20-01,TCRBV20-or09_02												CSATPGTGKNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTGGCCCCAGGGTAGGGGGCGGCCACACAGATACGCAGTATTTTGGCCCA	CASSGPRVGGGHTDTQYF	In	VDJ	1	123	1.7632917072247652E-4	2.1153174781976118E-4	54	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	5	0	2	11	5	22	34	52	45	57		TCRBV12-03,TCRBV12-04												CASSGPRVGGGHTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCACTAGCGTTGAAGACCCAGTACTTCGGGCCA	CASSLSLALKTQYF	In	VDJ	1	123	1.7632917072247652E-4	2.1153174781976118E-4	42				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	3	6	6	5	4	24	36	48	41	52	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01				01,02								CASSLSLALKTQYF+X+TCRBJ02-05		TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCCCCCGGACTAGCGGGGGGGTCAATGAGCAGTTCTTCGGGCCA	CASSPRTSGGVNEQFF	In	VDJ	1	123	1.7632917072247652E-4	2.1153174781976118E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	1	0	6	4	1	24	36	55	40	56	TCRBV09,TCRBV21													CASSPRTSGGVNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGGAGGGCAGAACTCACCGGGGAGCTGTTTTTTGGAGAA	CSARRAELTGELFF	In	VDJ	1	124	1.777627412161552E-4	2.1325151812723892E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	10	0	4	2	7	26	34	42	36	49		TCRBV20-01,TCRBV20-or09_02												CSARRAELTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCAGCTAGCGGGGGGGCCGGAGGAGACCCAGTACTTCGGGCCA	CSASQLAGGPEETQYF	In	VDJ	1	125	1.7919631170983387E-4	2.1497128843471665E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	4	0	5	4	6	26	37	53	41	59		TCRBV20-01,TCRBV20-or09_02												CSASQLAGGPEETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCAGGTTTAGTGCGGAGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSRFSAESSYNEQFF	In	VDJ	1	125	1.7919631170983387E-4	2.1497128843471665E-4	51	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	7	5	0	9	4	23	35	48	44	52	TCRBV09,TCRBV21					01,02								CASSRFSAESSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSQGSSYNSPLHF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	45	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	1	10	2	0	0	0	26	-1	-1	42	46		TCRBV03-01,TCRBV03-02												CASSQGSSYNSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD02-01*02	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAATGACAGCAGGGGGCTTAGATACGCAGTATTTTGGCCCA	CSAMTAGGLDTQYF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	4	0	5	8	2	26	34	50	42	52		TCRBV20-01,TCRBV20-or09_02												CSAMTAGGLDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTAGTAGTTGGGGCCAACGTCCTGACTTTCGGGGCC	CSARVVVGANVLTF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	1	5	8	3	0	4	26	-1	42	39	46		TCRBV20-01,TCRBV20-or09_02				01,02								CSARVVVGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD02-01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCCCTTTCTCACCTAAGCACAGATACGCAGTATTTTGGCCCA	CATSDSLSHLSTDTQYF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	51	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	4	9	0	11	0	24	40	-1	51	54		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDSLSHLSTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCRTGTATCTCTGTGCCAGCAGCTTACCCCTGCAGTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	126	1.8062988220351252E-4		40	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	4	5	7	6	0	19	34	-1	40	43	TCRBV07,TCRBV11													X+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCTCGGAAAGGGAAGCTTTCTTTGGACAA	CASSPSEREAFF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	36	TCRBV03						TCRBJ01	TCRBJ01-01	01	4	1	8	8	4	4	26	39	46	43	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPSEREAFF+TCRBV03-X+TCRBJ01-01	TCRBV03		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATCCCTAGCGGGAAGTATAGATACGCAGTATTTTGGCCCA	CSARSLAGSIDTQYF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	4	3	5	3	5	26	38	50	41	55		TCRBV20-01,TCRBV20-or09_02												CSARSLAGSIDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGCAAGTTTAGCGGGATTTCCTACAATGAGCAGTTCTTCGGGCCA	CASSKFSGISYNEQFF	In	VDJ	1	128	1.8349702319086987E-4	2.2013059935714987E-4	48				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	5	3	1	6	2	33	44	58	50	60	TCRBV25,TCRBV27,TCRBV28	TCRBV25-01,TCRBV25-or09_02,TCRBV27-01,TCRBV28-01												CASSKFSGISYNEQFF+X+TCRBJ02-01		TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCGGGACTACGGGACTTGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	128	1.8349702319086987E-4		52				TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	0	0	9	3	1	10	18	35	43	36	53	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03				01,02								X+X+TCRBJ01-01		TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACTTTGGGACCGTCGAACACCGGGGAGCTGTTTTTTGGAGAA	CATLGPSNTGELFF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	42	TCRBV24						TCRBJ02	TCRBJ02-02	01	10	0	7	0	3	3	24	32	40	35	43		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATLGPSNTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAGATAACCGTAGTGCAGGGGATAGTTACTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSQITVVQGIVTGANVLTF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	63				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	4	2	2	15	7	18	30	51	45	58	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												CASSQITVVQGIVTGANVLTF+X+TCRBJ02-06		TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACCTCTAGCGGGAGCGGCCGAGCAGTACTTCGGGCCG		Out	VDJ	1	130	1.8636416417822723E-4		44	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	4	2	6	3	4	26	40	53	43	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAACCGGGACCGTCTATGGCTACACCTTCGGTTCG	CASSLTGTVYGYTF	In	VDJ	1	130	1.8636416417822723E-4	2.2357013997210533E-4	42	TCRBV24						TCRBJ01	TCRBJ01-02	01	6	0	7	4	6	3	24	36	47	42	50		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLTGTVYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGAAGGACAGTCTTATGGCTACACCTTCGGTTCG	CASSEGQSYGYTF	In	VDJ	1	132	1.8923130516558455E-4	2.270096805870608E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	2	5	5	0	3	23	-1	44	39	47	TCRBV02,TCRBV12													CASSEGQSYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCTCCCCAAGGCCCGAAGCTTTCTTTGGACAA	CASSSPRPEAFF	In	VDJ	1	133	1.9066487565926323E-4	2.2872945089453853E-4	36	unresolved						TCRBJ01	TCRBJ01-01	01	5	5	4	8	6	3	24	36	45	42	48	TCRBV09,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSPRPEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTCACAGGGGACAGGGGGCGACGAGCAGTACTTCGGGCCG	CASSSQGTGGDEQYF	In	VDJ	1	134	1.920984461529419E-4	2.3044922120201626E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	0	5	5	1	26	39	56	44	57		TCRBV12-03,TCRBV12-04												CASSSQGTGGDEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGGGACAGGCCCCTACGAGCAGTACTTCGGGCCG	CASSQGTGPYEQYF	In	VDJ	1	134	1.920984461529419E-4	2.3044922120201626E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	4	2	1	2	26	40	49	41	51		TCRBV03-01,TCRBV03-02												CASSQGTGPYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCTAGCAGCCAACCCACCGGCCGTTAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	134	1.920984461529419E-4		49	TCRBV03						TCRBJ01	TCRBJ01-05	01	2	9	0	0	6	3	26	41	50	47	53		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGGCCGGTGGAGGGAAAAACTGTTTTTTGGCAGT	CSAGRWREKLFF	In	VDJ	1	134	1.920984461529419E-4	2.3044922120201626E-4	36	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	6	10	1	8	8	0	26	34	-1	42	47		TCRBV20-01,TCRBV20-or09_02												CSAGRWREKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD02-01*02	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTACCCCGGGGGAGGGGGGGACGCCCTCGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	134	1.920984461529419E-4		59	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	9	0	1	13	8	22	34	54	47	62		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTAGTCAGGGGGCTGGAAACACCATATATTTTGGAGAG	CSASSQGAGNTIYF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	4	1	2	4	0	26	37	-1	41	48		TCRBV20-01,TCRBV20-or09_02												CSASSQGAGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGGGGGGCAGGGGTAGTTTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	135	1.9353201664662058E-4		43	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	4	2	6	5	5	24	35	46	40	51		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCAGGGTTAGACAAAAACATTCAGTACTTCGGCGCC	CATSDSGLDKNIQYF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	2	4	3	3	0	5	24	-1	45	40	50		TCRBV24-01,TCRBV24-or09_02												CATSDSGLDKNIQYF+TCRBV24-X+TCRBJ02-04	TCRBV24	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAATCTGGGCAGACGGCTTTCTTTGGACAA	CASSQSGQTAFF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	8	0	11	3	5	26	41	48	44	53		TCRBV03-01,TCRBV03-02												CASSQSGQTAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAGCCAGAGGGACTTTAAATCAGCCCCAGCATTTTGGTGAT	CSAARGTLNQPQHF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	6	0	10	4	7	3	26	34	47	41	50		TCRBV20-01,TCRBV20-or09_02				01,02								CSAARGTLNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGCGGCACCCCCTAACTATGGCTACACCTTCGGTTCG	CSARAAPPNYGYTF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	7	5	0	1	6	26	37	42	38	48		TCRBV20-01,TCRBV20-or09_02				01,02								CSARAAPPNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGAGACTACCGGGACAGGGGATCACCCCTCCACTTTGGGAAC	CASRDYRDRGSPLHF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	0	2	10	8	1	23	34	52	42	53	TCRBV02,TCRBV12													CASRDYRDRGSPLHF+X+TCRBJ01-06	unresolved	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGAAGCGTGGAGGGGGGGTCTCTACGAGCAGTACTTCGGGCCG	CASSEAWRGGLYEQYF	In	VDJ	1	137	1.963991576339779E-4	2.3560853212444946E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	9	0	3	5	3	23	40	52	45	55	TCRBV02,TCRBV12													CASSEAWRGGLYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGAAGGATCCAGGGGTCATAAGTACTTCGGGCCG	CASSEGSRGHKYF	In	VDJ	1	137	1.963991576339779E-4	2.3560853212444946E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	2	11	4	5	23	39	49	43	54	TCRBV02,TCRBV12													CASSEGSRGHKYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCGACACAGGGAGAGGTTGGCATTTTGGTGAT	CSASDTGRGWHF	In	VDJ	1	138	1.9783272812765658E-4	2.373283024319272E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	3	3	15	4	8	26	37	47	41	55		TCRBV20-01,TCRBV20-or09_02												CSASDTGRGWHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTTACTGCAGGGGTGTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	138	1.9783272812765658E-4		40	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	4	2	4	5	2	24	36	47	41	49		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCACCGAAATCGGCATGAACACTGAAGCTTTCTTTGGACAA	CASTEIGMNTEAFF	In	VDJ	1	138	1.9783272812765658E-4	2.373283024319272E-4	42	TCRBV24						TCRBJ01	TCRBJ01-01	01	11	9	0	0	11	1	24	31	45	42	46		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTEIGMNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGGAATAAATGAAAAACTGTTTTTTGGCAGT	CASSGINEKLFF	In	VDJ	1	139	1.9926629862133526E-4	2.3904807273940492E-4	36	unresolved						TCRBJ01	TCRBJ01-04	01	5	1	8	5	1	3	23	34	38	35	41	TCRBV02,TCRBV09			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGINEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGAGTCTGGGGACAGGGTGCTTTAGCTTTCTTTGGACAA	CASSQGVWGQGALAFF	In	VDJ	1	140	2.0069986911501394E-4	2.4076784304688265E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	0	3	10	7	6	26	42	58	49	64		TCRBV03-01,TCRBV03-02												CASSQGVWGQGALAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCTACAGGGCCCAATCAGCCCCAGCATTTTGGTGAT	CASSPTGPNQPQHF	In	VDJ	1	140	2.0069986911501394E-4	2.4076784304688265E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	3	3	3	2	2	26	39	47	41	49		TCRBV03-01,TCRBV03-02												CASSPTGPNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCAAGTTAGTGGAGGCTCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	140	2.0069986911501394E-4		49	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	10	1	0	9	2	26	37	51	46	53		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTAACAGTGAACACTGAAGCTTTCTTTGGACAA	CSARVTVNTEAFF	In	VDJ	1	142	2.0356701010237126E-4	2.442073836618381E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	3	5	0	2	0	26	39	-1	41	45		TCRBV20-01,TCRBV20-or09_02												CSARVTVNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTATGGGGAGAAGGGGGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLWGEGGSNQPQHF	In	VDJ	1	142	2.0356701010237126E-4	2.442073836618381E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	5	1	0	11	0	24	36	-1	47	53	TCRBV24,TCRBV27													CASSLWGEGGSNQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGTGGACAGTTTAACTATGGCTACACCTTCGGTTCG	CASSLAGGQFNYGYTF	In	VDJ	1	142	2.0356701010237126E-4	2.442073836618381E-4	48				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	1	5	1	4	2	18	35	45	39	47	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGGQFNYGYTF+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTCTTTACTTCTGTGCCACCACTATTTTAACCAAACGAGGGAAACCGGGCCCATGGATTATGGCTACACCTTCGGTTCG		Out	VDJ	1	143	2.0500058059604994E-4		62	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	8	11	0	5	15	17	13	23	43	38	60		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGGGGCCCCGGAAACACCATATATTTTGGAGAG	CSARGPGNTIYF	In	VDJ	1	143	2.0500058059604994E-4	2.4592715396931587E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	4	2	4	0	4	26	-1	40	34	44		TCRBV20-01,TCRBV20-or09_02												CSARGPGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTCAGGACAGGGTGGTCGGAGGAGCACAGATACGCAGTATTTTGGCCCA	CASSSGQGGRRSTDTQYF	In	VDJ	1	143	2.0500058059604994E-4	2.4592715396931587E-4	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	3	0	2	10	18	31	41	33	51	TCRBV07,TCRBV11													CASSSGQGGRRSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCTAGCGGGATCAGCACAGATACGCAGTATTTTGGCCCA	CASSLASGISTDTQYF	In	VDJ	1	144	2.0643415108972861E-4	2.476469242767936E-4	48				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	0	5	3	0	0	2	18	-1	43	35	45	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLASGISTDTQYF+X+TCRBJ02-03		TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCCATACAGGCAGAGCACTGAAGCTTTCTTTGGACAA	CASSPYRQSTEAFF	In	VDJ	1	145	2.078677215834073E-4	2.4936669458427134E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	4	4	4	5	26	38	47	42	52		TCRBV12-03,TCRBV12-04												CASSPYRQSTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCCGGGGGAGGTCTGGAAACACCATATATTTTGGAGAG	CASSPRGRSGNTIYF	In	VDJ	1	145	2.078677215834073E-4	2.4936669458427134E-4	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	4	8	2	1	2	3	26	39	47	41	50		TCRBV03-01,TCRBV03-02				01,02								CASSPRGRSGNTIYF+TCRBV03-X+TCRBJ01-03	TCRBV03	TCRBD02-01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGGGACGGTACAAGAGACCCAGTACTTCGGGCCA	CASSLGTVQETQYF	In	VDJ	1	145	2.078677215834073E-4	2.4936669458427134E-4	42	unresolved						TCRBJ02	TCRBJ02-05	01	1	1	7	2	0	4	18	-1	38	34	42	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGTVQETQYF+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAATGCAAGAGAGTTAGCCCCTAACAATGAGCAGTTCTTCGGGCCA	CNARELAPNNEQFF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	5	7	5	2	5	26	40	46	42	51		TCRBV20-01,TCRBV20-or09_02				01,02								CNARELAPNNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTCCGGACTAGCGGAAACACAGATACGCAGTATTTTGGCCCA	CATSDFRTSGNTDTQYF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	51	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	1	5	2	2	3	24	41	53	43	56		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDFRTSGNTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGTAGTACACGACGGTCGGCTAATGAAAAACTGTTTTTTGGCAGT	CASSTRRSANEKLFF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	45	TCRBV24						TCRBJ01	TCRBJ01-04	01	11	2	7	3	9	6	24	31	43	40	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSTRRSANEKLFF+TCRBV24-X+TCRBJ01-04	TCRBV24		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGGAGCAGGGTTCAGGCAACACAGATACGCAGTATTTTGGCCCA	CASSLEQGSGNTDTQYF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	4	3	2	4	9	18	32	41	36	50	TCRBV07,TCRBV11													CASSLEQGSGNTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCATGGGGCCGTGGACGGAGATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	147	2.1073486257076462E-4		50	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	7	0	0	1	12	26	36	42	37	54		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGCCCAGGACGGACAGGGAAACAATGAGCAGTTCTTCGGGCCA	CSAAQDGQGNNEQFF	In	VDJ	1	147	2.1073486257076462E-4	2.528062351992268E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	1	3	5	9	2	26	35	52	44	54		TCRBV20-01,TCRBV20-or09_02												CSAAQDGQGNNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTATATGTGGATCCCAAAAAGACCCAGTACTTCGGGCCA	CASSLYVDPKKTQYF	In	VDJ	1	147	2.1073486257076462E-4	2.528062351992268E-4	45	TCRBV12						TCRBJ02	TCRBJ02-05	01	2	1	8	6	5	8	22	37	45	42	53		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLYVDPKKTQYF+TCRBV12-X+TCRBJ02-05	TCRBV12		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCAGGGCGGGAGGGGCAATGAGTAGTTCTTCGGGCCA	CATSDLQGGRGNE*FF	Stop	VDJ	1	147	2.1073486257076462E-4		48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	7	0	14	4	9	24	42	55	46	64		TCRBV24-01,TCRBV24-or09_02												CATSDLQGGRGNE*FF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGCTGTGTATTTCTGTGCCAGCAGCTAAGATTGAGGCTAGAGTTCCAGGGGTTAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	147	2.1073486257076462E-4		61	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	2	0	15	1	13	30	51	45	52		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCACAGGGGACTGAAGCTTTCTTTGGACAA	CASSPQGTEAFF	In	VDJ	1	148	2.121684330644433E-4	2.545260055067045E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	2	5	1	0	26	39	-1	40	47		TCRBV03-01,TCRBV03-02												CASSPQGTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGCGAGGGGGTGAGCAGTTCTTCGGGCCA	CASSPRGGEQFF	In	VDJ	1	149	2.1360200355812197E-4	2.5624577581418226E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	5	1	9	4	0	26	39	-1	43	49		TCRBV03-01,TCRBV03-02												CASSPRGGEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTATTTGCGGGAGAGGATGGCGGGGAGCTGTTTTTTGGAGAA	CASSLFAGEDGGELFF	In	VDJ	1	149	2.1360200355812197E-4	2.5624577581418226E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	2	7	2	7	3	7	18	33	43	36	50	TCRBV07,TCRBV11													CASSLFAGEDGGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAAAACCCGACTAGCCGGTTACAATGAGCAGTTCTTCGGGCCA	CASKTRLAGYNEQFF	In	VDJ	1	151	2.164691445454793E-4	2.596853164291377E-4	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	11	2	7	4	9	4	24	31	47	40	51		TCRBV24-01,TCRBV24-or09_02				01,02								CASKTRLAGYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAATCCCGGGGCCGGTTACGAGCAGTACTTCGGGCCG	CASNPGAGYEQYF	In	VDJ	1	152	2.1790271503915797E-4	2.614050867366155E-4	39	TCRBV24						TCRBJ02	TCRBJ02-07	01	11	7	0	4	8	4	24	31	44	39	48		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASNPGAGYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCGGTTCCCCTCAGGGTCACTGAAGCTTTCTTTGGACAA	CASSPVPLRVTEAFF	In	VDJ	1	152	2.1790271503915797E-4	2.614050867366155E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	3	4	11	1	24	36	52	47	53		TCRBV24-01,TCRBV24-or09_02												CASSPVPLRVTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGACCCCGGGGCGACTGATACGCAGTATTTTGGCCCA	CASSDPGATDTQYF	In	VDJ	1	152	2.1790271503915797E-4	2.614050867366155E-4	42	unresolved						TCRBJ02	TCRBJ02-03	01	5	7	0	6	7	4	23	34	46	41	50	TCRBV02,TCRBV09			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDPGATDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCACAGAGACTAGCGGGTGGCCAAGAGACCCAGTACTTCGGGCCA	CSAQRLAGGQETQYF	In	VDJ	1	153	2.1933628553283665E-4	2.631248570440932E-4	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	2	4	1	5	3	26	34	49	39	52		TCRBV20-01,TCRBV20-or09_02				01,02								CSAQRLAGGQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAATGGACAGGGGTTCCCTCTATGGCTACACCTTCGGTTCG	CSARMDRGSLYGYTF	In	VDJ	1	153	2.1933628553283665E-4	2.631248570440932E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	1	2	4	2	6	26	38	49	40	55		TCRBV20-01,TCRBV20-or09_02												CSARMDRGSLYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGAACTAGCGGGAGTTACGAGCTGTTTTTTGGAGAA	CSARDRTSGSYELFF	In	VDJ	1	153	2.1933628553283665E-4	2.631248570440932E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	3	2	11	4	4	26	40	55	44	59		TCRBV20-01,TCRBV20-or09_02												CSARDRTSGSYELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGCAGGGCAGGGACGACAAGAGACCCAGTACTTCGGGCCA	CATSAGQGRQETQYF	In	VDJ	1	153	2.1933628553283665E-4	2.631248570440932E-4	45	TCRBV24						TCRBJ02	TCRBJ02-05	01	5	0	7	2	7	2	24	37	49	44	51		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSAGQGRQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGATTCCGCCAGGACTACCAAGAGACCCAGTACTTCGGGCCA	CASRFRQDYQETQYF	In	VDJ	1	153	2.1933628553283665E-4	2.631248570440932E-4	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	7	1	10	0	9	0	24	35	-1	44	49		TCRBV24-01,TCRBV24-or09_02				01,02								CASRFRQDYQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGCCGGGGGTAGCGGGGGCTACGAGCAGTACTTCGGGCCG	CSAAGGSGGYEQYF	In	VDJ	1	154	2.2076985602651532E-4	2.6484462735157095E-4	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	5	2	3	9	0	26	34	-1	43	52		TCRBV20-01,TCRBV20-or09_02												CSAAGGSGGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATATGGGGCATAGTGAATTCTTCGGGCCA	CSARDMGHSEFF	In	VDJ	1	154	2.2076985602651532E-4	2.6484462735157095E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	7	0	16	3	8	26	40	48	43	56		TCRBV20-01,TCRBV20-or09_02												CSARDMGHSEFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTGGCGGGGGGGCACCAAGAGACCCAGTACTTCGGGCCA	CSARVAGGHQETQYF	In	VDJ	1	156	2.2363699701387265E-4	2.682841679665264E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	1	7	0	0	2	1	26	39	50	41	51		TCRBV20-01,TCRBV20-or09_02												CSARVAGGHQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCAAATTCCAGGGACAAGGGGTCAGCCCCAGCATTTTGGTGAT	CATSDLQIPGTRGQPQHF	In	VDJ	1	156	2.2363699701387265E-4	2.682841679665264E-4	54	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	0	6	6	9	5	24	42	57	51	62		TCRBV24-01,TCRBV24-or09_02												CATSDLQIPGTRGQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCCCACAGATCTACTAATGAAAAACTGTTTTTTGGCAGT	CASSPHRSTNEKLFF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	3	5	2	4	4	24	36	44	40	48		TCRBV24-01,TCRBV24-or09_02												CASSPHRSTNEKLFF+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCTCCTCTAGCGGGGTCAACAATGAGCAGTTCTTCGGGCCA	CSATSSSGVNNEQFF	In	VDJ	1	158	2.2650413800123E-4	2.717237085814819E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	4	3	5	6	3	26	36	51	42	54		TCRBV20-01,TCRBV20-or09_02												CSATSSSGVNNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTCTCCGGGACATAAGCATTTATGGCTACACCTTCGGTTCG	CASSLRDISIYGYTF	In	VDJ	1	158	2.2650413800123E-4	2.717237085814819E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	6	5	4	8	23	35	45	39	53	TCRBV02,TCRBV09													CASSLRDISIYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAATCAGGGGGCACCTATGGCTACACCTTCGGTTCG	CSARESGGTYGYTF	In	VDJ	1	159	2.2793770849490868E-4	2.734434788889596E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	0	4	2	2	26	40	50	42	52		TCRBV20-01,TCRBV20-or09_02												CSARESGGTYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTTAAAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	159	2.2793770849490868E-4		35	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	5	9	1	1	2	26	37	40	38	42		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCCGCTATCAGGGCCCCTCCAATGAGCAGTTCTTCGGGCCA	CASSRYQGPSNEQFF	In	VDJ	1	159	2.2793770849490868E-4	2.734434788889596E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	4	3	6	6	6	18	30	41	36	47	TCRBV05,TCRBV11													CASSRYQGPSNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCTTCGGCGGTCTCCTACGAGCAGTACTTCGGGCCG	CASSPSAVSYEQYF	In	VDJ	1	160	2.2937127898858736E-4	2.7516324919643734E-4	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	7	5	0	6	1	24	36	46	42	47		TCRBV24-01,TCRBV24-or09_02				01,02								CASSPSAVSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCCCTCGAACTAGCGTTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	161	2.30804849482266E-4		46	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	3	6	1	7	1	26	39	53	46	54		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGATTGGACAGGGGCGAAGGGAGAGGTGAAGCTTTCTTTGGACAA	CSAGLDRGEGRGEAFF	In	VDJ	1	161	2.30804849482266E-4	2.7688301950391504E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	2	7	5	12	26	35	49	40	61		TCRBV20-01,TCRBV20-or09_02												CSAGLDRGEGRGEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAATCTAGCGGGGACACAGATACGCAGTATTTTGGCCCA	CASSQSSGDTDTQYF	In	VDJ	1	162	2.3223841997594468E-4	2.786027898113928E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	4	3	2	1	1	26	41	51	42	52		TCRBV03-01,TCRBV03-02												CASSQSSGDTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCGCAAGTCAAACAGGGTACCGAAGCTTTCTTTGGACAA	CASSSQVKQGTEAFF	In	VDJ	1	163	2.3367199046962336E-4	2.803225601188705E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	3	8	10	4	26	39	55	49	59		TCRBV12-03,TCRBV12-04												CASSSQVKQGTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGAGAGGGAGGGGGCACTGAAGCTTTCTTTGGACAA	CATSGEGGGTEAFF	In	VDJ	1	163	2.3367199046962336E-4	2.803225601188705E-4	42	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	9	0	4	4	2	24	37	48	41	50		TCRBV24-01,TCRBV24-or09_02												CATSGEGGGTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAACGCGGGAAGGTCCACAGATACGCAGTATTTTGGCCCA	CASNAGRSTDTQYF	In	VDJ	1	164	2.3510556096330203E-4	2.8204233042634826E-4	42	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	11	7	3	2	5	5	24	31	42	36	47		TCRBV24-01,TCRBV24-or09_02												CASNAGRSTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGCGGAGTTATGGCGGGGAGCACAGATACGCAGTATTTTGGCCCA	CSGVMAGSTDTQYF	In	VDJ	1	165	2.365391314569807E-4	2.8376210073382597E-4	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	9	7	3	0	10	0	26	31	-1	41	47		TCRBV20-01,TCRBV20-or09_02												CSGVMAGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTCTACAGTGTCCAACTCACCCCTCCACTTTGGGAAC	CASSSTVSNSPLHF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	3	5	10	2	8	26	39	45	41	53		TCRBV12-03,TCRBV12-04												CASSSTVSNSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTAAGCCGACGAACACTGAAGCTTTCTTTGGACAA	CSASKPTNTEAFF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	3	2	7	1	6	0	26	37	-1	43	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASKPTNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTGGGCGGGGGGAACAATGAGCAGTTCTTCGGGCCA	CASSLGGGNNEQFF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	7	1	5	2	1	18	32	42	34	43	TCRBV07,TCRBV11													CASSLGGGNNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCRGCCRTGTATSKCTGTGCTAGCAGCCAGGGAAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSQGSSYNEQFF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	4	3	0	0	3	18	-1	35	30	38	TCRBV07,TCRBV11													CASSQGSSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGTTGGGGGTCCGGATACGCAGTATTTTGGCCCA	CASSLVGGPDTQYF	In	VDJ	1	168	2.408398429380167E-4	2.889214116562592E-4	42	TCRBV12						TCRBJ02	TCRBJ02-03	01	1	6	1	6	2	4	26	42	49	44	53		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLVGGPDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCGATTTTAGGAAGTAGCGGGAGGGCCTCGGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	168	2.408398429380167E-4		52	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	11	5	0	5	14	5	24	31	56	45	61		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCTAGCAGCTTAGCTCCGGGGGCGAGGAGCGAGCAGTACTTCGGGCCG	CASSLAPGARSEQYF	In	VDJ	1	169	2.422734134316954E-4	2.9064118196373695E-4	45	unresolved						TCRBJ02	TCRBJ02-07	01	0	6	0	6	3	6	18	35	44	38	50	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAPGARSEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGGAAATACCCAAAACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	170	2.4370698392537407E-4		46	TCRBV03						TCRBJ02	TCRBJ02-05	01	4	1	8	0	0	10	26	-1	42	39	52		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGCAGACAGGGGGCTCCATGGCTACACCTTCGGTTCG	CASSADRGLHGYTF	In	VDJ	1	170	2.4370698392537407E-4	2.9236095227121465E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	0	6	2	3	24	37	49	39	52		TCRBV24-01,TCRBV24-or09_02												CASSADRGLHGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCAGAGCCTCAGGGACCCAGTACTTCGGGCCA	CASSPRASGTQYF	In	VDJ	1	171	2.4514055441905274E-4	2.940807225786924E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	4	4	7	9	0	26	39	-1	48	52		TCRBV03-01,TCRBV03-02												CASSPRASGTQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGATGTACAGCGGGAGAGAGATACGCAGTATTTTGGCCCA	CSADVQRERDTQYF	In	VDJ	1	173	2.4800769540641004E-4	2.975202631936479E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	6	2	5	8	2	26	34	50	42	52		TCRBV20-01,TCRBV20-or09_02												CSADVQRERDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCACGACGGCGGGAGGGACCAATGAGCAGTTCTTCGGGCCA	CASSTTAGGTNEQFF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	45	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	7	0	6	6	2	26	38	53	44	55		TCRBV03-01,TCRBV03-02												CASSTTAGGTNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACGTGGATAGCTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	174	2.494412659000887E-4		46	TCRBV03						TCRBJ01	TCRBJ01-02	01	0	1	8	0	3	3	26	43	49	46	52		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGCCCCGGGGGAGCTTCTACAATGAGCAGTTCTTCGGGCCA	CSAREPRGSFYNEQFF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	8	2	3	4	5	26	40	50	44	55		TCRBV20-01,TCRBV20-or09_02												CSAREPRGSFYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGTGAGGGGGCCAACCTACGAGCAGTACTTCGGGCCG	CSARDVRGPTYEQYF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	5	0	2	4	3	26	40	51	44	54		TCRBV20-01,TCRBV20-or09_02												CSARDVRGPTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATTGCGTACAGGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSLLRTGGTGELFF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	3	1	4	9	0	24	36	-1	45	53		TCRBV24-01,TCRBV24-or09_02												CASSLLRTGGTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCATTACCGGGACTAGTGTCGACGAGCAGTACTTCGGGCCG	CASSITGTSVDEQYF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	8	5	6	5	18	30	44	36	49	TCRBV07,TCRBV11					01,02								CASSITGTSVDEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTTGGGACTAGCGGGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSFGTSGSSYEQYF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	0	2	0	1	0	18	32	-1	33	47	TCRBV07,TCRBV11													CASSFGTSGSSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGTCCAGGGGTCCTACGAGCAGTACTTCGGGCCG	CASSQVQGSYEQYF	In	VDJ	1	175	2.508748363937674E-4	3.0095980380860334E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	2	1	2	0	23	39	-1	41	47	TCRBV01,TCRBV04													CASSQVQGSYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTAGAAGGGAAACAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	175	2.508748363937674E-4		49	unresolved						TCRBJ02	TCRBJ02-01	01	0	0	8	0	1	5	18	35	40	36	45	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAGAAGTCCCCTAGCGGGGCGCCATGGGAAGACCCAGTACTTCGGGCCA		Out	VDJ	1	175	2.508748363937674E-4		56	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	4	3	6	9	10	25	39	57	48	67		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAATCTGGCTCTTCTCTGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	176	2.5230840688744607E-4		43	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	9	0	5	5	8	26	38	46	43	54		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCGGGGTTGGGGAAAAACTGTTTTTTGGCAGT	CASSLAGVGEKLFF	In	VDJ	1	176	2.5230840688744607E-4	3.0267957411608104E-4	42				TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	0	8	3	8	0	5	18	-1	40	35	45	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGVGEKLFF+X+TCRBJ01-04		TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGAGATCCGGGACAGGGGGCGAGCAGTTCTTCGGGCCA	CASSLRSGTGGEQFF	In	VDJ	1	176	2.5230840688744607E-4	3.0267957411608104E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	0	0	10	7	0	18	32	-1	39	51	TCRBV05,TCRBV11													CASSLRSGTGGEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCTACAGGGGGGAAAAACTGTTTTTTGGCAGT	CSASYRGEKLFF	In	VDJ	1	178	2.551755478748034E-4	3.061191147310365E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	3	1	8	2	0	26	37	-1	39	47		TCRBV20-01,TCRBV20-or09_02												CSASYRGEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTCGAGGGGGGAGGTATGGCTACACCTTCGGTTCG	CATSRGGRYGYTF	In	VDJ	1	180	2.580426888621608E-4	3.0955865534599197E-4	39	TCRBV24						TCRBJ01	TCRBJ01-02	01	6	5	1	5	2	4	24	36	44	38	48		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSRGGRYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCCGTTCAAGTCATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	180	2.580426888621608E-4		50	TCRBV24						TCRBJ01	TCRBJ01-01	01	0	4	6	0	5	5	24	42	49	47	54		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGGACAGGGGAGGTCAGCCCCAGCATTTTGGTGAT	CASSLDRGGQPQHF	In	VDJ	1	180	2.580426888621608E-4	3.0955865534599197E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	1	2	6	0	3	18	-1	41	32	44	TCRBV05,TCRBV11													CASSLDRGGQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VJ	1	181	2.5947625935583945E-4		35	TCRBV03						TCRBJ01	TCRBJ01-05	01	3	0	0	1	0	0	26	-1	-1	-1	40		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAAGGGGGTTTGGCAGGGGAGTACTTCGGGCCG	CASSQEGGLAGEYF	In	VDJ	1	181	2.5947625935583945E-4	3.1127842565346973E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	2	11	11	0	18	35	-1	46	52	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQEGGLAGEYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCCGGGGTAGCGGGGTCTGGGGGGCCAACGTCCTGACTTTCGGGGCC	CASSFRGSGVWGANVLTF	In	VDJ	1	184	2.637769708368754E-4	3.164377365759029E-4	54	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-06	01	6	5	3	4	8	5	24	36	52	44	57		TCRBV24-01,TCRBV24-or09_02												CASSFRGSGVWGANVLTF+TCRBV24-X+TCRBJ02-06	TCRBV24	TCRBD02-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCAGCTTCTACATCTGCAGTGCTAGAGATTGGGCCGGCAGGTGGACGGGGACCCTACTAACTGAAGCTTTCTTTGGACAA	CSARDWAGRWTGTLLTEAFF	In	VDJ	1	185	2.652105413305541E-4	3.1815750688338066E-4	60	TCRBV20						TCRBJ01	TCRBJ01-01	01	0	0	7	5	19	7	15	29	53	48	60		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDWAGRWTGTLLTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCATAGCGGACAGGGGTCTTCAAGAGACCCAGTACTTCGGGCCA	CASSIADRGLQETQYF	In	VDJ	1	185	2.652105413305541E-4	3.1815750688338066E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	1	2	2	0	4	18	-1	44	35	48	TCRBV07,TCRBV11													CASSIADRGLQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGACAGATACTATGGCTACACCTTCGGTTCG	CSARDRYYGYTF	In	VDJ	1	186	2.666441118242328E-4	3.198772771908584E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	5	3	0	2	26	-1	43	37	45		TCRBV20-01,TCRBV20-or09_02												CSARDRYYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCTCCGCCTCAGTAATTCACCCCTCCACTTTGGGAAC	CASSLRLSNSPLHF	In	VDJ	1	186	2.666441118242328E-4	3.198772771908584E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	4	5	6	8	0	24	36	-1	44	47		TCRBV24-01,TCRBV24-or09_02												CASSLRLSNSPLHF+TCRBV24-X+TCRBJ01-06	TCRBV24	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCTACTAGCACAGATACGCAGTATTTTGGCCCA	CASSQATSTDTQYF	In	VDJ	1	187	2.6807768231791146E-4	3.215970474983361E-4	42	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	3	10	0	2	0	26	42	-1	44	47		TCRBV03-01,TCRBV03-02				01,02								CASSQATSTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAGGGACCCTCACCTACGAGCAGTACTTCGGGCCG	CSAGTLTYEQYF	In	VDJ	1	187	2.6807768231791146E-4	3.215970474983361E-4	36	TCRBV20						TCRBJ02	TCRBJ02-07	01	6	0	7	2	1	5	26	34	40	35	45		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAGTLTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCTCCCGGGACTCTAAGGGGGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	187	2.6807768231791146E-4		38	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	13	0	10	8	4	8	24	29	39	33	47		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGGGACAGGGAATCAGCCCCAGCATTTTGGTGAT	CASSQDGTGNQPQHF	In	VDJ	1	188	2.6951125281159013E-4	3.233168178058139E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	0	3	4	1	0	26	43	-1	44	53		TCRBV03-01,TCRBV03-02												CASSQDGTGNQPQHF+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCCTTGGGGCGTACGATGAGCAGTTCTTCGGGCCA	CATSLGAYDEQFF	In	VDJ	1	188	2.6951125281159013E-4	3.233168178058139E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	7	0	8	4	5	24	35	44	39	49		TCRBV24-01,TCRBV24-or09_02												CATSLGAYDEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CRRRRGACTCAGCCSTGTATCTCTRCGCCAGCAGCCAGTTGCCGGGGAGCTATGGCTACACCTTCGGTTCG	XASSQLPGSYGYTF	In	VDJ	1	189	2.709448233052688E-4	3.250365881132916E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	8	3	4	5	2	23	37	47	42	49	TCRBV04,TCRBV07,TCRBV17					01,02								XASSQLPGSYGYTF+X+TCRBJ01-02	unresolved	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTATGTCCGGGACGGGGAATTGGGTTCAGTACTTCGGGCCG	CASSMSGTGNWVQYF	In	VDJ	1	189	2.709448233052688E-4	3.250365881132916E-4	45	TCRBV24						TCRBJ02	TCRBJ02-07	01	6	0	7	10	6	13	24	36	47	42	60		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSMSGTGNWVQYF+TCRBV24-X+TCRBJ02-07	TCRBV24		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCTGTGCCAGCAGCTTAGGCAACTCTTCTTGGACAGGACCCAACCCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	189	2.709448233052688E-4		68				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	1	1	4	0	12	8	2	18	37	30	45	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												X+X+TCRBJ01-06		TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTGAGCCCCTACAAGAACTAATGAAAAACTGTTTTTTGGCAGT	CASS*APTRTNEKLFF	Stop	VDJ	1	190	2.723783937989475E-4		48	TCRBV12						TCRBJ01	TCRBJ01-04	01	0	3	6	1	4	2	26	43	50	47	52		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASS*APTRTNEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCGCCACAGGGGTAAGAGAAACACCATATATTTTGGAGAG		Out	VDJ	1	191	2.7381196429262616E-4		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	3	2	5	3	5	23	32	42	35	47	TCRBV09,TCRBV12													X+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATGGGCAGGGGGCTCGGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLWAGGSAGANVLTF	In	VDJ	1	192	2.7524553478630484E-4	3.301958990357248E-4	54	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	6	4	0	2	7	4	24	36	51	43	55		TCRBV24-01,TCRBV24-or09_02												CASSLWAGGSAGANVLTF+TCRBV24-X+TCRBJ02-06	TCRBV24	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGATACGATAGGAGCTTGCGAGCAGTACTTCGGGCCG		Out	VDJ	1	193	2.7667910527998346E-4		44	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	10	2	6	9	4	24	38	51	47	55		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATGGGATCCCGTTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSHGIPLNTGELFF	In	VDJ	1	194	2.7811267577366214E-4	3.3363543965068027E-4	48	TCRBV03						TCRBJ02	TCRBJ02-02	01	3	0	8	1	1	7	26	40	45	41	52		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHGIPLNTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAGGGGCGGGACACAGACTAGGATTCAGTACTTCGGCGCC	CSARDRGGTQTRIQYF	In	VDJ	1	200	2.867140987357342E-4	3.4395406149554666E-4	48	TCRBV20						TCRBJ02	TCRBJ02-04	01	0	0	6	10	7	9	26	40	53	47	62		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDRGGTQTRIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTTAGGTGGACATCGGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSFRWTSGGNQPQHF	In	VDJ	1	200	2.867140987357342E-4	3.4395406149554666E-4	51	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	6	8	2	2	13	0	24	36	-1	49	55		TCRBV24-01,TCRBV24-or09_02												CASSFRWTSGGNQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAGGGGGACACGGGAGACCCAGTACTTCGGGCCA	CSARRGTRETQYF	In	VDJ	1	201	2.8814766922941287E-4	3.4567383180302436E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	0	6	5	3	3	26	38	47	41	50		TCRBV20-01,TCRBV20-or09_02												CSARRGTRETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCAGGGCCGGCCCCGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	201	2.8814766922941287E-4		49	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	4	3	4	0	8	24	-1	47	42	55		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-03	TCRBV24	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAAGGTGACTAGCGGGGGACCCACCTCCTACAATGAGCAGTTCTTCGGGCCA	CSARKVTSGGPTSYNEQFF	In	VDJ	1	201	2.8814766922941287E-4	3.4567383180302436E-4	57	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	2	2	0	5	6	24	36	53	41	59		TCRBV20-01,TCRBV20-or09_02												CSARKVTSGGPTSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCTGGACAGCTCACTGAAGCTTTCTTTGGACAA	CASSSGQLTEAFF	In	VDJ	1	202	2.8958123972309155E-4	3.473936021105021E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	1	5	4	2	2	26	39	47	41	49		TCRBV12-03,TCRBV12-04												CASSSGQLTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACCTGGCGGGACAGGGAGCTTCTGGCTACACCTTCGGTTCG	CASSHLAGQGASGYTF	In	VDJ	1	203	2.9101481021677017E-4	3.491133724179799E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	3	7	6	6	26	40	55	46	61		TCRBV03-01,TCRBV03-02												CASSHLAGQGASGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAATGACAGGTTCTATGGCTACACCTTCGGTTCG	CSANDRFYGYTF	In	VDJ	1	203	2.9101481021677017E-4	3.491133724179799E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	2	4	4	2	2	26	36	44	38	46		TCRBV20-01,TCRBV20-or09_02												CSANDRFYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGAAAATGCCAGCCCCTACGAGCAGTACTTCGGGCCG	CASSENASPYEQYF	In	VDJ	1	203	2.9101481021677017E-4	3.491133724179799E-4	42	unresolved						TCRBJ02	TCRBJ02-07	01	2	4	5	2	5	2	23	38	46	43	48	TCRBV02,TCRBV09			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSENASPYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCAAAGGGGTAGGGCGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	204	2.9244838071044885E-4		40	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	5	2	8	2	6	19	31	38	33	44		TCRBV05-06,TCRBV05-07												X+TCRBV05-X+TCRBJ01-04	TCRBV05	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCTCGGTAGCGGGAGGGCTGGGGGGAGAGACCCAGTACTTCGGGCCA	CSAPSVAGGLGGETQYF	In	VDJ	1	205	2.938819512041275E-4	3.5255291303293534E-4	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	5	0	4	7	8	26	35	53	42	61		TCRBV20-01,TCRBV20-or09_02												CSAPSVAGGLGGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGCCCCCGGCGGGGGCGGAAACATTCAGTACTTCGGCGCC	CSAAPGGGGNIQYF	In	VDJ	1	205	2.938819512041275E-4	3.5255291303293534E-4	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	5	7	2	6	7	3	26	35	49	42	52		TCRBV20-01,TCRBV20-or09_02												CSAAPGGGGNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCCCCACACAGGGGAATGGGACGAGCAGTACTTCGGGCCG	XASSPHTGEWDEQYF	In	VDJ	1	206	2.953155216978062E-4	3.5427268334041305E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	3	2	5	5	6	23	36	48	41	54	TCRBV01,TCRBV07,TCRBV17													XASSPHTGEWDEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAACGGGGGCCGCACAATGAGCAGTTCTTCGGGCCA	CSAKRGPHNEQFF	In	VDJ	1	206	2.953155216978062E-4	3.5427268334041305E-4	39	TCRBV20						TCRBJ02	TCRBJ02-01	01	4	6	0	5	3	3	26	36	45	39	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAKRGPHNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACTGGGGACAGCCAAGAGACCCAGTACTTCGGGCCA	CSATGDSQETQYF	In	VDJ	1	206	2.953155216978062E-4	3.5427268334041305E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	0	5	1	3	0	26	36	-1	39	46		TCRBV20-01,TCRBV20-or09_02												CSATGDSQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAGCCAGAAGAGACCCAGTACTTCGGGCCA	CASSQEPEETQYF	In	VDJ	1	207	2.967490921914849E-4	3.559924536478908E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	4	5	3	2	0	26	43	-1	45	48		TCRBV03-01,TCRBV03-02												CASSQEPEETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCACGGACAGGGGGGGAGACCCAGTACTTCGGGCCA	CSAPRTGGETQYF	In	VDJ	1	207	2.967490921914849E-4	3.559924536478908E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	1	1	5	5	1	26	34	49	39	50		TCRBV20-01,TCRBV20-or09_02												CSAPRTGGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGATCCCCGTAGCTACTACAATGAGCAGTTCTTCGGGCCA	CAISDPRSYYNEQFF	In	VDJ	1	207	2.967490921914849E-4	3.559924536478908E-4	45				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	5	7	3	8	2	23	35	47	43	49	TCRBV06,TCRBV10	TCRBV06-08,TCRBV10-03				01,02								CAISDPRSYYNEQFF+X+TCRBJ02-01		TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTGTGCCACCAGTGACCCGAACCAATACAGGGAAGGTGCACTAGGTAGCGGGAGGCCCCGGACACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	207	2.967490921914849E-4		80	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	4	5	1	2	30	7	1	15	55	45	62		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGCACCCCTCGAGGGGCCCAACGAGCAGTACTTCGGGCCG	CSARAPLEGPNEQYF	In	VDJ	1	208	2.9818266268516355E-4	3.577122239553685E-4	45	TCRBV20						TCRBJ02	TCRBJ02-07	01	3	5	2	5	11	4	26	37	53	48	57		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARAPLEGPNEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGTAAGGGGGGGATACGAGCAGTACTTCGGGCCG	CATSVRGGYEQYF	In	VDJ	1	208	2.9818266268516355E-4	3.577122239553685E-4	39	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	9	0	4	3	1	24	37	47	40	48		TCRBV24-01,TCRBV24-or09_02												CATSVRGGYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGGTATTACGGGCCCACAGATACGCAGTATTTTGGCCCA	CASRYYGPTDTQYF	In	VDJ	1	209	2.9961623317884223E-4	3.5943199426284627E-4	42	TCRBV24						TCRBJ02	TCRBJ02-03	01	7	8	0	2	7	1	24	35	46	42	47		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRYYGPTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGTAGCTTAGGGCAGAGCAATATTAACTATGGCTACACCTTCGGTTCG	CASSLGQSNINYGYTF	In	VDJ	1	209	2.9961623317884223E-4	3.5943199426284627E-4	48							TCRBJ01	TCRBJ01-02	01	1	4	5	1	2	8	18	34	39	36	47	TCRBV11,TCRBV12	TCRBV11-03,TCRBV12-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGQSNINYGYTF+X+TCRBJ01-02			TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACCTCTACAGGGGGTATGGCTACACCTTCGGTTCG	CATSDLYRGYGYTF	In	VDJ	1	211	3.024833741661996E-4	3.6287153487780173E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	3	1	5	5	0	24	38	-1	43	51		TCRBV24-01,TCRBV24-or09_02												CATSDLYRGYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCAGGGGGCGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLAGGGANVLTF	In	VDJ	1	212	3.0391694465987826E-4	3.6459130518527944E-4	45				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	0	5	0	4	0	0	18	-1	-1	35	42	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGGGANVLTF+X+TCRBJ02-06		TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCGCCTCGAGGGGACAGGGGACAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	213	3.053505151535569E-4		47	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	9	0	2	5	8	3	24	33	51	41	54		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGCAGGACAGGGAGTATATGAAAAACTGTTTTTTGGCAGT	CSASAGQGVYEKLFF	In	VDJ	1	214	3.0678408564723556E-4	3.680308458002349E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	1	3	6	4	5	26	37	49	41	54		TCRBV20-01,TCRBV20-or09_02												CSASAGQGVYEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTATGGGGCCTATCAGCCCCAGCATTTTGGTGAT	CATSDYGAYQPQHF	In	VDJ	1	214	3.0678408564723556E-4	3.680308458002349E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	7	0	5	2	2	24	40	47	42	49		TCRBV24-01,TCRBV24-or09_02												CATSDYGAYQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCACTCTCACAGGGGGGGAACTGAAGCTTTCTTTGGACAA	CASSHSHRGGTEAFF	In	VDJ	1	215	3.0821765614091423E-4	3.6975061610771266E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	3	1	5	5	3	23	37	50	42	53	TCRBV01,TCRBV04													CASSHSHRGGTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCTCCGGTTAGGAGAAAAACTGTTTTTTGGCAGT	CSASLRLGEKLFF	In	VDJ	1	216	3.096512266345929E-4	3.7147038641519037E-4	39	TCRBV20						TCRBJ01	TCRBJ01-04	01	3	1	8	8	10	0	26	37	-1	47	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASLRLGEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ACTCGGCCGTGTATSTCTGTGCCAGCAGGTTCCAGGGGGGACTAGCGGCTTGGAGCGACGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	217	3.110847971282716E-4		64				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	0	5	0	9	10	17	28	48	37	58	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03				01,02								X+X+TCRBJ02-02		TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCCAGTGTAAGGGGCTCCTACACAGATACGCAGTATTTTGGCCCA	CSARPSVRGSYTDTQYF	In	VDJ	1	217	3.110847971282716E-4	3.731901567226681E-4	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	5	2	2	9	6	26	38	52	47	58		TCRBV20-01,TCRBV20-or09_02												CSARPSVRGSYTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCACCAGTGGCGGGACTAGCGAGACCTACGAGCAGTACTTCGGGCCG	CATSGGTSETYEQYF	In	VDJ	1	220	3.153855086093076E-4	3.7834946764510135E-4	45				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	6	2	3	3	36	48	61	51	64	TCRBV23,TCRBV24,TCRBV25	TCRBV23-or09_02,TCRBV24-01,TCRBV24-or09_02,TCRBV25-01,TCRBV25-or09_02				01,02								CATSGGTSETYEQYF+X+TCRBJ02-07		TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGACTAGCGGGGCGGAGTGAGTTCTCCTACGAGCAGTACTTCGGGCCG	CSARLAGRSEFSYEQYF	In	VDJ	1	220	3.153855086093076E-4	3.7834946764510135E-4	51	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	2	3	0	1	11	26	35	47	36	58		TCRBV20-01,TCRBV20-or09_02												CSARLAGRSEFSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGGTAGCTCGGACAATGAGCAGTTCTTCGGGCCA	CASSGSSDNEQFF	In	VDJ	1	221	3.168190791029863E-4	3.8006923795257905E-4	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	5	7	5	1	4	24	37	42	38	46		TCRBV24-01,TCRBV24-or09_02				01,02								CASSGSSDNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTATTCCCTTAGCGGGAGTTACCGGGGAGCTGTTTTTTGGAGAA	CSAIPLAGVTGELFF	In	VDJ	1	223	3.196862200903436E-4	3.835087785675345E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	5	2	5	6	2	26	36	51	42	53		TCRBV20-01,TCRBV20-or09_02												CSAIPLAGVTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGCAGGGACGTCGGCACTGAAGCTTTCTTTGGACAA	CSAGRDVGTEAFF	In	VDJ	1	223	3.196862200903436E-4	3.835087785675345E-4	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	5	0	7	4	4	5	26	35	44	39	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAGRDVGTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
SGACTCGGCYSTSTATCTCTGTGCCAGCAGCCCCCGGGACAGGGGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPRDRGSGANVLTF	In	VDJ	1	223	3.196862200903436E-4	3.835087785675345E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	0	2	0	4	0	19	31	-1	35	45	TCRBV05,TCRBV07													CASSPRDRGSGANVLTF+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTTCCGGGGACAATAATCAGCCCCAGCATTTTGGTGAT	CSASSGDNNQPQHF	In	VDJ	1	224	3.2111979058402227E-4	3.8522854887501227E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	0	6	4	5	2	26	37	48	42	50		TCRBV20-01,TCRBV20-or09_02												CSASSGDNNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGATCGGGGCGCGAGTTTGGATGAGCAGTTCTTCGGGCCA	CASSDRGASLDEQFF	In	VDJ	1	225	3.2255336107770094E-4	3.8694831918249E-4	45	TCRBV24						TCRBJ02	TCRBJ02-01	01	3	7	0	8	1	10	24	39	45	40	55		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDRGASLDEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGGGGACTAGGTTCCCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	226	3.239869315713796E-4		46	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	0	8	6	1	5	26	42	51	43	56		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGACAGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSQTGGYNEQFF	In	VDJ	1	226	3.239869315713796E-4	3.8866808948996774E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	2	1	3	0	0	26	-1	-1	40	49		TCRBV03-01,TCRBV03-02												CASSQTGGYNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCTTAGGGCTAGCGGGAGTATCCGAGCAGTTCTTCGGGCCA	CSASLGLAGVSEQFF	In	VDJ	1	226	3.239869315713796E-4	3.8866808948996774E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	4	2	10	7	5	26	37	54	44	59		TCRBV20-01,TCRBV20-or09_02												CSASLGLAGVSEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGGGGGGCCACCGGGGAGCTGTTTTTTGGAGAA	CATSGGATGELFF	In	VDJ	1	226	3.239869315713796E-4	3.8866808948996774E-4	39	TCRBV24						TCRBJ02	TCRBJ02-02	01	5	6	0	4	1	0	24	37	-1	38	44		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSGGATGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGACAGTTTCTATGGCTACACCTTCGGTTCG	CSASDSFYGYTF	In	VDJ	2	228	3.2685407255873697E-4	3.921076301049232E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	5	4	1	3	26	37	43	38	46		TCRBV20-01,TCRBV20-or09_02												CSASDSFYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGATCGCGGAYAGTTCTGGGCACAGATACGCAGTATTTTGGCCCA	CSARSRXVLGTDTQYF	In	VDJ	2	229	3.2828764305241565E-4	3.938274004124009E-4	48	TCRBV20			unresolved			TCRBJ02	TCRBJ02-03	01	2	7	5	1	2	10	26	38	44	40	54		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02										CSARSRXVLGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	unresolved	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTTCAGGCGGTTAACACTGAAGCTTTCTTTGGACAA	CASSLQAVNTEAFF	In	VDJ	2	230	3.297212135460943E-4	3.9554717071987866E-4	42	TCRBV03						TCRBJ01	TCRBJ01-01	01	4	4	4	2	2	5	26	39	45	41	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLQAVNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTACGGGACAGGAAATGAAAAACTGTTTTTTGGCAGT	CASSYGTGNEKLFF	In	VDJ	2	230	3.297212135460943E-4	3.9554717071987866E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	0	4	5	3	1	26	38	49	41	50		TCRBV03-01,TCRBV03-02												CASSYGTGNEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGCAGCGGGAGTTGGGAGACCCAGTACTTCGGGCCA	CSGSGSWETQYF	In	VDJ	2	230	3.297212135460943E-4	3.9554717071987866E-4	36	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	7	6	2	5	2	4	26	33	43	35	47		TCRBV20-01,TCRBV20-or09_02												CSGSGSWETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGATCGCCAGGGAAAACCTATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	230	3.297212135460943E-4		56	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	3	0	4	8	23	40	49	44	57	TCRBV01,TCRBV04													X+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTCCGAGCGGGGGGACCTACGAGCAGTACTTCGGGCCG	CSPSGGTYEQYF	In	VDJ	2	231	3.31154784039773E-4	3.9726694102735637E-4	36	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	8	6	1	2	3	1	26	32	44	35	45		TCRBV20-01,TCRBV20-or09_02												CSPSGGTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCCGGCGGGAGGGTGGTACGAGCAGTACTTCGGGCCG	CSASPAGGWYEQYF	In	VDJ	2	232	3.325883545334517E-4	3.989867113348341E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	7	0	4	4	3	26	37	50	41	53		TCRBV20-01,TCRBV20-or09_02												CSASPAGGWYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
SGACTCGGCYSTSTATCTCTGTGCCAGCAGCTTCGACAGGGAAAGACGAGCAGTACTTCGGGCCG		Out	VDJ	2	233	3.340219250271303E-4		40	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	2	3	5	1	4	19	33	41	34	45	TCRBV05,TCRBV07													X+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTATGGACAGGGGAGTCAACGAGCAGTACTTCGGGCCG	CASSMDRGVNEQYF	In	VDJ	2	233	3.340219250271303E-4	4.0070648164231183E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	2	5	2	5	23	35	46	37	51	TCRBV02,TCRBV12													CASSMDRGVNEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTTACAGGGACCTCTCTAACTATGGCTACACCTTCGGTTCG	CASSYRDLSNYGYTF	In	VDJ	2	233	3.340219250271303E-4	4.0070648164231183E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	3	0	1	6	23	35	42	36	48	TCRBV02,TCRBV12													CASSYRDLSNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCGGCCCGCGGCTACAATGAGCAGTTCTTCGGGCCA	CASSLSARGYNEQFF	In	VDJ	2	235	3.3688906601448765E-4	4.041460222572673E-4	45				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	7	5	3	10	0	24	36	-1	46	50	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01				01,02								CASSLSARGYNEQFF+X+TCRBJ02-01		TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGCCTCAGGGGAGGCACTGAAGCTTTCTTTGGACAA	CASSLRGGTEAFF	In	VDJ	2	235	3.3688906601448765E-4	4.041460222572673E-4	39	unresolved						TCRBJ01	TCRBJ01-01	01	6	4	2	4	3	3	23	34	43	37	46	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRGGTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCAGCTTCTACATCTGCAGTGCTACAGGGATTAGGCAGGGGCCTTACTGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSATGIRQGPYWSSYNEQFF	In	VDJ	2	236	3.3832263650816633E-4	4.0586579256474505E-4	60	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	2	0	11	11	15	25	42	36	53		TCRBV20-01,TCRBV20-or09_02												CSATGIRQGPYWSSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCTAGGGAACTCCTACAATGAGCAGTTCTTCGGGCCA	CSARDLGNSYNEQFF	In	VDJ	2	236	3.3832263650816633E-4	4.0586579256474505E-4	45	TCRBV20						TCRBJ02	TCRBJ02-01	01	0	0	8	0	4	1	26	40	48	44	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDLGNSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATGGCCCAGGGGGCGCCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	237	3.39756207001845E-4		49	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	4	0	2	5	2	26	40	53	45	55		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCCCCCGGGCTAGCGGGCCGCCAGTTCTTCGGGCCA		Out	VDJ	2	237	3.39756207001845E-4		43	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	4	4	13	9	4	26	39	56	48	60		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCTCGCTAGCGGAATACGAGCAGTACTTCGGGCCG	CASSLAEYEQYF	In	VDJ	2	237	3.39756207001845E-4	4.075855628722228E-4	36	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	8	4	5	4	3	2	26	35	45	38	47		TCRBV03-01,TCRBV03-02				01,02								CASSLAEYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAGATCGACTAGCGGGAGACTTAGGTGAGCAGTTCTTCGGGCCA	CSAREDRLAGDLGEQFF	In	VDJ	2	237	3.39756207001845E-4	4.075855628722228E-4	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	2	2	9	5	7	26	40	57	45	64		TCRBV20-01,TCRBV20-or09_02												CSAREDRLAGDLGEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAGTCCGGGGGCGCGGGGACACTGAAGCTTTCTTTGGACAA	CSAREVRGRGDTEAFF	In	VDJ	2	237	3.39756207001845E-4	4.075855628722228E-4	48	TCRBV20						TCRBJ01	TCRBJ01-01	01	0	6	0	3	5	6	26	40	51	45	57		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAREVRGRGDTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTGGGACTAGAGAGCTACGAGCAGTACTTCGGGCCG	CASSLGLESYEQYF	In	VDJ	2	237	3.39756207001845E-4	4.075855628722228E-4	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	8	3	2	4	24	36	46	38	50		TCRBV24-01,TCRBV24-or09_02				01,02								CASSLGLESYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGCCGGGACAGACTATGGCTACACCTTCGGTTCG	CSARAGTDYGYTF	In	VDJ	2	238	3.411897774955237E-4	4.093053331797005E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	5	3	4	0	26	37	-1	41	48		TCRBV20-01,TCRBV20-or09_02												CSARAGTDYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATTCGGCTAGCGGGAATTCACCCTACGAGCAGTACTTCGGGCCG	CASSQDSASGNSPYEQYF	In	VDJ	2	239	3.4262334798920236E-4	4.110251034871783E-4	54	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	4	3	2	5	6	26	43	57	48	63		TCRBV03-01,TCRBV03-02												CASSQDSASGNSPYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCATTGATAGCGGGATCGTGGGCCCCTACAATGAGCAGTTCTTCGGGCCA	CASIDSGIVGPYNEQFF	In	VDJ	2	239	3.4262334798920236E-4	4.110251034871783E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	5	3	2	4	9	23	33	45	37	54	TCRBV06,TCRBV10													CASIDSGIVGPYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACCGACTAGCGGGAGCGGACAATGAGCAGTTCTTCGGGCCA	CATSDRLAGADNEQFF	In	VDJ	2	240	3.4405691848288103E-4	4.12744873794656E-4	48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	2	2	5	2	3	24	38	52	40	55		TCRBV24-01,TCRBV24-or09_02												CATSDRLAGADNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCAACCCAACAATCAGTCCCAGCATTTTGGTGAT	CSAQPNNQSQHF	In	VDJ	2	241	3.454904889765597E-4	4.1446464410213374E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	3	6	11	7	6	26	35	45	42	51		TCRBV20-01,TCRBV20-or09_02												CSAQPNNQSQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCGAGGACAGGGACCGCTTTCTTTGGACAA	CSAPRTGTAFF	In	VDJ	2	243	3.48357629963917E-4	4.179041847170892E-4	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	3	11	4	3	26	35	47	39	50		TCRBV20-01,TCRBV20-or09_02												CSAPRTGTAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCATCAGGGGGAAATCAGCCCCAGCATTTTGGTGAT	CASSSSGGNQPQHF	In	VDJ	2	244	3.497912004575957E-4	4.196239550245669E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	4	1	4	4	1	24	36	47	40	48		TCRBV24-01,TCRBV24-or09_02												CASSSSGGNQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGTCCAAAGGGGGGCTTAAGGTCGCAGACCCAGTACTTCGGGCCA	CASSPKGGLRSQTQYF	In	VDJ	2	246	3.5265834144495304E-4	4.2306349563952237E-4	48	TCRBV03						TCRBJ02	TCRBJ02-05	01	6	5	1	6	5	12	26	37	48	42	60		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPKGGLRSQTQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGACAGAAAAGGACAAGACTCACAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	246	3.5265834144495304E-4		49	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	1	6	2	8	7	24	35	48	43	55		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTGGGTAGGCAATCAGCCCCAGCATTTTGGTGAT	CSARDWVGNQPQHF	In	VDJ	2	247	3.540919119386317E-4	4.2478326594700013E-4	42	TCRBV20						TCRBJ01	TCRBJ01-05	01	0	0	9	2	2	3	26	40	45	42	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDWVGNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTAGGTCAGGGGCGGGTGAAAAACTGTTTTTTGGCAGT	CSASRSGAGEKLFF	In	VDJ	2	248	3.555254824323104E-4	4.2650303625447783E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	4	2	7	5	4	26	37	48	42	52		TCRBV20-01,TCRBV20-or09_02												CSASRSGAGEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCATTTTGACAGTCTGGATCAGCCCCAGCATTTTGGTGAT	CASSHFDSLDQPQHF	In	VDJ	2	248	3.555254824323104E-4	4.2650303625447783E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	2	5	5	4	5	23	37	46	41	51	TCRBV01,TCRBV04													CASSHFDSLDQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGAACCTAGAGGTCCAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	250	3.5839262341966774E-4		44	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	4	8	4	4	5	26	40	48	44	53		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCGCGGGAGGGCACAATGAGTAGTTCTTCGGGCCA	CASSFAGGHNE*FF	Stop	VDJ	2	252	3.6125976440702504E-4		42	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	7	0	14	3	10	24	36	48	39	58		TCRBV24-01,TCRBV24-or09_02												CASSFAGGHNE*FF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTATCCCGGGTAGAGGGAAACACCATATATTTTGGAGAG	CASSLSRVEGNTIYF	In	VDJ	2	254	3.641269053943824E-4	4.368216580993443E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	2	8	4	4	3	5	26	41	48	44	53		TCRBV12-03,TCRBV12-04				01,02								CASSLSRVEGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12	TCRBD02-01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTTGTCTAGCGGGTCGAGTAGGATACGCAGTATTTTGGCCCA		Out	VDJ	2	254	3.641269053943824E-4		46	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	4	6	3	8	24	36	47	39	55		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGCAACAGGGGGTATCACTGAAGCTTTCTTTGGACAA	CSAATGGITEAFF	In	VDJ	2	256	3.6699404638173975E-4	4.4026119871429974E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	1	4	3	3	26	35	46	38	49		TCRBV20-01,TCRBV20-or09_02												CSAATGGITEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGGCGCCGACAGGGCGGGCGAGCAGTTCTTCGGGCCA	CSAGADRAGEQFF	In	VDJ	2	257	3.684276168754184E-4	4.4198096902177744E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	2	3	10	7	5	26	34	48	41	53		TCRBV20-01,TCRBV20-or09_02												CSAGADRAGEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTGACCGGGGACCCGGGGGTGAGCAGTTCTTCGGGCCA	CASSDRGPGGEQFF	In	VDJ	2	257	3.684276168754184E-4	4.4198096902177744E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	8	2	9	12	0	23	34	-1	46	52	TCRBV09,TCRBV12													CASSDRGPGGEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCCGGAGGTTGGACAGGGACGTGGGGCACTGAAGCTTTCTTTGGACAA	CSAPGGWTGTWGTEAFF	In	VDJ	2	258	3.698611873690971E-4	4.437007393292552E-4	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	3	4	11	8	26	34	53	45	61		TCRBV20-01,TCRBV20-or09_02												CSAPGGWTGTWGTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCAGGGCTCTTCCCTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	259	3.712947578627758E-4		46	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	4	3	0	1	9	26	36	42	37	51		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGCGCGGGAGGGACACCGGGGAGCTGTTTTTTGGAGAA	CATSERGRDTGELFF	In	VDJ	2	261	3.7416189885013313E-4	4.4886005025168837E-4	45	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	7	0	3	2	0	24	38	-1	40	49		TCRBV24-01,TCRBV24-or09_02												CATSERGRDTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGCCTACCTGGACGGATGAAAAACTGTTTTTTGGCAGT	CSAPTWTDEKLFF	In	VDJ	2	262	3.7559546934381175E-4	4.5057982055916613E-4	39	TCRBV20						TCRBJ01	TCRBJ01-04	01	6	1	7	6	8	2	26	34	46	42	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPTWTDEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGCCACAGGGGCAAATCAGCCCCAGCATTTTGGTGAT	CSAATGANQPQHF	In	VDJ	2	262	3.7559546934381175E-4	4.5057982055916613E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	3	2	4	3	2	26	35	45	38	47		TCRBV20-01,TCRBV20-or09_02												CSAATGANQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACAGACAGGGTAACACCGGGGAGCTGTTTTTTGGAGAA	CASSHRQGNTGELFF	In	VDJ	2	266	3.8132975131852646E-4	4.5745890178907706E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	2	3	2	2	1	26	40	49	42	50		TCRBV03-01,TCRBV03-02												CASSHRQGNTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATATAACGGACAGCCAGCCCCAGCATTTTGGTGAT	CATSDITDSQPQHF	In	VDJ	2	266	3.8132975131852646E-4	4.5745890178907706E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	1	5	7	5	1	24	39	50	44	51		TCRBV24-01,TCRBV24-or09_02												CATSDITDSQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCTAGCGGCTACAACACCGGGGAGCTGTTTTTTGGAGAA	CSARPSGYNTGELFF	In	VDJ	2	269	3.856304627995625E-4	4.626182127115102E-4	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	4	5	2	2	4	26	37	46	39	50		TCRBV20-01,TCRBV20-or09_02				01,02								CSARPSGYNTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCAGGACAAGCGAATGAAAAACTGTTTTTTGGCAGT	CSAPGQANEKLFF	In	VDJ	2	269	3.856304627995625E-4	4.626182127115102E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	6	5	3	4	26	35	43	38	47		TCRBV20-01,TCRBV20-or09_02												CSAPGQANEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCTAACCGGGACAGGGGGCTACGAGCAGTACTTCGGGCCG	CASSLTGTGGYEQYF	In	VDJ	2	270	3.8706403329324116E-4	4.64337983018988E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	1	3	5	0	23	36	-1	41	52	TCRBV01,TCRBV04													CASSLTGTGGYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGACAGGGGACTAGCGGGCCTGGGGAGTTCACCTACGAGCAGTACTTCGGGCCG	CSARQGTSGPGEFTYEQYF	In	VDJ	2	270	3.8706403329324116E-4	4.64337983018988E-4	57	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	0	4	2	3	13	24	36	51	39	64		TCRBV20-01,TCRBV20-or09_02				01,02								CSARQGTSGPGEFTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCTAGCAGCCAAGATAGTCTGCTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSQDSLLNTGELFF	In	VDJ	2	272	3.8993117428059846E-4	4.6777752363394345E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	5	8	1	0	6	23	-1	43	40	49	TCRBV01,TCRBV04					01,02								CASSQDSLLNTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAACGGGGGACCGGGGATACGCAGTATTTTGGCCCA	CASSQERGTGDTQYF	In	VDJ	2	273	3.9136474477427714E-4	4.694972939414212E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	8	2	6	1	6	23	40	47	41	53	TCRBV01,TCRBV04													CASSQERGTGDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTAACCGGGACAGTGTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	274	3.927983152679558E-4		41	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	0	5	7	4	2	24	36	47	40	49		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GCTGGCAAGCCACGTTTGGTGCCAGCCAGACCTCTGTACCTCTGTGCCAGCAGTCCGGGGACAACCTACGAGCAGTACTTCGGGCCG	CASSPGTTYEQYF	In	VDJ	2	277	3.9709902674899184E-4	4.7637637517133213E-4	39				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	6	2	3	1	42	54	63	57	64	TCRBV25,TCRBV27,TCRBV28	TCRBV25-01,TCRBV25-or09_02,TCRBV27-01,TCRBV28-01												CASSPGTTYEQYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCCTTCTCTCAGGGGTTGAACACTGAAGCTTTCTTTGGACAA	CSARPFSQGLNTEAFF	In	VDJ	2	278	3.985325972426705E-4	4.7809614547880984E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	2	0	10	1	26	37	53	47	54		TCRBV20-01,TCRBV20-or09_02												CSARPFSQGLNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGGGAATAGCAAGAACTACGAGCAGTACTTCGGGCCG	CASSQGNSKNYEQYF	In	VDJ	2	279	3.999661677363492E-4	4.798159157862876E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	5	7	3	4	5	23	39	47	43	52	TCRBV01,TCRBV04					01,02								CASSQGNSKNYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCGGACAACGGGACGGGGTTCCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	280	4.0139973823002787E-4		44	unresolved						TCRBJ02	TCRBJ02-03	01	14	0	7	2	10	7	23	26	41	36	48	TCRBV01,TCRBV04			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACTGGGGCGGCGTTCCCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSHWGGVPSGANVLTF	In	VDJ	2	281	4.0283330872370655E-4	4.8325545640124306E-4	54	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	7	0	0	2	8	26	40	47	42	55		TCRBV03-01,TCRBV03-02												CASSHWGGVPSGANVLTF+TCRBV03-X+TCRBJ02-06	TCRBV03	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGCCGGCGTCCGACGGGATTAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSRRRPTGLNTGELFF	In	VDJ	2	281	4.0283330872370655E-4	4.8325545640124306E-4	54	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	8	3	2	12	3	26	39	56	51	59		TCRBV03-01,TCRBV03-02												CASSRRRPTGLNTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAACCTCTTGGGGAAAACTGTTTTTTGGCAGT	CASSQETSWGKLFF	In	VDJ	2	282	4.0426687921738517E-4	4.8497522670872076E-4	42	TCRBV03						TCRBJ01	TCRBJ01-04	01	0	6	2	10	8	0	26	43	-1	51	55		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQETSWGKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTTAGGACCGCTAACACCGGGGAGCTGTTTTTTGGAGAA	CATSDFRTANTGELFF	In	VDJ	2	286	4.100011611920999E-4	4.918543079386317E-4	48	TCRBV24						TCRBJ02	TCRBJ02-02	01	1	1	7	2	2	4	24	41	47	43	51		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSDFRTANTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCCAAGATCGCTTCTATGGCTACACCTTCGGTTCG	CASSQDRFYGYTF	In	VDJ	2	287	4.1143473168577855E-4	4.935740782461094E-4	39	unresolved						TCRBJ01	TCRBJ01-02	01	2	2	8	4	0	6	20	-1	37	35	43	TCRBV01,TCRBV23			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDRFYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTCGGCAGCGGGCGGACGAAGGGCAAAAACATTCAGTACTTCGGCGCC	CSARVGSGRTKGKNIQYF	In	VDJ	2	288	4.1286830217945723E-4	4.952938485535872E-4	54	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	1	6	4	3	5	11	26	39	50	44	61		TCRBV20-01,TCRBV20-or09_02				01,02								CSARVGSGRTKGKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGGGGAACTAACTCCTACAATGAGCAGTTCTTCGGGCCA	CARGTNSYNEQFF	In	VDJ	2	289	4.143018726731359E-4	4.97013618861065E-4	39	unresolved						TCRBJ02	TCRBJ02-01	01	9	0	8	0	0	5	22	-1	34	30	39	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CARGTNSYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCGGAGGCCCCACTGAAGCTTTCTTTGGACAA	CASGGPTEAFF	In	VDJ	2	290	4.157354431668146E-4	4.987333891685427E-4	33	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	8	10	1	4	0	3	26	-1	40	35	43		TCRBV03-01,TCRBV03-02												CASGGPTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAAGGCAGACTAGCACAGATACGCAGTATTTTGGCCCA	CASSLRQTSTDTQYF	In	VDJ	2	295	4.229032956352079E-4	5.073322407059313E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	2	10	0	5	0	26	41	-1	46	50		TCRBV12-03,TCRBV12-04				01,02								CASSLRQTSTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAGGGGCTGCCTACGAGCAGTACTTCGGGCCG	CASSQEGAAYEQYF	In	VDJ	2	295	4.229032956352079E-4	5.073322407059313E-4	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	5	2	2	0	3	26	-1	48	43	51		TCRBV03-01,TCRBV03-02												CASSQEGAAYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTACCCAGGGGCGCATGGAGACCCAGTACTTCGGGCCA	CSASTQGRMETQYF	In	VDJ	2	295	4.229032956352079E-4	5.073322407059313E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	4	2	5	4	6	26	37	47	41	53		TCRBV20-01,TCRBV20-or09_02												CSASTQGRMETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTATAAGCGGGGGTTTGGAGACCCAGTACTTCGGGCCA	CSAISGGLETQYF	In	VDJ	2	300	4.300711481036013E-4	5.159310922433199E-4	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	4	6	2	5	2	4	26	36	46	38	50		TCRBV20-01,TCRBV20-or09_02												CSAISGGLETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTTTACAGGGATAAGGACAGCCCCAGCATTTTGGTGAT	CATSLQG*GQPQHF	Stop	VDJ	2	300	4.300711481036013E-4		42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	3	7	2	7	24	36	44	38	51		TCRBV24-01,TCRBV24-or09_02												CATSLQG*GQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGCCATGGGGAGGGCCATAGCCAAAAACATTCAGTACTTCGGCGCC	CSAAMGRAIAKNIQYF	In	VDJ	2	302	4.329382890909586E-4	5.193706328582755E-4	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	6	9	0	0	7	4	26	34	48	41	52		TCRBV20-01,TCRBV20-or09_02												CSAAMGRAIAKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTTTCGGGTCCGGGAGGGTATACAATGAGCAGTTCTTCGGGCCA	CSASFGSGRVYNEQFF	In	VDJ	2	302	4.329382890909586E-4	5.193706328582755E-4	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	8	0	4	9	2	26	37	54	46	56		TCRBV20-01,TCRBV20-or09_02												CSASFGSGRVYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCATCAGCCCCGCGGGGGGGCTCGGTGAGCAGTTCTTCGGGCCA	CASISPAGGLGEQFF	In	VDJ	2	302	4.329382890909586E-4	5.193706328582755E-4	45	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	11	7	0	9	11	5	24	31	51	42	56		TCRBV24-01,TCRBV24-or09_02												CASISPAGGLGEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCGGAGGACAGGGCCCTAGAGTATGGCTACACCTTCGGTTCG	CSARAEDRALEYGYTF	In	VDJ	2	304	4.3580543007831594E-4	5.22810173473231E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	1	3	5	4	8	26	39	51	43	59		TCRBV20-01,TCRBV20-or09_02												CSARAEDRALEYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGACATACAGGGGTTAGTGGCCACCGGGGAGCTGTTTTTTGGAGAA	CSARDIQGLVATGELFF	In	VDJ	2	306	4.386725710656733E-4	5.262497140881864E-4	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	3	2	4	3	8	26	40	50	43	58		TCRBV20-01,TCRBV20-or09_02												CSARDIQGLVATGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGACAGCGGGGGCGCACAGATACGCAGTATTTTGGCCCA	CSAGQRGRTDTQYF	In	VDJ	2	306	4.386725710656733E-4	5.262497140881864E-4	42	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	6	2	1	4	1	26	35	47	39	48		TCRBV20-01,TCRBV20-or09_02												CSAGQRGRTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCAGGTGACCTACGAGCAGTACTTCGGGCCG	CSASQVTYEQYF	In	VDJ	2	308	4.4153971205303065E-4	5.296892547031419E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	4	2	1	3	26	37	42	38	45		TCRBV20-01,TCRBV20-or09_02												CSASQVTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCTGGCAGGGGAGGGAATTCACCCCTCCACTTTGGGAAC	CASSSGRGGNSPLHF	In	VDJ	2	310	4.44406853040388E-4	5.331287953180973E-4	45	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	4	9	0	7	7	0	26	39	-1	46	53		TCRBV12-03,TCRBV12-04												CASSSGRGGNSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12	TCRBD02-01*02	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACAGGGTGAGCTCCTACGAGCAGTACTTCGGGCCG	CATSDRVSSYEQYF	In	VDJ	2	310	4.44406853040388E-4	5.331287953180973E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	3	0	0	4	24	-1	43	38	47		TCRBV24-01,TCRBV24-or09_02												CATSDRVSSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGGGGGGTTTACGGCACCTCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	311	4.458404235340667E-4		47	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	8	1	0	1	12	26	34	42	35	54		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGCGAGGGGGAATGAACACTGAAGCTTTCTTTGGACAA	CASSPRGGMNTEAFF	In	VDJ	2	313	4.48707564521424E-4	5.382881062405305E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	5	1	0	4	2	26	39	49	43	51		TCRBV03-01,TCRBV03-02												CASSPRGGMNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACAACACGGACGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CATSDNTDGNTGELFF	In	VDJ	2	313	4.48707564521424E-4	5.382881062405305E-4	48	TCRBV24						TCRBJ02	TCRBJ02-02	01	4	1	7	1	6	2	24	38	48	44	50		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSDNTDGNTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAACAGGGCTGGAATCACTGAAGTTTTCTTTGGACAA	CSARNRAGITEVFF	In	VDJ	2	314	4.5014113501510265E-4	5.400078765480082E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	3	3	13	1	16	26	38	45	39	61		TCRBV20-01,TCRBV20-or09_02												CSARNRAGITEVFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCTCGGCTAGCGGGGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	316	4.5300827600246E-4		52	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	0	4	2	1	6	0	26	40	-1	46	56		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTTTCAGCTAGCGGGAAGAGAGCAGTACTTCGGGCCG	CSARDFQLAGREQYF	In	VDJ	2	319	4.5730898748349603E-4	5.486067280853969E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	4	3	7	7	3	26	40	56	47	59		TCRBV20-01,TCRBV20-or09_02												CSARDFQLAGREQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGACAGGTACCGGGGAGCTGTTTTTTGGAGAA	CASSQTGTGELFF	In	VDJ	2	323	4.630432694582107E-4	5.554858093153079E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	2	4	5	0	1	26	-1	46	40	47		TCRBV03-01,TCRBV03-02												CASSQTGTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAGGGGTTCCTACAATGAGCAGTTCTTCGGGCCA	CSARRGSYNEQFF	In	VDJ	2	323	4.630432694582107E-4	5.554858093153079E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	5	2	1	0	1	26	-1	43	38	44		TCRBV20-01,TCRBV20-or09_02												CSARRGSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTTGGAGGGGGAACTAATGAAAAACTGTTTTTTGGCAGT	CSVGGGTNEKLFF	In	VDJ	2	324	4.6447683995188936E-4	5.572055796227856E-4	39	TCRBV20						TCRBJ01	TCRBJ01-04	01	7	5	1	1	4	0	26	33	-1	37	43		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSVGGGTNEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCTCGGGGCGCAGTATTTTGGCCCA	CATSDLLGAQYF	In	VDJ	2	325	4.6591041044556804E-4	5.589253499302633E-4	36	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	8	3	10	2	0	24	42	-1	44	49		TCRBV24-01,TCRBV24-or09_02												CATSDLLGAQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTAACCGTCCGGGACAGGGAGTCGTCTATGGCTACACCTTCGGTTCG	CASSNRPGQGVVYGYTF	In	VDJ	2	325	4.6591041044556804E-4	5.589253499302633E-4	51	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	3	4	8	6	24	36	53	44	59		TCRBV24-01,TCRBV24-or09_02												CASSNRPGQGVVYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCGACTAGCGGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CATSDLRLAGNTGELFF	In	VDJ	2	328	4.7021112192660407E-4	5.640846608526965E-4	51	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	2	4	1	1	0	24	42	-1	43	53		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDLRLAGNTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCCGGAGGGGTTCTCCTACGAGCAGTACTTCGGGCCG	CSASPEGFSYEQYF	In	VDJ	2	334	4.7881254488867607E-4	5.744032826975629E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	10	0	0	3	3	26	37	46	40	49		TCRBV20-01,TCRBV20-or09_02												CSASPEGFSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGTCGCGCGAGCTTTCCTACGAGCAGTACTTCGGGCCG	CSARGSRELSYEQYF	In	VDJ	2	335	4.8024611538235475E-4	5.761230530050407E-4	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	6	7	1	9	2	26	39	51	48	53		TCRBV20-01,TCRBV20-or09_02				01,02								CSARGSRELSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGCTGTGTATTTCTGTGCCAGCAGCCAAGGAGAGCAACTAGCGGGAGATATTTGGGCCAAAAACATTCAGTACTTCGGCGCC	CASSQGEQLAGDIWAKNIQYF	In	VDJ	2	337	4.831132563697121E-4	5.795625936199961E-4	63	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	1	3	2	1	7	8	13	29	47	36	55		TCRBV03-01,TCRBV03-02												CASSQGEQLAGDIWAKNIQYF+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGAGCCGGGACGGCGGAAACACCATATATTTTGGAGAG	CSASRDGGNTIYF	In	VDJ	2	338	4.845468268633908E-4	5.812823639274739E-4	39	TCRBV20						TCRBJ01	TCRBJ01-03	01	6	0	7	4	5	3	26	34	44	39	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASRDGGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCCAACAGGGGAGATACGCAGTATTTTGGCCCA	CASSSNRGDTQYF	In	VDJ	2	340	4.8741396785074813E-4	5.847219045424293E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	2	5	4	0	26	38	-1	42	49		TCRBV03-01,TCRBV03-02												CASSSNRGDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGTTCCCGGGACAGGGGGGAGAGAGACCCAGTACTTCGGGCCA	CSAVPGTGGRETQYF	In	VDJ	2	340	4.8741396785074813E-4	5.847219045424293E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	0	1	4	6	3	26	35	52	41	55		TCRBV20-01,TCRBV20-or09_02												CSAVPGTGGRETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGACGTTCTTAATGAAAAACTGTTTTTTGGCAGT	CASSLADVLNEKLFF	In	VDJ	2	340	4.8741396785074813E-4	5.847219045424293E-4	45							TCRBJ01	TCRBJ01-04	01	0	1	7	4	0	5	18	-1	39	35	44	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLADVLNEKLFF+X+TCRBJ01-04			TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGCGGACAGGGGGCTACGAGCAGTACTTCGGGCCG	CATSERTGGYEQYF	In	VDJ	2	341	4.888475383444268E-4	5.86441674849907E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	1	1	3	2	0	24	38	-1	40	50		TCRBV24-01,TCRBV24-or09_02												CATSERTGGYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCGGAGGGAAAGAGGTACGAGCAGTACTTCGGGCCG	CASSSEGKRYEQYF	In	VDJ	2	342	4.902811088381055E-4	5.881614451573848E-4	42	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	10	0	4	2	7	24	36	44	38	51		TCRBV24-01,TCRBV24-or09_02												CASSSEGKRYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTAGGCCTATAGCGGGAGGGGTAACCTACGAGCAGTACTTCGGGCCG	CSASRPIAGGVTYEQYF	In	VDJ	2	343	4.917146793317842E-4	5.898812154648625E-4	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	5	0	2	8	4	26	37	56	45	60		TCRBV20-01,TCRBV20-or09_02												CSASRPIAGGVTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCCCCTTATCAGGTATATATGGCTACACCTTCGGTTCG	CARSPLSGIYGYTF	In	VDJ	2	345	4.945818203191415E-4	5.933207560798179E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	4	5	7	4	18	30	41	37	45	TCRBV05,TCRBV11	TCRBV05-03,TCRBV11-03												CARSPLSGIYGYTF+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTCTCCCAGGGCCCCTTCTTAGCTAACTATGGCTACACCTTCGGTTCG	CASSFSQGPFLANYGYTF	In	VDJ	2	345	4.945818203191415E-4	5.933207560798179E-4	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	3	0	4	11	18	32	41	36	52	TCRBV07,TCRBV11													CASSFSQGPFLANYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACYTAGCGGGGGATATTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	346	4.960153908128201E-4		40	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	9	5	2	4	0	4	24	-1	42	33	46		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGATATTCCAGCACCTGAGCAGTTCTTCGGGCCA	CASSQDIPAPEQFF	In	VDJ	2	347	4.974489613064988E-4	5.967602966947735E-4	42	unresolved						TCRBJ02	TCRBJ02-01	01	0	4	5	9	5	4	23	40	48	45	52	TCRBV01,TCRBV04			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDIPAPEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATTGTAGCGGGACCAAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	352	5.046168137748921E-4		49	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	3	5	3	2	3	3	26	40	51	43	54		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAAGATCGAATAGCGCGAGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	353	5.060503842685708E-4		46	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	5	6	6	9	4	26	38	52	47	56		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCAGGACAGGGCATCCTACGAGCAGTACTTCGGGCCG	CSAQDRASYEQYF	In	VDJ	2	358	5.132182367369642E-4	6.156777700770285E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	3	1	3	2	26	34	45	37	47		TCRBV20-01,TCRBV20-or09_02												CSAQDRASYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGAAAGCCTCGGACAGGGGTTCAGAACACGTATGGCTACACCTTCGGTTCG	CASRKPRTGVQNTYGYTF	In	VDJ	2	362	5.189525187116789E-4	6.225568513069395E-4	54	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	1	2	5	8	11	26	37	54	45	65		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRKPRTGVQNTYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGGATATGTCCATTTCCATTCCGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	363	5.203860892053576E-4		52	TCRBV03						TCRBJ02	TCRBJ02-01	01	4	1	8	5	0	19	26	-1	42	39	61		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGGAGCGGGGGGGCCTTCTGGAGAGACCCAGTACTTCGGGCCA	CSAGAGGPSGETQYF	In	VDJ	2	364	5.218196596990363E-4	6.259963919218949E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	6	0	4	3	8	26	34	47	37	55		TCRBV20-01,TCRBV20-or09_02												CSAGAGGPSGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTGAAGACAGCAGCTTCTACATCTGCAGTGCCATCCGAAGGACTAGCCCGCCCCTAAGAGAGGACGGGGAGCTGTTTTTTGGAGAA	CSAIRRTSPPLREDGELFF	In	VDJ	2	364	5.218196596990363E-4	6.259963919218949E-4	57	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	1	7	7	8	17	24	32	48	40	65		TCRBV20-01,TCRBV20-or09_02				01,02								CSAIRRTSPPLREDGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATAGGAGGGCCCGATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	367	5.261203711800722E-4		46	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	0	10	0	5	2	4	26	43	51	45	55		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCTACGGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSASYGSSYNEQFF	In	VDJ	2	373	5.347217941421442E-4	6.414743246891945E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	8	2	0	3	0	26	37	-1	40	46		TCRBV20-01,TCRBV20-or09_02												CSASYGSSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCTCCGGGTGGCCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSFSGWPGANVLTF	In	VDJ	2	373	5.347217941421442E-4	6.414743246891945E-4	48	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	6	8	4	2	5	4	24	36	45	41	49		TCRBV24-01,TCRBV24-or09_02				01,02								CASSFSGWPGANVLTF+TCRBV24-X+TCRBJ02-06	TCRBV24	TCRBD02-01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTATGGGCGCGGAGGGGGCCAAGGAGGGACCCAGTACTTCGGGCCA	CASSYGRGGGQGGTQYF	In	VDJ	2	377	5.404560761168589E-4	6.483534059191055E-4	51	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	5	0	7	10	8	26	39	56	49	64		TCRBV12-03,TCRBV12-04												CASSYGRGGGQGGTQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCCACAGGGAATCGGTGAAGCTTTCTTTGGACAA	CSASPQGIGEAFF	In	VDJ	3	380	5.44756787597895E-4	6.535127168415387E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	3	3	7	3	6	26	37	46	40	52		TCRBV20-01,TCRBV20-or09_02												CSASPQGIGEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGAGGAGTAGCGGGCGCGCCTACGAGCAGTACTTCGGGCCG	CSAGRSSGRAYEQYF	In	VDJ	3	383	5.49057499078931E-4	6.586720277639718E-4	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	5	4	2	8	4	26	35	50	43	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSAGRSSGRAYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGAGGAGACAAAAACATTCAGTACTTCGGCGCC	CSARDRGDKNIQYF	In	VDJ	3	388	5.562253515473243E-4	6.672708793013605E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	0	10	2	3	4	1	26	40	48	44	49		TCRBV20-01,TCRBV20-or09_02												CSARDRGDKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAACCTGGACTAGCGGGAATCCCGCCGACGCGAGCAGTACTTCGGGCCG		Out	VDJ	3	394	5.648267745093963E-4		55	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	1	3	6	4	12	24	38	54	42	66		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCTATACCCGGTAGCGGGAGAGGGGACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	3	395	5.66260345003075E-4		49	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	11	5	2	3	9	5	26	32	50	41	55		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TATGTCTGTGCCAGCAGCTTTTGACAGGGACAGGGACTAGCGGGAGGGCCGTTCACCTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	396	5.676939154967537E-4		68				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	0	0	3	12	10	6	20	48	32	58	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-02,TCRBV11-03												X+X+TCRBJ02-07		TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTTCGGGACAGTGAGCAATCAGCCCCAGCATTTTGGTGAT	CSAFGTVSNQPQHF	In	VDJ	3	402	5.762953384588257E-4	6.913476636060487E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	5	1	3	2	26	35	45	38	47		TCRBV20-01,TCRBV20-or09_02												CSAFGTVSNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCGGGGCGAGGGCCCACGGTGTTAATGAAAAACTGTTTTTTGGCAGT	CASGARAHGVNEKLFF	In	VDJ	3	404	5.791624794461831E-4	6.947872042210042E-4	48	unresolved						TCRBJ01	TCRBJ01-04	01	8	7	0	4	0	15	22	-1	36	31	51	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGARAHGVNEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAAAGGACAGGGGACGGCCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	3	406	5.820296204335403E-4		50	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	1	2	3	2	5	26	41	52	43	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAATGGGGGGGCCTCCTACGAGCAGTACTTCGGGCCG	CASNGGASYEQYF	In	VDJ	3	407	5.83463190927219E-4	6.999465151434375E-4	39	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	11	9	0	0	5	1	24	31	43	36	44		TCRBV24-01,TCRBV24-or09_02												CASNGGASYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAAGGGGACCGGGACGGACGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSQERGPGRTNTGELFF	In	VDJ	3	407	5.83463190927219E-4	6.999465151434375E-4	57	TCRBV03						TCRBJ02	TCRBJ02-02	01	0	0	7	0	3	9	24	41	49	44	58		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQERGPGRTNTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCCCTTAGGGACAGGTTACAATGAGCAGTTCTTCGGGCCA	CATSDPLGTGYNEQFF	In	VDJ	3	413	5.920646138892911E-4	7.102651369883038E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	0	4	4	6	1	24	39	53	45	54		TCRBV24-01,TCRBV24-or09_02												CATSDPLGTGYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTACGGGGGGGAGGCAGATACGCAGTATTTTGGCCCA	CASSYGGEADTQYF	In	VDJ	3	415	5.949317548766484E-4	7.137046776032593E-4	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	8	0	4	1	3	26	39	48	40	51		TCRBV12-03,TCRBV12-04												CASSYGGEADTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCCCTCTCCTACGAGCAGTACTTCGGGCCG	CASSSLSYEQYF	In	VDJ	3	416	5.963653253703271E-4	7.15424447910737E-4	36	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	4	10	0	3	0	24	36	-1	39	41		TCRBV24-01,TCRBV24-or09_02				01,02								CASSSLSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGTTCGGGACTAGCGGGAGGGGACTACAATGAGCAGTTCTTCGGGCCA	CASSSGLAGGDYNEQFF	In	VDJ	3	416	5.963653253703271E-4	7.15424447910737E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	0	0	3	3	2	22	33	52	36	54	TCRBV07,TCRBV11													CASSSGLAGGDYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCCTATCTACGGACAGGCTAGCCCGAGACCCAGTACTTCGGGCCA		Out	VDJ	3	417	5.977988958640058E-4		53	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	1	4	5	9	7	24	39	55	48	62		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACTCGGACAAGCCTCCTAGATACGCAGTATTTTGGCCCA	CSATRTSLLDTQYF	In	VDJ	3	418	5.992324663576845E-4	7.188639885256925E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	6	5	3	8	26	36	44	39	52		TCRBV20-01,TCRBV20-or09_02												CSATRTSLLDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGTTCCCGCGGGAGGGGGTACGAGCAGTACTTCGGGCCG	CASSRGRGYEQYF	In	VDJ	3	421	6.035331778387205E-4	7.240232994481257E-4	39	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	9	7	0	4	5	2	26	34	48	39	50		TCRBV03-01,TCRBV03-02												CASSRGRGYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGACAGAAACACAGATACGCAGTATTTTGGCCCA	CASSQDRNTDTQYF	In	VDJ	3	423	6.064003188260778E-4	7.274628400630812E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	4	5	2	0	3	23	-1	43	40	46	TCRBV01,TCRBV04													CASSQDRNTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCACCAGATCGGGACTCCCTCTTTAGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	428	6.135681712944711E-4		50	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	10	5	7	10	23	33	46	40	56	TCRBV09,TCRBV12					01,02								X+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTGAAGCGGGTCTTGCAGATACGCAGTATTTTGGCCCA	CASSEAGLADTQYF	In	VDJ	3	429	6.150017417881498E-4	7.377814619079476E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	6	4	4	3	5	23	34	43	37	48	TCRBV09,TCRBV12					01,02								CASSEAGLADTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAATCGGGATCAGGACTCTACGAGCAGTACTTCGGGCCG	CASSQSGSGLYEQYF	In	VDJ	3	430	6.164353122818285E-4	7.395012322154253E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	1	10	3	9	0	23	38	-1	47	52	TCRBV01,TCRBV04					01,02								CASSQSGSGLYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCCCTCAAACAGGGGGGATGAAAAACTGTTTTTTGGCAGT	CSASPSNRGDEKLFF	In	VDJ	3	432	6.193024532691858E-4	7.429407728303807E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	3	1	6	8	1	26	37	53	45	54		TCRBV20-01,TCRBV20-or09_02												CSASPSNRGDEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAGGGGCTCGGCTACGAGCAGTACTTCGGGCCG	CASSQEGLGYEQYF	In	VDJ	3	437	6.264703057375792E-4	7.515396243677695E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	7	0	3	0	4	18	-1	40	35	44	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQEGLGYEQYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCTGAACCGATGGGGCGGGAGAGGCTAGTGAGCAGTTCTTCGGGCCA	CAT*TDGAGEASEQFF	Stop	VDJ	3	466	6.680438500542606E-4		48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	9	7	2	9	12	7	24	33	52	45	59		TCRBV24-01,TCRBV24-or09_02												CAT*TDGAGEASEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCAGCGGGGGGAGACCCAGTACTTCGGGCCA	CSAQRGETQYF	In	VDJ	3	469	6.723445615352966E-4	8.065722742070569E-4	33	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	6	2	5	2	0	26	34	-1	36	44		TCRBV20-01,TCRBV20-or09_02												CSAQRGETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGACTAGGGACAGTCGCCGAGCAGTACTTCGGGCCG	CSARLGTVAEQYF	In	VDJ	3	469	6.723445615352966E-4	8.065722742070569E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	5	6	6	4	26	35	48	41	52		TCRBV20-01,TCRBV20-or09_02												CSARLGTVAEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCTTCTAGCGGGGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	3	470	6.737781320289753E-4		50	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	3	4	2	1	3	0	24	39	-1	42	52		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCCACGACGGAGGAAACAATGAGCAGTTCTTCGGGCCA	CASSHDGGNNEQFF	In	VDJ	3	471	6.75211702522654E-4	8.100118148220124E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	10	1	5	7	2	20	31	43	38	45	TCRBV01,TCRBV23													CASSHDGGNNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
RAGACWCRGCMCTGTATCTCTGCGCCAGCAGCCAAGAGAATCAAGCGGGAGGACCGACAGGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	3	476	6.823795549910474E-4		61	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	0	6	1	1	6	8	20	37	52	43	60	TCRBV04,TCRBV23													X+X+TCRBJ02-04	unresolved	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGCTTACAGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	485	6.952816894341553E-4		37	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	3	5	3	4	0	26	39	-1	43	47		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCGGACCTTTCGCAGAGTTACAATGAGCAGTTCTTCGGGCCA	CASSPDLSQSYNEQFF	In	VDJ	3	498	7.139181058519781E-4	8.564456131239112E-4	48	TCRBV24						TCRBJ02	TCRBJ02-01	01	6	1	7	4	2	12	24	36	42	38	54		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPDLSQSYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGGGGACAGGGTCCAACACTGAAGCTTTCTTTGGACAA	CATSEGTGSNTEAFF	In	VDJ	3	500	7.167852468393355E-4	8.598851537388666E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	3	2	1	3	24	38	48	39	51		TCRBV24-01,TCRBV24-or09_02												CATSEGTGSNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGGGGACTCRGCYGTGTATSTCTGTGCCAGCAGCATCCTGGCTAGCGCGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSILASASSYNEQFF	In	VDJ	3	502	7.196523878266928E-4	8.633246943538221E-4	51	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	4	6	0	7	4	18	30	43	37	47	TCRBV07,TCRBV11					01,02								CASSILASASSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCGGCCTAGCGGAAAATTGGTATTTTGGCCCA		Out	VDJ	3	508	7.282538107887648E-4		38	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	4	5	14	6	7	26	37	50	43	57		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGACCCGGGACGGTCAATCAGCCCCAGCATTTTGGTGAT	CASRPGTVNQPQHF	In	VDJ	3	512	7.339880927634795E-4	8.805223974285995E-4	42	TCRBV24						TCRBJ01	TCRBJ01-05	01	7	0	7	3	4	3	24	35	44	39	47		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRPGTVNQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCAAAGGGACACAGAAAAACTGTTTTTTGGCAGT	CASSQRDTEKLFF	In	VDJ	3	514	7.368552337508368E-4	8.839619380435549E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	0	6	8	5	2	26	37	48	42	50		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSQRDTEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGGGACTAGCGGGGGGTCCGACCTACAATGAGCAGTTCTTCGGGCCA	CSAREGLAGGPTYNEQFF	In	VDJ	3	516	7.397223747381942E-4	8.874014786585104E-4	54	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	0	1	2	0	5	26	-1	55	40	60		TCRBV20-01,TCRBV20-or09_02												CSAREGLAGGPTYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCGGGACCACTAGCACAGATACGCAGTATTTTGGCCCA	CSAPGTTSTDTQYF	In	VDJ	3	518	7.425895157255516E-4	8.908410192734658E-4	42	TCRBV20						TCRBJ02	TCRBJ02-03	01	5	0	7	0	3	4	26	35	43	38	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPGTTSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCATTTGGGAGGGACGGTAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	3	520	7.454566567129089E-4		44	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	9	0	4	5	5	26	35	47	40	52		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGAAGGATACGGCATTCAGTACTTCGGCGCC	CSAREGYGIQYF	In	VDJ	3	522	7.483237977002663E-4	8.977201005033767E-4	36	TCRBV20						TCRBJ02	TCRBJ02-04	01	3	1	8	9	0	9	26	-1	40	37	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAREGYGIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGCTAGCTCCTACGAGCAGTACTTCGGGCCG	CASSLAASSYEQYF	In	VDJ	3	522	7.483237977002663E-4	8.977201005033767E-4	42				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	4	8	0	2	0	18	35	-1	37	41	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03				01,02								CASSLAASSYEQYF+X+TCRBJ02-07		TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	3	523	7.497573681939449E-4		43	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	8	5	1	1	0	26	43	-1	44	47		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCAGGACTAGCGGTCAATGAGCAGTTCTTCGGGCCA	CSAPGLAVNEQFF	In	VDJ	4	530	7.597923616496956E-4	9.114782629631986E-4	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	1	5	6	3	1	26	35	48	38	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSAPGLAVNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTCCGGGACTAGCGGGAGGAGTTTTTCTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	4	533	7.640930731307316E-4		55	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	0	1	3	2	9	18	31	48	33	57	TCRBV07,TCRBV11													X+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCACCTCGCTGATCCGCTCGGGAAACTATGGCTACACCTTCGGTTCG	CASTSLIRSGNYGYTF	In	VDJ	4	534	7.655266436244103E-4	9.183573441931095E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	7	8	3	2	15	0	18	28	-1	43	48	TCRBV07,TCRBV11													CASTSLIRSGNYGYTF+X+TCRBJ01-02	unresolved	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTTCGGACTAGCGGGAAAGGGCTACGAGCAGTACTTCGGGCCG	CSAFGLAGKGYEQYF	In	VDJ	4	537	7.698273551054463E-4	9.235166551155427E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	1	3	3	3	5	26	35	50	38	55		TCRBV20-01,TCRBV20-or09_02												CSAFGLAGKGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCTAAGATCCGGGGCGGGGACCTACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	4	538	7.71260925599125E-4		58	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	7	3	2	13	5	23	40	59	53	64		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGTGATTTTGGGGGAACGGGCGAGCAGTACTTCGGGCCG	CASSDFGGTGEQYF	In	VDJ	4	551	7.898973420169477E-4	9.47593439420231E-4	42	unresolved						TCRBJ02	TCRBJ02-07	01	5	6	1	6	7	6	23	34	46	41	52	TCRBV02,TCRBV09			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDFGGTGEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGACGATGACTAGCGGAAAATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	552	7.913309125106263E-4		49	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	2	5	4	4	4	26	40	53	44	57		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGTCGGGGGGGTCTTTCCTACGAGCAGTACTTCGGGCCG	CASSQGRGGLSYEQYF	In	VDJ	4	561	8.042330469537344E-4	9.647911424950084E-4	48	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	1	8	0	1	2	4	26	42	52	44	56		TCRBV03-01,TCRBV03-02												CASSQGRGGLSYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACAGACAGGGGAAACTGAAGCTTTCTTTGGACAA	CSARQTGETEAFF	In	VDJ	4	562	8.056666174474131E-4	9.665109128024861E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	2	2	5	2	2	26	38	48	40	50		TCRBV20-01,TCRBV20-or09_02												CSARQTGETEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCCGGACGCCGAGGCAATGAGCAGTTCTTCGGGCCA	CATSDSGRRGNEQFF	In	VDJ	4	563	8.071001879410918E-4	9.682306831099638E-4	45	TCRBV24						TCRBJ02	TCRBJ02-01	01	2	1	7	6	2	7	24	40	46	42	53		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSDSGRRGNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTAGCCGCATGCGGGAGGGCCTTTCCAATGAGCAGTTCTTCGGGCCA	CSSRMREGLSNEQFF	In	VDJ	4	573	8.214358928778784E-4	9.85428386184741E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	7	0	6	8	6	26	32	49	40	55		TCRBV20-01,TCRBV20-or09_02												CSSRMREGLSNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGGCCAGGAATACCTTCGGCCGAGCAGTACTTCGGGCCG	CARPGIPSAEQYF	In	VDJ	4	573	8.214358928778784E-4	9.85428386184741E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	11	4	4	6	3	12	24	31	38	34	50		TCRBV24-01,TCRBV24-or09_02												CARPGIPSAEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTTCGGACTAGCGGGTTCTCAGATACGCAGTATTTTGGCCCA	CATSDFRTSGFSDTQYF	In	VDJ	4	577	8.271701748525931E-4	9.923074674146521E-4	51	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	1	4	4	2	4	24	41	54	43	58		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDFRTSGFSDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGGGGGGGATTAAGGGGCACAGATACGCAGTATTTTGGCCCA	CASRGGLRGTDTQYF	In	VDJ	4	581	8.329044568273078E-4	9.99186548644563E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	9	1	1	0	8	26	-1	43	37	51		TCRBV03-01,TCRBV03-02												CASRGGLRGTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGGCAGGGATGATGTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSAREAGMMSGANVLTF	In	VDJ	4	583	8.357715978146652E-4	0.0010026260892595186	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	0	4	3	1	2	6	26	40	47	42	53		TCRBV20-01,TCRBV20-or09_02												CSAREAGMMSGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCCTCCTACTAGCAAGGGATACAATGAGCAGTTCTTCGGGCCA	CASSPPTSKGYNEQFF	In	VDJ	4	591	8.472401617640945E-4	0.0010163842517193404	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	3	7	4	5	6	23	36	47	41	53	TCRBV01,TCRBV04					01,02								CASSPPTSKGYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCCAACCTAAAAAAGGGACAGTACTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	607	8.701772896629532E-4		52	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	0	5	3	9	2	20	35	51	44	53	TCRBV01,TCRBV23													X+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAACCGCCTCAGCTCAGCGGCACTCTGATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	620	8.88813706080776E-4		53	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	6	5	8	12	7	23	38	55	50	62	TCRBV01,TCRBV04					01,02								X+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGTGCTACGAGCAGTACTTCGGGCCG		Out	VJ	4	640	9.174851159543494E-4		37	TCRBV03						TCRBJ02	TCRBJ02-07	01	0	0	0	3	0	4	26	-1	43	-1	47		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGATGGGGGCTCAAGCAATCAGCCCCAGCATTTTGGTGAT	CAISDGGSSNQPQHF	In	VDJ	4	646	9.260865389164214E-4	0.0011109716186306158	45				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	6	0	1	3	3	23	35	44	38	47	TCRBV06,TCRBV10	TCRBV06-08,TCRBV10-03												CAISDGGSSNQPQHF+X+TCRBJ01-05		TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCGGATATTAGACAGCCGCCGAAACACCATATATTTTGGAGAG		Out	VDJ	4	655	9.389886733595295E-4		47				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	2	5	5	8	5	18	30	43	38	48	TCRBV05,TCRBV11	TCRBV05-03,TCRBV11-03												X+X+TCRBJ01-03		TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCGGCCGGGGAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	4	662	9.490236668152802E-4		43	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	6	8	3	1	5	0	24	36	-1	41	46		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAATAAGCCGGGACAGGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	4	677	9.705272242204602E-4		50	TCRBV06			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	4	0	6	0	23	38	-1	44	52		TCRBV06-01,TCRBV06-08												X+TCRBV06-X+TCRBJ02-03	TCRBV06	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCACGAGAGGGGCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	5	685	9.819957881698896E-4		46	TCRBV20						TCRBJ01	TCRBJ01-03	01	0	5	2	2	7	0	26	40	-1	47	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTCCGCAGGGACTGTACAATGAGCAGTTCTTCGGGCCA	CATSPQGLYNEQFF	In	VDJ	5	690	9.89163640638283E-4	0.0011866415121596359	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	10	4	5	1	24	36	47	41	48		TCRBV24-01,TCRBV24-or09_02				01,02								CATSPQGLYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTATGCGCCCCGCGGGGGGGCTAACAGATACGCAGTATTTTGGCCCA	CSAMRPAGGLTDTQYF	In	VDJ	5	693	9.934643521193188E-4	0.001191800823082069	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	7	0	3	8	3	26	36	53	44	56		TCRBV20-01,TCRBV20-or09_02												CSAMRPAGGLTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAATTTGAGGCGGGCCACAATCTCTAAAGCAGATACGCAGTATTTTGGCCCA	CASNLRRATISKADTQYF	In	VDJ	5	697	9.991986340940335E-4	0.0011986799043119801	54	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	7	7	4	4	7	15	26	36	48	43	63		TCRBV03-01,TCRBV03-02				01,02								CASNLRRATISKADTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGTGTTTTGGAAACCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSVLETSYNEQFF	In	VDJ	5	701	0.0010049329160687482	0.001205558985541891	45	unresolved						TCRBJ02	TCRBJ02-01	01	4	1	8	0	4	3	23	36	43	40	46	TCRBV02,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVLETSYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGTTTGGGGCGGTCGGGGGAGCAGTACTTCGGGCCG	CASSLGRSGEQYF	In	VDJ	5	702	0.001006366486562427	0.0012072787558493688	39	TCRBV03						TCRBJ02	TCRBJ02-07	01	6	7	0	7	3	8	26	37	45	40	53		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGRSGEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGTCCGAGGCGGGGGAAGGACAATGAGCAGTTCTTCGGGCCA	CASSPRRGKDNEQFF	In	VDJ	5	736	0.0010551078833475017	0.0012657509463036116	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	7	2	5	6	4	26	37	50	43	54		TCRBV03-01,TCRBV03-02												CASSPRRGKDNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAACCCAAGAGACCCAGTACTTCGGGCCA	CSARTQETQYF	In	VDJ	5	749	0.0010737442997653245	0.0012881079603008223	33	TCRBV20						TCRBJ02	TCRBJ02-05	01	2	3	7	1	0	0	26	-1	-1	38	40		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARTQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAACGGACAGATACGAGCAGTACTTCGGGCCG		Out	VDJ	5	754	0.0010809121522337179		37	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	5	4	3	1	26	38	47	41	48		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGCCCCTTGGTCCCCCAATGAGCAGTTCTTCGGGCCA	CASSLAPWSPNEQFF	In	VDJ	5	778	0.001115317844082006	0.0013379812992176765	45	TCRBV12						TCRBJ02	TCRBJ02-01	01	0	0	10	6	5	5	26	43	50	48	55		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAPWSPNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCTCACTCCAGACAGGGGGCGCGCTGAGCAGTTCTTCGGGCCA	CASSLTPDRGRAEQFF	In	VDJ	5	790	0.00113252069000615	0.0013586185429074094	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	2	0	9	9	4	18	30	49	39	53	TCRBV07,TCRBV11													CASSLTPDRGRAEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGGGGGGCCGGGACTAGCGGGAGAGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	5	798	0.0011439892539555794		55	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	1	0	2	4	7	2	23	39	60	46	62	TCRBV01,TCRBV04													X+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCTGGGACCCGACAGGGGTCCAAGAGACCCAGTACTTCGGGCCA	CASWDPTGVQETQYF	In	VDJ	5	801	0.0011482899654366155	0.0013775360162896644	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	11	2	2	1	10	1	24	31	49	41	50		TCRBV24-01,TCRBV24-or09_02												CASWDPTGVQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTGGAAGCGGGGAAGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	5	823	0.0011798285162975461		47	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	6	3	2	5	3	26	40	52	45	55		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAAAGACCGATGAACACTGAAGCTTTCTTTGGACAA	CSAKRPMNTEAFF	In	VDJ	6	873	0.0012515070409814797	0.0015013594784280611	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	4	2	7	0	3	3	26	36	42	39	45		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAKRPMNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCCGGGGTTGGGGCAATGAGCAGTTCTTCGGGCCA	CASSFRGWGNEQFF	In	VDJ	6	883	0.0012658427459182665	0.0015185571815028384	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	8	3	6	1	6	26	40	46	41	52		TCRBV12-03,TCRBV12-04												CASSFRGWGNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCTCTGGGGCTAGCGGGGGGGCTGGTAGGGCAGTTCTTCGGGCCA	CSARPLGLAGGLVGQFF	In	VDJ	6	886	0.0012701434573993025	0.0015237164924252716	51	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	0	12	10	8	26	37	59	47	67		TCRBV20-01,TCRBV20-or09_02												CSARPLGLAGGLVGQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGGGACTAGCGATTTATGAGCAGTTCTTCGGGCCA	CSAREGLAIYEQFF	In	VDJ	6	897	0.0012859127328297677	0.0015426339658075267	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	0	6	8	0	4	26	-1	50	40	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSAREGLAIYEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGAGAAACTAGCGGGGAAAAACAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	6	933	0.0013375212706021999		49	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	3	3	2	7	5	26	35	52	42	57		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCATGCCAGATCCCATTTATTCCGACAATGAGCAGTTCTTCGGGCCA	CASSMPDPIYSDNEQFF	In	VDJ	6	944	0.0013532905460326653	0.0016234631702589802	51	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	4	5	5	4	15	26	38	45	42	60		TCRBV03-01,TCRBV03-02												CASSMPDPIYSDNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGAATTACAGGGGTAATGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	6	966	0.0013848290968935962		40	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	3	2	8	5	4	26	35	47	40	51		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCACGGACAGGGACCCTCTGGAAACACCATATATTTTGGAGAG	CASSHGQGPSGNTIYF	In	VDJ	7	1017	0.0014579411920712083	0.0017490064027048547	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	1	3	0	3	3	18	30	41	33	44	TCRBV07,TCRBV11													CASSHGQGPSGNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTTGGGACTAGCGGGAGCCTACAATGAGCAGTTCTTCGGGCCA	CSALGLAGAYNEQFF	In	VDJ	7	1056	0.0015138504413246764	0.0018160774446964864	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	0	2	2	3	0	26	34	-1	37	51		TCRBV20-01,TCRBV20-or09_02												CSALGLAGAYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAAAAGGGAGCAGAGCCAAAAACATTCAGTACTTCGGCGCC	CASSQKGSRAKNIQYF	In	VDJ	7	1083	0.0015525568446540007	0.0018625112429983852	48	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	2	9	2	0	3	3	26	41	49	44	52		TCRBV03-01,TCRBV03-02												CASSQKGSRAKNIQYF+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGCTGTAGCGGGAGGGCCTATTCACGTAGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	7	1088	0.0015597246971223938		55	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	5	0	6	6	13	26	35	52	41	65		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATTATCGGGACTAGCGGCAGATACGCAGTATTTTGGCCCA	CSARLSGLAADTQYF	In	VDJ	7	1089	0.0015611582676160725	0.0018728298648432516	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	0	5	4	5	0	26	38	-1	43	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSARLSGLAADTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGACAGGCTCTATGGCTACACCTTCGGTTCG	CSARDRLYGYTF	In	VDJ	7	1094	0.001568326120084466	0.0018814287163806402	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	4	4	0	2	26	-1	44	37	46		TCRBV20-01,TCRBV20-or09_02												CSARDRLYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGCGGGACTCGCGGGCACTGAAGCTTTCTTTGGACAA	CASSQAGLAGTEAFF	In	VDJ	8	1136	0.00162853608081897	0.001953659069294705	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	0	10	4	1	6	23	39	46	40	52	TCRBV01,TCRBV04					01,02								CASSQAGLAGTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTTATGACGGATTTACCTGACCAAGAGACCCAGTACTTCGGGCCA	CSARVMTDLPDQETQYF	In	VDJ	8	1140	0.0016342703627936848	0.0019605381505246157	51	TCRBV20						TCRBJ02	TCRBJ02-05	01	1	1	8	0	7	8	26	39	49	46	57		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARVMTDLPDQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAAAGGGACTACGATACTCTAGTGAGCAGTTCTTCGGGCCA	CASSQKGLRYSSEQFF	In	VDJ	8	1151	0.0016500396382241502	0.001979455623906871	48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	0	9	9	2	11	26	41	50	43	61		TCRBV03-01,TCRBV03-02				01,02								CASSQKGLRYSSEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAAGGACATCTAGCACAGATACGCAGTATTTTGGCCCA	CASSLRTSSTDTQYF	In	VDJ	8	1153	0.0016529067792115076	0.0019828951645218264	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	1	6	0	1	3	26	41	47	42	50		TCRBV12-03,TCRBV12-04												CASSLRTSSTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAGAGCGGTGGGCTACAATGAGCAGTTCTTCGGGCCA	CSARRAVGYNEQFF	In	VDJ	8	1189	0.0017045153169839397	0.0020448068955910247	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	6	5	3	2	4	26	38	45	40	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSARRAVGYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCAGACTAGCGGGAGTCATGAACACCGGGGAGCTGTTTTTTGGAGAA	CSASRLAGVMNTGELFF	In	VDJ	8	1235	0.0017704595596931586	0.0021239163297350006	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	3	2	2	1	2	4	26	37	51	39	55		TCRBV20-01,TCRBV20-or09_02												CSASRLAGVMNTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATTGGAAAGGGGATTGTACGAGCAGTACTTCGGGCCG	CSARLERGLYEQYF	In	VDJ	8	1250	0.0017919631170983386	0.0021497128843471665	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	5	2	4	6	4	26	38	49	44	53		TCRBV20-01,TCRBV20-or09_02												CSARLERGLYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACGGACTAGCGGGGGTCAATGAGCAGTTCTTCGGGCCA	CASSQDGLAGVNEQFF	In	VDJ	8	1255	0.001799130969566732	0.002158311735884555	48	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	1	2	6	1	1	26	43	57	44	58		TCRBV03-01,TCRBV03-02												CASSQDGLAGVNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGAGACAGGGCGTGAAAAACTGTTTTTTGGCAGT	CSARETGREKLFF	In	VDJ	8	1281	0.0018364038024023775	0.0022030257638789765	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	2	3	7	3	2	26	37	47	40	49		TCRBV20-01,TCRBV20-or09_02												CSARETGREKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGAGGGCCGGGGGAGCAGTACTTCGGGCCG	CASSLAGGPGEQYF	In	VDJ	9	1317	0.0018880123401748097	0.0022649374949481747	42				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	9	0	7	0	6	18	-1	42	35	48	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGGPGEQYF+X+TCRBJ02-07		TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCTGTGTACTTSTGTGCCACCTACCCCTGGACTAGCGGGAGGGTAACCCCCCCTAACGCGAGAACTCGTCCCTTCGGGCCA	CATYPWTSGRVTPPNARTRPF	In	VDJ	10	1474	0.0021130829076823608	0.002534941433222179	63	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02			10	1	0	18	9	28	12	19	43	28	71	TCRBV06,TCRBV10							TCRBJ02-01,TCRBJ02-05						CATYPWTSGRVTPPNARTRPF+X+TCRBJ02-X	unresolved	TCRBD02-01*02	TCRBJ02	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGATCGGAATTCAGATACGCAGTATTTTGGCCCA	CASSQDRNSDTQYF	In	VDJ	10	1480	0.002121684330644433	0.0025452600550670453	42	unresolved						TCRBJ02	TCRBJ02-03	01	0	1	8	4	2	3	23	40	45	42	48	TCRBV01,TCRBV04			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDRNSDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGCTACACCGGGGAGCTGTTTTTTGGAGAA	CASSLAGYTGELFF	In	VDJ	11	1596	0.002287978507911159	0.0027447534107344625	42				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	8	0	3	0	1	18	-1	39	35	40	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGYTGELFF+X+TCRBJ02-02		TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACTGCCCGGGACAGGGACAGCCAAAAACATTCAGTACTTCGGCGCC	CSARELPGTGTAKNIQYF	In	VDJ	11	1633	0.0023410206161772694	0.0028083849121111385	54	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	0	0	3	0	7	2	26	40	56	47	58		TCRBV20-01,TCRBV20-or09_02												CSARELPGTGTAKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATACAGGGGAAAATGCCTACAATGAGCAGTTCTTCGGGCCA	CATSDTGENAYNEQFF	In	VDJ	11	1670	0.0023940627244433805	0.0028720164134878145	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	3	2	2	0	6	24	-1	46	39	52		TCRBV24-01,TCRBV24-or09_02												CATSDTGENAYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCTGTCGGCAGCGGAGGGGGGGGTGAAAAACTGTTTTTTGGCAGT	CSAPVGSGGGGEKLFF	In	VDJ	12	1787	0.0025617904722037847	0.0030732295394627096	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	5	9	0	7	15	1	26	35	57	50	58		TCRBV20-01,TCRBV20-or09_02												CSAPVGSGGGGEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCACCCCCCCCGGGGACAACTACGAGTCGACTAACTATGGCTACACCTTCGGTTCG	CATPPGDNYESTNYGYTF	In	VDJ	12	1793	0.002570391895165857	0.0030835481613075756	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	10	0	6	0	9	12	23	30	45	39	57	TCRBV02,TCRBV12													CATPPGDNYESTNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACGACTTGGTGGGGGCATAAGGCGAGCAGTACTTCGGGCCG	CASSQDDLVGA*GEQYF	Stop	VDJ	12	1812	0.0025976297345457517		51	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	6	0	6	9	6	26	43	58	52	64		TCRBV03-01,TCRBV03-02												CASSQDDLVGA*GEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACGGACTAGCCGGGGGATCAATGAGCAGTTCTTCGGGCCA	CSARERTSRGINEQFF	In	VDJ	12	1823	0.002613399009976217	0.0031351412705319078	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	1	7	6	2	8	26	40	50	42	58		TCRBV20-01,TCRBV20-or09_02				01,02								CSARERTSRGINEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGTATAGAGCCGGGGAGCTGTTTTTTGGAGAA	CASSPYRAGELFF	In	VDJ	12	1859	0.002665007547748649	0.003197053001601106	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	4	5	8	6	4	2	26	39	46	43	48		TCRBV03-01,TCRBV03-02				01,02								CASSPYRAGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAAAATGGACGGGACTTAATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	13	1920	0.0027524553478630483		50	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	10	4	11	3	24	36	53	47	56		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCCGAGGACAGGGGGCGAGGCTACACCTTCGGTTCG	CATSDSEDRGRGYTF	In	VDJ	13	1931	0.0027682246232935137	0.003320876463739503	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	1	0	8	4	2	24	40	55	44	57		TCRBV24-01,TCRBV24-or09_02												CATSDSEDRGRGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGAGGGACTAGGCTACAATGAGCAGTTCTTCGGGCCA	CSASEGLGYNEQFF	In	VDJ	14	2075	0.0029746587743832422	0.0035685233880162967	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	0	8	3	3	1	26	37	48	40	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSASEGLGYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGGCGTGGACAGGGCACTGATGGCTACACCTTCGGTTCG	CATRRGQGTDGYTF	In	VDJ	16	2474	0.003546653401361032	0.004254711740699912	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	1	3	6	4	5	24	35	47	39	52		TCRBV24-01,TCRBV24-or09_02												CATRRGQGTDGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGCAAGTTTAGCGGGATTTCCTACAATGAGCAGTTCTTCGGGCCA	CASSKFSGISYNEQFF	In	VDJ	17	2504	0.003589660516171392	0.004306304849924244	48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	5	3	1	6	2	24	35	49	41	51		TCRBV24-01,TCRBV24-or09_02												CASSKFSGISYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGACTAGCGGGAGGTCTAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	17	2604	0.003733017565539259		50	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	2	1	0	0	5	24	-1	50	37	55		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTAGGAGGGACCGAGCAGTACTTCGGGCCG	CATSDLGGTEQYF	In	VDJ	17	2616	0.003750220411463403	0.004498919124361751	39	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	10	0	6	1	2	24	41	48	42	50		TCRBV24-01,TCRBV24-or09_02												CATSDLGGTEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATTTCCGGGACTCCCGAACGAGATTTGGCTACACCTTCGGTTCG	CASSQDFRDSRTRFGYTF	In	VDJ	18	2683	0.003846269634539874	0.004614143734962758	54	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	0	10	7	5	13	26	43	54	48	67		TCRBV03-01,TCRBV03-02				01,02								CASSQDFRDSRTRFGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTACCGACAACGGACAGCCCCAGCATTTTGGTGAT		Out	VDJ	19	2800	0.004013997382300278		41	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	2	6	7	2	5	26	41	47	43	52		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-05	TCRBV12	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAGGGGCAGGGGGCCGCCTACGAGCAGTACTTCGGGCCG	CASSQGQGAAYEQYF	In	VDJ	19	2801	0.004015430952793957	0.004817076631245131	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	0	2	4	2	23	37	49	41	51	TCRBV01,TCRBV04													CASSQGQGAAYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAATCCGTTCAGGGGACATGAACACTGAAGCTTTCTTTGGACAA	CSAREIRSGDMNTEAFF	In	VDJ	20	3049	0.004370956435226268	0.0052435796674996085	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	6	0	11	0	26	40	-1	51	57		TCRBV20-01,TCRBV20-or09_02												CSAREIRSGDMNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTAAGAGTTAGTGAGCAGTTCTTCGGGCCA	CATSDLRVSEQFF	In	VDJ	23	3470	0.004974489613064988	0.005967602966947734	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	5	8	9	6	0	24	41	-1	47	50		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDLRVSEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGTATACAGGGGGATGGAGAGACCCAGTACTTCGGGCCA	CASIQGDGETQYF	In	VDJ	27	4118	0.005903443292968767	0.007082014126193306	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	9	3	1	4	3	4	23	31	42	34	46	TCRBV02,TCRBV12													CASIQGDGETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGGAGGGTCGAGCGGTAACTCCTACGAGCAGTACTTCGGGCCG	CSARGGSSGNSYEQYF	In	VDJ	28	4181	0.0059937582340705235	0.007190359655564403	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	0	0	0	11	26	-1	44	37	55		TCRBV20-01,TCRBV20-or09_02												CSARGGSSGNSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCGGGGACAACCTACGAGCAGTACTTCGGGCCG	CASSPGTTYEQYF	In	VDJ	34	5118	0.007337013786647438	0.008801784433671038	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	6	2	3	1	24	36	45	39	46		TCRBV24-01,TCRBV24-or09_02												CASSPGTTYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCATGGGACAGTGTAGGACAGCCCCAGCATTTTGGTGAT	CASSLSWDSVGQPQHF	In	VDJ	39	5908	0.008469534476653587	0.010160402976578449	48				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	5	7	7	7	24	36	50	43	57	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01												CASSLSWDSVGQPQHF+X+TCRBJ01-05		TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATGGGGCCGCGGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSLWGRGGTGELFF	In	VDJ	45	6854	0.00982569216367361	0.011787305687452385	48	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	6	7	2	4	10	0	24	36	-1	46	53		TCRBV24-01,TCRBV24-or09_02												CASSLWGRGGTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGCGGGACTAGCGAGACCTACGAGCAGTACTTCGGGCCG	CATSGGTSETYEQYF	In	VDJ	100	15134	0.021695655851333005	0.026027003833368017	45	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	6	2	2	3	24	37	49	39	52		TCRBV24-01,TCRBV24-or09_02				01,02								CATSGGTSETYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATCCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA	CSARSLAGSTDTQYF	In	VDJ	103	15522	0.022251881202880328	0.026694274712669375	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	4	3	0	3	0	26	38	-1	41	50		TCRBV20-01,TCRBV20-or09_02												CSARSLAGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CACCAGCCAAACAGCTTTGTACTTCTGTCCTGGGAGAAAACAAGGAAGCGAACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CPGRKQGSEQSRANVLTF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	54	TCRBV22	TCRBV22-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	5	6	6	5	10	9	25	36	50	46	59						01,02								CPGRKQGSEQSRANVLTF+TCRBV22-01+TCRBJ02-06	TCRBV22-01*01	TCRBD02-01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCCGGGCGGGTCGGCCACTGAAGCTTTCTTTGGACAA	CASSPGGSATEAFF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	42	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	4	7	4	4	3	5	23	36	44	39	49						01,02							Vb 7.1	CASSPGGSATEAFF+TCRBV04-01+TCRBJ01-01	TCRBV04-01*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAAACTACAGGGAAACCCTATGGCTACACCTTCGGTTCG	CASSQETTGKPYGYTF	In	VDJ	1	54	7.741280665864823E-5	9.286759660379759E-5	48	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	3	3	4	4	5	23	40	50	44	55													Vb 7.1	CASSQETTGKPYGYTF+TCRBV04-01+TCRBJ01-02	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATCTCGTGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	74	1.0608421653222165E-4		40	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	4	10	6	1	4	23	40	43	41	47						01,02							Vb 7.1	X+TCRBV04-01+TCRBJ02-01	TCRBV04-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAAACAGGCGTCTACGAGCAGTACTTCGGGCCG	CASSQETGVYEQYF	In	VDJ	1	88	1.2615420344372303E-4	1.5133978705804052E-4	42	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	4	3	1	3	23	40	46	41	49													Vb 7.1	CASSQETGVYEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCCAGGACAGGGGGGGTTTAGAGAAAAACTGTTTTTTGGCAGT	CASSPGQGGFREKLFF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	48	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	1	1	8	2	8	23	36	48	38	56													Vb 7.1	CASSPGQGGFREKLFF+TCRBV04-01+TCRBJ01-04	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAACACGACAGGAGCCCCCCCAACGAGCAGTACTTCGGGCCG	CASSQHDRSPPNEQYF	In	VDJ	1	106	1.5195847232993913E-4	1.8229565259263972E-4	48	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	2	4	5	3	10	23	38	47	41	57													Vb 7.1	CASSQHDRSPPNEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATCTGGGATCCGGAAACACCATATATTTTGGAGAG	CASSQDLGSGNTIYF	In	VDJ	1	134	1.920984461529419E-4	2.3044922120201626E-4	45	TCRBV04	TCRBV04-01	01				TCRBJ01	TCRBJ01-03	01	0	0	8	4	3	3	23	40	47	43	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 7.1	CASSQDLGSGNTIYF+TCRBV04-01+TCRBJ01-03	TCRBV04-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAAATAGAACTGTCCTACGAGCAGTACTTCGGGCCG	CASSQEIELSYEQYF	In	VDJ	4	532	7.626595026370529E-4	9.149178035781541E-4	45	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	3	10	1	6	1	23	40	49	46	50						01,02							Vb 7.1	CASSQEIELSYEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCTCCCAGACATCTGTATACTTCTGTGCCAGCAGTTACCTAGGGACAGGGATCGCCAAAAACATTCAGTACTTCGGCGCC	CASSYLGTGIAKNIQYF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	51	TCRBV06	TCRBV06-09	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	3	0	3	1	4	3	26	40	53	44	56													Vb 13.1	CASSYLGTGIAKNIQYF+TCRBV06-09+TCRBJ02-04	TCRBV06-09*01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGGCAACAGGCTCCCAATGAAAAACTGTTTTTTGGCAGT	CASRQQAPNEKLFF	In	VDJ	1	92	1.318884854184377E-4	1.5821886828795145E-4	42	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	3	4	5	3	5	26	37	45	40	50			01,02										Vb 12	CASRQQAPNEKLFF+TCRBV10-01+TCRBJ01-04	TCRBV10-01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTTCTGCGCCAGTGGATCCTCCTTATTTAGCCGAGACACCGGCGCCATAGCAATCAGCCCTAGCATTTTGGTGAT		Out	VDJ	1	123	1.7632917072247652E-4		65	TCRBV10	TCRBV10-01					TCRBJ01	TCRBJ01-05	01	9	2	6	14	22	23	4	12	38	34	61			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-01+TCRBJ01-05	TCRBV10-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGAGTCTTTGAAGTCTTTTGGTGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	171	2.4514055441905274E-4		53	TCRBV10	TCRBV10-01					TCRBJ01	TCRBJ01-05	01	0	0	10	2	13	1	26	43	58	56	59			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-01+TCRBJ01-05	TCRBV10-01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCACCCGCTTCGGTCGTCTCCTCTACGAGCAGTACTTCGGGCCG	CATRFGRLLYEQYF	In	VDJ	1	177	2.5374197738112475E-4	3.043993444235588E-4	42	TCRBV10	TCRBV10-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	10	8	5	3	7	9	26	33	43	40	52			01,02			01,02							Vb 12	CATRFGRLLYEQYF+TCRBV10-01+TCRBJ02-07	TCRBV10-01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGCTCCGGACAGCCCAATCAGCCCCAGCATTTTGGTGAT	CASSSGQPNQPQHF	In	VDJ	2	233	3.340219250271303E-4	4.0070648164231183E-4	42	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	1	5	3	4	2	26	37	47	41	49			01,02										Vb 12	CASSSGQPNQPQHF+TCRBV10-01+TCRBJ01-05	TCRBV10-01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGGGCGGGGGCGCAGGTTCAACGGGAGGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	69	9.891636406382829E-5		53	TCRBV12	TCRBV12-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	7	2	4	1	18	22	33	41	34	59						01,02								X+TCRBV12-01+TCRBJ02-05	TCRBV12-01*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCTTTTCCGGGACAGGGGGTTGGTCGCGAGAAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	101	1.4479061986154577E-4		55	TCRBV12	TCRBV12-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	0	1	9	3	12	22	37	51	40	63														X+TCRBV12-01+TCRBJ01-04	TCRBV12-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCCCGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CATSPSSYNSPLHF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	5	11	2	0	2	0	18	30	-1	32	35														CATSPSSYNSPLHF+TCRBV15-01+TCRBJ01-06	TCRBV15-01*01	TCRBD02-01*02	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATCAACACAGTTCGACCCCCTACGAGCAGTACTTCGGGCCG	CATSRDQHSSTPYEQYF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	51	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	5	2	5	8	18	35	44	40	52														CATSRDQHSSTPYEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGACCCCAGGACGGGGCTAATGAAAAACTGTTTTTTGGCAGT	CATSRPQDGANEKLFF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	2	8	3	3	8	0	18	33	-1	41	46														CATSRPQDGANEKLFF+TCRBV15-01+TCRBJ01-04	TCRBV15-01*01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGGGGACAGGGAAGTCGTGTTGAGGACGAGCAGTACTTCGGGCCG	CATSRGQGSRVEDEQYF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	51	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	3	5	0	14	18	-1	41	32	55														CATSRGQGSRVEDEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCACGAACAATATAGAGGACCAAGAGACCCAGTACTTCGGGCCA	CATTNNIEDQETQYF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	7	11	1	0	11	0	18	28	-1	39	43														CATTNNIEDQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGCTACAGGGGGCTCCAAGAGACCCAGTACTTCGGGCCA	CATSSYRGLQETQYF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	3	0	1	2	1	18	32	43	34	44														CATSSYRGLQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGACCCGGGACAGCGAACACTGAAGCTTTCTTTGGACAA	CATSRPGTANTEAFF	In	VDJ	1	128	1.8349702319086987E-4	2.2013059935714987E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	0	5	1	3	1	18	33	43	36	44														CATSRPGTANTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCTTCGGGGGGGGCCAGAACACTGAAGCTTTCTTTGGACAA	CATFGGGQNTEAFF	In	VDJ	1	132	1.8923130516558455E-4	2.270096805870608E-4	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	8	8	0	1	2	4	18	27	37	29	41														CATFGGGQNTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATCGGGGGGGCAGCCCCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CATSRDRGGSPSGANVLTF	In	VDJ	1	155	2.22203426520194E-4	2.6656439765904865E-4	57	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-06	01	0	8	0	0	1	6	18	35	44	36	50														CATSRDRGGSPSGANVLTF+TCRBV15-01+TCRBJ02-06	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCTCACGACAGGGAAATAATTCACCCCTCCACTTTGGGAAC	CATSSRQGNNSPLHF	In	VDJ	1	166	2.3797270195065936E-4	2.8548187104130373E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	2	3	5	4	2	18	30	41	34	43														CATSSRQGNNSPLHF+TCRBV15-01+TCRBJ01-06	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCTTCGGACTAGCGGATTAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	168	2.408398429380167E-4		52	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	1	5	0	3	5	18	30	43	33	48						01,02								X+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTACCACCAGCTCCCGGACAGGGTGGGAGGAGGAGACCCAGTACTTCGGGCCA	CTTSSRTGWEEETQYF	In	VDJ	1	189	2.709448233052688E-4	3.250365881132916E-4	48	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	1	3	5	4	9	18	30	42	34	51														CTTSSRTGWEEETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGTCGGGTTCGGGGACAGTTTGTTCTTCGGGCCA	CATSRVGFGDSLFF	In	VDJ	1	223	3.196862200903436E-4	3.835087785675345E-4	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	0	5	15	9	3	18	34	50	43	53														CATSRVGFGDSLFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCACACGGACTAGCGGCTACAATGAGCAGTTCTTCGGGCCA	CATSTRTSGYNEQFF	In	VDJ	2	243	3.48357629963917E-4	4.179041847170892E-4	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	1	5	3	3	0	18	31	-1	34	44						01,02								CATSTRTSGYNEQFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGATACGGGCAGGGTCAGCCCCAGCATTTTGGTGAT	CATSRYGQGQPQHF	In	VDJ	2	244	3.497912004575957E-4	4.196239550245669E-4	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	4	3	6	6	0	18	33	-1	39	44														CATSRYGQGQPQHF+TCRBV15-01+TCRBJ01-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATGTGGCAGGGGATGAAAAACTGTTTTTTGGCAGT	CATSRDVAGDEKLFF	In	VDJ	2	274	3.927983152679558E-4	4.712170642488989E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	4	2	6	5	0	18	35	-1	40	46														CATSRDVAGDEKLFF+TCRBV15-01+TCRBJ01-04	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAAGGACAGCCACACCTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CATSREGQPHLSGANVLTF	In	VDJ	2	286	4.100011611920999E-4	4.918543079386317E-4	57	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	0	1	5	0	1	8	18	35	42	36	50														CATSREGQPHLSGANVLTF+TCRBV15-01+TCRBJ02-06	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAGAGGGCGGGCTGGAATGAGCAGTTCTTCGGGCCA	CATSRERAGWNEQFF	In	VDJ	2	303	4.3437185958463727E-4	5.210904031657532E-4	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	7	4	7	4	4	18	35	44	39	48						01,02								CATSRERAGWNEQFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATGATGAATTGGGGTCTGGCTACACCTTCGGTTCG	CATSRDDELGSGYTF	In	VDJ	2	323	4.630432694582107E-4	5.554858093153079E-4	45	TCRBV15	TCRBV15-01	01				TCRBJ01	TCRBJ01-02	01	0	6	2	7	9	2	18	35	48	44	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSRDDELGSGYTF+TCRBV15-01+TCRBJ01-02	TCRBV15-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGACCGCGCAGGGGGCTCCGGGGAGCTGTTTTTTGGAGAA	CATSRDRAGGSGELFF	In	VDJ	3	381	5.461903580915736E-4	6.552324871490164E-4	48	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	4	0	6	5	1	18	35	48	40	49														CATSRDRAGGSGELFF+TCRBV15-01+TCRBJ02-02	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAACGAGAAGCGGGAGGGAAGAGACCCAGTACTTCGGGCCA	CATSRTRSGREETQYF	In	VDJ	3	397	5.691274859904324E-4	6.827488120686601E-4	48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	6	0	3	6	0	18	33	-1	39	49														CATSRTRSGREETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAATTCGACTAGCGGGGGAGGCATTCAGTACTTCGGCGCC	CATSNSTSGGGIQYF	In	VDJ	3	425	6.092674598134351E-4	7.309023806780367E-4	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	4	2	2	9	4	3	18	31	47	35	50														CATSNSTSGGGIQYF+TCRBV15-01+TCRBJ02-04	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTACCACCTGTTCTGACTAGCGGCTAAGACCCAGTACTTCGGGCCA		Out	VDJ	4	541	7.75561637080161E-4		41	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	8	2	5	6	6	3	18	27	42	33	45						01,02								X+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGCAGGGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CATSRGRANTGELFF	In	VDJ	4	572	8.200023223841998E-4	9.837086158772635E-4	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	4	3	0	1	0	18	34	-1	35	40														CATSRGRANTGELFF+TCRBV15-01+TCRBJ02-02	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCCAAGACTAGCTCGACTTTTCCTACGAGCAGTACTTCGGGCCG	CATSQD*LDFSYEQYF	Stop	VDJ	4	581	8.329044568273078E-4		48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	2	7	1	3	8	18	30	40	33	48						01,02								CATSQD*LDFSYEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCGCTAGCACTGGGGGAGGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	4	583	8.357715978146652E-4		49	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	9	1	2	11	0	18	30	-1	41	47														X+TCRBV15-01+TCRBJ01-05	TCRBV15-01*01	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGGGACAGCCATCAGCCCCAGCATTTTGGTGAT	CATSRGDSHQPQHF	In	VDJ	4	668	9.576250897773521E-4	0.0011488065653951257	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	1	0	5	5	0	2	18	-1	41	34	43														CATSRGDSHQPQHF+TCRBV15-01+TCRBJ01-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGGCCCGTTGGGGCCAACGTCCTGACTTTCGGGGCC	CATSRGPVGANVLTF	In	VDJ	5	733	0.0010508071718664657	0.0012605916353811786	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	1	9	0	3	0	4	18	-1	37	34	41														CATSRGPVGANVLTF+TCRBV15-01+TCRBJ02-06	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGTTGGGGGCCTCAAGAGACCCAGTACTTCGGGCCA	CATSSWGPQETQYF	In	VDJ	5	789	0.0011310871195124713	0.0013568987725999316	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	6	0	2	2	2	18	32	40	34	42														CATSSWGPQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCTCAACAGTGCAGCGGAGGAATACGGGAGGGCCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	6	910	0.0013045491492475905		56	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	11	8	0	0	22	1	18	24	54	46	55														X+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGATTCGGATGTGTCGGGGGCAGGTAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	6	929	0.0013317869886274852		56	TCRBV15	TCRBV15-01	01				TCRBJ02	TCRBJ02-05	01	0	6	0	3	12	4	18	35	53	47	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGTGGAGGCCCTGGGGGGGGCCAACGTCCTGACTTTCGGGGCC	CATSRVEALGGANVLTF	In	VDJ	7	1080	0.0015482561331729647	0.001857351932075952	51	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	1	10	1	4	1	8	18	34	40	35	48														CATSRVEALGGANVLTF+TCRBV15-01+TCRBJ02-06	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCTTGGAAGAGCGGGGGACCCCTCGGGACGAGCAGTACTTCGGGCCG	CARSLEERGTPRDEQYF	In	VDJ	2	330	4.730782629139614E-4	5.675242014676519E-4	51	TCRBV05	TCRBV05-03		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	6	2	5	3	10	18	34	45	37	55			01,02											CARSLEERGTPRDEQYF+TCRBV05-03+TCRBJ02-07	TCRBV05-03	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTAGCGGACGACACTGAAGCTTTCTTTGGACAA	CASSLADDTEAFF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	39	TCRBV07	TCRBV07-02	01				TCRBJ01	TCRBJ01-01	01	0	1	7	3	0	1	18	-1	39	35	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLADDTEAFF+TCRBV07-02+TCRBJ01-01	TCRBV07-02*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCCTAGCTGGTTGGACTGAAGCTTTCTTTGGACAA	CASSLAGWTEAFF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	39	TCRBV07	TCRBV07-02	01				TCRBJ01	TCRBJ01-01	01	0	0	10	5	1	4	18	35	38	36	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAGWTEAFF+TCRBV07-02+TCRBJ01-01	TCRBV07-02*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTCGGCGGGATCTACGAGCAGTACTTCGGGCCG	CASSFGGIYEQYF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	39	TCRBV07	TCRBV07-02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	7	3	3	2	1	18	32	40	34	41														CASSFGGIYEQYF+TCRBV07-02+TCRBJ02-07	TCRBV07-02*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGTTATCAGGGAGTCACTGAAGCTTTCTTTGGACAA	CASSYQGVTEAFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	39	TCRBV07	TCRBV07-02	01				TCRBJ01	TCRBJ01-01	01	6	4	3	4	4	3	18	29	38	33	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYQGVTEAFF+TCRBV07-02+TCRBJ01-01	TCRBV07-02*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCCCAACCTAAACACCAATTCAATTAGCTAACTATGGCTACACCTTCGGTTCG	CASSLAPT*TPIQLANYGYTF	Stop	VDJ	1	83	1.1898635097532968E-4		63	TCRBV07	TCRBV07-02	01				TCRBJ01	TCRBJ01-02	01	0	3	6	0	10	13	18	35	48	45	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAPT*TPIQLANYGYTF+TCRBV07-02+TCRBJ01-02	TCRBV07-02*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCGAAGGGGACACCGGGGAGCTGTTTTTTGGAGAA	CASSEGDTGELFF	In	VDJ	1	101	1.4479061986154577E-4	1.7369680105525106E-4	39	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	5	2	3	2	0	18	30	-1	32	37														CASSEGDTGELFF+TCRBV07-02+TCRBJ02-02	TCRBV07-02*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTAGTCGCTGGGGGCGAAGCTTTCTTTGGACAA	CASSLVAGGEAFF	In	VDJ	1	137	1.963991576339779E-4	2.3560853212444946E-4	39	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	6	0	8	5	0	18	34	-1	39	45														CASSLVAGGEAFF+TCRBV07-02+TCRBJ01-01	TCRBV07-02*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAAGGAGGGACTCTCCTACGAGCAGTACTTCGGGCCG	CASKEGLSYEQYF	In	VDJ	1	171	2.4514055441905274E-4	2.940807225786924E-4	39	TCRBV07	TCRBV07-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	0	10	0	4	0	18	28	-1	32	38						01,02								CASKEGLSYEQYF+TCRBV07-02+TCRBJ02-07	TCRBV07-02*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCGCCCCGGGACAGGGTTGGGAGCAGTACTTCGGGCCG	CASAPGQGWEQYF	In	VDJ	1	216	3.096512266345929E-4	3.7147038641519037E-4	39	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	0	3	7	5	4	18	27	41	32	45														CASAPGQGWEQYF+TCRBV07-02+TCRBJ02-07	TCRBV07-02*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTCCCAGGTAGCCCTCGAGCAGTACTTCGGGCCG	CASSSQVALEQYF	In	VDJ	2	269	3.856304627995625E-4	4.626182127115102E-4	39	TCRBV07	TCRBV07-02	01				TCRBJ02	TCRBJ02-07	01	4	4	4	6	2	7	18	31	37	33	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSQVALEQYF+TCRBV07-02+TCRBJ02-07	TCRBV07-02*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGGCGGGGGCTCTTCTACGAGCAGTACTTCGGGCCG	CASRRGLFYEQYF	In	VDJ	2	336	4.816796858760334E-4	5.778428233125184E-4	39	TCRBV07	TCRBV07-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	7	2	3	0	5	18	-1	36	29	41														CASRRGLFYEQYF+TCRBV07-02+TCRBJ02-07	TCRBV07-02*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTAGCGGGTCCAGCACAGATACGCAGTATTTTGGCCCA	CASSPSGSSTDTQYF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	4	4	0	1	3	18	30	39	31	42						01,02								CASSPSGSSTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGACAGCTCCGAATCAGCCCCAGCATTTTGGTGAT	CASSRTAPNQPQHF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	1	5	4	1	5	18	30	37	31	42														CASSRTAPNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTGGGGACAGGGTCAGGAATGAGCAGTTCTTCGGGCCA	CASSFGDRVRNEQFF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	0	3	7	2	5	18	32	43	34	48														CASSFGDRVRNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTCTTTCGGCTAGCGGGGGGATAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	42	6.020996073450418E-5		53	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	4	1	5	8	2	18	34	53	42	55														X+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGGGTGGGGGGGACACAGATACGCAGTATTTTGGCCCA	CASSPGGGDTDTQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	9	0	2	6	1	18	30	43	36	44														CASSPGGGDTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTAAGGACAGGACTAAACACAGATACGCAGTATTTTGGCCCA	CASSLRTGLNTDTQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	4	2	4	6	18	30	41	34	47														CASSLRTGLNTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGGGGACAGGGATGGGAGCAGTTCTTCGGGCCA	CASSPGGQGWEQFF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	0	3	10	5	4	18	30	44	35	48														CASSPGGQGWEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCATCGGAGCGGAGCGGGGCGAGGGGCAGTATTTTGGCCCA	CASSIGAERGEGQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	6	3	11	10	6	18	30	47	40	53														CASSIGAERGEGQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGGACAGTTTCGGCACAGATACGCAGTATTTTGGCCCA	CASSPDSFGTDTQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	5	1	2	5	18	30	38	32	43														CASSPDSFGTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGCCGGGACAGCCAAGAGACCCAGTACTTCGGGCCA	CASSLGRDSQETQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	0	5	1	3	0	18	34	-1	37	44														CASSLGRDSQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGGACTAGCAGGCACAGATACGCAGTATTTTGGCCCA	CASSFGLAGTDTQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	1	7	1	1	2	18	32	41	33	43						01,02								CASSFGLAGTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGGGAGGGACGGCCTCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	45	6.45106722155402E-5		50	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	0	0	3	7	18	32	42	35	49														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTAAAAGAGGGCGAGGCACAGATACGCAGTATTTTGGCCCA	CASSFKRGRGTDTQYF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	11	0	1	5	4	18	32	42	37	46														CASSFKRGRGTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGTCCGGAGTGAACACTGAAGCTTTCTTTGGACAA	CASSLSGVNTEAFF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	10	2	0	4	0	18	32	-1	36	40														CASSLSGVNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGGGGACAGGGGGCATGGTCTATAATTCACCCCTCCACTTTGGGAAC	CASSPGTGGMVYNSPLHF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	54	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	0	0	3	3	5	18	30	45	33	50														CASSPGTGGMVYNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGAACCCCGGCCCGATCGGAGTGAAGCTTTCTTTGGACAA	CASSSEPRPDRSEAFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	4	10	2	7	18	0	18	31	-1	49	53														CASSSEPRPDRSEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGCCACCTATCCTACGAGCAGTACTTCGGGCCG	CASSLGHLSYEQYF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	4	9	1	5	0	18	34	-1	39	42						01,02								CASSLGHLSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGCAGACACGGGGGTCGAGATGGCTACACCTTCGGTTCG	CASSRRHGGRDGYTF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	5	8	2	6	8	5	18	30	44	38	49														CASSRRHGGRDGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCCAGCCTCGAAGGGACACTGAAGCTTTCTTTGGACAA	CASSPQPRRDTEAFF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	5	3	3	12	0	18	30	-1	42	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPQPRRDTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGGACGGACAGGGTCGCAGATACGCAGTATTTTGGCCCA	CASSGTDRVADTQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	3	4	5	3	18	30	43	35	46														CASSGTDRVADTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCCCAGGACGGGGCGAGAGGTGGCTACACCTTCGGTTCG	CASSAQDGARGGYTF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-02	01	5	7	0	7	9	6	18	30	44	39	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAQDGARGGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCACGGCCAGTCGATCGGTACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	53	7.597923616496956E-5		49	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-02	01	5	4	5	5	7	9	18	30	40	37	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTATGGGACTAGCGGGAGGGCCTTCATCAGATACGCAGTATTTTGGCCCA	CASSPMGLAGGPSSDTQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	57	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	0	0	4	5	7	18	30	51	35	58														CASSPMGLAGGPSSDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGAAATTACAGGGAGGGTTGAGGGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	53	7.597923616496956E-5		53	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	9	0	1	9	6	18	30	46	39	52														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCATGACAGGGGGCGGAACTGAAGCTTTCTTTGGACAA	CASSMTGGGTEAFF	In	VDJ	1	54	7.741280665864823E-5	9.286759660379759E-5	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	0	5	2	3	18	30	42	32	45														CASSMTGGGTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCGGAAGGGTTCGCTAGGGTATGGCTACACCTTCGGTTCG		Out	VDJ	1	54	7.741280665864823E-5		46	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-02	01	5	5	3	5	5	10	18	30	39	35	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTATAGACAGGGTGCTTAGAAGAATGGCTACACCTTCGGTTCG	CASSYRQGA*KNGYTF	Stop	VDJ	1	54	7.741280665864823E-5		48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	2	3	6	3	11	18	31	41	34	52														CASSYRQGA*KNGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACGTCCGCAAAGTCAGAGACCCAGTACTTCGGGCCA	CASSTSAKSETQYF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-05	01	5	3	7	4	0	12	18	-1	32	30	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSTSAKSETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGAGCGGGACCCCCAACAATGAGCAGTTCTTCGGGCCA	CASSRSGTPNNEQFF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	6	3	5	3	6	18	30	40	33	46														CASSRSGTPNNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGGCCAGGTGAAATCTCGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	55	7.88463771523269E-5		52	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	4	4	4	16	18	30	38	34	54														X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGTGTTTATCAGGGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLGVYQGSYNEQFF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	51	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	4	3	0	10	0	18	32	-1	42	47														CASSLGVYQGSYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTAGTTCGGATCTAATGGCTACACCTTCGGTTCG		Out	VDJ	1	56	8.027994764600557E-5		43	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-02	01	1	1	8	6	6	4	18	34	43	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGGATAGAACCTCAAGGGGACCCCCTCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	56	8.027994764600557E-5		55	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	6	0	7	0	15	5	18	29	49	44	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCATTCCCCCGACTAGCGGGAGGGCGCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	57	8.171351813968424E-5		52	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	2	0	7	8	2	18	30	52	38	54														X+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGACTAGAAGCCCCGGGGAGCTGTTTTTTGGAGAA	CASSRTRSPGELFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	1	8	6	1	5	18	30	38	31	43						01,02								CASSRTRSPGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACTGGATCTGGACCCTGAAGCTTTCTTTGGACAA	CASSLLDLDPEAFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	2	1	7	6	8	1	18	33	45	41	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLLDLDPEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGACGGGGCCCCAATGACTAGCGGCTACGAGCAGTACTTCGGGCCG	CASSLDGAPMTSGYEQYF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	2	5	3	12	0	18	35	-1	47	56						01,02								CASSLDGAPMTSGYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCACGGGAAGCGGGGGGGCCAGGAGAGACCCAGTACTTCGGGCCA	CASSPREAGGPGETQYF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	6	0	4	8	5	18	30	48	38	53														CASSPREAGGPGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCGGCTTACGGACAGGGGAAAGAGACCCAGTACTTCGGGCCA	CASSAAYGQGKETQYF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	1	2	3	9	1	18	30	48	39	49														CASSAAYGQGKETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGGGGAGGGCAGCCGATTAGCTCTGGAAACACCATATATTTTGGAGAG	CASSGGGQPISSGNTIYF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	5	9	0	0	2	11	18	30	39	32	50														CASSGGGQPISSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCACCCGCCGGGACACCTGAAAAACTGTTTTTTGGCAGT	CASSSPAGTPEKLFF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	0	6	7	8	2	18	31	45	39	47														CASSSPAGTPEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGCCTAATCGACAGGGGTTTAACTATGGCTACACCTTCGGTTCG	CASSSPNRQGFNYGYTF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	51	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	2	2	1	9	2	18	31	48	40	50														CASSSPNRQGFNYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGACTTGGGACACTGTACCAAGAGACCCAGTACTTCGGGCCA	CASSGLGTLYQETQYF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	0	6	0	6	4	18	30	42	36	46														CASSGLGTLYQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGGACACCAGCAATCAGCCCCAGCATTTTGGTGAT	CASSSDTSNQPQHF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	1	6	1	1	2	18	31	37	32	39														CASSSDTSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCCGAGTGGGGAGCACAGATACGCAGTATTTTGGCCCA	CASSSRVGSTDTQYF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	4	6	2	0	7	0	18	31	-1	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSRVGSTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGTGTGCGCACAGATACGCAGTATTTTGGCCCA	CASSLGVRTDTQYF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	3	0	9	1	0	5	18	-1	35	32	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGVRTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCCCGACAGGGGGCGACTGGCTACACCTTCGGTTCG	CASSARQGATGYTF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	0	7	4	3	18	30	44	34	47														CASSARQGATGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGTTACAAACAGGTCTCGTCTATGGCTACACCTTCGGTTCG	CASSLLQTGLVYGYTF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	4	4	7	6	18	32	44	39	50														CASSLLQTGLVYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGTGCCCAGGGCAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	64	9.174851159543494E-5		43	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	4	3	3	5	2	18	32	42	37	44														X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGGGACAGCAAGAGACGCCCAGTACTTCGGGCCA	CASSPGTARDAQYF	In	VDJ	1	65	9.318208208911361E-5	1.1178506998605267E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	0	5	9	3	9	18	30	40	33	49														CASSPGTARDAQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAGTCTGCCGGGGGGAGGGCAGATACGCAGTATTTTGGCCCA	CASSQSAGGRADTQYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	8	1	4	8	4	18	30	45	38	49						01,02								CASSQSAGGRADTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTTAGTGGGGGAGCCAATCAGCCCCAGCATTTTGGTGAT	CASSLSGGANQPQHF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	5	6	1	3	6	3	18	30	41	36	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLSGGANQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTCCGGGGGTACCAAGAGACCCAGTACTTCGGGCCA	CASSLVRGYQETQYF	In	VDJ	1	66	9.461565258279228E-5	1.135048402935304E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	1	8	2	0	2	1	18	34	42	36	43														CASSLVRGYQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAGTGGCTAGCGGGCACACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	67	9.604922307647095E-5		50	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	4	4	2	4	4	18	35	47	39	51						01,02								X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCAAGGGACAGAGCTATGGCTACACCTTCGGTTCG	CASSFKGQSYGYTF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	5	4	3	2	18	32	42	35	44														CASSFKGQSYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGATACAGGGGCCGACGAGCAGTACTTCGGGCCG	CASSLDTGADEQYF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	2	5	1	3	18	35	43	36	46														CASSLDTGADEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCCGACGCGCAGGGGGCTCCTACGAGCAGTACTTCGGGCCG	CASRRAGGSYEQYF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	4	1	0	7	0	18	27	-1	34	41														CASRRAGGSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCCCCATGGCGGGGGGCTTCTTTGAGCAGTTCTTCGGGCCA	CASSPPMAGGFFEQFF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	7	1	9	9	6	18	30	47	39	53														CASSPPMAGGFFEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCGGGGACAGGGTTGACTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	70	1.0034993455750697E-4		47	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	0	3	7	3	5	18	32	44	35	49														X+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGATCCCTAGCGGGTACCATGAGCAGTTCTTCGGGCCA	CASSWIPSGYHEQFF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	4	4	8	6	4	18	31	45	37	49						01,02								CASSWIPSGYHEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTCTAGGTAATCAGGCCACCCCTCCACTTTGGGAAC	CASSLV*VIRPPLHF	Stop	VDJ	1	72	1.0321707554486431E-4		45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-06	01	1	4	4	11	10	1	18	34	48	44	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLV*VIRPPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGATTCGGGGGTCTATGGCTACACCTTCGGTTCG	CASSLDSGVYGYTF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	3	8	2	4	5	1	18	32	43	37	44														CASSLDSGVYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGACAGCGGACTAGCGGGAGGAAGGGAAATGAGCAGTTCTTCGGGCCA	CASRQRTSGRKGNEQFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	1	1	7	5	6	18	29	48	34	54														CASRQRTSGRKGNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGACAGGGACCCCTCGAGCAGTACTTCGGGCCG	CASSLGQGPLEQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	2	3	6	0	6	18	-1	41	34	47														CASSLGQGPLEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTACAGAGCACCGGGGAGCTGTTTTTTGGAGAA	CASSLVQSTGELFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	3	5	4	1	2	18	34	39	35	41														CASSLVQSTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGATTCAGGGGGGTATGGAGCTTTCTTTGGACAA	CASSLDSGGYGAFF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	1	10	5	6	18	32	44	37	50														CASSLDSGGYGAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCTGGAGGGACCTAAACCGGGGTGAGCAGTTCTTCGGGCCA	CASSSWRDLNRGEQFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	10	0	9	3	13	18	31	40	34	53														CASSSWRDLNRGEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCTGGGATAGGGGGGCCAATGAAAAACTGTTTTTTGGCAGT	CASSFWDRGANEKLFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	3	5	1	5	7	3	18	32	45	39	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFWDRGANEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGCCGGGGAGCTCGGGGGTCGATGAGCAGTTCTTCGGGCCA	CASRPGSSGVDEQFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	8	2	8	11	3	18	29	46	40	49														CASRPGSSGVDEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAATCAGGGAGGAAACGGTGAAAAACTGTTTTTTGGCAGT	CASSNQGGNGEKLFF	In	VDJ	1	79	1.13252069000615E-4	1.3586185429074094E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	5	9	1	7	5	6	18	30	41	35	47														CASSNQGGNGEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGTGACAGGGGTCAATGAGCAGTTCTTCGGGCCA	CASSFVTGVNEQFF	In	VDJ	1	79	1.13252069000615E-4	1.3586185429074094E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	2	2	6	3	1	18	32	43	35	44														CASSFVTGVNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGATATGACAGGGTGAACACTGAAGCTTTCTTTGGACAA	CASRYDRVNTEAFF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	3	0	4	0	18	29	-1	33	40														CASRYDRVNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAAGGGAGGGGGGCAGAGGGTCACATCCCCAGCATTTTGGTGAT	CASSPREGGRGSHPQHF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	9	0	10	4	16	18	30	41	34	57														CASSPREGGRGSHPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTTAATGGTTGGGACAGAACTCACCTCAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLNGWDRTHLNTGELFF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	60	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	0	5	2	10	10	18	30	47	40	57														CASSLNGWDRTHLNTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGCTTCGGGACAACACGAGCAGTACTTCGGGCCG	CASSLASGQHEQYF	In	VDJ	1	84	1.2041992146900836E-4	1.444607058281296E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	6	5	6	2	18	32	44	38	46														CASSLASGQHEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTAAGAGCGGACAGGGGGCAAGTCTACGAGCAGTACTTCGGGCCG	CASSLRADRGQVYEQYF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	51	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	0	3	8	4	18	30	49	38	53														CASSLRADRGQVYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATGGGACAGGGGGTACTCTGGAAACACCATATATTTTGGAGAG	CASSLWDRGYSGNTIYF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	51	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	0	1	0	1	2	18	33	45	34	47														CASSLWDRGYSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGAGGCAGGACGGCCAGAAACTGTTTTTTGGCAGT	CASSLRQDGQKLFF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	3	1	7	11	6	6	18	32	42	38	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRQDGQKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCTGGCTACCGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSSGYRSYNEQFF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-01	01	4	9	0	0	2	5	18	31	36	33	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGYRSYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACATGCAGGGGCTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLHAGASNQPQHF	In	VDJ	1	90	1.290213444310804E-4	1.5477932767299599E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	4	2	0	4	1	18	33	43	37	44														CASSLHAGASNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGGGGACAACACAGATACGCAGTATTTTGGCCCA	CASSPGDNTDTQYF	In	VDJ	1	92	1.318884854184377E-4	1.5821886828795145E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	6	2	4	1	18	30	40	34	41														CASSPGDNTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTCTAGACCAGCGGGGGGCCTACACCGGGGAGCTGTTTTTTGGAGAA	CASSLDQRGAYTGELFF	In	VDJ	1	92	1.318884854184377E-4	1.5821886828795145E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	6	6	1	3	8	3	18	29	46	37	49														CASSLDQRGAYTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTTCACTAGTGGCGGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	93	1.333220559121164E-4		43	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	3	8	4	3	6	18	29	37	32	43						01,02								X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGGGGGGATTTCCACAGATACGCAGTATTTTGGCCCA	CASSPGGISTDTQYF	In	VDJ	1	94	1.3475562640579507E-4	1.6165840890290694E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	4	1	2	1	6	18	30	38	31	44														CASSPGGISTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGAGCAGAGGGGGCTCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLSRGGSNTGELFF	In	VDJ	1	94	1.3475562640579507E-4	1.6165840890290694E-4	51	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	5	0	0	6	1	18	32	45	38	46														CASSLSRGGSNTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACACAGGGAGGGCTATGGCTACACCTTCGGTTCG	CASSLHREGYGYTF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	2	9	0	4	4	0	18	33	-1	37	44														CASSLHREGYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGGAGGAGGAGCGGGAAGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSGRRSGKSSYEQYF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	6	3	0	9	4	18	30	46	39	50														CASSGRRSGKSSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGAGGGACACATAATTCACCCCTCCACTTTGGGAAC	CASSLGGTHNSPLHF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	3	9	0	5	0	4	18	-1	39	32	43														CASSLGGTHNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTACCCAGGACTAGCCGGATTGAATGAGCAGTTCTTCGGGCCA	CASSYPGLAGLNEQFF	In	VDJ	1	97	1.3905633788683107E-4	1.6681771982534013E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	1	7	7	5	7	18	31	44	36	51						01,02								CASSYPGLAGLNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCCAGACTAGCGGAGCCTACGAGCAGTACTTCGGGCCG	CASSSQTSGAYEQYF	In	VDJ	1	98	1.4048990838050974E-4	1.6853749013281787E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	2	5	2	4	2	18	31	44	35	46						01,02								CASSSQTSGAYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTAGGTTGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSLGWGNQPQHF	In	VDJ	1	99	1.4192347887418842E-4	1.702572604402956E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	1	0	9	2	3	0	18	34	-1	37	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGWGNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCACCAACTATGGACAGGGCTATGGCTACACCTTCGGTTCG	CASTNYGQGYGYTF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	1	3	4	8	0	18	28	-1	36	44														CASTNYGQGYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGTCAGGGGGACTCGGGGAGACCCAGTACTTCGGGCCA	CASRSGGLGETQYF	In	VDJ	1	100	1.433570493678671E-4	1.7197703074777333E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	4	1	5	2	7	18	29	38	31	45														CASRSGGLGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGGGGACAGGGGGCCGTCGGGAGCAGTACTTCGGGCCG	CASSWGTGGRREQYF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	0	7	2	6	18	31	45	33	51														CASSWGTGGRREQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCAAAGGGGGCGGCATTGAAGCTTTCTTTGGACAA	CASSPKGGGIEAFF	In	VDJ	1	106	1.5195847232993913E-4	1.8229565259263972E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	5	0	7	5	5	18	30	42	35	47														CASSPKGGGIEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAATACGGGGGCGGTCGGGGAGCTGTTTTTTGGAGAA	CASSNTGAVGELFF	In	VDJ	1	107	1.5339204282361778E-4	1.8401542290011745E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-02	01	5	6	0	7	5	3	18	30	41	35	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSNTGAVGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGAGAACGGATCAAACACTGAAGCTTTCTTTGGACAA	CASSENGSNTEAFF	In	VDJ	1	107	1.5339204282361778E-4	1.8401542290011745E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	1	8	2	6	3	18	30	39	36	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSENGSNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGTCGTAGGGGGCCTGAACACTGAAGCTTTCTTTGGACAA	CASSVVGGLNTEAFF	In	VDJ	1	107	1.5339204282361778E-4	1.8401542290011745E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	5	0	0	5	1	18	30	42	35	43														CASSVVGGLNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGGGGGTCCTAAATGAAAAACTGTTTTTTGGCAGT	CASSLGGVLNEKLFF	In	VDJ	1	107	1.5339204282361778E-4	1.8401542290011745E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	1	9	1	5	0	5	18	-1	40	34	45														CASSLGGVLNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTACTAGCGGAAGAGACCCAGTACTTCGGGCCA	CASSLVLAEETQYF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	3	5	3	1	0	18	34	-1	35	43						01,02								CASSLVLAEETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGTCCCTTTGGCAGGGGTATAATTCACCCCTCCACTTTGGGAAC	CASSLSLWQGYNSPLHF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	51	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	3	4	2	4	10	0	18	32	-1	42	48														CASSLSLWQGYNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCCCAGGGGGTCGGGGGAAACACCATATATTTTGGAGAG	CASSAQGVGGNTIYF	In	VDJ	1	111	1.5912632479833248E-4	1.908945041300284E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	4	1	4	3	5	18	30	40	33	45														CASSAQGVGGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGCTGATAGCGGGGGGTTCGATGAGCAGTTCTTCGGGCCA	CASSQADSGGFDEQFF	In	VDJ	1	112	1.6055989529201113E-4	1.9261427443750614E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	5	1	8	8	4	18	30	48	38	52														CASSQADSGGFDEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTCTGTGGTTACCCGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	112	1.6055989529201113E-4		50	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-02	01	5	2	7	4	19	0	18	30	-1	49	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCACAACATGTTCCCTACGAGCAGTACTTCGGGCCG	CASSPQHVPYEQYF	In	VDJ	1	113	1.619934657856898E-4	1.9433404474498387E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	6	2	2	8	18	30	35	32	43														CASSPQHVPYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTCCCGTGGTCGGGAGGGCCAGATACGCAGTATTTTGGCCCA	CASSLPWSGGPDTQYF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	8	0	4	10	1	18	30	48	40	49														CASSLPWSGGPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGGGGGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSFGGSYNEQFF	In	VDJ	1	115	1.6486060677304716E-4	1.9777358535993933E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	8	1	1	0	0	18	-1	-1	32	39														CASSFGGSYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTGCCCCCCCAGCGGGGGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	116	1.6629417726672584E-4		47	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	6	2	2	10	0	18	30	-1	40	48														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTAAGACGGGGAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	117	1.677277477604045E-4		43	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	0	8	3	1	0	0	18	-1	-1	35	40														X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCACTATACAGGACTCCTACAATGAGCAGTTCTTCGGGCCA	CASSFTIQDSYNEQFF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	3	4	0	6	1	18	32	43	38	44														CASSFTIQDSYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCCTGCAGGTGGTCCAGATACGCAGTATTTTGGCCCA	CASSFPAGGPDTQYF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	4	4	4	5	5	18	32	41	37	46														CASSFPAGGPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTGCGCCGGACGTACCCTACGAGCAGTACTTCGGGCCG	CASSAPDVPYEQYF	In	VDJ	1	118	1.6916131825408316E-4	2.0293289628237253E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	6	1	7	2	6	4	18	29	39	35	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAPDVPYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGATAGCGGCTACAAGAGACCCAGTACTTCGGGCCA	CASSLG*RLQETQYF	Stop	VDJ	1	120	1.7202845924144052E-4		45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	5	5	2	2	3	18	34	42	36	45						01,02								CASSLG*RLQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGACGGACAGGGGAATCAGCCCCAGCATTTTGGTGAT	CASSPDGQGNQPQHF	In	VDJ	1	123	1.7632917072247652E-4	2.1153174781976118E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	1	2	4	6	0	18	30	-1	36	45														CASSPDGQGNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAAGGCTAGCGGGAGGGTAATGAGCAGTTCTTCGGGCCA	CASSLEG*REGNEQFF	Stop	VDJ	1	124	1.777627412161552E-4		48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	4	0	7	3	1	18	35	50	38	51														CASSLEG*REGNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCTGGGGCAGGGAGAAGGATGAGCAGTTCTTCGGGCCA	CASSFWGREKDEQFF	In	VDJ	1	124	1.777627412161552E-4	2.1325151812723892E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-01	01	3	4	3	8	6	6	18	32	43	38	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFWGREKDEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGTGGACTAGCGGAGTCCACAGATACGCAGTATTTTGGCCCA	CASSRGLAESTDTQYF	In	VDJ	1	125	1.7919631170983387E-4	2.1497128843471665E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	1	5	2	3	4	18	30	43	33	47						01,02								CASSRGLAESTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTACCCTGGCGGGGGGGCCAATGAGCAGTTCTTCGGGCCA	CASSYPGGGANEQFF	In	VDJ	1	125	1.7919631170983387E-4	2.1497128843471665E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	7	0	6	6	1	18	31	46	37	47														CASSYPGGGANEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAACTAGCAGGGAGGTCGACAGATACGCAGTATTTTGGCCCA	CASSQLAGRSTDTQYF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	3	7	3	2	10	18	30	38	32	48						01,02								CASSQLAGRSTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGGGACAGGGCCTTATCAGCCCCAGCATTTTGGTGAT	CASSSGTGPYQPQHF	In	VDJ	1	126	1.8062988220351252E-4	2.1669105874219438E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	0	3	5	2	4	18	31	42	33	46														CASSSGTGPYQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAACTAGCGGTGGGGATACGCAGTATTTTGGCCCA	CASSLTSGGDTQYF	In	VDJ	1	128	1.8349702319086987E-4	2.2013059935714987E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	3	5	6	0	4	18	-1	41	33	45						01,02								CASSLTSGGDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAACAGGGAGGTAACAATGAGCAGTTCTTCGGGCCA	CASSLEQGGNNEQFF	In	VDJ	1	128	1.8349702319086987E-4	2.2013059935714987E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-01	01	0	3	3	5	0	5	18	-1	41	35	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEQGGNNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTCAAAGCGGTGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSQSGANTGELFF	In	VDJ	1	128	1.8349702319086987E-4	2.2013059935714987E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	6	5	0	4	2	18	29	38	33	40						01,02								CASSQSGANTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTACCTTGGGGGAGGAACAATGAGCAGTTCTTCGGGCCA	CASSLPWGRNNEQFF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	9	1	5	9	1	18	30	45	39	46														CASSLPWGRNNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGGCTAGCTTGGCCGGGGAGCTGTTTTTTGGAGAA	CASSLGASLAGELFF	In	VDJ	1	132	1.8923130516558455E-4	2.270096805870608E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	1	4	7	6	3	4	18	34	42	37	46						01,02								CASSLGASLAGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGACAGGGGGTCCGGGAGACCCAGTACTTCGGGCCA	CASSRQGVRETQYF	In	VDJ	1	134	1.920984461529419E-4	2.3044922120201626E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	2	1	5	1	5	18	30	40	31	45														CASSRQGVRETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCTAGCCCCGTCGACAGCTACACAGATACGCAGTATTTTGGCCCA	CASSSSPVDSYTDTQYF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	51	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	4	2	5	2	11	3	18	31	47	42	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSSPVDSYTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAGCCAGGGGTGGGCGAGCAGTACTTCGGGCCG	CASSLEPGVGEQYF	In	VDJ	1	138	1.9783272812765658E-4	2.373283024319272E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	2	6	2	4	18	35	43	37	47														CASSLEPGVGEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTTGGGGACAGGGAGCCCAGCCCCAGCATTTTGGTGAT	CASSWGQGAQPQHF	In	VDJ	1	139	1.9926629862133526E-4	2.3904807273940492E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	3	7	3	4	18	29	41	32	45														CASSWGQGAQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGGGGGGAAAGGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSSGGKAGANVLTF	In	VDJ	1	142	2.0356701010237126E-4	2.442073836618381E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-06	01	4	8	1	2	0	5	18	-1	38	31	43														CASSSGGKAGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACACAGGGACGGAGAGACCCAGTACTTCGGGCCA	CASSLHRDGETQYF	In	VDJ	1	144	2.0643415108972861E-4	2.476469242767936E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	3	3	4	1	4	18	33	40	34	44														CASSLHRDGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCAGAACAGGTCCTGCGACGGGAGACCCAGTACTTCGGGCCA	CASSSEQVLRRETQYF	In	VDJ	1	149	2.1360200355812197E-4	2.5624577581418226E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	3	4	5	0	11	18	-1	40	35	51														CASSSEQVLRRETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCATCCGGGACAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	149	2.1360200355812197E-4		46	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	3	0	7	1	6	0	18	32	-1	38	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGACAGGTGGGGTTCACCGGGGAGCTGTTTTTTGGAGAA	CASSLGQVGFTGELFF	In	VDJ	1	153	2.1933628553283665E-4	2.631248570440932E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	2	4	4	0	7	18	-1	40	34	47														CASSLGQVGFTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGACAGGGGCGGCGAGACCCAGTACTTCGGGCCA	CASSFDRGGETQYF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	2	2	5	1	4	18	32	41	33	45														CASSFDRGGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGTCGGGACAGGGGCCTATGGCTACACCTTCGGTTCG	CASSPVGTGAYGYTF	In	VDJ	1	161	2.30804849482266E-4	2.7688301950391504E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	2	4	6	1	18	30	46	36	47														CASSPVGTGAYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAGGGTGTTCTCCAGCCCCAGCATTTTGGTGAT	CASSLEGVLQPQHF	In	VDJ	1	164	2.3510556096330203E-4	2.8204233042634826E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	0	0	9	7	0	7	18	-1	38	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEGVLQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTGGGCTATCCGGTTTCGATGAGCAGTTCTTCGGGCCA	CASSPGLSGFDEQFF	In	VDJ	1	167	2.3940627244433804E-4	2.8720164134878143E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	8	0	8	3	12	18	30	37	33	49														CASSPGLSGFDEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGACAGGCGACTTTATGGCTACACCTTCGGTTCG	CASSLDRRLYGYTF	In	VDJ	1	167	2.3940627244433804E-4	2.8720164134878143E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	4	5	0	6	18	-1	39	32	45														CASSLDRRLYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGCCAGGGAATTGGCCATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLGQGIGHSNQPQHF	In	VDJ	1	168	2.408398429380167E-4	2.889214116562592E-4	54	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	1	4	3	0	2	9	18	34	41	36	50														CASSLGQGIGHSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGCCAGGGAACTACAATGAGCAGTTCTTCGGGCCA	CASSLGPGNYNEQFF	In	VDJ	1	169	2.422734134316954E-4	2.9064118196373695E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	4	3	3	3	2	18	34	42	37	44														CASSLGPGNYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTACCCCGGGTCCCCCCCCGATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	170	2.4370698392537407E-4		55	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	5	8	4	0	6	11	18	30	40	36	51						01,02								X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTCCGGGACAGCAACGGCAGCCCCAGCATTTTGGTGAT	CASSPGQQRQPQHF	In	VDJ	1	170	2.4370698392537407E-4	2.9236095227121465E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	5	7	3	6	18	29	39	32	45														CASSPGQQRQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGCACCCCCGCTACAGCCCCAGCATTTTGGTGAT	CASSFAPPLQPQHF	In	VDJ	1	172	2.465741249127314E-4	2.958004928861701E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	3	4	9	7	10	0	18	32	-1	42	45						01,02								CASSFAPPLQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAAAACAGGGTCCTCCCTCTTCCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	178	2.551755478748034E-4		52	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	3	3	6	3	12	18	33	42	36	54														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGACGGGAGAGGGACCTACGAGCAGTACTTCGGGCCG	CASSLDGRGTYEQYF	In	VDJ	1	179	2.566091183684821E-4	3.0783888503851427E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	8	2	2	0	5	18	-1	41	35	46														CASSLDGRGTYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGCAGGCCCGAGGCTATGGCTACACCTTCGGTTCG	CASSLGQARGYGYTF	In	VDJ	1	179	2.566091183684821E-4	3.0783888503851427E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	7	0	4	0	10	18	-1	37	32	47														CASSLGQARGYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGCGGGGTACGAGAAAAACTGTTTTTTGGCAGT	CASSLGGVREKLFF	In	VDJ	1	185	2.652105413305541E-4	3.1815750688338066E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	1	7	3	8	0	5	18	-1	40	34	45														CASSLGGVREKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTTGTGGGACTAGCGGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CASSLVGLAGGYNEQFF	In	VDJ	1	188	2.6951125281159013E-4	3.233168178058139E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	0	1	3	5	0	18	30	-1	35	50														CASSLVGLAGGYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAAACAACGACATGACAATGAGCAGTTCTTCGGGCCA	CASSKQRHDNEQFF	In	VDJ	1	191	2.7381196429262616E-4	3.2847612872824705E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	2	6	5	7	2	18	30	41	37	43														CASSKQRHDNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGACTAGCGGGGAGGGGGGAATACGCAGTATTTTGGCCCA		Out	VDJ	1	194	2.7811267577366214E-4		47	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	1	3	7	1	8	18	30	43	31	51														X+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGACTTTATCCTCCAAGAGACCCAGTACTTCGGGCCA	CASSDFILQETQYF	In	VDJ	1	197	2.8241338725469817E-4	3.3879475057311344E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	5	2	10	1	0	7	18	-1	34	30	41						01,02								CASSDFILQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTCCCGACAGATTGAACACTGAAGCTTTCTTTGGACAA	CASSPDRLNTEAFF	In	VDJ	1	197	2.8241338725469817E-4	3.3879475057311344E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	5	0	4	2	18	29	38	33	40														CASSPDRLNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAAAACTAGCGGGGGTTACTACAATGAGCAGTTCTTCGGGCCA	CASSKTSGGYYNEQFF	In	VDJ	1	199	2.852805282420555E-4	3.422342911880689E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	3	2	3	3	3	18	30	44	33	47														CASSKTSGGYYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGCTTGATCCGGCGCAGGGTTTTCAGTTCTTCGGGCCA	CASRLDPAQGFQFF	In	VDJ	1	200	2.867140987357342E-4	3.4395406149554666E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	4	3	13	13	4	18	29	47	42	51														CASRLDPAQGFQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGAAAGGGGACTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLKGDSYNEQFF	In	VDJ	1	201	2.8814766922941287E-4	3.4567383180302436E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	5	2	0	3	1	18	32	40	35	41														CASSLKGDSYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGACTCTTTACCGGGGAGCTGTTTTTTGGAGAA	CASSLGLFTGELFF	In	VDJ	1	205	2.938819512041275E-4	3.5255291303293534E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	1	2	10	5	0	4	18	-1	38	34	42						01,02								CASSLGLFTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATCCGACAGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLSDSSNQPQHF	In	VDJ	1	205	2.938819512041275E-4	3.5255291303293534E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	2	5	0	3	0	18	33	-1	36	41														CASSLSDSSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTCTTCGTGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSPLRATNEKLFF	In	VDJ	1	206	2.953155216978062E-4	3.5427268334041305E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	5	4	10	0	1	7	18	30	33	31	40						01,02								CASSPLRATNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTTCAAAGGGTAGCGGGACTTACGAGCAGTACTTCGGGCCG	CASSPSKGSGTYEQYF	In	VDJ	1	211	3.024833741661996E-4	3.6287153487780173E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	5	3	4	11	2	18	30	49	41	51														CASSPSKGSGTYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCACCTTCGGGCTTAGCAATCAGCCCCAGCATTTTGGTGAT	CASTFGLSNQPQHF	In	VDJ	1	214	3.0678408564723556E-4	3.680308458002349E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	3	8	0	0	1	1	18	32	37	33	38				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTFGLSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTGGCGATGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	221	3.168190791029863E-4		46	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	5	9	0	0	2	4	18	30	35	32	39				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGTCGACTAGCGGGTTAGAAGATACGCAGTATTTTGGCCCA	CASSLSTSGLEDTQYF	In	VDJ	1	221	3.168190791029863E-4	3.8006923795257905E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	2	4	5	3	5	18	32	45	35	50						01,02								CASSLSTSGLEDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAACCGTGGGCCACCGGGGAGCTGTTTTTTGGAGAA	CASSQPWATGELFF	In	VDJ	1	222	3.1825264959666497E-4	3.817890082600568E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	8	0	4	7	0	18	30	-1	37	41														CASSQPWATGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTATACGGGGCCGTAATGAAAAACTGTTTTTTGGCAGT	CASSIRGRNEKLFF	In	VDJ	1	222	3.1825264959666497E-4	3.817890082600568E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	6	7	0	4	5	2	18	29	39	34	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSIRGRNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCGGACGGTCTAGTTGGACAGATACGCAGTATTTTGGCCCA	CASGRSSWTDTQYF	In	VDJ	2	229	3.2828764305241565E-4	3.938274004124009E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	8	1	7	3	0	11	18	-1	31	27	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGRSSWTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCGACTAGCGGGAGGCCCCACAGATACGCAGTATTTTGGCCCA	CASSLRLAGGPTDTQYF	In	VDJ	2	241	3.454904889765597E-4	4.1446464410213374E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	2	1	2	2	3	18	32	47	34	50														CASSLRLAGGPTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGCCGGACTAGCGGGGGGACACAATGAGCAGTTCTTCGGGCCA	CASSLAGLAGGHNEQFF	In	VDJ	2	242	3.469240594702384E-4	4.1618441440961144E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	1	1	5	4	2	18	32	50	36	52														CASSLAGLAGGHNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTACTCCGGGACTCAGGTGAGCAATGAGCAGTTCTTCGGGCCA	CASSYSGTQVSNEQFF	In	VDJ	2	244	3.497912004575957E-4	4.196239550245669E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	0	10	6	5	8	18	31	42	36	50						01,02								CASSYSGTQVSNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACAAGGACAGGGGGCCTACGAGCAGTACTTCGGGCCG	CASSLQGQGAYEQYF	In	VDJ	2	247	3.540919119386317E-4	4.2478326594700013E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	1	1	2	3	0	18	33	-1	36	46														CASSLQGQGAYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGATTCTAGCGGGAGGATACCCTACGAGCAGTACTTCGGGCCG	CASSLDSSGRIPYEQYF	In	VDJ	2	253	3.626933349007037E-4	4.351018877918665E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	4	1	2	5	4	18	32	48	37	52														CASSLDSSGRIPYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGYTTTGGGGGACAGGGGGCGAGCCAAGAGACCCAGTACTTCGGGCCA	CASSFGGQGASQETQYF	In	VDJ	2	253	3.626933349007037E-4	4.351018877918665E-4	51	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	0	1	3	3	18	32	47	35	50														CASSFGGQGASQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTCAGGAACGCTGGACCAGATGAAAAACTGTTTTTTGGCAGT	CASSLRNAGPDEKLFF	In	VDJ	2	255	3.6556047588806107E-4	4.38541428406822E-4	48	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	5	1	7	6	12	3	18	30	46	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRNAGPDEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGAGGACGAGGGAATCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLEDEGISGANVLTF	In	VDJ	2	255	3.6556047588806107E-4	4.38541428406822E-4	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	3	10	1	0	0	10	18	-1	37	32	47														CASSLEDEGISGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCACCTTCCCCCAGACTAGCGGCCCCGATACGCAGTATTTTGGCCCA	CASTFPQTSGPDTQYF	In	VDJ	2	261	3.7416189885013313E-4	4.4886005025168837E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	2	5	6	6	4	18	32	47	38	51						01,02								CASTFPQTSGPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGATCGGGACACCGCGTAGATACGCAGTATTTTGGCCCA	CASSLGSGHRVDTQYF	In	VDJ	2	261	3.7416189885013313E-4	4.4886005025168837E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	0	6	5	4	6	18	34	44	38	50														CASSLGSGHRVDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGCAGGAGCGATTACGAGCAGTACTTCGGGCCG	CASSLGRSDYEQYF	In	VDJ	2	274	3.927983152679558E-4	4.712170642488989E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	3	4	4	4	3	6	18	32	39	35	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGRSDYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGGGGCCTAACTCTGGAAACACCATATATTTTGGAGAG	CASSRGPNSGNTIYF	In	VDJ	2	275	3.942318857616345E-4	4.7293683455637667E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-03	01	5	6	0	0	1	4	18	30	37	31	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRGPNSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGCCTTGGTCCTAGCAATCAGCYCCAGCATTTTGGTGAT	CASSLGLGPSNQXQHF	In	VDJ	2	275	3.942318857616345E-4	4.7293683455637667E-4	48	TCRBV11	TCRBV11-03	01	unresolved			TCRBJ01	TCRBJ01-05	01	1	0	10	0	5	3	18	34	41	39	44				TCRBD01,TCRBD02										CASSLGLGPSNQXQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	unresolved	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGGAGGGAATGGCCAAAAACATTCAGTACTTCGGCGCC	CASREGMAKNIQYF	In	VDJ	2	284	4.071340202047425E-4	4.884147673236762E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	6	10	0	1	0	4	18	-1	35	29	39														CASREGMAKNIQYF+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGAGAGGACAGAATTCGAATAGTACTCAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	286	4.100011611920999E-4		50	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	1	5	6	3	14	18	29	38	32	52														X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGTACTAGCGGGTCTTATGGATACGCAGTATTTTGGCCCA	CASSLVLAGLMDTQYF	In	VDJ	2	287	4.1143473168577855E-4	4.935740782461094E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	3	4	6	3	7	18	32	44	35	51						01,02								CASSLVLAGLMDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTTGCAGGCGGAAACACCATATATTTTGGAGAG	CASSLVAGGNTIYF	In	VDJ	2	290	4.157354431668146E-4	4.987333891685427E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	1	4	4	4	3	1	18	34	41	37	42														CASSLVAGGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGGACGGGCCCTCACTGGGGGTGGTGAAAAACTGTTTTTTGGCAGT	CASSQGRALTGGGEKLFF	In	VDJ	2	292	4.186025841541719E-4	5.021729297834981E-4	54	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	5	6	1	7	18	3	18	30	53	48	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGRALTGGGEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGTTCTAGCTTCTACAATGAGCAGTTCTTCGGGCCA	CASSLGSSFYNEQFF	In	VDJ	2	317	4.544418464961387E-4	5.451671874704415E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	4	7	3	5	2	18	32	42	37	44						01,02								CASSLGSSFYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCGACAGGAGGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	321	4.601761284708534E-4		41	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	2	4	4	2	3	18	32	40	34	43														X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCACTCGGGGTGGCGGGGGGGTTCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	324	4.6447683995188936E-4		56	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	7	0	0	11	2	18	30	50	41	52														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTACAGGGGGCGGCCACAATGAGCAGTTCTTCGGGCCA	CASSPTGGGHNEQFF	In	VDJ	2	337	4.831132563697121E-4	5.795625936199961E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	0	5	3	4	18	30	42	33	46														CASSPTGGGHNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGAACTGACAGGGGGCCCTATGGCTACACCTTCGGTTCG	CASRTDRGPYGYTF	In	VDJ	2	357	5.117846662432855E-4	6.139579997695508E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	0	4	4	1	18	29	43	33	44														CASRTDRGPYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCCTCCCCCGACAGTCGTTYTATAATTCACCCCTCCACTTTGGGAAC	CASSPLPRQSFYNSPLHF	In	VDJ	2	357	5.117846662432855E-4	6.139579997695508E-4	54	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	2	5	3	10	5	18	30	45	40	50														CASSPLPRQSFYNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCCTTCCCTGGACAGGGGAGACTACATGAACACTGAAGCTTTCTTTGGACAA	CASSFPSLDRGDYMNTEAFF	In	VDJ	2	363	5.203860892053576E-4	6.242766216144172E-4	60	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	1	2	0	9	8	18	32	50	41	58														CASSFPSLDRGDYMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTACGCAGGACCACTGCATCGGGGGCTGAAGCTTTCTTTGGACAA	CASSLRRTTASGAEAFF	In	VDJ	2	366	5.246868006863935E-4	6.294359325368504E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	8	2	6	19	0	18	30	-1	49	55														CASSLRRTTASGAEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATTTGGTGGGGGCCCCAATGAGCAGTTCTTCGGGCCA	CASSLFGGGPNEQFF	In	VDJ	2	366	5.246868006863935E-4	6.294359325368504E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	6	0	6	6	2	18	33	45	39	47														CASSLFGGGPNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGTTGGGACAGGGCCCGACGAGCAGTACTTCGGGCCG	CASSLVGTGPDEQYF	In	VDJ	2	376	5.390225056231803E-4	6.466336356116278E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	3	5	4	4	18	32	45	36	49														CASSLVGTGPDEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAATCTACCACAGGGTACGGGGGTCGAGTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	3	386	5.533582105599669E-4		56	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	5	3	3	7	9	13	18	30	45	39	58				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAACTAGCTCCACCGGGGAGCTGTTTTTTGGAGAA	CASSQTSSTGELFF	In	VDJ	3	387	5.547917810536456E-4	6.655511089938827E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	3	7	4	3	2	18	30	39	33	41						01,02								CASSQTSSTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGTTGGGGGGTCCTACGAGCAGTACTTCGGGCCG	CASSPVGGSYEQYF	In	VDJ	3	400	5.734281974714684E-4	6.879081229910933E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	9	1	1	6	0	18	30	-1	36	42														CASSPVGGSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCCTGGCGGGGGACCCCCTAGGGTCGCAGTACTTCGGGCCG	CASSSLAGDPLGSQYF	In	VDJ	3	402	5.762953384588257E-4	6.913476636060487E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	4	7	2	9	5	13	18	31	43	36	56														CASSSLAGDPLGSQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCGGGCTCGGGGGACAATCAGCCCCAGCATTTTGGTGAT	CASSAGSGDNQPQHF	In	VDJ	3	403	5.777289089525044E-4	6.930674339135265E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	5	8	2	3	7	1	18	30	43	37	44														CASSAGSGDNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGATGGAGGGGGCGATGGGTGCAATGAAGCTTTCTTTGGACAA		Out	VDJ	3	448	6.422395811680445E-4		50	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	5	0	7	5	11	18	32	44	37	55														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTTCACTAGCGGCGGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	464	6.651767090669034E-4		43	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	3	5	4	3	3	18	29	40	32	43						01,02								X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTCTTGGTGGCGCTAGGGACGAGCAGTACTTCGGGCCG	CASSLGGARDEQYF	In	VDJ	3	479	6.866802664720834E-4	8.237699772818343E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	6	5	3	5	13	0	18	29	-1	42	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGARDEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCTCGCCGGGGCCGCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	3	486	6.96715259927834E-4		49	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-03	01	5	7	0	0	8	2	18	30	43	38	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAACGGACCGGGGGGCTATAATTCACCCCTCCACTTTGGGAAC	CASSLNGPGGYNSPLHF	In	VDJ	3	497	7.124845353582995E-4	8.547258428164335E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	2	8	1	3	7	0	18	33	-1	40	47														CASSLNGPGGYNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAACCCGGGTTATAGCACAGATACGCAGTATTTTGGCCCA	CASNPGYSTDTQYF	In	VDJ	3	510	7.311209517761221E-4	8.77082856813644E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	7	8	4	0	3	4	18	28	35	31	39						01,02								CASNPGYSTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGTGGGGAGGCGGATTGTCCGCTGAAGCTTTCTTTGGACAA	CASSPWGGGLSAEAFF	In	VDJ	4	560	8.027994764600557E-4	9.630713721875306E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	9	1	6	5	11	18	30	41	35	52														CASSPWGGGLSAEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTTAGCGGGGGGGGAGACAATGAGCAGTTCTTCGGGCCA	CASSLSGGGDNEQFF	In	VDJ	4	602	8.630094371945599E-4	0.0010353017251015955	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	5	0	5	2	3	18	30	43	32	46														CASSLSGGGDNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGTCCAGGGTGGCGGCGAGCAGTACTTCGGGCCG	CASSPVQGGGEQYF	In	VDJ	4	608	8.716108601566319E-4	0.001045620346946462	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	3	6	6	6	18	30	41	36	47														CASSPVQGGGEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTTCTAGCGGGACAACAGATACGCAGTATTTTGGCCCA	CASSFSSGTTDTQYF	In	VDJ	4	608	8.716108601566319E-4	0.001045620346946462	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	4	3	3	2	2	18	32	43	34	45														CASSFSSGTTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTGGCCCCTCGCAATGAGCAGTTCTTCGGGCCA	CASSLVAPRNEQFF	In	VDJ	4	641	9.189186864480281E-4	0.001102372767093227	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	9	0	6	1	6	18	34	38	35	44														CASSLVAPRNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGGACAGGACCACCGGGGAGCTGTTTTTTGGAGAA	CASSPDRTTGELFF	In	VDJ	4	643	9.217858274353853E-4	0.0011058123077081826	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	1	4	4	2	2	18	30	39	32	41														CASSPDRTTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGGACGTACAGCACAGATACGCAGTATTTTGGCCCA	CASSPGTYSTDTQYF	In	VDJ	4	667	9.561915192836735E-4	0.0011470867950876481	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	5	0	7	0	3	4	18	30	38	33	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGTYSTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCGGAGTCGGGGGGCCCGGTACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	5	765	0.0010966814276641833		53	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	8	1	0	8	6	18	30	45	38	51														X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACCCGGGACGCTGTATGAAAAACTGTTTTTTGGCAGT	CASSLPGTLYEKLFF	In	VDJ	5	776	0.0011124507030946485	0.001334541758602721	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-04	01	2	0	7	6	3	5	18	33	41	36	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLPGTLYEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCCAGCGGGAGGGCCCGACGAGCAGTACTTCGGGCCG	CASSFPAGGPDEQYF	In	VDJ	6	837	0.0011998985032090476	0.0014394477473588627	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	6	0	5	3	4	18	32	45	35	49														CASSFPAGGPDEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGGATGGACTAGCGGGGTCCTACGAGCAGTACTTCGGGCCG	CASRDGLAGSYEQYF	In	VDJ	6	861	0.0012343041950573356	0.0014807222347383285	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	1	3	1	4	0	18	29	-1	33	45														CASRDGLAGSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGCAGCCGTATTATTACAGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	6	879	0.0012601084639435518		50	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	3	5	3	14	0	18	34	-1	48	52														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGCCCCGGACAGCTTCTACGAGCAGTACTTCGGGCCG	CASSPAPDSFYEQYF	In	VDJ	6	895	0.0012830455918424104	0.0015391944251925713	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	5	3	8	3	18	30	44	38	47														CASSPAPDSFYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGCCGGGGCAGAGGGAACCGGGGAGCTGTTTTTTGGAGAA	CASSAGAEGTGELFF	In	VDJ	6	922	0.0013217519951717346	0.00158562822349447	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-02	01	5	7	0	5	3	7	18	30	38	33	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAGAEGTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAAGAAACAGGGGGCTGATTTTGGCTACACCTTCGGTTCG	CASKKQGADFGYTF	In	VDJ	7	984	0.0014106333657798122	0.0016922539825580895	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	3	0	7	4	6	18	28	41	32	47														CASKKQGADFGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCTTACAGGGGACCAGCTCCTACGAGCAGTACTTCGGGCCG	CASSFLQGTSSYEQYF	In	VDJ	8	1169	0.0016758439071103662	0.00201041148944147	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	3	2	0	3	5	18	32	42	35	47														CASSFLQGTSSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGCCCCGCGGCACTCTGGAAACACCATATATTTTGGAGAG	CASSLAPRHSGNTIYF	In	VDJ	10	1453	0.002082977927315109	0.0024988262567651465	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	3	7	5	0	6	2	18	32	42	38	44						01,02								CASSLAPRHSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD02-01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGATTCATCCTGGACTAGCGGGTCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	11	1612	0.0023109156358100177		55	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	1	4	2	8	2	18	35	54	43	56						01,02								X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGGTTTCAGGCGGCGGCACCATATATTTTGGAGAG	CASSWVSGGGTIYF	In	VDJ	15	2209	0.003166757220536184	0.003798972609218313	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-03	01	4	4	4	9	6	6	18	31	41	37	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSWVSGGGTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTCTTTCGGCTAGCGGGGGGGATAGATACGCAGTATTTTGGCCCA	CASSLVFRLAGGIDTQYF	In	VDJ	17	2572	0.0036871433097415414	0.00442324923083273	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	4	0	5	8	2	18	34	54	42	56														CASSLVFRLAGGIDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGTCCGGGACAGGGGTGCTCACCCCTCCACTTTGGGAAC		Out	VDJ	18	2658	0.003810430372197907		46	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	0	2	10	5	3	18	31	46	36	49														X+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACTGGGACAGGGACTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	21	3157	0.004525782048543564		49	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	0	3	0	3	3	18	30	42	33	45														X+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGGGCCCGGTACGAATGAACACTGAAGCTTTCTTTGGACAA	CASSLGGPVRMNTEAFF	In	VDJ	60	9010	0.012916470148044826	0.015495130470374378	51	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	3	6	0	0	1	10	18	32	39	33	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGPVRMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACCACAGGGGGCCAGTGGAGGGGCTACACCTTCGGTTCG	CASSTTGGQWRGYTF	In	VDJ	65	9859	0.014133571497178017	0.016955215461422972	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	0	8	3	9	18	30	42	33	51														CASSTTGGQWRGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAACACGAACCTACAGGATTACAATGAGCAGTTCTTCGGGCCA	CASSNTNLQDYNEQFF	In	VDJ	90	13641	0.01955533510427075	0.023459386764303758	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	4	4	11	2	18	30	46	41	48														CASSNTNLQDYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTAGAAGGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	43	6.164353122818285E-5		37	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-05	01	3	5	4	3	3	0	26	40	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCTCGGGACAGGTTTTCTATGAGCAGTTCTTCGGGCCA	CASSGQVFYEQFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	39	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	12	0	4	8	6	6	26	31	45	37	51														CASSGQVFYEQFF+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGACAGGAACTATGGCTACACCTTCGGTTCG	CASGLDRNYGYTF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	39	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	3	4	2	0	0	26	-1	-1	42	47														CASGLDRNYGYTF+TCRBV12-05+TCRBJ01-02	TCRBV12-05*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCCTACGCACAGGAGACATTCAGTACTTCGGCGCC	CASGLRTGDIQYF	In	VDJ	1	64	9.174851159543494E-5	1.1006529967857494E-4	39	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	6	3	4	8	7	2	26	37	49	44	51														CASGLRTGDIQYF+TCRBV12-05+TCRBJ02-04	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCACCCCCTCATGGAGTCATGGCTACACCTTCGGTTCG	CASTPSWSHGYTF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	39	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	12	10	2	6	14	2	26	31	49	45	51														CASTPSWSHGYTF+TCRBV12-05+TCRBJ01-02	TCRBV12-05*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCGGGCAGAACCAAGAGACCCAGTACTTCGGGCCA	CASGQNQETQYF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	36	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	12	6	4	0	1	4	26	31	38	32	42						01,02								CASGQNQETQYF+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTAGGAGGGGACCCCATGGTGGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	82	1.1755278048165102E-4		53	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	10	0	4	1	13	26	43	50	44	63														X+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCCGGACCTTGGGCACTGAAGCTTTCTTTGGACAA	CASRTLGTEAFF	In	VDJ	1	90	1.290213444310804E-4	1.5477932767299599E-4	36	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	12	1	7	4	5	6	26	31	40	36	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRTLGTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTACCCGCCGGGACAGCCTCTAACTATGGCTACACCTTCGGTTCG	CASGLVPAGTASNYGYTF	In	VDJ	1	97	1.3905633788683107E-4	1.6681771982534013E-4	54	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	0	5	0	7	3	26	43	57	50	60														CASGLVPAGTASNYGYTF+TCRBV12-05+TCRBJ01-02	TCRBV12-05*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCACCACGATGGCGACAGGGGGCTTGGAGACCCAGTACTTCGGGCCA	CASTTMATGGLETQYF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	48	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	12	2	0	5	15	3	26	31	56	46	59														CASTTMATGGLETQYF+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTACACAGGGGGGGGACAGCCCCAGCATTTTGGTGAT	CASGYTGGGQPQHF	In	VDJ	1	112	1.6055989529201113E-4	1.9261427443750614E-4	42	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	3	1	7	2	4	26	39	49	41	53														CASGYTGGGQPQHF+TCRBV12-05+TCRBJ01-05	TCRBV12-05*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTCGCAGGGGTTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASRRGSGANVLTF	In	VDJ	1	140	2.0069986911501394E-4	2.4076784304688265E-4	42	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	8	4	2	1	2	1	26	35	43	37	44														CASRRGSGANVLTF+TCRBV12-05+TCRBJ02-06	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGGTCCGGACTAGTTCCCTCCGGGGAGCTGTTTTTTGGAGAA	CASGSGLVPSGELFF	In	VDJ	1	164	2.3510556096330203E-4	2.8204233042634826E-4	45	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	1	8	6	4	6	26	37	48	41	54						01,02								CASGSGLVPSGELFF+TCRBV12-05+TCRBJ02-02	TCRBV12-05*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCTTAAATGACGGCACTGAAGCTTTCTTTGGACAA	CASGLNDGTEAFF	In	VDJ	1	186	2.666441118242328E-4	3.198772771908584E-4	39	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	6	2	7	4	7	2	26	37	47	44	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGLNDGTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCTACGGGTGGGAGCAGTACTTCGGGCCG	CASGYGWEQYF	In	VDJ	1	207	2.967490921914849E-4	3.559924536478908E-4	33	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	8	4	7	3	3	26	37	44	40	47						01,02								CASGYGWEQYF+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTACCGGGAGGGGTGGTCGCTGAAGCTTTCTTTGGACAA	CASGLVPGGVVAEAFF	In	VDJ	1	220	3.153855086093076E-4	3.7834946764510135E-4	48	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	8	0	6	2	7	26	43	53	45	60														CASGLVPGGVVAEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGATCACGTGAAGGATGGAAACACCATATATTTTGGAGAG	CASGLDHVKDGNTIYF	In	VDJ	2	228	3.2685407255873697E-4	3.921076301049232E-4	48	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-03	01	1	1	8	3	10	0	26	42	-1	52	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGLDHVKDGNTIYF+TCRBV12-05+TCRBJ01-03	TCRBV12-05*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGGGGGAGGATACGAGCAGTACTTCGGGCCG	CASGLGGGYEQYF	In	VDJ	2	280	4.0139973823002787E-4	4.815356860937653E-4	39	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	9	1	4	1	1	26	42	49	43	50														CASGLGGGYEQYF+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGTGGAGGGGGACATGAACACTGAAGCTTTCTTTGGACAA	CASVEGDMNTEAFF	In	VDJ	2	304	4.3580543007831594E-4	5.22810173473231E-4	42	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	7	0	6	0	6	0	26	36	-1	42	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASVEGDMNTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGCCAAATCTACCTCACGGGGTTACAATGAGCAGTTCTTCGGGCCA	CASAKSTSRGYNEQFF	In	VDJ	2	314	4.5014113501510265E-4	5.400078765480082E-4	48	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	8	3	4	14	1	26	36	55	50	56														CASAKSTSRGYNEQFF+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTATGCGGGCGGCTAGCGGGAGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	373	5.347217941421442E-4		58	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	4	3	1	10	0	23	40	-1	50	59														X+TCRBV12-05+TCRBJ02-02	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCCCATCAGGTCTAACAGTTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	483	6.924145484467981E-4		47	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	3	5	4	13	1	26	37	54	50	55														X+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCTCCTTGAGGGGCACTGAAGCTTTCTTTGGACAA	CASGSLRGTEAFF	In	VDJ	4	635	9.10317263485956E-4	0.0010920541452483607	39	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	6	5	2	4	7	0	26	37	-1	44	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGSLRGTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGCACGCGCGCAGGACACTAGACTTCGGGCCG		Out	VDJ	9	1291	0.001850739507339164		40	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-07	01	1	1	6	14	10	4	26	42	57	52	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCCTGGACTAGCGGATTTACAATGAGCAGTTCTTCGGGCCA	CASLD*RIYNEQFF	Stop	VDJ	1	44	6.307710172186152E-5		42	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	1	5	4	2	3	20	29	41	31	44						01,02								CASLD*RIYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAGACGGGGACAGGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	45	6.45106722155402E-5		49	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	0	3	1	4	0	20	34	-1	38	47														X+TCRBV23-01+TCRBJ02-02	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAGTGGGCTAGCGGGGGTAACTACAATGAGCAGTTCTTCGGGCCA	CASSQWASGGNYNEQFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	51	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	2	3	5	3	20	34	49	39	52														CASSQWASGGNYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGGACTAGCGGGAGTCAATGAGCAGTTCTTCGGGCCA	CASSQGLAGVNEQFF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	45	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	1	2	6	0	1	20	-1	48	35	49														CASSQGLAGVNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATCCCGACAGAGACCCTACGAGCAGTACTTCGGGCCG	CASSQSRQRPYEQYF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	45	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	2	5	2	2	4	20	37	44	39	48														CASSQSRQRPYEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAACCGCCAGTTGATGGGGGAGACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	60	8.601422962072026E-5		44	TCRBV23	TCRBV23-01	01				TCRBJ01	TCRBJ01-02	01	10	6	1	3	13	2	20	27	45	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV23-01+TCRBJ01-02	TCRBV23-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTCGACAGGTGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CASSSTGGGYNEQFF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	45	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-01	01	6	2	4	4	3	7	20	31	40	34	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSTGGGYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCGTCAGAGTTGGCCGGCGAGTTCCAAAAACATTCAGTACTTCGGCGCC	CASSRQSWPASSKNIQYF	In	VDJ	1	150	2.1503557405180065E-4	2.5796554612165997E-4	54	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-04	01	4	4	5	2	2	16	20	33	38	35	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRQSWPASSKNIQYF+TCRBV23-01+TCRBJ02-04	TCRBV23-01*01		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATGTCAAGGGGCGACTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	161	2.30804849482266E-4		50	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	1	5	2	0	4	3	20	36	45	40	48														X+TCRBV23-01+TCRBJ01-03	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAGGGCGGTAATGAAAAACTGTTTTTTGGCAGT	CASSQGGNEKLFF	In	VDJ	1	185	2.652105413305541E-4	3.1815750688338066E-4	39	TCRBV23	TCRBV23-01	01				TCRBJ01	TCRBJ01-04	01	3	8	0	4	0	2	20	-1	38	34	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGGNEKLFF+TCRBV23-01+TCRBJ01-04	TCRBV23-01*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATCCCTCCCCCGACAGGGGGCCTAACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	191	2.7381196429262616E-4		53	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	2	0	5	8	3	20	37	55	45	58														X+TCRBV23-01+TCRBJ01-01	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAAGCCGACCCGTAGGTATCCTACGAGCAGTACTTCGGGCCG	CASSQADP*VSYEQYF	Stop	VDJ	1	195	2.795462462673408E-4		48	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-07	01	2	2	7	1	3	9	20	35	41	38	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQADP*VSYEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTTGGGACTATGAGACCTACGAGCAGTACTTCGGGCCG	CASSWDYETYEQYF	In	VDJ	1	210	3.010498036725209E-4	3.61151764570324E-4	42	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	9	2	1	5	20	32	40	33	45						01,02								CASSWDYETYEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TGTATCTCTGCGCCAGCAGTCAATGGTCCGGGCCATGACTCTGGTGGGGAGGCTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	322	4.61609698964532E-4		67	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	9	1	0	22	2	8	24	52	46	54														X+TCRBV23-01+TCRBJ02-03	TCRBV23-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCATCTCCCGGCGGACAGGGGACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	332	4.759454039013187E-4		52	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	1	2	3	9	0	20	34	-1	43	52														X+TCRBV23-01+TCRBJ02-02	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCGACAGCCCCGGGGAGCTGTTTTTTGGAGAA	CASSSDSPGELFF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	2	5	6	2	2	23	36	43	38	45														CASSSDSPGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGGACGAGGGTCGAACACTGAAGCTTTCTTTGGACAA	CASGRGSNTEAFF	In	VDJ	1	41	5.877639024082551E-5	7.051058260658707E-5	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	8	11	0	1	4	2	23	32	41	36	43														CASGRGSNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACCGGGACACCTCTCCTACAATGAGCAGTTCTTCGGGCCA	CASRPGHLSYNEQFF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	6	0	3	3	23	34	43	37	46														CASRPGHLSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACTGAACCCCCGGACAGGGGTGGTTCTATATACGAGCAGTACTTCGGGCCG	CASTEPPDRGGSIYEQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	54	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	1	2	4	10	10	23	33	52	43	62														CASTEPPDRGGSIYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGTCTAGCTACTACGAGCAGTACTTCGGGCCG	CASRSSYYEQYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	36	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	4	7	3	2	2	23	34	41	36	43						01,02								CASRSSYYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAGGGGAACGGAAACACCATATATTTTGGAGAG	CASSQGNGNTIYF	In	VDJ	1	43	6.164353122818285E-5	7.395012322154253E-5	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	4	2	4	0	3	23	-1	41	35	44														CASSQGNGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACTCACCGGTCTAGCGGGAGTACCGGGGAGCTGTTTTTTGGAGAA	CASTHRSSGSTGELFF	In	VDJ	1	44	6.307710172186152E-5	7.566989352902026E-5	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	7	4	2	5	9	1	23	33	52	42	53														CASTHRSSGSTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCGGACAGGGGCTCCGTTTTAATGAAAAACTGTTTTTTGGCAGT	CASSYSGQGLRFNEKLFF	In	VDJ	1	45	6.45106722155402E-5	7.738966383649799E-5	54	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	1	2	4	1	8	23	40	50	41	58														CASSYSGQGLRFNEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGGGGGACAGGGTATGAACACTGAAGCTTTCTTTGGACAA	CASSYSGGQGMNTEAFF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	3	0	3	2	23	40	52	43	54														CASSYSGGQGMNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGTACAACAGGCGAGAATGAAAAACTGTTTTTTGGCAGT	CASTTGENEKLFF	In	VDJ	1	46	6.594424270921886E-5	7.910943414397572E-5	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	9	3	4	5	4	4	23	31	40	35	44														CASTTGENEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACCTGTCCCTCCCCGACAAGAGACCCAGTACTTCGGGCCA	CASRPVPPRQETQYF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	6	2	8	2	14	0	23	34	-1	48	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRPVPPRQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTATGCCAGGATCCATCTCTCCCGAGCAGTACTTCGGGCCG	CASSMPGSISPEQYF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	4	6	4	12	23	35	43	39	55														CASSMPGSISPEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTGGACAGCGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	48	6.881138369657621E-5		41	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	1	5	4	0	2	23	-1	45	39	47														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCGACAGGCAGGCAGGAAACACCATATATTTTGGAGAG	CASSFDRQAGNTIYF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	2	4	4	2	6	23	36	44	38	50														CASSFDRQAGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCACCACACAGGGGAACACTGAAGCTTTCTTTGGACAA	CAITTQGNTEAFF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	3	3	1	7	0	23	30	-1	37	43														CAITTQGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGGGGGTACCGGGACTAACTATGGCTACACCTTCGGTTCG	CAISGGTGTNYGYTF	In	VDJ	1	48	6.881138369657621E-5	8.25489747589312E-5	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	5	6	1	0	0	8	23	-1	40	35	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CAISGGTGTNYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCAGCAGGGGGTCTCTATGGCTACACCTTCGGTTCG	CASSPAGGLYGYTF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	1	4	4	3	23	35	46	39	49														CASSPAGGLYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCCAGCCGGCGGCTACACCTTCGGTTCG	CASSSPAGGYTF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	36	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	4	4	5	8	3	5	23	36	42	39	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSPAGGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATCGCCCCAGGGCCTAATCAGCCCCAGCATTTTGGTGAT	CASIAPGPNQPQHF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	4	3	4	6	3	23	33	44	39	47														CASIAPGPNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATGGACGTACTCTCTGGAAACACCATATATTTTGGAGAG	CASMDVLSGNTIYF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-03	01	7	1	7	0	1	5	23	33	38	34	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASMDVLSGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCTGTGATTACGGGGGGGCCGGATACAATGAGCAGTTCTTCGGGCCA	CASCDYGGAGYNEQFF	In	VDJ	1	50	7.167852468393355E-5	8.598851537388666E-5	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	8	8	0	4	8	5	23	32	48	40	53														CASCDYGGAGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGCTGATCCAACGTAAACAGGGGATGTGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	50	7.167852468393355E-5		56	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	2	2	14	4	23	34	55	48	59														X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACCTAATCTAGGGACAGAAAAGAACGAGCAGTACTTCGGGCCG	CASRPNLGTEKNEQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	5	5	10	6	23	34	51	44	57														CASRPNLGTEKNEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGGTCAGGTACTATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	51	7.311209517761221E-5		47	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	6	4	4	0	5	5	23	34	43	39	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCCGACGCTACGCTCCTACGAGCAGTACTTCGGGCCG	CASSSPTLRSYEQYF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	4	2	7	0	4	6	23	36	43	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSPTLRSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGTGTGGGGAATCCTTTTCGATGAGCAGTTCTTCGGGCCA	CASSVWGILFDEQFF	In	VDJ	1	52	7.454566567129089E-5	8.942805598884213E-5	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	5	0	8	8	5	10	23	35	44	40	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVWGILFDEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATCAACGGGAATGCAGGACCCAAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	52	7.454566567129089E-5		49	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	8	3	5	4	13	23	33	42	37	55														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGGAGGTCAGGGGGCGTATTGGCCGGGGAGCTGTTTTTTGGAGAA	CASSGRSGGVLAGELFF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	4	0	6	7	7	23	35	50	42	57														CASSGRSGGVLAGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACCCGGACTAGCGGGAAGGACGAGCAGTACTTCGGGCCG	CASSTRTSGKDEQYF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	1	3	5	4	3	23	35	51	39	54														CASSTRTSGKDEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATACGGGGGGACGGCACAGATACGCAGTATTTTGGCCCA	CAIRGDGTDTQYF	In	VDJ	1	55	7.88463771523269E-5	9.458736691127534E-5	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	10	8	1	1	2	3	23	30	39	32	42														CAIRGDGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCGCGATGCGGGGATTTACCGGGGAGCTGTTTTTTGGAGAA	CATAMRGFTGELFF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	10	7	3	5	7	4	23	30	43	37	47														CATAMRGFTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGCAGGCCGGGGAGGACAGCCCCAGCATTTTGGTGAT	CASSYSAGRGGQPQHF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	0	9	1	7	9	1	23	40	55	49	56														CASSYSAGRGGQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGTCAGCAGTTACTCGGGCCGTACCTTTGTGGAAAAACTGTTTTTTGGCAGT	CVSSYSGRTFVEKLFF	In	VDJ	1	56	8.027994764600557E-5	9.630713721875307E-5	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	8	0	8	0	12	23	-1	44	40	56														CVSSYSGRTFVEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGAGATTAGACAGGGGGGATGGCTACACCTTCGGTTCG	CASRRLDRGDGYTF	In	VDJ	1	57	8.171351813968424E-5	9.80269075262308E-5	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	1	6	7	1	23	34	50	41	51														CASRRLDRGDGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAGCCGGGGGGAAACACTGAAGCTTTCTTTGGACAA	CASSQPGGNTEAFF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	8	1	2	4	1	23	35	46	39	47														CASSQPGGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAAACAAGGGGCTCTGAACACTGAAGCTTTCTTTGGACAA	CASSYKQGALNTEAFF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	5	2	0	5	3	23	38	48	43	51														CASSYKQGALNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATGTTTAGGAAGGGGAATGAGCAGTTCTTCGGGCCA	CASMFRKGNEQFF	In	VDJ	1	58	8.314708863336292E-5	9.974667783370853E-5	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	5	2	7	9	0	23	33	-1	42	47														CASMFRKGNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACAAAAGAACAGACAGGGGAGAACACTGAAGTTTTCTTTGGACAA	CATKEQTGENTEVFF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	2	2	13	10	13	23	30	48	40	61														CATKEQTGENTEVFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGCGGGGGCCCGAAAAATGAGCAGTTCTTCGGGCCA	CASSYGGGPKNEQFF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	7	2	7	1	7	23	38	46	39	53														CASSYGGGPKNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCCCGGGACAGGGCTACGAGCAGTACTTCGGGCCG	CASSYSPGQGYEQYF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	3	3	3	0	23	40	-1	43	52														CASSYSPGQGYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGGGACAAGGTAGACTATGGCTACACCTTCGGTTCG	CASSRDKVDYGYTF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	6	3	1	6	23	35	42	36	48														CASSRDKVDYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATATGGGGGGTGGCTATGGCTACACCTTCGGTTCG	CASSYMGGGYGYTF	In	VDJ	1	60	8.601422962072026E-5	1.03186218448664E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	3	9	1	4	3	3	23	37	46	40	49														CASSYMGGGYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAAGGCAGGGTGGGGGCGGATGAACACTGAAGCTTTCTTTGGACAA	CASSYKAGWGRMNTEAFF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	54	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	6	0	0	10	3	23	38	54	48	57														CASSYKAGWGRMNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCTGTCGGAACGGACTGAGCAGTTCTTCGGGCCA	CASSYLSERTEQFF	In	VDJ	1	61	8.744780011439892E-5	1.0490598875614173E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	2	1	7	9	10	0	23	38	-1	48	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYLSERTEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCAAGTGGGGGGCGACTAGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSYPSGGRLANTGELFF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	57	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	2	6	0	0	7	6	23	38	51	45	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYPSGGRLANTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCGGGACAGTGGAAACACCATATATTTTGGAGAG	CASSYRDSGNTIYF	In	VDJ	1	62	8.88813706080776E-5	1.0662575906361946E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	0	5	3	1	0	23	38	-1	39	46														CASSYRDSGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCTCATTATTAGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	63	9.031494110175626E-5		40	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	5	8	6	9	0	23	35	-1	44	47						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGACAGGAATTAATGAAAAACTGTTTTTTGGCAGT	CASSYSTGINEKLFF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	2	4	4	0	3	23	-1	46	40	49														CASSYSTGINEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAAGCTAGCGGGAGACCCGAGCAGTACTTTGGGCCG	CASKASGRPEQYF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	4	2	19	3	16	23	33	46	36	62														CASKASGRPEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGGGACCCCACAGATACGCAGTATTTTGGCCCA	CASSRDPTDTQYF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-03	01	6	0	7	2	2	2	23	34	41	36	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRDPTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01		TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGAACTAGCGGGGGTGCACAGATACGCAGTATTTTGGCCCA	CASSYSN*RGCTDTQYF	Stop	VDJ	1	67	9.604922307647095E-5		51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	3	2	1	2	1	23	40	53	42	54														CASSYSN*RGCTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCTCAGGCCAGGATCGGACTGAAGCTTTCTTTGGACAA	CASTSGQDRTEAFF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	4	4	5	3	10	23	33	40	36	50														CASTSGQDRTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGGCGGGAGCGGGGGATACGCAGTATTTTGGCCCA	CASSYGAGAGDTQYF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	6	3	6	8	0	23	38	-1	46	53						01,02								CASSYGAGAGDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGGGGCTTAACTATGGCTACACCTTCGGTTCG	CASSYGGLNYGYTF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	2	6	0	1	1	1	23	38	45	39	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYGGLNYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCGGGGCTTAGTCAGCCCCAGCATTTTGGTGAT	CASSSGLSQPQHF	In	VDJ	1	68	9.748279357014962E-5	1.1694438090848586E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	4	7	0	6	1	4	23	36	42	37	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGLSQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCACGTCTTTCGGGGACAGTGCGTGCTTTCTTTGGACAA	CASSPRLSGTVRAFF	In	VDJ	1	69	9.891636406382829E-5	1.186641512159636E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	5	11	13	5	23	34	54	47	59														CASSPRLSGTVRAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCCACGGACTGGATGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSYPTDWMGNQPQHF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	2	1	10	2	5	6	23	38	48	43	54						01,02								CASSYPTDWMGNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCGCCCGGACAGTACGAGCAGTACTTCGGGCCG	CASSSPGQYEQYF	In	VDJ	1	71	1.0178350505118563E-4	1.2210369183091906E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	1	5	4	5	0	23	36	-1	41	47														CASSSPGQYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAAACAGCGGGAGGCGCCCCTACGAGCAGTACTTCGGGCCG	CASRNSGRRPYEQYF	In	VDJ	1	72	1.0321707554486431E-4	1.238234621383968E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	6	1	2	4	4	23	34	47	38	51														CASRNSGRRPYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCTTAGGCGGACCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	72	1.0321707554486431E-4		41	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-03	01	10	1	7	0	8	0	23	30	-1	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGATACACCAGGGTGAGAGAGCGATGGCTACACCTTCGGTTCG		Out	VDJ	1	73	1.0465064603854297E-4		46	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	3	6	2	10	23	38	45	40	55														X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACACCGGGACAGGGGGTGGCGAGCAGTACTTCGGGCCG	CASSYTGTGGGEQYF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	0	1	6	3	3	23	38	52	41	55														CASSYTGTGGGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCGGCAGGGGGGCGATGGAATGAGCAGTTCTTCGGGCCA	CASSYPAGGRWNEQFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	4	1	7	4	7	23	38	49	42	56														CASSYPAGGRWNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAGTAGGGTTCGGGACACTGAAGCTTTCTTTGGACAA	CASSYSRVRDTEAFF	In	VDJ	1	74	1.0608421653222165E-4	1.2726300275335225E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	2	5	3	3	3	6	23	38	45	41	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSRVRDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGCTCCCGGCAGCTCCTACGAGCAGTACTTCGGGCCG	CASRAPGSSYEQYF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	6	4	5	0	9	0	23	34	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRAPGSSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCAAAAAGGGGGGCGAGACACTGAAGCTTTCTTTGGACAA	CASRQKGGRDTEAFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	6	5	1	3	6	5	23	34	46	40	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRQKGGRDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGTCGAAACAGGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSYSVETGVNTEAFF	In	VDJ	1	77	1.1038492801325766E-4	1.3242231367578547E-4	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	2	0	7	0	23	40	-1	47	54														CASSYSVETGVNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTGGCAGGGGGGAAACGAGCAGTACTTCGGGCCG	CASSWQGGNEQYF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	1	5	2	3	23	36	45	38	48														CASSWQGGNEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCCTAACCCCAGTAGTGACTATGGCTACACCTTCGGTTCG	CASPNPSSDYGYTF	In	VDJ	1	79	1.13252069000615E-4	1.3586185429074094E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	8	4	5	3	8	5	23	32	43	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASPNPSSDYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGGCCGACCAGGCACAGATACACAGTATTTTGGCCCA	CASGRPGTDTQYF	In	VDJ	1	80	1.1468563949429368E-4	1.3758162459821867E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	8	3	5	12	12	5	23	32	48	44	53														CASGRPGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCGGGGCGGGGGGAACAATGAGCAGTTCTTCGGGCCA	CASRGGGNNEQFF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	8	7	1	5	4	1	23	32	44	36	45														CASRGGGNNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCACCCGGACAGGGGCTAACTATGGCTACACCTTCGGTTCG	CAITRTGANYGYTF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	10	1	2	0	6	0	23	30	-1	36	45														CAITRTGANYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCAGACATCTGTGTACTTGTGTGCCAGCAATGAAATCCCCGGGACAGGGACCTTGCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	83	1.1898635097532968E-4		59	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	0	3	0	11	6	22	32	52	43	58														X+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTGGACAGGGGGCGAAGACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	84	1.2041992146900836E-4		46	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	0	3	1	4	23	36	48	37	52														X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGAAACAGGGGGCTGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASRETGGWSNQPQHF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	0	1	4	3	23	34	47	38	50														CASRETGGWSNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCTTTGAGCCGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASFEPGTGELFF	In	VDJ	1	85	1.2185349196268703E-4	1.4618047613560733E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	8	8	4	4	7	0	23	32	-1	39	43						01,02								CASFEPGTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCTGAGGGGGACACTGAAGCTTTCTTTGGACAA	CASSSEGDTEAFF	In	VDJ	1	86	1.232870624563657E-4	1.4790024644308506E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	5	1	3	3	0	23	36	-1	39	45														CASSSEGDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCTAGAGGGAAGGGAGCAGTACTTCGGGCCG	CASSLEGREQYF	In	VDJ	1	93	1.333220559121164E-4	1.599386385954292E-4	36	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	11	0	7	3	4	23	35	43	38	47														CASSLEGREQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACGGGGGGAATCAGCCCCAGCATTTTGGTGAT	CASSDGGNQPQHF	In	VDJ	1	93	1.333220559121164E-4	1.599386385954292E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	5	8	1	4	2	0	23	35	-1	37	44														CASSDGGNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTCCGGGACAGGGGTTATGTTGAACACTGAAGCTTTCTTTGGACAA	CASSSGTGVMLNTEAFF	In	VDJ	1	94	1.3475562640579507E-4	1.6165840890290694E-4	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	2	0	4	6	23	34	48	38	54														CASSSGTGVMLNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGACCGGGACAGAGCACAGATACGCAGTATTTTGGCCCA	CASSYGPGQSTDTQYF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	5	0	5	0	23	38	-1	43	50														CASSYGPGQSTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGGTACGCCCGGGACGCAACTTCACCCCTCCACTTTGGGAAC	CAIRYARDATSPLHF	In	VDJ	1	95	1.3618919689947374E-4	1.6337817921038467E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	2	0	7	9	4	5	23	38	47	42	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CAIRYARDATSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTCGGGACAGGGAGCACGAGCAGTACTTCGGGCCG	CAISRDREHEQYF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	3	5	1	3	23	35	45	36	48														CAISRDREHEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCCGACAAAGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	98	1.4048990838050974E-4		40	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	2	6	4	4	3	23	34	42	38	45														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACTGCGGACAGGAAATTTTCCTACGAGCAGTACTTCGGGCCG	CATADRKFSYEQYF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	1	4	1	4	6	23	30	41	34	47														CATADRKFSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTACGTGACGGGGGGCCCCGGGGAGCTGTTTTTTGGAGAA	CASSYYVTGGPGELFF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	1	8	1	6	6	2	23	39	52	45	54														CASSYYVTGGPGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTTGAGGGACTTAACGAGCAGTACTTCGGGCCG	CASSFEGLNEQYF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	0	10	5	4	2	23	36	46	40	48						01,02								CASSFEGLNEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCAGGGACATCGGAACACTGAAGCTTTCTTTGGACAA	CASSQGHRNTEAFF	In	VDJ	1	103	1.476577608489031E-4	1.7713634167020652E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	6	1	3	3	23	34	43	37	46														CASSQGHRNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACACAGGCGCCCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRHRRPNTGELFF	In	VDJ	1	104	1.4909133134258178E-4	1.7885611197768426E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	3	4	0	2	4	23	34	41	36	45														CASRHRRPNTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGTGGGCCAAGAGACCCAGTACTTCGGGCCA	CASSYVGQETQYF	In	VDJ	1	104	1.4909133134258178E-4	1.7885611197768426E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	2	0	9	1	2	0	23	38	-1	40	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYVGQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCCTTCGGCAATCAGCCCCAGCATTTTGGTGAT	CASSAFGNQPQHF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	5	10	0	2	0	5	23	-1	37	35	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAFGNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGGACAGGGCACAGATACGCAGTATTTTGGCCCA	CASGQGTDTQYF	In	VDJ	1	105	1.5052490183626045E-4	1.80575882285162E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	8	1	4	1	0	0	23	-1	-1	32	39														CASGQGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCTCCAGGGGGAACACTGAAGCTTTCTTTGGACAA	CAISRGNTEAFF	In	VDJ	1	108	1.5482561331729645E-4	1.8573519320759518E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	4	2	1	4	0	23	30	-1	34	40														CAISRGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCAGACAGGGGGGAATGGGAGTACATGAAAAACTGTTTTTTGGCAGT	CASSRQGGMGVHEKLFF	In	VDJ	1	109	1.5625918381097513E-4	1.8745496351507291E-4	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	2	1	6	2	12	23	34	45	36	57														CASSRQGGMGVHEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTGGGACACAGAATGAAAAACTGTTTTTTGGCAGT	CASSYSGTQNEKLFF	In	VDJ	1	110	1.576927543046538E-4	1.8917473382255067E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	0	6	5	1	3	23	40	47	41	50														CASSYSGTQNEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGAGACCAGGGGCTGAAGCTTTCTTTGGACAA	CASRRPGAEAFF	In	VDJ	1	111	1.5912632479833248E-4	1.908945041300284E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	2	6	5	0	23	34	-1	39	45														CASRRPGAEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGATACGACCAGAAGCTACGAGCAGTACTTCGGGCCG	CASSDTTRSYEQYF	In	VDJ	1	111	1.5912632479833248E-4	1.908945041300284E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	5	2	7	3	5	6	23	35	43	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDTTRSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACTAGAGGACTAGCGGGAGGATCGGGGGAGCTGTTTTTTGGAGAA	CATRGLAGGSGELFF	In	VDJ	1	113	1.619934657856898E-4	1.9433404474498387E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	10	1	1	8	5	4	23	30	49	35	53														CATRGLAGGSGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGGACTAGCGGGGTACTCACCTACGAGCAGTACTTCGGGCCG	CASSRTSGVLTYEQYF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	1	3	2	1	6	23	35	48	36	54														CASSRTSGVLTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATCCCAGCGGAACCTACGAGCAGTACTTCGGGCCG	CASSYPSGTYEQYF	In	VDJ	1	116	1.6629417726672584E-4	1.9949335566741706E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	6	5	2	4	2	23	37	46	41	48						01,02								CASSYPSGTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACTGAACACGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	117	1.677277477604045E-4		50	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	9	5	23	35	48	44	53														X+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGGGGGGACCGGGACCTCCTCCTACAATGAGCAGTTCTTCGGGCCA	CASGGTGTSSYNEQFF	In	VDJ	1	117	1.677277477604045E-4	2.012131259748948E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	8	9	1	0	0	11	23	-1	38	32	49														CASGGTGTSSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCCCCCTAGCGGGATCCTACGAGCAGTACTTCGGGCCG	CASTPLAGSYEQYF	In	VDJ	1	119	1.7059488874776184E-4	2.0465266658985026E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	4	3	1	5	0	23	33	-1	38	47														CASTPLAGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGTTACTGGTTTCAATGAGCAGTTCTTCGGGCCA	CAISVTGFNEQFF	In	VDJ	1	119	1.7059488874776184E-4	2.0465266658985026E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	3	10	6	3	5	23	35	41	38	46						01,02								CAISVTGFNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAAAAATCCTGGACTAGCGGGAGGGCCAAAGAGACCCAGTACTTCGGGCCA	CASKKSWTSGRAKETQYF	In	VDJ	1	120	1.7202845924144052E-4	2.06372436897328E-4	54	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	7	1	0	3	9	3	23	33	57	42	60														CASKKSWTSGRAKETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGAACGCGGGAGCAATGAGCAGTTCTTCGGGCCA	CASSEERGSNEQFF	In	VDJ	1	121	1.734620297351192E-4	2.0809220720480572E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	7	2	6	7	0	23	35	-1	42	49														CASSEERGSNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCCCCCCTCGCGGGTACAATGAGCAGTTCTTCGGGCCA	CASSFPPRGYNEQFF	In	VDJ	1	121	1.734620297351192E-4	2.0809220720480572E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	7	4	4	9	0	23	36	-1	45	50						01,02								CASSFPPRGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGGGGGGACTACAATGAGCAGTTCTTCGGGCCA	CAIRGDYNEQFF	In	VDJ	1	122	1.7489560022879784E-4	2.0981197751228345E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	6	6	1	3	0	1	23	-1	39	34	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CAIRGDYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCCAGCAGAGTCTCACTGAAGCTTTCTTTGGACAA	CAIQQSLTEAFF	In	VDJ	1	122	1.7489560022879784E-4	2.0981197751228345E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	10	4	5	4	2	8	23	30	35	32	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CAIQQSLTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGGACGCAGGAAAACTATGGCTACACCTTCGGTTCG	CARTQENYGYTF	In	VDJ	1	123	1.7632917072247652E-4	2.1153174781976118E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	9	4	4	2	4	2	23	31	39	35	41														CARTQENYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGCGGGTATACAATGAGCAGTTCTTCGGGCCA	CASSYSRVYNEQFF	In	VDJ	1	124	1.777627412161552E-4	2.1325151812723892E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	7	4	4	0	2	23	-1	45	40	47						01,02								CASSYSRVYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGCCGAAACAGCGGGATGAACACTGAAGCTTTCTTTGGACAA	CAISRNSGMNTEAFF	In	VDJ	1	127	1.820634526971912E-4	2.1841082904967214E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	6	3	0	7	0	23	34	-1	41	48														CAISRNSGMNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCATAGCGGGAGTCTACGAGCAGTACTTCGGGCCG	CASTIAGVYEQYF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	5	2	3	3	1	23	33	45	36	46														CASTIAGVYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGATCCGGGACAGGGGTCTCCGGGGAGCTGTTTTTTGGAGAA	CASSRSGTGVSGELFF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	0	2	6	6	3	23	35	51	41	54														CASSRSGTGVSGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCGATGGCGGTTACAATGAGCAGTTCTTCGGGCCA	CASSYSDGGYNEQFF	In	VDJ	1	129	1.8493059368454855E-4	2.218503696646276E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	7	5	4	5	1	23	40	49	45	50						01,02								CASSYSDGGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCCCTCGAGGATAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	130	1.8636416417822723E-4		46	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	11	1	5	5	3	23	40	49	45	52														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCGCGGGCGGGGCCCTGGCACTGAAGCTTTCTTTGGACAA	CASSYRGRGPGTEAFF	In	VDJ	1	131	1.8779773467190588E-4	2.2528991027958307E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	2	7	3	4	5	6	23	38	49	43	55														CASSYRGRGPGTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGCACAGGGCGGGGAGCAGTTCTTCGGGCCA	CASSYAQGGEQFF	In	VDJ	1	132	1.8923130516558455E-4	2.270096805870608E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	3	3	10	2	4	23	38	46	40	50														CASSYAQGGEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAACGAGTTTCCACGGACTAGCGGGAGAGCACGAGCAGTACTTCGGGCCG	CASRTSFHGLAGEHEQYF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	54	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	1	2	5	13	3	23	34	60	47	63														CASRTSFHGLAGEHEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTCCTCCAGGGACACTGAAGCTTTCTTTGGACAA	CASSSSRDTEAFF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	3	3	6	0	23	34	-1	40	45														CASSSSRDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCGCTTCCAGGGACAGGGGACCTATGGCTACACCTTCGGTTCG	CASRRFQGQGTYGYTF	In	VDJ	1	135	1.9353201664662058E-4	2.32168991509494E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	2	4	9	2	23	34	53	43	55														CASRRFQGQGTYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCAGACAGGGACGTCAGCCCCAGCATTTTGGTGAT	CASTRQGRQPQHF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	2	3	6	3	3	23	33	43	36	46														CASTRQGRQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCTTCGACGGTTCCTACGAGCAGTACTTCGGGCCG	CASFDGSYEQYF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	8	2	7	1	3	3	23	32	38	35	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASFDGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCTTCTCAGGGTGGGGAGACAGCGAGCAGTACTTCGGGCCG	CASFSGWGDSEQYF	In	VDJ	1	136	1.9496558714029923E-4	2.3388876181697172E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	8	2	5	6	15	0	23	32	-1	47	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASFSGWGDSEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAACCCTCGGGGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASNPRGSNQPQHF	In	VDJ	1	139	1.9926629862133526E-4	2.3904807273940492E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	7	8	3	0	5	0	23	33	-1	38	43														CASNPRGSNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTCGAAAGGAACCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	139	1.9926629862133526E-4		44	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	0	1	8	0	4	0	23	40	-1	44	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATGGGACTAGCGGGAGATTCCTACAATGAGCAGTTCTTCGGGCCA	CASMGLAGDSYNEQFF	In	VDJ	1	142	2.0356701010237126E-4	2.442073836618381E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	0	2	1	1	2	23	33	48	34	50														CASMGLAGDSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGTGACGGGGCGTCACCCCTCCACTTTGGGAAC	CASSGDGASPLHF	In	VDJ	1	143	2.0500058059604994E-4	2.4592715396931587E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	5	7	0	10	6	1	23	35	46	41	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGDGASPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGTGGGGACAGGGGACTAGAAGTTCCTACGAGCAGTACTTCGGGCCG	CASSYSWGQGTRSSYEQYF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	57	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	2	1	3	9	23	40	53	43	62														CASSYSWGQGTRSSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTAGTACGGGACACTACTACGAGCAGTACTTCGGGCCG	CAISSTGHYYEQYF	In	VDJ	1	146	2.0930129207708594E-4	2.5108646489174904E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	6	3	5	3	23	35	46	40	49														CAISSTGHYYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGCGCGGGGGTCGAACAGATACGCAGTATTTTGGCCCA	CASSYSRGGRTDTQYF	In	VDJ	1	147	2.1073486257076462E-4	2.528062351992268E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	7	2	3	2	4	23	40	49	42	53														CASSYSRGGRTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTTTGGACAGGGCGGCGGACACCGGGGAGCTGTTTTTTGGAGAA	CAISLDRAADTGELFF	In	VDJ	1	147	2.1073486257076462E-4	2.528062351992268E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	1	3	3	1	6	23	36	45	37	51														CAISLDRAADTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACGGACAGGAGGGAGGGCAGCCCCAGCATTTTGGTGAT	CASSDGQEGGQPQHF	In	VDJ	1	149	2.1360200355812197E-4	2.5624577581418226E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	5	1	4	7	3	8	23	35	45	38	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDGQEGGQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTAGTCCCAGGGCGGGGTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	149	2.1360200355812197E-4		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	3	7	3	4	8	0	23	37	-1	45	51														X+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTCGCCCAACTTTGGGGGAAGGCACACCATATATTTTGGAGAG		Out	VDJ	1	151	2.164691445454793E-4		38	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-03	01	14	6	1	8	11	5	23	26	42	37	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGGGGGACAGGGGACAGATACGCAATATTTTGGCCCA	CAISGGQGTDTQYF	In	VDJ	1	152	2.1790271503915797E-4	2.614050867366155E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	2	15	2	12	23	35	47	37	59														CAISGGQGTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCCCGATACCAGGGGCAGGGGGGACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	152	2.1790271503915797E-4		44	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	11	4	1	3	13	1	23	29	49	42	50														X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCCTACGGACGGCGAGGGGAATAATCARCCCCAGCATTTTGGTGAT	CASPTDGEGNNQPQHF	In	VDJ	1	155	2.22203426520194E-4	2.6656439765904865E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	8	5	2	4	13	3	23	32	50	45	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASPTDGEGNNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGATCCAGGGGGGCGGTGGAAACACCATATATTTTGGAGAG	CASRIQGGGGNTIYF	In	VDJ	1	156	2.2363699701387265E-4	2.682841679665264E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	4	1	3	4	4	23	34	45	38	49														CASRIQGGGGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAACACTAGCGGGGGAAGTTCCTACGAGCAGTACTTCGGGCCG	CANTSGGSSYEQYF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	10	3	2	1	2	4	23	30	43	32	47														CANTSGGSSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCAGATGACCGGGGAGCTGTTTTTTGGAGAA	CASRQMTGELFF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	4	5	5	1	3	23	34	38	35	41														CASRQMTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGCGGCCACATGGGAGCTATGGCTACACCTTCGGTTCG	CASSYSRPHGSYGYTF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	9	2	4	10	0	23	40	-1	50	55														CASSYSRPHGSYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTTCGCCGGCCCCAATCAGCCCCAGCATTTTGGTGAT	CASSYFAGPNQPQHF	In	VDJ	1	157	2.2507056750755133E-4	2.700039382740041E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	1	9	0	3	5	2	23	39	47	44	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYFAGPNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGCTAGCGGGAGTAGGCCAGAGACCCAGTACTTCGGGCCA	CASSYSASGSRPETQYF	In	VDJ	1	161	2.30804849482266E-4	2.7688301950391504E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	4	2	4	2	6	23	40	52	42	58														CASSYSASGSRPETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCAACTAGCGGCTCCCTACGAGCAGTACTTCGGGCCG	CASRQLAAPYEQYF	In	VDJ	1	162	2.3223841997594468E-4	2.786027898113928E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	3	5	2	3	3	23	34	45	37	48						01,02								CASRQLAAPYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTTGACAGGGAGGCCCTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSDLTGRPSYNSPLHF	In	VDJ	1	164	2.3510556096330203E-4	2.8204233042634826E-4	54	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	1	2	3	0	1	5	23	39	47	40	52														CASSDLTGRPSYNSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCTCGCGGGTCCTAGCGGGACAAGAGACCCAGTACTTCGGGCCA	CASSRVLAGQETQYF	In	VDJ	1	167	2.3940627244433804E-4	2.8720164134878143E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	8	4	3	2	9	0	23	32	-1	41	50														CASSRVLAGQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCGAGTACGGGACTAGCGGGGGGGCTAGGCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	170	2.4370698392537407E-4		59	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	4	0	0	6	8	5	22	35	59	43	64														X+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGAGGAGGTTTAGTCTACAATGAGCAGTTCTTCGGGCCA	CASSGGGLVYNEQFF	In	VDJ	1	171	2.4514055441905274E-4	2.940807225786924E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	10	1	3	0	9	23	-1	40	35	49														CASSGGGLVYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGGGGGCCCGACCGCTACGAGCAGTACTTCGGGCCG	CASSRGPDRYEQYF	In	VDJ	1	173	2.4800769540641004E-4	2.975202631936479E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	5	6	0	3	1	7	23	35	42	36	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRGPDRYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGTGGCTAGCTCCCACGGCTGGTACAATGAGCAGTTCTTCGGGCCA	CASSYVASSHGWYNEQFF	In	VDJ	1	174	2.494412659000887E-4	2.992400335011256E-4	54	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	4	7	4	4	12	23	38	47	42	59						01,02								CASSYVASSHGWYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCGACGGACAGGGTTACCAAGAGACCCAGTACTTCGGGCCA	CASTDGQGYQETQYF	In	VDJ	1	175	2.508748363937674E-4	3.0095980380860334E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	1	3	0	5	2	23	33	46	38	48														CASTDGQGYQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCTCCCTTTGAGAGAGGCTATGGCTACACCTTCGGTTCG	CASSSPFERGYGYTF	In	VDJ	1	175	2.508748363937674E-4	3.0095980380860334E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	4	11	1	4	12	0	23	36	-1	48	52														CASSSPFERGYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATGGCAAAGAGACCCAGTACTTCGGGCCA	CASSYGKETQYF	In	VDJ	1	176	2.5230840688744607E-4	3.0267957411608104E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	9	0	3	1	1	23	37	41	38	42														CASSYGKETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGACTAGAGCAGATACGCAGTATTTTGGCCCA	CASSYGTRADTQYF	In	VDJ	1	183	2.6234340034319675E-4	3.147179662684252E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	0	8	4	0	2	23	-1	46	38	48						01,02								CASSYGTRADTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCTCCGGCGGGCAGCTAACTATGGCTACACCTTCGGTTCG	CASSSLRRAANYGYTF	In	VDJ	1	184	2.637769708368754E-4	3.164377365759029E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	4	7	4	0	7	3	23	36	48	43	51						01,02								CASSSLRRAANYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGGCTTGGAAGGGACTCTAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	185	2.652105413305541E-4		44	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	0	10	5	9	3	23	32	47	41	50						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGATCTCGGAGGGGGGATGGAAAAACTGTTTTTTGGCAGT	CASSYDLGGGMEKLFF	In	VDJ	1	188	2.6951125281159013E-4	3.233168178058139E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-04	01	2	5	1	8	8	4	23	38	52	46	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYDLGGGMEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCGCCCGCCCGGCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	192	2.7524553478630484E-4		41	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	8	5	3	8	0	23	34	-1	42	45						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCGTAGCGGGGGTGCGTCAGATACGCAGTATTTTGGCCCA	CASRSGGASDTQYF	In	VDJ	1	193	2.7667910527998346E-4	3.319156693432025E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	8	5	2	4	2	5	23	32	43	34	48														CASRSGGASDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGGGGGCAATAGCAATCAGCCCCAGCATTTTGGTGAT	CASGGNSNQPQHF	In	VDJ	1	193	2.7667910527998346E-4	3.319156693432025E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	6	0	0	0	2	23	-1	38	32	40														CASGGNSNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGTTACAATTCACCCCTCCACTTTGGGAAC	CASSYGYNSPLHF	In	VDJ	1	198	2.8384695774837684E-4	3.405145208805912E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	2	0	10	7	0	4	23	-1	40	38	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYGYNSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGATGACTAGCGGGAGTCGTGAGCAGTTCTTCGGGCCA	CASSYSMTSGSREQFF	In	VDJ	1	201	2.8814766922941287E-4	3.4567383180302436E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	2	2	9	3	3	23	40	55	43	58														CASSYSMTSGSREQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGGCGGGGGCGCGAAGRATCAGCCCCAGCATTTTGGTGAT	CAISGGGAKXQPQHF	In	VDJ	1	203	2.9101481021677017E-4	3.491133724179799E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	5	7	2	5	1	8	23	35	43	36	51														CAISGGGAKXQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTCGAAAAGGGGGCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	206	2.953155216978062E-4		43	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	5	1	4	4	0	23	40	-1	44	50														X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGGCTATGGGCCTATGGCTACACCTTCGGTTCG	CASRGLWAYGYTF	In	VDJ	1	208	2.9818266268516355E-4	3.577122239553685E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	7	0	4	0	7	23	-1	39	34	46														CASRGLWAYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATCGGGGGCGCGGGACTCCAGCTTCCTAGGGAGCAGTTCTTCGGGCCA	CASIGGAGLQLPREQFF	In	VDJ	1	215	3.0821765614091423E-4	3.6975061610771266E-4	51	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-01	01	7	6	0	10	2	21	23	33	41	35	62				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASIGGAGLQLPREQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTCTACAGGGGTTCAGCCCCAGCATTTTGGTGAT	CASSSTGVQPQHF	In	VDJ	1	216	3.096512266345929E-4	3.7147038641519037E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	2	6	4	1	23	34	45	38	46														CASSSTGVQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGCTTGACAGGGGGCGCGAGCGAGCAGTACTTCGGGCCG	CASRGLTGGASEQYF	In	VDJ	1	219	3.1395193811562894E-4	3.766296973376236E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	0	6	6	5	23	34	50	40	55														CASRGLTGGASEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGACTCGGGGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSYSTRGSYNEQFF	In	VDJ	1	219	3.1395193811562894E-4	3.766296973376236E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	8	2	1	4	0	23	40	-1	44	50														CASSYSTRGSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCAGACGGATTGGACTGAAGCTTTCTTTGGACAA	CASSSQTDWTEAFF	In	VDJ	1	222	3.1825264959666497E-4	3.817890082600568E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	4	1	8	5	7	4	23	36	46	43	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSQTDWTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTTCCCGGGCTAGCGGAGAAATTTTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	226	3.239869315713796E-4		56	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	4	5	4	7	8	23	39	53	46	61						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACAGCCCGGGGGGCCTACGAGCAGTACTTCGGGCCG	CASSTARGAYEQYF	In	VDJ	2	227	3.254205020650583E-4	3.9038785979744544E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	8	1	2	6	0	23	35	-1	41	48														CASSTARGAYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGAGTTAGCGGGAGTACCCCTTTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	228	3.2685407255873697E-4		56	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	5	2	0	5	9	23	35	49	40	58														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCACTCAATAATTGGGGGCGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	2	229	3.2828764305241565E-4		53	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	6	0	1	14	2	23	34	54	48	56														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGAAGGAGACTAGCGGGGGATCCCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	233	3.340219250271303E-4		55	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	2	2	0	6	4	23	34	52	40	56														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGACAGGGGACGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSGQGTGTGELFF	In	VDJ	2	233	3.340219250271303E-4	4.0070648164231183E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	1	2	4	0	5	23	-1	44	35	49														CASSGQGTGTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGGAGTACTAGCGGAAATCCCGGGGGCTACACAGATACGCAGTATTTTGGCCCA	CASSGSTSGNPGGYTDTQYF	In	VDJ	2	234	3.35455495520809E-4	4.024262519497896E-4	60	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	3	5	2	6	15	21	33	47	39	62						01,02								CASSGSTSGNPGGYTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTTCATGACTAGCGGGGATCGCGCGCAGTATTTTGGCCCA	CASSYFMTSGDRAQYF	In	VDJ	2	238	3.411897774955237E-4	4.093053331797005E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	2	3	10	4	6	23	39	54	43	60														CASSYFMTSGDRAQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGTCACCACTCAGGGTTGGAAAACTGTTTTTTGGCAGT	CASRSPLRVGKLFF	In	VDJ	2	241	3.454904889765597E-4	4.1446464410213374E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	4	3	10	9	4	23	34	48	43	52														CASRSPLRVGKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGAGGCAGCTCAGCCAAAAACATTCAGTACTTCGGCGCC	CASSYGGSSAKNIQYF	In	VDJ	2	241	3.454904889765597E-4	4.1446464410213374E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	2	10	1	0	0	6	23	-1	43	38	49														CASSYGGSSAKNIQYF+TCRBV06-08+TCRBJ02-04	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTTTGGGACAGGGGACTATGGCTACACCTTCGGTTCG	CASSYFGTGDYGYTF	In	VDJ	2	251	3.598261939133464E-4	4.3166234717691105E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	2	3	2	0	23	39	-1	41	51														CASSYFGTGDYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCCCGGGACGGAGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	252	3.6125976440702504E-4		49	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	2	0	7	1	4	3	23	38	47	42	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCTGGACAGGGGAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	258	3.698611873690971E-4		40	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	1	2	5	3	0	23	33	-1	36	45														X+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGAGAACAGGGTAATCAGCCCCAGCATTTTGGTGAT	CAIREQGNQPQHF	In	VDJ	2	259	3.712947578627758E-4	4.454205096367329E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	3	4	3	1	23	34	43	37	44														CAIREQGNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTTACGGCGGCTCCTACGAGCAGTACTTCGGGCCG	CAISYGGSYEQYF	In	VDJ	2	260	3.7272832835645445E-4	4.4714027994421067E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	7	5	0	1	0	23	38	-1	39	43						01,02								CAISYGGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCAGGGGGCAGGGGCTACACCTTCGGTTCG	CASSSGGRGYTF	In	VDJ	2	261	3.7416189885013313E-4	4.4886005025168837E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	0	8	0	3	23	-1	44	36	47														CASSSGGRGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGGAAGGGGAAACATTCAGTACTTCGGCGCC	CASSEGRGNIQYF	In	VDJ	2	263	3.7702903983749043E-4	4.5229959086664383E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-04	01	5	5	2	6	6	0	23	35	-1	41	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEGRGNIQYF+TCRBV06-08+TCRBJ02-04	TCRBV06-08*01		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCGCACCGGGACAGGTTCCTACGAGCAGTACTTCGGGCCG	CASRRTGTGSYEQYF	In	VDJ	2	264	3.784626103311691E-4	4.540193611741216E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	4	1	7	1	23	34	49	41	50														CASRRTGTGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCCCGGACAGGCCTACGCAGTATTTTGGCCCA	CASSPPDRPTQYF	In	VDJ	2	271	3.8849760378691984E-4	4.6605775332646574E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	4	8	5	2	23	35	47	40	49														CASSPPDRPTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGACAGCCTAACTGGAAACACCATATATTTTGGAGAG	CASRDSLTGNTIYF	In	VDJ	2	275	3.942318857616345E-4	4.7293683455637667E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	1	5	2	0	5	23	-1	40	34	45														CASRDSLTGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGAGAACGAAACTACGAGCAGTACTTCGGGCCG	CASSYGERNYEQYF	In	VDJ	2	278	3.985325972426705E-4	4.7809614547880984E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	2	10	2	3	0	7	23	-1	42	38	49														CASSYGERNYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCGAGACAGGGGCGGGATACAATGAGCAGTTCTTCGGGCCA	CASSETGAGYNEQFF	In	VDJ	2	284	4.071340202047425E-4	4.884147673236762E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	2	2	4	3	5	23	34	45	37	50														CASSETGAGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTACCAGCAGGGTGGACAGGGGCTACGAGCAGTACTTCGGGCCG	CTSRVDRGYEQYF	In	VDJ	2	286	4.100011611920999E-4	4.918543079386317E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	2	3	3	0	23	34	-1	37	46														CTSRVDRGYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCCTACCGCGGTCAGCCCCAGCATTTTGGTGAT	CASSAYRGQPQHF	In	VDJ	2	287	4.1143473168577855E-4	4.935740782461094E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	5	7	5	6	7	0	23	35	-1	42	46						01,02								CASSAYRGQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATCCCGGCCGGGGGGGTCGCCTACGAGCAGTACTTCGGGCCG	CASIPAGGVAYEQYF	In	VDJ	2	287	4.1143473168577855E-4	4.935740782461094E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	7	8	0	2	7	3	23	33	48	40	51														CASIPAGGVAYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGACTCCCACGGCGGGGCAACCGGGGAGCTGTTTTTTGGAGAA	CASDSHGGATGELFF	In	VDJ	2	299	4.286375776099226E-4	5.142113219358422E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	8	7	3	5	10	2	23	32	48	42	50														CASDSHGGATGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAACCCAATGAAGACTAGCGCCTACACCGGGGAGCTGTTTTTTGGAGAA	CASNPMKTSAYTGELFF	In	VDJ	2	306	4.386725710656733E-4	5.262497140881864E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	2	6	3	10	3	23	33	51	43	54						01,02								CASNPMKTSAYTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGACGGACTAGCGGGGAGGTATTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	312	4.472739940277453E-4		53	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	1	3	3	3	7	23	38	53	41	60														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCCAGACAGGGGGCTCCAAGAGACCCAGTACTTCGGGCCA	CASRPDRGLQETQYF	In	VDJ	2	318	4.5587541698981736E-4	5.468869577779192E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	2	0	1	4	1	23	34	48	38	49														CASRPDRGLQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAATGTGCTCGCGGGATTCACAGATACGCAGTATTTTGGCCCA	CASSYNVLAGFTDTQYF	In	VDJ	2	356	5.103510957496068E-4	6.12238229462073E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	7	3	2	9	2	23	38	53	47	55														CASSYNVLAGFTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCAGCGGGAGCCCTGCGGGAGCAGTACTTCGGGCCG	CASSPAGALREQYF	In	VDJ	3	382	5.476239285852523E-4	6.569522574564941E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	6	2	7	2	8	23	35	45	37	53														CASSPAGALREQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCGTTCACTAGCGGGTCCTACGAGCAGTACTTCGGGCCG	CASSSFTSGSYEQYF	In	VDJ	3	382	5.476239285852523E-4	6.569522574564941E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	3	4	1	5	0	23	36	-1	41	50						01,02								CASSSFTSGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTATACCGGAGGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	385	5.519246400662884E-4		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	10	0	0	5	2	23	35	46	40	48														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACCGGACTCCCTACGGGGGCGAGCAGTACTTCGGGCCG	CASSDRTPYGGEQYF	In	VDJ	3	411	5.891974729019337E-4	7.068255963733484E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	8	2	6	14	0	23	35	-1	49	55														CASSDRTPYGGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGAAAGAGACCCAGTACTTCGGGCCA	CASSYGKETQYF	In	VDJ	3	413	5.920646138892911E-4	7.102651369883038E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	2	0	8	3	0	0	23	-1	-1	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYGKETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCGGGGACAGTCTGAAAAACTGTTTTTTGGCAGT	CASSYRGQSEKLFF	In	VDJ	3	418	5.992324663576845E-4	7.188639885256925E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	0	5	7	2	2	23	38	47	40	49														CASSYRGQSEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCTGAACAGACCACCTTCCTACGAGCAGTACTTCGGGCCG	CASLNRPPSYEQYF	In	VDJ	3	441	6.322045877122939E-4	7.584187055976804E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	5	1	4	7	23	32	40	36	47														CASLNRPPSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCGGTTACACAGGGGGGTGAAACTACGAGCAGTACTTCGGGCCG		Out	VDJ	3	459	6.5800885659851E-4		46	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	1	3	7	6	23	32	47	39	53														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGATCGACAGGGTTGGATACGCAGTATTTTGGCCCA	CASSYGSTGLDTQYF	In	VDJ	3	472	6.766452730163327E-4	8.117315851294901E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	2	3	6	5	3	23	38	50	43	53														CASSYGSTGLDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTACGGGCTCTATGGTACTGAAGCTTTCTTTGGACAA	CASSYYGLYGTEAFF	In	VDJ	3	527	7.554916501686595E-4	9.063189520407655E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	1	8	0	5	2	8	23	39	45	41	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYYGLYGTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCCTCTATCAGCCCCAGCATTTTGGTGAT	CASSYSLYQPQHF	In	VDJ	4	555	7.956316239916624E-4	9.54472520650142E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	0	4	10	5	1	2	23	40	43	41	45						01,02								CASSYSLYQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACTCGAAACGCGGGAGTTTACCACAATGAGCAGTTCTTCGGGCCA	CASTRNAGVYHNEQFF	In	VDJ	4	556	7.97065194485341E-4	9.561922909576197E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	7	2	5	8	6	23	33	48	41	54														CASTRNAGVYHNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCCGCAACCGGGGGGAGAGACCAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	4	560	8.027994764600557E-4		44	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	7	8	1	3	2	8	23	33	42	35	50														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAACGGCAGAATGAAGCTTTCTTTGGACAA	CASSQRQNEAFF	In	VDJ	4	562	8.056666174474131E-4	9.665109128024861E-4	36	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	5	4	5	7	6	2	23	35	44	41	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQRQNEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGCCCAAACTTATAAGAACACTGAAGCTTTCTTTGGACAA	CASAQTYKNTEAFF	In	VDJ	4	568	8.14268040409485E-4	9.768295346473525E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	8	3	10	1	6	5	23	32	41	38	46						01,02								CASAQTYKNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAAGTGATAGCGGGGCGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	590	8.458065912704158E-4		44	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	5	3	4	6	2	23	33	47	39	49														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTTCAAGGGGGTTCGGATGGCTACACCTTCGGTTCG	CASSFQGGSDGYTF	In	VDJ	4	599	8.587087257135239E-4	0.0010301424141791623	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	5	1	6	4	5	23	36	46	40	51														CASSFQGGSDGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTCGGGACTAGCGCACAATGAGCAGTTCTTCGGGCCA	CASSDSGLAHNEQFF	In	VDJ	5	711	0.001019268621005535	0.0012227566886166684	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	0	6	5	0	1	23	-1	50	40	51						01,02								CASSDSGLAHNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCAAATTAGCAGGGGAGGCTCACCCCTCCACTTTGGGAAC	CASQISRGGSPLHF	In	VDJ	5	738	0.001057975024334859	0.0012691904869185672	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	8	4	2	10	8	4	23	32	46	40	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASQISRGGSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCTAACCGGCTTCCGGAGGGGCGAGAGGCAGCCCCAGCATTTTGGTGAT	CASLTGFRRGERQPQHF	In	VDJ	6	911	0.0013059827197412692	0.001566710750112215	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	8	10	0	7	13	8	23	32	51	45	59														CASLTGFRRGERQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTCTGGGTTCACCCCTCCACTTTGGGAAC	CASSYSLGSPLHF	In	VDJ	6	959	0.0013747941034378455	0.001649259724871146	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	0	0	9	9	3	0	23	40	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSLGSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGAAGGGACGGCGAACACTGAAGCTTTCTTTGGACAA	CASSYSEGTANTEAFF	In	VDJ	7	1037	0.0014866126019447818	0.0017834018088544094	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	0	0	7	1	4	3	23	40	49	44	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSEGTANTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACATCGAGGCTAGCGGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	7	1108	0.0015883961069959674		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	4	5	4	7	0	23	38	-1	45	52						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTAACCAGCCGGGACAGGGGACGCGCAGATACGCAGTATTTTGGCCCA	CASSLTSRDRGRADTQYF	In	VDJ	7	1123	0.0016098996644011475	0.0019313020552974944	54	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	0	2	4	9	5	23	36	55	45	60														CASSLTSRDRGRADTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCCGATTTACCACTGAAGCTTTCTTTGGACAA	CASSYSRFTTEAFF	In	VDJ	8	1262	0.0018091659630224827	0.0021703501280368994	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	0	2	8	4	2	5	23	40	44	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSRFTTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTCATGGACGAGACTACGAGCAGTACTTCGGGCCG	CASSYSHGRDYEQYF	In	VDJ	9	1290	0.0018493059368454854	0.002218503696646276	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	0	1	7	3	4	4	23	40	48	44	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSHGRDYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGTTATGGGACTAGCGGAGCCCGGGGACTAGGCGAGCAGTACTTCGGGCCG	CASYGTSGARGLGEQYF	In	VDJ	9	1391	0.001994096556707031	0.002392200497701527	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	9	0	5	6	4	15	23	31	46	35	61						01,02								CASYGTSGARGLGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCAGGGGGGATTGGCGAGCAGTACTTCGGGCCG	CASSSGGIGEQYF	In	VDJ	9	1410	0.002021334396086926	0.002424876133543604	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	1	6	0	6	23	-1	43	36	49														CASSSGGIGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTGACTTCGCCGGGGAGCAGTACTTCGGGCCG	CASSYSDFAGEQYF	In	VDJ	11	1605	0.002300880642354267	0.002760231343501762	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	2	10	7	1	8	23	40	45	41	53						01,02								CASSYSDFAGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGTTCAGACACTGAAGCTTTCTTTGGACAA	CASSYGSDTEAFF	In	VDJ	11	1697	0.0024327691277727047	0.0029184502117897133	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	5	3	4	0	23	38	-1	42	45														CASSYGSDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCCGGACAGGGGATGACCGGGGAGCTGTTTTTTGGAGAA	CASSYPGQGMTGELFF	In	VDJ	11	1700	0.0024370698392537403	0.0029236095227121468	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	1	2	5	3	3	23	38	50	41	53														CASSYPGQGMTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCCCGTACAACACAGATACGCAGTATTTTGGCCCA	CASSPPYNTDTQYF	In	VDJ	18	2779	0.003983892401933026	0.004779241684480621	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	6	2	7	1	23	35	45	42	46														CASSPPYNTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAACCCGCTAGCGGGGCGTTAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	26	3946	0.005656869168056035		43	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	10	4	3	3	5	5	23	30	44	35	49														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACGGGACAGACCTACGAGCAGTACTTCGGGCCG	CASTGQTYEQYF	In	VDJ	35	5292	0.007586455052547527	0.009101024467172165	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	5	2	1	1	23	33	41	34	42														CASTGQTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAAGGCGGGAGTCCCGATTCGAGCAGTACTTCGGGCCG	CASRRRESRFEQYF	In	VDJ	43	6506	0.009326809631873432	0.011188825620450133	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	7	2	6	3	8	23	34	44	37	52														CASRRRESRFEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCCTCCGGGGGCGACACTGAAGCTTTCTTTGGACAA	CASSASGGDTEAFF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	5	6	0	3	6	1	24	36	48	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSASGGDTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATTCCGGGACAGGGGCTATGGCTACACCTTCGGTTCG	CASSFRDRGYGYTF	In	VDJ	1	42	6.020996073450418E-5	7.22303529140648E-5	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	2	4	4	0	24	36	-1	40	50													Vb 18	CASSFRDRGYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGGCCTTCGGGACAGGGAGTACTTCGGCGCC	CASSPGLRDREYF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	2	0	3	14	7	0	24	39	-1	46	55													Vb 18	CASSPGLRDREYF+TCRBV18-01+TCRBJ02-04	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATCGGGAAGCTCTGGAAACACCATATATTTTGGAGAG	CASSPSGSSGNTIYF	In	VDJ	1	47	6.737781320289753E-5	8.082920445145347E-5	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	2	8	3	0	1	2	24	39	45	40	47													Vb 18	CASSPSGSSGNTIYF+TCRBV18-01+TCRBJ01-03	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCGGGACTAGCGGGAGGTGCCTACGAGCAGTACTTCGGGCCG	CASSAGLAGGAYEQYF	In	VDJ	1	49	7.024495419025487E-5	8.426874506640893E-5	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	0	1	2	2	2	24	36	53	38	55													Vb 18	CASSAGLAGGAYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGAGGGGACAGGGAGGCAATCAGCCCCAGCATTTTGGTGAT	CASSPRGQGGNQPQHF	In	VDJ	1	51	7.311209517761221E-5	8.77082856813644E-5	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	0	3	2	3	2	24	38	50	41	52													Vb 18	CASSPRGQGGNQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGACCGGTCTACGAGCAGTACTTCGGGCCG	CASSPGPVYEQYF	In	VDJ	1	53	7.597923616496956E-5	9.114782629631986E-5	39	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-07	01	3	0	7	3	0	4	24	-1	43	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPGPVYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01		TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGCGGCAGCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	58	8.314708863336292E-5		37	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	2	7	5	7	0	3	24	-1	43	39	46						01,02							Vb 18	X+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCCCAGGGGTTACGCTACACCTTCGGTTCG	CASSPPQGLRYTF	In	VDJ	1	59	8.458065912704158E-5	1.0146644814118626E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	2	9	1	4	24	41	48	42	52													Vb 18	CASSPPQGLRYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAAAGAAACAGGGGGCGAAAGATACGAGCAGTACTTCGGGCCG		Out	VDJ	1	60	8.601422962072026E-5		50	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	3	0	4	5	6	24	39	53	44	59													Vb 18	X+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAAGCAGGGTCCAAGAGACCCAGTACTTCGGGCCA	CASSSRVQETQYF	In	VDJ	1	63	9.031494110175626E-5	1.0834552937109719E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	4	3	1	2	1	24	36	43	38	44													Vb 18	CASSSRVQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACGCGGGTCTAGCACAGATACGCAGTATTTTGGCCCA	CASSPRGSSTDTQYF	In	VDJ	1	67	9.604922307647095E-5	1.1522461060100813E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	7	4	0	0	3	24	-1	45	40	48						01,02							Vb 18	CASSPRGSSTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACAGGGGGCACGGAATGAAAAACTGTTTTTTGGCAGT	CASSPQGARNEKLFF	In	VDJ	1	70	1.0034993455750697E-4	1.2038392152344133E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	5	0	5	0	4	24	-1	47	40	51													Vb 18	CASSPQGARNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCGATTCGAGTCCTGAAGCTTTCTTTGGACAA	CASSPDSSPEAFF	In	VDJ	1	73	1.0465064603854297E-4	1.2554323244587452E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	11	2	6	6	2	24	38	47	44	49													Vb 18	CASSPDSSPEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACAAGCGGCAGCCCAAGAGACCCAGTACTTCGGGCCA	CASSPQAAAQETQYF	In	VDJ	1	75	1.0751778702590032E-4	1.2898277306082998E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	6	5	1	1	4	24	40	46	41	50						01,02							Vb 18	CASSPQAAAQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGGCGGGGATCAGGGGGATCAGCCCCAGCATTTTGGTGAT	CASSPGGDQGDQPQHF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	4	1	5	9	0	24	39	-1	48	55													Vb 18	CASSPGGDQGDQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGTGGGACAGGGGGCTAATTGATGAAAAACTGTTTTTTGGCAGT	CASSPWDRGLIDEKLFF	In	VDJ	1	76	1.0895135751957899E-4	1.3070254336830774E-4	51	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	0	0	6	2	6	24	38	52	40	58													Vb 18	CASSPWDRGLIDEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTATCCTCCTCACAGGGGATCATGAACACTGAAGCTTTCTTTGGACAA	CASSLSSSQGIMNTEAFF	In	VDJ	1	78	1.1181849850693633E-4	1.341420839832632E-4	54	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	2	0	10	4	24	37	54	47	58													Vb 18	CASSLSSSQGIMNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCGGGACAGCCCCTTCAACCTACGAGCAGTACTTCGGGCCG	CASSPGTAPSTYEQYF	In	VDJ	1	81	1.1611920998797234E-4	1.393013949056964E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	5	2	1	9	24	38	46	39	55													Vb 18	CASSPGTAPSTYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCAGAGTCCGGGCCGGGGAGCTGTTTTTTGGAGAA	CASRVRAGELFF	In	VDJ	1	94	1.3475562640579507E-4	1.6165840890290694E-4	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	8	8	4	6	6	0	24	33	-1	39	43						01,02							Vb 18	CASRVRAGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAACCGGCGGGGACGATTCGGAAAAACTGTTTTTTGGCAGT	CASSPTGGDDSEKLFF	In	VDJ	1	96	1.3762276739315242E-4	1.650979495178624E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	2	7	3	8	4	8	24	39	49	43	57													Vb 18	CASSPTGGDDSEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD02-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTGGAGCGGGGCTGAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	98	1.4048990838050974E-4		47	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	6	3	0	3	3	24	37	47	40	50													Vb 18	X+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGAGGGACACCCGAGCGAGAGACCCAGTACTTCGGGCCA	CASSRGTPERETQYF	In	VDJ	1	102	1.4622419035522442E-4	1.754165713627288E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	0	6	4	2	8	24	37	45	39	53													Vb 18	CASSRGTPERETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGTGAGGACCGCCTATAATTCACCCCTCCACTTTGGGAAC	CASSPVRTAYNSPLHF	In	VDJ	1	103	1.476577608489031E-4	1.7713634167020652E-4	48	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-06	01	2	1	7	2	4	2	24	39	47	43	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPVRTAYNSPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACGCCAGGGGGGAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	107	1.5339204282361778E-4		44	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	4	1	5	2	1	24	40	49	42	50													Vb 18	X+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGATCATAAACACTGAAGCTTTCTTTGGACAA	CASSPPIINTEAFF	In	VDJ	1	108	1.5482561331729645E-4	1.8573519320759518E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	0	2	8	2	0	5	24	-1	43	41	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPIINTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGGACAGGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSRTGSNQPQHF	In	VDJ	1	108	1.5482561331729645E-4	1.8573519320759518E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	1	3	1	0	0	24	-1	-1	37	45													Vb 18	CASSRTGSNQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGAGGGGTAGATGAGCAGTTCTTCGGGCCA	CASSRGVDEQFF	In	VDJ	1	114	1.6342703627936849E-4	1.960538150524616E-4	36	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-01	01	4	5	2	8	1	3	24	37	43	38	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSRGVDEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTGCCCGGGACGTAGTTATAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	119	1.7059488874776184E-4		52	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-05	01	4	0	7	0	5	7	24	37	47	42	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01		TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGTCGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSPPSGTGELFF	In	VDJ	1	153	2.1933628553283665E-4	2.631248570440932E-4	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	8	4	4	2	0	24	41	-1	43	47						01,02							Vb 18	CASSPPSGTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD02-01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTCTGGGCAGGGAAGCTAACTATGGCTACACCTTCGGTTCG	CASSPLGREANYGYTF	In	VDJ	1	156	2.2363699701387265E-4	2.682841679665264E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	3	0	6	3	24	38	49	44	52													Vb 18	CASSPLGREANYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTGACACGGGAGAACCTACGAGCAGTACTTCGGGCCG	CAS*HGRTYEQYF	Stop	VDJ	1	158	2.2650413800123E-4		39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	8	2	2	4	2	24	34	44	38	46													Vb 18	CAS*HGRTYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTATTTCTGTGCCAGCTCACCACCGTGGGGGAATTGATGGGAAACGGGAGAGGGGACGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	173	2.4800769540641004E-4		65	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	8	2	8	20	8	7	24	50	44	58													Vb 18	X+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCAGTACTGTACAACAATGAGCAGTTCTTCGGGCCA	CASSPPVLYNNEQFF	In	VDJ	1	176	2.5230840688744607E-4	3.0267957411608104E-4	45	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-01	01	0	3	6	5	8	0	24	41	-1	49	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPVLYNNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01		TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGAAGTACTGAGACCCAGTACTTCGGGCCA	CASSPGSTETQYF	In	VDJ	1	176	2.5230840688744607E-4	3.0267957411608104E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-05	01	3	0	8	5	0	6	24	-1	42	38	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPGSTETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01		TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTCCGACGGAATCTTATGGCTACACCTTCGGTTCG	CASSPPTESYGYTF	In	VDJ	1	189	2.709448233052688E-4	3.250365881132916E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-02	01	3	1	8	5	6	4	24	38	47	44	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPTESYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01		TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
GGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGACTCGCAGGAGGGGAGAAGCGGGAGATCTTGGGACCCAGTACTTCGGGCCA	CASSPTRRRGEAGDLGTQYF	In	VDJ	1	190	2.723783937989475E-4	3.2675635842076934E-4	60	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	6	2	7	18	7	21	35	61	53	68													Vb 18	CASSPTRRRGEAGDLGTQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGGGATTTTAGCCAAAAACATTCAGTACTTCGGCGCC	CASSPGILAKNIQYF	In	VDJ	1	195	2.795462462673408E-4	3.35355209958158E-4	45	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-04	01	2	0	8	0	0	4	24	-1	43	39	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPGILAKNIQYF+TCRBV18-01+TCRBJ02-04	TCRBV18-01*01		TCRBJ02-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCGGTCCCGATGGCTACACCTTCGGTTCG	CASSPGPDGYTF	In	VDJ	1	220	3.153855086093076E-4	3.7834946764510135E-4	36	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	8	5	6	0	5	24	-1	41	38	46						01,02							Vb 18	CASSPGPDGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGCCGGGCCTCTCTGGAAACACCATATATTTTGGAGAG	CASSPPGLSGNTIYF	In	VDJ	1	220	3.153855086093076E-4	3.7834946764510135E-4	45	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-03	01	3	8	0	0	3	2	24	38	45	41	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPGLSGNTIYF+TCRBV18-01+TCRBJ01-03	TCRBV18-01*01		TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGGGACAGGAACACTGAAGCTTTCTTTGGACAA	CASSRDRNTEAFF	In	VDJ	1	220	3.153855086093076E-4	3.7834946764510135E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	5	1	0	0	24	-1	-1	37	44													Vb 18	CASSRDRNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGAGCGCGGAACACTGAAGCTTTCTTTGGACAA	CASSPGARNTEAFF	In	VDJ	2	232	3.325883545334517E-4	3.989867113348341E-4	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	9	2	1	0	4	24	-1	43	38	47													Vb 18	CASSPGARNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCCGGGACACTGTATGGCTACACCTTCGGTTCG	CASSAGTLYGYTF	In	VDJ	2	232	3.325883545334517E-4	3.989867113348341E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	6	5	3	3	24	36	45	39	48													Vb 18	CASSAGTLYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCCGGGACAGGGGGTGGCTACACCTTCGGTTCG	CASSAGTGGGYTF	In	VDJ	2	234	3.35455495520809E-4	4.024262519497896E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	1	7	3	0	24	36	-1	39	50													Vb 18	CASSAGTGGGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGTACACGGGGGGAACGGCAGCCCCAGCATTTTGGTGAT	CASTRGERQPQHF	In	VDJ	2	237	3.39756207001845E-4	4.075855628722228E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	9	8	1	7	4	5	24	32	43	36	48													Vb 18	CASTRGERQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD02-01*01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCTCCGACAGGGTCGGGTATGGCTACACCTTCGGTTCG	CASSPSDRVGYGYTF	In	VDJ	2	250	3.5839262341966774E-4	4.299425768694333E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	3	5	4	5	24	38	49	42	54													Vb 18	CASSPSDRVGYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTTGGATAGGTTAATTCACCCCTCCACTTTGGGAAC	CASSLG*VNSPLHF	Stop	VDJ	2	252	3.6125976440702504E-4		42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-06	01	4	1	8	6	2	5	24	37	42	39	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSLG*VNSPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01		TCRBJ01-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTTGGGGAGGGAATGAGCAGTTCTTCGGGCCA	CASSPWGGNEQFF	In	VDJ	2	278	3.985325972426705E-4	4.7809614547880984E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	9	0	7	3	0	24	38	-1	41	48													Vb 18	CASSPWGGNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCGGGCTTAACACTGAAGCTTTCTTTGGACAA	CASSPGLNTEAFF	In	VDJ	2	288	4.1286830217945723E-4	4.952938485535872E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	3	8	0	2	1	2	24	38	43	39	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPGLNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCCCGGGACAGGGGAGGTACGAGCAGTACTTCGGGCCG	CASSPPGQGRYEQYF	In	VDJ	2	292	4.186025841541719E-4	5.021729297834981E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	2	4	3	3	24	38	51	41	54													Vb 18	CASSPPGQGRYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGGTGGGGCGAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPPVGRNTGELFF	In	VDJ	2	301	4.3150471859727997E-4	5.176508625507977E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	7	0	2	3	2	24	41	49	44	51													Vb 18	CASSPPVGRNTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTTCTGACGGGGAAGTGATCTATGGCTACACCTTCGGTTCG	CASSPSDGEVIYGYTF	In	VDJ	2	306	4.386725710656733E-4	5.262497140881864E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	3	8	3	4	6	7	24	38	49	44	56													Vb 18	CASSPSDGEVIYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD02-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCTCCCGGGACAGGGGTACCCACAGATACGCAGTATTTTGGCCCA	CASSPGTGVPTDTQYF	In	VDJ	2	318	4.5587541698981736E-4	5.468869577779192E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	0	2	2	4	4	24	35	49	39	53													Vb 18	CASSPGTGVPTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAAGGCTAGCGGGAGACGAGGAGACCCAGTACTTCGGGCCA	CASSPRLAGDEETQYF	In	VDJ	2	327	4.687775514329254E-4	5.623648905452188E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	4	2	5	3	5	24	39	52	42	57													Vb 18	CASSPRLAGDEETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATCGACCGGGACAGGGAGATTTACTAATGAAAAACTGTTTTTTGGCAGT	CASSPSTGTGRFTNEKLFF	In	VDJ	2	334	4.7881254488867607E-4	5.744032826975629E-4	57	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	0	3	2	6	6	24	39	54	45	60													Vb 18	CASSPSTGTGRFTNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCTCAGATACCGGGACAGGGCGAATCGGGAAACACCATATATTTTGGAGAG	CASSQIPGQGESGNTIYF	In	VDJ	2	346	4.960153908128201E-4	5.950405263872958E-4	54	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	0	3	4	9	7	24	35	53	44	60													Vb 18	CASSQIPGQGESGNTIYF+TCRBV18-01+TCRBJ01-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTAGATCCTTGGAGGGGAACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	363	5.203860892053576E-4		46	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	10	0	5	9	2	24	38	53	47	55													Vb 18	X+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCGGACAGGGGCTCCTACGAGCAGTACTTCGGGCCG	CASSADRGSYEQYF	In	VDJ	2	364	5.218196596990363E-4	6.259963919218949E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	2	0	2	0	24	36	-1	38	47													Vb 18	CASSADRGSYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCGGGCAGGGTGTGAACACTGAAGCTTTCTTTGGACAA	CASSPGQGVNTEAFF	In	VDJ	3	435	6.236031647502218E-4	7.48100083752814E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	3	0	4	2	24	38	47	42	49													Vb 18	CASSPGQGVNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATCCAGGTCTAACTATGGCTACACCTTCGGTTCG	CASSPSRSNYGYTF	In	VDJ	3	437	6.264703057375792E-4	7.515396243677695E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	4	0	2	1	24	39	45	41	46													Vb 18	CASSPSRSNYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCGCGCCTGGGGACTCGGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSAPGDSATNEKLFF	In	VDJ	3	441	6.322045877122939E-4	7.584187055976804E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	6	0	10	0	8	3	24	35	49	43	52						01,02							Vb 18	CASSAPGDSATNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD02-01	TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCTGCCGTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPPAVSGANVLTF	In	VDJ	3	448	6.422395811680445E-4	7.704570977500245E-4	48	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-06	01	0	10	0	0	1	3	24	41	44	42	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPAVSGANVLTF+TCRBV18-01+TCRBJ02-06	TCRBV18-01*01		TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTTGGGCCTCACTAGCGGGGAATCGGGTGAGCAGTTCTTCGGGCCA	CASLGLTSGESGEQFF	In	VDJ	3	477	6.83813125484726E-4	8.203304366668787E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	3	3	9	8	7	24	34	52	42	59													Vb 18	CASLGLTSGESGEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATACCGTCGGACAGGAGGAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	3	500	7.167852468393355E-4		50	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	1	4	3	7	4	24	39	53	46	57													Vb 18	X+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAACAGTCGGGACAGGGTTGGATACGCAGTATTTTGGCCCA	CASSPTVGTGLDTQYF	In	VDJ	4	537	7.698273551054463E-4	9.235166551155427E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	3	6	6	3	24	39	54	45	57													Vb 18	CASSPTVGTGLDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATCATTAAGCAACTATGGCTACACCTTCGGTTCG	CASSPSLSNYGYTF	In	VDJ	4	601	8.615758667008813E-4	0.0010335819547941177	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	2	6	7	2	6	0	24	39	-1	45	48						01,02							Vb 18	CASSPSLSNYGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD02-01	TCRBJ01-02*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAACCCCCCTAGCGGGTGAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	609	8.730444306503106E-4		46	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	4	4	7	6	2	24	39	53	45	55						01,02							Vb 18	X+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGCGGGTTGGATCAGCCCCAGCATTTTGGTGAT	CASSRGLDQPQHF	In	VDJ	4	609	8.730444306503106E-4	0.0010473401172539395	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	4	7	4	5	0	4	24	-1	42	37	46						01,02							Vb 18	CASSRGLDQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD02-01	TCRBJ01-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAACAACAATGGAACATTTACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CASSTTMEHLQSRANVLTF	In	VDJ	4	671	9.619258012583882E-4	0.001153965876317559	57	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-06	01	5	1	8	5	8	14	24	36	47	44	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSTTMEHLQSRANVLTF+TCRBV18-01+TCRBJ02-06	TCRBV18-01*01		TCRBJ02-06*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
TTTCTGTGCCAGCTCACCACCGTGGGTGCCGGGGCCTTACACCCACAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	5	790	0.00113252069000615		64	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-04	01	0	7	0	0	9	10	4	21	35	30	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01		TCRBJ01-04*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCTTTCCCAGCGGGGGGGCCCCACAATGAGCAGTTCTTCGGGCCA	CASSAFPAGGPHNEQFF	In	VDJ	5	792	0.0011353878309935074	0.0013620580835223648	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	6	0	5	8	4	24	36	54	44	58													Vb 18	CASSAFPAGGPHNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGTTCGGGACAGCAAGAGACCCAGTACTTCGGGCCA	CASSGQQETQYF	In	VDJ	6	955	0.0013690598214631308	0.0016423806436412353	36	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	9	0	5	2	3	0	24	32	-1	35	42													Vb 18	CASSGQQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTAGGAGGACAGGGGATGCCGAGCAGTACTTCGGGCCG	CASSPRRTGDAEQYF	In	VDJ	6	959	0.0013747941034378455	0.001649259724871146	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	1	2	6	5	4	24	38	52	43	56													Vb 18	CASSPRRTGDAEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCTTACTTGGGGACAGGCTTTACAATGAGCAGTTCTTCGGGCCA	CASSLLGDRLYNEQFF	In	VDJ	7	1075	0.0015410882807045713	0.0018487530805385633	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	4	4	8	3	24	35	51	43	54													Vb 18	CASSLLGDRLYNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCCCCTGGGCGGTTAGCGGTCCCCTTATCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	13	1896	0.00271804965601476		55	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	5	5	1	11	8	24	33	50	44	58						01,02							Vb 18	X+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01	TCRBJ02-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAACCTTCCCGATAATGAACACTGAAGCTTTCTTTGGACAA	CASSPTFPIMNTEAFF	In	VDJ	13	1897	0.0027194832265084387	0.00326240427328526	48	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	2	2	8	0	8	3	24	39	49	47	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPTFPIMNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220B	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				5109	4258	787	62	0	2155	1767	352	36	0	697559	581473	107534	8552	0	0.135612622	9.32422161	0.125622138	9.6823988				221021	0.0201223399	0.0266942754	0.0222518817	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/09/2016 09:50:34	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8334311771270614	MSKCC- Snyder- P01-02		4447.0	
